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Resumen	
	
1.	Introducción	
Uno	de	los	objetivos	de	la	Química	Orgánica	a	los	que	se	atribuye	mayor	importancia	
en	los	últimos	tiempos	es	el	desarrollo	de	nuevas	metodologías	para	la	exploración	del	
espacio	 químico	 con	 la	 finalidad	 de	 identificar	 nuevas	 entidades	 químicas	 bioactivas	
que	sirvan	como	base	para	el	desarrollo	de	nuevos	fármacos.	Esta	exploración	require	
nuevos	 procesos	 sintéticos,	 siendo	 de	 especial	 importancia	 los	 que	 permiten	 la	
construcción	de	varios	enlaces	en	una	misma	operación	sintética,	como	las	reacciones	
multicomponente.		
La	 síntesis	 orientada	 a	 diversidad	 (Diversity-Oriented	 Synthesis,	 DOS)	 es	 una	
aproximación	 relativamente	 reciente	 a	 la	 identificación	 de	 moléculas	 orgánicas	
bioactivas,	 diseñada	 para	 explorer	 regiones	 amplias	 del	 espacio	 químico.	 Pone	 el	
énfasis	en	la	generación	de	esqueletos	variados,	dando	lugar	a	moléculas	con	variedad	
de	formas	tridimensionales.	No	está	dirigida	a	la	obtención	de	moleculas	específicas,	y	
las	 quimiotecas	 derivadas	 de	 DOS	 se	 utilizan	 sobre	 todo	 para	 la	 identificación	 de	
nuevos	 ligandos	 (hit)	 para	 dianas	 biológicas	 a	 través	 de	 técnicas	 de	 cribado	 de	 alto	
rendimiento	 (high-throughput	 screening)	 para	 su	 aplicación	 en	 descubrimiento	 de	
fármacos	y	química	biológica.	
Una	de	las	estrategias	más	eficaces	en	síntesis	orientada	a	diversidad	se	conoce	como	
construcción/acoplamiento/emparejamiento	(build/couple/pair),	en	 la	que	el	paso	de	
construcción	(build)	implica	sintetizar	(o,	idealmente,	adquirir	de	fuentes	comerciales)	
compuestos	 de	 artida	 que	 contengan	 grupos	 funcionales	 que	 permitan	 los	 pasos	
posteriores.	En	la	etapa	de	acoplamiento	(couple)	se	construye	una	estructura	central,	
idealmente	por	medio	de	una	reacción	multicomponente,	y	finalmente	en	la	etapa	de	
emparejamiento	 (pair)	 se	 hace	 reaccionar	 los	 grupos	 funcionales	mencionados	 para	
generar	diversidad	y	complejidad	molecular,	principalmente	a	través	de	reacciones	de	
ciclación.		
	
2.	Objetivos	
Esta	 tesis	 se	basa	en	el	 empleo	del	pirrol,	una	estructura	privilegiada	bien	 conocida,	
como	núcleo	central	 sobre	el	que	construir	una	 serie	de	quimiotecas	basadas	en	 los	
principios	 de	 la	 síntesis	 orientada	 a	 diversidad	 mediante	 la	 aproximación	
build/couple/pair.	Sus	objetivos	concretos	son:	
1.	 Adaptación	 de	 una	 reacción	 mecanoquímica	 multicomponente	 previamente	
desarrollada	por	nuestro	grupo	a	la	síntesis	de	derivados	de	pirrol	portadores	en	sus	
posiciones	N-1,	C-2	 y	C-5	de	grupos	 funcionales	 adecuados	para	 la	 generación	de	
complejidad	 estructural	 en	 la	 etapa	 de	 emparejamiento.	 También	 fue	 necesario	
adaptar	la	reacción	multicomponente	a	la	preparación	de	moléculas	simétricas	que	
contienen	dos	anillos	de	pirrol	en	los	extremos	de	un	espaciador.		
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2.		Síntesis	 de	 derivados	 de	 pirrol	 fusionados	 basada	 en	 reacciones	 catalizadas	 por	
metals	 de	 transición.	 En	 particular,	 se	 consideraron	 de	 interés	 las	 siguientes	
transformaciones:		
a) Síntesis	de	derivados	de	pirrolo[1,2-c]quinazolina	por	combinación	de	procesos	
de	acoplamiento	cruzado	de	C-arilación	y	N-	arilación.	
b) Síntesis	 de	 esqueletos	 de	 pirrolo[2,1-a]isoquinolina	 and	 benzo[c]pirrolo[1,2-
a]azepina	por	medio	de	reacciones	de	Heck	intramoleculares.	
c) Síntesis	 de	 esqueletos	 de	 pirrolo[1,2-a]azepina	 and	 pirrolo[1,2-a]azocina	 por	
metátesis	con	cierre	de	anillo.	
3.	 Síntesis	 de	 esqueletos	 de	 pirrolo[2,1-a]isoindol	 y	 pirrolo[2,1-a]isoquinolina	 por	
medio	de	reacciones	de	Diels-Alder	intramoleculares.	
4.	 Investigación	 de	 procesos	 de	 anelación	 en	 sustratos	 pirrólicos	 mediada	 por	 la	
generación	de	intermedios	de	oxonio,	con	las	siguientes	posibilidades:	
a) Ciclación	 del	 sistema	 de	 oxonio	 sobre	 un	 grupo	 arilo	 en	 C-5,	 utilizando	 una	
transformación	 relacionada	 con	 la	 síntesis	 de	 Pommeranz-Fritsch	 de	
isoquinolinas.	
b) Ciclación	 del	 sistema	 de	 oxonio	 sobre	 un	 metileno	 activo	 situado	 en	 C-2	 y	
vecino	a	un	éster,	mediante	la	transformación	de	dicha	función	en	un	acetal	de	
cetena.		
5.	 Síntesis	 de	macrociclos	 basada	 en	 reacciones	 de	metátesis	 con	 cierre	 de	 anillo	 a	
partir	de	bis-pirroles	simétricos.		
6.	 Síntesis	de	anillos	de	tamaño	medio	por	metátesis	de	cierre	de	anillo.	Los	pirroles	
de	 partida	 necesarios	 procederían	 de	 β,δ-dialilaminoenonas,	 que	 a	 su	 vez	
procederían	de	un	proceso	dominó	de	formación	de	enaminona	/isomerización	/aza	
Michael.	
7.		Preparación	de	basada	en	una	reacción	de	Hantzsch	doble,	en	la	que	la	formación	
de	uno	de	los	anillos	de	pirrol	constituye	la	etapa	de	macrociclación.	
8.		Estudio	de	 las	quimiotecas	mencionadas	en	 los	apartados	anteriores	por	métodos	
de	 cribado	 de	 alto	 rendimiento,	 a	 través	 del	 programa	Open	 Innovation	 in	 Drug	
Discovery	(OIDD)	de	Lilly.	
9.	 Adiestramiento	 en	 técnicas	 sintéticas	 no	 convencionales,	 especialmente	
mecanoquímica	y	síntesis	en	flujo.		
	
3.	Resultados	y	discusión	
1. La	 capacidad	de	 sintetizar	pirroles	de	partida	portadores	de	determinados	grupos	
funcionales	en	las	posiciones	N-1,	C-2	y	C-5	de	derivados	de	pirrol	era	crucial	para	el	
desarrollo	de	nuestro	proyecto.	Por	tanto,	fue	necesario	verificar	la	adecuación	de	
una	 síntesis	 mecanoquímica	 multicomponente	 de	 pirroles	 previamente	
desarrollada	 por	 nuestro	 grupo	 para	 esta	 finalidad.	 Aunque	 la	 introducción	 de	
algunos	 de	 los	 sustituyentes	 planificados	 podía	 ser	 en	 principio	 problemática	 por	
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diversas	razones,	como	impedimento	estérico	en	el	caso	de	grupos	5-(o-iodometilo)	
o	baja	estabilidad	potencial	de	anillos	de	furano	o	grupos	acetal	en	las	condiciones	
de	 reacción.	 Sin	 embargo,	 no	 se	 dieron	 problemas	 significativos	 gracias	 a	 la	
suavidad	 de	 nuestro	 método	 y	 los	 derivados	 de	 pirrol	 deseados	 pudieron	
prepararse.		
2. Se	 sintetizaron	 varios	 esqueletos	 heterocíclicos	 poco	 habituales	 a	 partir	 de	
precursores	 pirrólicos	 utilizando	 reacciones	 catalizadas	 por	metales	 de	 transición.	
Concretamente,	se	implementaron	con	éxito	los	siguientes	procesos:	(a)	Síntesis	de	
of	 pirrolo[1,2-c]quinazolinas	 por	 medio	 de	 un	 proceso	 domino	 iniciado	 por	 una	
reacción	 de	 Ullmann.	 (b)	 Síntesis	 de	 esqueletos	 de	 pirrolo[2,1-a]isoquinolina	 y	
benzo[c]pirrolo[1,2-a]azepina	por	reacciones	de	Heck	 intramoleculares.	(c)	Síntesis	
de	pirrolo[1,2-a]azepinas	y	pirrolo[1,2-a]azocinas	por	 reacciones	de	metátesis	 con	
cierre	de	anillo.	
3. Se	 obtuvieron	 esqueletos	 de	 5,6-dihidropirrolo[2,1-a]isoquinolina	 y	 pirrolo[2,1-
a]isoindol	utilizando	reacciones	intramoleculares	Diels-Alder	a	partir	de	precursores	
procedentes	de	reacciones	de	metátesis	cruzada	de	1-alil-5-(2-furil)pirroles.	
4. La	posibilidad	de	obtener	pirroles	portadores	de	una	function	acetal	en	el	extreme	
de	 una	 cadena	 unida	 al	 nitrógeno	 permite	 generar	 intermedios	 de	 oxonio	 por	
tratamiento	 con	 ácidos	de	Brønsted	o	 Lewis.	 Estos	 intermedios	permitieron	 crear	
pirroles	 fusionados	mediante	procesos	de	ciclación	sobre	sustituyentes	adecuados	
presents	en	las	posiciones	C-2	o	C-5,	proporcionando,	respectivamente,	esqueletos	
de	 pirrolizina	 y	 relacionados	 y	 esqueletos	 de	 pirrolo[2,1-a]isoquinolina	 y	
relacionados.	
5. Se	investigó	también	la	síntesis	de	sistemas	macrocíclicos	portadores	de	anillos	de	
pirrol	como	parte	de	su	estructura.	Condcretamente,	se	ha	demostrado	la	viabilidad	
de	 las	 siguientes	 estrategias:	 (a)	 Síntesis	 de	macrociclos	 basada	 en	 reacciones	 de	
metátesis	con	cierre	de	anillo,	empleando	como	materiales	de	partida	bis-pirroles	
simétricos	 en	 los	 que	 cada	 anillo	 de	 pirrol	 es	 portador	 de	 un	 sustituyente	
homoalílico.	 (b)	 Síntesis	 de	 anillos	 de	 tamaño	medio	 derivados	 del	 esqueleto	 de	
pirrolo[1,2-a][1,5]diazonina	 por	 metátesis	 con	 cierre	 de	 anillo.	 (c)	 Macrociclación	
multicomponente	en	una	 sola	etapa	por	medio	de	 reacciones	de	Hantzch	dobles,	
actuando	una	de	ellas	como	la	etapan	de	cierre	del	macrociclo.		
6. Las	 quimiotecas	 obtenidas	 se	 estudiaron	 por	 metodologías	 de	 cribado	 de	 alto	
rendimiento	 gracias	 a	 una	 colaboración	 con	 Lilly	 a	 través	 del	 programa	 Open	
Innovation	in	Drug	Discovery	(OIDD).		
7. Finalmente,	como	parte	de	los	requisitos	para	optar	a	la	mención	internacional	de	
la	 tesis	 doctoral,	 llevé	 a	 cabo	 una	 estancia	 de	 tres	 meses	 en	 el	 laboratoriuo	 del	
profesor	Steven	Ley	en	el	Department	of	Química	de	la	Universidad	de	Cambridge,	
trabajando	 en	 el	 desarrollo	 de	 reacciones	 de	 homologación	 fotoquímica	 para	
lamobtención	de	aldehídos	alifáticos	en	condiciones	de	flujo.		
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4.	Conclusiones	
Los	 principales	 esqueletos	 moleculares	 generados	 en	 esta	 tesis	 se	 resumen	 a	
continuación.	 Para	 su	 construcción	 ha	 sido	 necesario	 el	 desarrollo	 de	 nueva	
metodologia	 sintética,	 y	 su	 estudio	 por	 técnicas	 de	 cribado	 de	 alto	 rendimiento	 ha	
dado	 lugar	 a	 algunos	 compuestos	 interesantes	 como	 puntos	 de	 partida	 para	 una	
optimización	futura.		
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Summary	
1.	Introduction		
One	of	the	goals	of	synthetic	Organic	Chemistry	in	recent	years	is	the	development	of	
new	ways	to	explore	chemical	space	in	order	to	identify	new	biologically	active	entities	
and	use	them	to	uncover	new	therapeutic	targets.	The	exploration	of	chemical	space	
requires	new	synthetic	processes,	ideally	allowing	the	construction	of	several	bonds	in	
a	 single	 operation.	 In	 this	 connection,	 the	 MCR	 chemical	 space,	 defined	 as	 the	
ensemble	of	all	possible	molecules	that	can	be	obtained	by	multicomponent	synthetic	
processes,	is	of	particular	interest.	
Diversity-Oriented	Synthesis	 (DOS)	 is	a	 recent	approach	 to	 the	 identification	of	 small	
bioactive	 molecules	 that	 is	 is	 designed	 to	 explore	 broader	 extensions	 of	 chemical	
space,	its	emphasis	being	on	the	generation	of	diverse	scaffolds	with	varied	molecular	
shapes.	It	is	not	directed	at	a	specific	biological	target,	and	DOS	libraries	are	used	for	
the	fast	high-throughput	identification	of	new	ligands	for	varied	targets	in	an	effort	to	
locate	hit	compounds	in	medicinal	chemistry	and	chemical	biology.	
One	 of	 the	 most	 effective	 strategies	 for	 the	 fast	 generation	 of	 diverse	 molecular	
libraries	 endowed	with	molecular	diversity	 and	 complexity	 is	 the	 “build/couple/pair”	
strategy,	where	the	build	step	involves	synthesizing	or	purchasing	building	blocks	that	
contain	suitable	functionality	for	the	subsequent	steps.	In	the	couple	step,	the	desired	
structural	 core	 is	 constructed,	 ideally	 using	 a	 multicomponent	 reaction	 that	 is	
compatible	 with	 the	 presence	 of	 the	 functional	 groups	 needed	 for	 the	 complexity-
generating	event	 in	 the	 final	phase.	 Finally,	 in	 the	pair	 step,	 these	 functional	 groups	
react	to	provide	structural	complexity	and	diversity,	mainly	via	cyclization	reactions.	
	
2.	Objectives	
This	 thesis	 is	 based	 on	 the	 use	 of	 pyrrole,	 a	well-known	 privileged	 structure,	 as	 the	
central	 core	 on	which	 to	 build	 a	 variety	 of	 DOS	 libraries	 using	 the	build-couple-pair	
approach.	More	specifically,	the	objectives	that	have	been	pursued	are:	
1.	 Adaptation	 of	 a	 known,	 in	 house-developed	 mechanochemical	 multicomponent	
reaction	 to	 the	 preparation	 of	 pyrrole	 derivatives	 bearing	 functional	 groups	 that	
allow	 suitable	 complexity-generating	 reactions	 at	 the	 pair	 stage	 at	 their	 N-1,	 C-2	
and	 C-5	 positions.	 The	 mechanochemical	 pyrrole	 synthesis	 also	 needed	 to	 be	
adapted	to	the	preparation	of	symmetrical	molecules	containing	two	pyrrole	units	
at	the	end	of	a	spacer.	
2.		Synthesis	of	fused	pyrrole	derivatives	based	on	transition	metal-catalyzed	reactions.	
In	particular,	the	following	transformations	were	considered	of	interest:	
a) Synthesis	 of	 pyrrolo[1,2-c]quinazolines	 by	 combination	 of	 C-arylation	 and	
N-arylation	cross-coupling	processes.	
b) Synthesis	 of	 pyrrolo[2,1-a]isoquinoline	 and	 benzo[c]pyrrolo[1,2-a]azepine	
frameworks	by	intramolecular	Heck	reactions.	
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c) Synthesis	of	pyrrolo[1,2-a]azepine	and	pyrrolo[1,2-a]azocine	frameworks	by	
ring-closing	metathesis.	
3.	 Synthesis	 of	 pyrrolo[2,1-a]isoindole	 and	 pyrrolo[2,1-a]isoquinoline	 frameworks	 by	
intramolecular	Diels-Alder	reactions.	
4.	 Investigation	 of	 ring-formation	 processes	 on	 pyrrole-derived	 substrates	 via	 the	
generation	of	oxonium	intermediates.	Two	possibilities	were	studied:	
a) Cyclization	 onto	 a	 C-5	 aryl	 substituent,	 using	 a	 transformation	 related	 to	 the	
Pommeranz-Fritsch	isoquinoline	synthesis.	
b) Cyclization	of	an	oxonium	species	from	an	acetal	under	Noyori-type	conditions	
onto	a	C-2	active	methylene	group	adjacent	to	an	ester	via	the	formation	of	a	
ketene	acetal	intermediate.	
5.	 Synthesis	 of	 macrocycles	 based	 on	 ring-closing	 metathesis	 reactions,	 using	 as	
starting	materials	symmetrical	bis-pyrrole	derivatives.	
6.	 Synthesis	 of	 diaza	 medium-sized	 rings	 by	 ring-closing	 metathesis.	 The	 starting	
pyrroles	 would	 be	 constructed	 by	 the	 Hantzsch	 method	 from	 β,δ-
diallylaminoenones,	 which	 would	 in	 turn	 be	 available	 via	 an	 enaminone	
formation/double	bond	isomerization/aza	Michael	domino	sequence.	
7.		Preparation	of	macrocycles	based	on	a	double	Hantzsch	pyrrole	synthesis,	with	one	
of	these	reactions	serving	as	the	macrocyclization	event.	
8.		Study	 of	 the	 libraries	 synthesized	 by	 the	 above	 methods	 using	 high-throughput	
screening	 methodologies.	 These	 studies	 were	 performed	 thanks	 to	 our	
collaboration	with	the	Lilly	Open	Innovation	in	Drug	Discovery	(OIDD)	program.	
9.	 Training	 in	 non-conventional	 synthetic	methodologies	 such	 as	mechanochemistry	
and	synthesis	in	flow.	
	
3.	Results	and	discussion	
1. The	 ability	 to	 synthesize	 starting	 pyrroles	 bearing	 suitable	 functionalities	 was	
crucial	to	the	success	of	our	DOS	project.	Therefore,	we	needed	to	verify	whether	
the	mechanochemical	multicomponent	pyrrole	synthesis	previously	developed	by	
our	 group	 and	 based	 on	 the	 Hantzsch	 reaction	 was	 compatible	 with	 the	
functionalities	planned	to	be	present	at	their	N-1,	C-2	and	C-5	positions	in	order	to	
carry	out	complexity-generating	reactions	at	the	final	pair	stage.	The	introduction	
of	some	of	these	groups	could	be	in	principle	troublesome	for	a	variety	of	reasons	
such	as	the	steric	hindrance	due	to	the	o-iodophenyl	substituent	or	the	potential	
low	stability	of	the	furan	ring	or	the	acetal	function	under	the	reaction	conditions.	
In	 the	 event,	 these	 concerns	 proved	 to	 be	 largely	 unfounded	 thanks	 to	 the	
mildness	 of	 our	method	 and	 the	 usual	 reaction	 conditions	 of	 our	method	 gave	
good	results,	allowing	the	preparation	of	a	large	library	of	starting	pyrroles.	
2. A	 number	 of	 unusual	 fused	 pyrrole	 heterocyclic	 frameworks	were	 synthesisized	
from	 suitable	 pyrrole	 precursors	 using	 transition	 metal-catalyzed	 reactions.	 In	
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particular,	the	following	processes	were	successfully	implemented:	(a)	Synthesis	of	
pyrrolo[1,2-c]quinazolines	 by	 an	 Ullmann	 coupling-initiated	 domino	 process.	 (b)	
Synthesis	 of	 pyrrolo[2,1-a]isoquinoline	 and	 benzo[c]pyrrolo[1,2-a]azepine	
frameworks	by	ring-closing	Heck	reactions.	(c)	Synthesis	of	pyrrolo[1,2-a]azepines	
and	pyrrolo[1,2-a]azocines	by	ring-closing	metathesis.	
3. 5,6-Dihydropyrrolo[2,1-a]isoquinoline	 and	 pyrrolo[2,1-a]isoindole	 frameworks	
were	 obtained	 using	 intramolecular	 Diels-Alder	 reactions	 from	 precursors	
obtained	by	cross-metathesis	of	1-allyl-5-(2-furyl)pyrroles.	
4. The	possibility	to	synthesize	pyrrole	derivatives	with	a	nitrogen	substituent	ending	
in	an	acetal	group	opened	up	the	possibility	to	readily	generate	oxonium	species	
by	 treatment	 with	 Brønsted	 or	 Lewis	 acids.	 These	 intermediates	 were	 suitable	
substrates	 for	 ring-creation	 processes	 leading	 to	 fused	 pyrrole	 systems	 by	
cyclization	onto	the	C-2	or	C-5	substituents,	leading	respectively,	to	pyrrolizine	and	
related	frameworks	or	pyrrolo[2,1-a]isoquinoline	and	related	frameworks.	
5. The	 synthesis	 of	 pyrrole-based	 macrocyclic	 structures	 was	 also	 investigated.	 In	
particular,	 the	 following	 strategies	 were	 successfully	 explored:	 (a)	 Synthesis	 of	
macrocycles	based	on	ring-closing	metathesis	reactions,	using	as	starting	materials	
symmetrical	 bis-pyrrole	 derivatives	 where	 each	 of	 the	 pyrrole	 rings	 bears	 an	
homoallyl	chain.	(b)	Synthesis	of	pyrrole-derived	medium-sized	rings	derived	from	
the	 pyrrolo[1,2-a][1,5]diazonine	 framework	 by	 ring-closing	 metathesis.	 (c)	 One-
pot	multicomponent	macrocyclization	 application	of	 a	one-pot	process	 involving	
two	Hantzch	pyrrole	syntheses,	one	of	which	acts	as	the	macrocyclization	event.		
6. The	 DOS	 libraries	 obtained	 were	 studied	 by	 high-throughput	 screening	
methodologies,	 in	collaboration	with	the	Lilly	Open	 Innovation	 in	Drug	Discovery	
(OIDD)	program.		
7. Finally,	as	part	of	the	requirements	for	the	International	Ph	D	Label,	I	carried	out	a	
three-month	 stay	 at	 the	 group	 of	 Professor	 Steven	 Ley	 at	 the	 Department	 of	
Chemistry,	 Cambridge	 University,	 working	 on	 the	 use	 of	 photochemical	
homologation	 reactions	 for	 the	 preparation	 of	 aliphatic	 aldehydes	 under	 flow	
chemistry	conditions.	
	
4.	Conclusions	
The	 main	 frameworks	 whose	 synthesis	 is	 described	 in	 this	 thesis	 are	 summarized	
below.	 Some	 new	 synthetic	 methodology	 was	 discovered	 in	 the	 course	 of	 this	
endeavour,	 and	 some	 interesting	 hit	 compounds	 for	 a	 number	 of	 diseases	 were	
identified	by	high-throughput	screening.	
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1.	Introduction	
	
1.1.	Diversity-Oriented	Synthesis	
One	of	the	goals	of	Organic	Chemistry	in	recent	years	is	the	development	of	new	ways	
to	explore	chemical	space	in	order	to	identify	new	biologically	active	entities	and	use	
them	 to	 uncover	 new	 therapeutic	 targets. 1 	Chemical	 space	 spans	 all	 organic	
compounds	having	certain	pre-defined	properties.	In	the	field	of	drug	discovery,	some	
of	 these	 parameters	 are	 lipophilicity,	 polarizability,	 molecular	 weight,	 etc.	 Chemical	
space	is	truly	astronomic	in	size,	and	it	has	been	estimated	that	the	number	of	existing	
organic	molecules	built	from	the	elements	normally	associated	with	life	(C,	H,	N,	S,	O),	
chemically	 stable	 and	with	 certain	drug	 like	properties	 (e.g.	molecular	weight	 below	
500	Daltons)	is	over	1063,2	a	mind-boggling	number	that	is	impossible	to	conceive	and	
that	 can	 be	 somehow	 placed	 in	 context	 by	 bearing	 in	 mind	 that	 the	 number	 of	
chemical	compounds	registered	in	the	Chemical	Abstracts	service	is	1,43.108,	the	age	
of	the	Universe	is	5.1017	seconds	and	the	number	of	atoms	in	Earth	is	in	the	1050	order	
of	magnitude.	Regarding	the	targets	at	which	these	molecules	are	addressed,	although	
the	 number	 of	 all	 possible	 proteic	 structures	 has	 been	 estimated	 to	 be	 20300,3	the	
human	proteome	comprises	only	about	250,000	proteins.	
The	exploration	of	 chemical	 space	 requires	new	synthetic	processes,	 ideally	allowing	
the	 construction	of	 several	 bonds	 in	 a	 single	operation.	 In	 this	 connection,	 the	MCR	
chemical	space,	defined	as	the	ensemble	of	all	possible	molecules	that	can	be	obtained	
by	multicomponent	synthetic	processes,	is	of	particular	interest.4		
In	order	to	place	Diversity-Oriented	Synthesis	(DOS)	in	context,	it	is	useful	to	compare	
it	with	 Target-Oriented	 Synthesis	 (TOS)	 and	 combinatorial	 synthesis.	 Regarding	 TOS,	
the	identification	and	characterization	of	natural	bioactive	entities	is	usually	followed	
by	their	total	synthesis,	which	is	normally	designed	using	the	retrosynthetic	approach.	
Using	 this	 approach,	 a	 single	 and	 defined	 molecular	 architecture	 is	 obtained,	
representing	a	single	point	in	chemical	space	(Figure	1.1).	
																																																								
1	 (a)	Reymond,	J.-L.;	Ruddigkeit,	L.;	Blum	L.	C.;	van	Deursen	R.	WIREs	Comput.	Mo.l	Sci.	2012,	2,	717;	
(b)	Ruddigkeit,	L.;	van	Deursen	R.;	Blum	L.	C.;	Reymond,	J.-L.	J.	Chem.	Inf.	Model.	2012,	52,	2864;	(c)	
Reymond,	J.-L.;	Awale,	M.,	ACS	Chem.	Neurosci,.2012,	3,	649.		
2	 Bohacek	R.	S.;	McMartin	C.;	Guida	W.	C.;	Med	Res	Rev.	1996,	16,	3.	
3	 O’Donovan	C.;	Apweiler	R.;	Bairoch	A.;	Trends	Biotechnol.,	2001,	19,	178.	
4	 (a)	Lenci	E.;	Guarna	A.;	Trabocchi	A.,	Molecules	2014,	19,	16506;	(b)	Bender	A.,	Fergus	S.,	Galloway	
W.	R.,	Glansdrop	F.	G.,	Marsden	D.	M.,	Nicholson	R.	L.,	Spandl	R.	J.,	Thomas	G.	L.,	Wyatt	E.	E.,	Glen	R.	
C.,	Spring	D.	R.	Ernst	Shering	Res	Found	Workshop,	2006,	58,	47;	 (c)	Lipinski	C.;	Hopkins	A.	Nature,	
2004	 ,432,	 855.	 (d)	Abdelraheem,	E.	M.	M.;	Camacho,	C.	 J.;	Dömling,	A.	Expert	Opin.	Drug	Discov.	
2015,	 10,	 1179.	 (e)	 Orru,	 R.;	 Ruijter,	 E.	 (Eds).	Multicomponent	 Reactions	 in	 Drug	 Discovery	 and	
Medicinal	Chemistry.	Elsevier,	2018.	
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Figure	1.1	
	
Combinatorial	 chemistry	has	been	widely	employed	 to	prepare	chemical	 libraries	via	
the	 generation	 of	 structural	 diversity	 by	 modification	 of	 functional	 groups	 and	
substituents	around	a	single	skeleton.	It	leads	to	the	exploration	of	only	a	small	region	
of	 chemical	 space,	 centered	 on	 the	 point	 corresponding	 to	 the	 original	 framework.	
Retrosynthetic	reasoning	is	still	the	prevalent	form	of	synthetic	design	(Figure	1.2).	
	
	
Figure	1.2	
	
Diversity-Oriented	Synthesis	 (DOS)	 is	a	more	recent	approach	to	 the	 identification	of	
small	bioactive	molecules	that	is	is	designed	to	explore	broader	extensions	of	chemical	
space,	its	emphasis	being	on	the	generation	of	diverse	scaffolds	with	varied	molecular	
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shapes.5	It	is	not	directed	at	a	specific	biological	target	and	DOS	libraries	are	used	for	
the	fast	high-throughput	identification	of	new	ligands	for	varied	targets	in	an	effort	to	
locate	 hit	 compounds	 in	medicinal	 chemistry	 and	 chemical	 biology.6	Because	 in	DOS	
there	 is	 no	 target	 molecule,	 the	 synthetic	 planning	 is	 prospective	 rather	 than	
retrosynthetic,	 proceeding	 from	 building	 blocks	 to	 to	 products.7 ,8 , 9 	The	 stringent	
characteristics	of	DOS	in	terms	of	synthetic	efficiency	have	been	a	driving	force	for	the	
advancement	 of	 synthetic	 methodology,	 in	 particular	 in	 the	 area	 of	 multiple	 bond-
forming	processes	such	as	domino	and	multicomponent	reactions	(Figure	1.3).	
	
	
Figure	1.3	
	
One	 of	 the	 most	 effective	 strategies	 for	 the	 fast	 generation	 of	 diverse	 molecular	
libraries	 endowed	with	molecular	diversity	 and	 complexity	 is	 the	 “build/couple/pair”																																																									
5	 For	a	monograph,	 see:	 Trabocchi,	A.;	 (ed.).	Diversity-Oriented	Synthesis.	Basics	and	Applications	 in	
Organic	Synthesis,	Drug	Discovery,	and	Chemical	Biology.	John	Wiley	&	Sons,	Hoboken,	2013.		
6	 (a)	Galloway,	W.	R.	J.	D.;	Isidro-Llobet,	A.;	Spring,	R.	D.	Nat.	Comm.,	2010,	80.	(b)	O’Connell,	K.	M.	G.;	
Galloway,	W.	 R.	 J.	 D.;	 Spring,	 D.	 R	 in:	 Trabocchi	 A.	 (ed.);	Diversity-Oriented	 synthesis:	 Basics	 and	
Applications	in	Organic	Synthesis,	Drug	Discovery,	and	Chemical	Biology,	2013,	Wiley,	chapter	1.	(c)	
Medina-Franco,	J.	L.;	Martínez-Mayorga,	K.;	Meurice,	N.	Expert	Opin.	Drug	Discov.	2014,	9,	151.	(d)	
Aliagas,	 I.;	Berger,	R.;	Goldberg,	K.;	Nishimura,	R.	T.;	Reilly,	J.;	Richardson,	P.;	Richter,	D.;	Sherer,	E.	
C.;	Sparling,	B.	A.;	Bryan,	M.	C.	J.	Med.	Chem.	2017,	60,	5955.	(f)	Kidd,	S.	L.;	Osberger,	T.	J.;	Mateu,	N.;	
Sore,	H.	F.;	Spring,	D.	R.	Front.	Chem.	2018,	6,	460.	 (g)	Gerry,	C.	 J.;	Schreiber,	S.	L.	Nat.	Rev.	Drug.	
Discov.	2018,	17,	333.	(h)	Pavlinov,	I.;	Gerlach,	E.	M.;	Aldrich,	L.	N.	Org.	Biomol.	Chem.	2018,	Advance	
Article.	(i)	Pawar,	T.	J.;	Jiang,	H.;	Vázquez,	M.	A.;	Villegas-Gómez,	C.;	Cruz-Cruz,	D.	Eur.	J.	Org.	Chem.	
2018,	1835.	
7	 (a)	Schreiber	S.	L.	Science,	2000,	287,	1964;	(b)	Burke,	M.	D.;	Berger,	E.	M.;	Schreiber,	M.	L.	Science,	
2003,	302,	5645;	(c)	Burke	M.	D.,	Schreiber	S.	L.,	Angew.	Chem.	Int.	Ed.,	2004,	43,	46;	(d)	Lipkus,	A.	
H.;	Yuan,	Q.;	Lucas,	K.	A.;	Funk,	S.	A.;	Bartelt,	W.	F.;	Schenk,	R.	J.;	Trippe	A.	J.	J.	Org.	Chem.,	2008	,	73,	
4443;	 (e)	 Schreiber,	 S.	 L.;	Nature,	2009,	457,	 153.	 (f)	 Biggs-Houck,	 J.;	 Younai,	 A.;	 Shaw,	 J.	 T.	Curr.	
Opin.	Chem.	Biol.,	2010,	14,	371.	
8	 Anoh,	V.;	Agbo,	S.;	Swande,	P.	Chem.	Sci.	Rev.	Lett.	2015,	4,	1148.		
9		 Sahn,	J.	J.;	Granger,	A.	B.;	Martin,	S.	F.	Org.	Biomol.	Chem.,	2014,	12,	7659.	
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strategy,10	first	proposed	by	Schreiber	in	200811	and	that	is	increasingly	employed	as	a	
fast	 method	 to	 yield	 small	 molecules	 with	 increased	 probability	 of	 success	 in	 the	
discovery12	and	optimization	phases	of	drug-discovery	research.		
In	this	strategy,	the	build	step	involves	synthesizing	or	purchasing	building	blocks	that	
contain	suitable	functionality	for	the	subsequent	steps.	In	the	couple	step,	the	desired	
structural	 core	 is	 constructed,	 ideally	 using	 a	 multicomponent	 reaction	 that	 is	
compatible	 with	 the	 presence	 of	 the	 functional	 groups	 needed	 for	 the	 complexity-
generating	event	 in	 the	 final	phase.	 Finally,	 in	 the	pair	 step,	 these	 functional	 groups	
react	 to	 provide	 structural	 complexity	 and	 diversity,	mainly	 via	 cyclization	 reactions	
(Figure	1.4).	The	use	of	MCRs	as	a	starting	point	for	subsequent	reactions	that	exploit	
the	core	connectivity	of	the	components	is	a	powerful	approach	to	achieving	efficiency	
and	diversity.	
	
	
Figure	1.4	
	
As	an	example	of	the	B/C/P	strategy,	we	will	mention	the	work	of	Hung	et	al.13	for	the	
generation	of	a	diverse	 library	of	bicyclic	derivatives.	 In	the	build	stage,	compounds	 I	
and	II	were	obtained	from	proline,	following	a	literature	procedure.	In	the	couple	stage	
other	 reactive	 appendages	 were	 introduced	 by	 functionalizing	 the	 proline	 or	 by																																																									
10	 Yi,	S.;	Varun,	B.	V.;	Choi,	Y.;	Park,	S.	B.	Front.	Chem.,	2018,	6,	507.	
11	 Nielsen,	T.	E.;	Schreiber,	S.	L.	Angew.	Chem.	Int.	Ed.,	2008,	47,	48.	
12	 Chauhan,	J.;	Luthra,	T.;	Gundla,	R.;	Ferraro,	A.;	Holzgrabe,	U.;	Sen,	S.	Org.	Biomol.	Chem.,	2017,	15,	
9108.	
13		 Hung,	A.	W.;	Ramek,	A.;	Wang,	Y.;	Kaya,	T.;	Wilson,	 J.	A.;	Clemons,	P.	A.;	Young,	D.	W.	 	Proc.	Natl.	
Acad.	Sci.	U.S.A.,	2011,	108,	6799.			
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coupling	 the	 amino	 group	 to	 generate	 intermediates	 III.	 The	 substituents	 thus	
introduced	 can	 undergo	 the	 final	 pair	 step	 to	 generate	 final	 bicyclic	 structures	 IV	
mostly	via	Ring	Closing	Metathesis	reactions	(Figure	1.5).	This	article	contains	also	an	
example	of	a	post-pairing	modification	 (defined	also	 subsequent	modification),	 since	
the	authors	transformed	the	architectures	initially	created	via	a	subsequent	hydrolysis	
of	the	methyl	ester	and	reduction	of	the	alkene	groups	to	give	the	final	derivatives	V.	
	
	
	
Figure	1.5	
	
Because	of	the	unconceivably	large	size	of	chemical	space,	which	makes	imposible	to	
even	attempt	 its	 full	 exploration,	a	 recent	 trend	 is	 to	direct	 the	construction	of	DOS	
libraries	 towards	 regions	 of	 chemical	 space	 where	 compounds	 have	 a	 higher	
probability	of	success.	One	possibility	 is	to	use	as	guidelines	the	structures	of	natural	
products,	which	can	be	considered	to	have	been	optimized	by	evolution	for	interaction	
with	biomolecules.14	Alternatively,	the	concept	of	privileged	structure	can	be	used	as	a	
guideline.15	Privileged	structures	are	defined	as	structural	fragments	that	are	common	
to	compounds	that	are	able	to	interact	with	varied	pharmacological	targets,	leading	to	
the	conclusion	that	they	have	a	particular	affinity	for	biomolecules.16		
	 	
																																																								
14		 (a)	Wetzel,	S.;	Bon,	R.	S.;	Kumar,	K.;	Waldmann,	H.	Angew.	Chem.	Int.	Ed.,	2011,	50,	10800;	(b)	Bon,	
R.	S.;	Waldmann,	H.	Acc.	Chem.	Res.,	2010,	43,	1103;	(c)	van	Hattum,	H.;	Waldmann,	H.	J.	Am.	Chem.	
Soc.,	2014,	136,	11853;	(d)	Chauhan,	I.;	Luthra,	T.;	Gundla	R.;	Ferraro,	A.;	Holzgrabe,	U.;	Sen,	S.	Org.	
Biomol.	Chem.,	2017,	15,	9108;	(e)	Laraia,	L.;	Robke,	L.;	Waldmann,	H.	Chem	2018,	4,	705.	
15		 Kim,	J.;	Kim,	H.;	Park,		S.	B.	J.	Am.	Chem.	Soc.	2014,	136,	14629.	
16		 Yet,	L.	Privileged	Structures	in	Drug	Discovery.	John	Wiley	&	Sons,	Hoboken,	EEUU	2018.	
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1.2.	Multicomponent	Mechanochemical	Synthesis		
This	 thesis	 is	 based	 on	 the	 use	 of	 a	 mechanochemical,	 generalized	 version	 of	 the	
multicomponent	Hantzsch	pyrrole	synthesis	as	the	couple	phase	of	a	build-couple-pair	
protocol	 for	 the	 generation	 of	 molecular	 diversity	 and	 complexity.	 In	 this	 Section,	
some	 background	 will	 be	 given	 on	 multicomponent	 reactions,	 mechanochemical	
synthesis	and	their	combined	use.	
	
Modern	 organic	 synthesis,	 besides	 being	 driven	 by	 the	 classical	 principles	 of	 regio-,	
chemo-	 and	 stereo-selectivity,	 is	 based	 on	 economic	 and	 environmental	 concerns	
toward	an	ideal	synthesis17	whose	characteristics	can	be	summarized	as:	
• Use	of	simple,	cheap	and	easily	available	starting	materials.	
• Low	environmental	impact.	
• Simple	methodology.	
• Possibility	of	automation.	
• Atom	economy.	
• Alternative	sources	of	energy.	
• Quantitative	conversion	of	the	starting	materials.	
• Capacity	to	generate	molecular	complexity	and	diversity.	
	
Multicomponent	 reactions	 (MCRs)18,	 are	 an	 efficient	 tool	 towards	 achieving	 these	
goals.	They	are	defined	as	convergent	transformations	in	which	three	or	more	starting	
materials	are	combined	to	generate	the	final	product	so	that	the	final	product	contains	
significant	structural	fragments	of	all	reactants.19.	The	transformation	may	take	place	
via	a	one-step	process,	when	all	the	starting	components	are	added	at	the	same	time,	
or	 sequentially,	 when	 the	 addition	 of	 the	 components	 is	 not	 simultaneous.	 In	 both	
cases,	but	the	overall	process	takes	place	with	no	purification	of	intermediates	(Figure	
1.6).	
	
	
																																																								
17	 Wender,	P.	A.;	Miller,	B.	L.	Nature	2009,	460,	197.	
18	 Leonardi,	M.;	Villacampa,	M.;	Menéndez,	J.	C.	Chem.	Sci.	2018,	9,	2042.	
19	 Dömling,	A.;	Wang,	W.;	Wang	K.	Chem.	Rev.	2012,	112,	3083.	
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Figure	1.6		
	
This	approach	to	synthetic	chemistry	has	several	advantages:	
• Several	 bonds	 are	 generated	 in	 a	 single	 operation,	 which	 represents	 a	more	
effective	synthetic	strategy	if	compared	with	classical	multi-step	synthesis.20	
• Because	 intermediates	 are	 not	 isolated,	 the	 number	 of	 isolation	 and	
purification	 steps	 is	 reduced.	 This	 involves	 reduced	 waste	 generation	 from	
organic	solvents	and	chromatographic	stationary	phases.	
• It	is	well	suited	to	the	fast	and	experimentally	simple	preparation	of	molecular	
libraries.	
	
MCRs	have	been	known	since	the	19th	century	(Strecker	reaction21,	Biginelli	reaction22,	
Hantzsch	dihydropyridine	synthesis23)	(Scheme	1.1).	Isocyanide-based	multicomponent	
reactions	 are	 widely	 employed	 in	 organic	 synthesis,	 mostly	 in	 the	 generation	 of	
peptides	or	peptide	mimics.	Due	to	the	high	reactivity	of	the	isocyanide	group,	whose	
carbon	 atom	 can	 act	 as	 both	 a	 nucleophile	 of	 an	 electrophile,	 they	 show	 a	 very	
versatile	nature.	The	 first	MCRs	using	 isocyanide	are	 the	Passerini	 (3CR)	and	 the	Ugi	
(4CR)	 reactions,	 described	 for	 the	 first	 time	 in	 1921	 and	1959,	 respectively	 (Scheme	
1.2).24																																																									
20	 For	 reviews	 about	 multibond	 forming	 reactions	 as	 a	 more	 eco-compatible	 chemistry,	 see:	 (a)	
Coquerel,	Y.;	Boddaert,	T.;	Presset,	M.;	Mailhol,	D.;	Rodriguez,	J.	in	Ideas	in	Chemistry	and	Molecular	
Sciences:	Advances	in	Synthetic	Chemistry;	Pignataro,	B.,	Ed.;	Wiley-VCH:	Weinheim,	Germany,	2010,	
Vol.	1,	Chapter	9,	187;	(b)	Bonne,	D.;	Constantieux,	T.;	Coquerel,	Y.;	Rodriguez,	J.	Chem.	Eur.	J.	2013,	
19,	2218.	(c)	For	a	Special	Issue	on	this	topic,	see:	Menéndez,	J.	C.	(ed.),	Curr.	Org.	Chem.	2013,	17,	
1919.	(d)	Cioc,	R.	C.;	Ruitjer,	E.;	Orru,	R.	V.	A.	Green	Chem.	2014,	16,	2958.	
21	 Strecker,	A.	Liebigs	Ann.	1850,	75,	27.		
22	 Biginelli,	P.	Chem.	Ber.	1891,	24,	1317.		
23	 Hantzsch,	A.	Ber.	Dtsch.	Chem.	Ges.	1890,	23,	1474.	
24	 For	reviews	of	 isonitrile-based	MCRs,	see:	(a)	Dömling,	A.;	Ugi,	 I.	Angew.	Chem.	Int.	Ed.	Engl.	2000,	
39,	3168;	(b)	Ugi,	A.	Pure	Appl.	Chem.	2001,	73,	187.	(c)	Ugi,	A.	Molecules	2003,	8,	53;	Dömling,	A.	
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Scheme	1.1	
	
	
Scheme	1.2	
	
The	 widespread	 application	 of	 multicomponent	 reactions	 in	 medicinal	 chemistry	 is	
relatively	recent.	Their	importance	and	relevance	in	drug	discovery	programs	and	the	
lead	 identification	process	 can	be	 correlated	 to	 their	 ability	 to	 generate	diverse	 and	
complex	 molecular	 libraries, 25 , 26 , 27 	both	 in	 combinatorial	 and	 diversity-oriented	
contexts.	 MCRs	 leading	 to	 the	 formation	 of	 heterocyclic	 products	 are	 increasingly	
																																																																																																																																																																		
Chem.	Rev.,	2006,	106,	17.	(d)	Sadjadi,	S.;	Heravi,	M.	M.;	Nazari,	N.	RSC	Adv.	2016,	6,	53203.	(e)	Song,	
B.;	Xu,	B.	Chem.	Soc.	Rev.	2017,	46,	1103.	
25	 (a)	 Orru,	 R.	 V.	 A.;	 de	 Greef,	 M.	 Synthesis	 2003,	 1471;	 (b)	 Tejedor,	 D.;	 González-Cruz,	 D.;	 Santos-
Exposito,	 A.;	Marrero-Tellado,	 J.	 J.;	 de	 Armas,	 P.;	 García-Tellado,	 F.	Chem.	 Eur.	 J.	 2005,	 11,	 3502;	
Some	 reviews	 on	 multicomponent	 reactions	 for	 the	 generation	 of	 molecular	 complexity	 and	
diversity:	 (a)	 Biggs-Houck,	 J.	 E.;	 Younai,	 A.;	 Shaw,	 J.	 T.	 Curr.	 Opin.	 Chem.	 Biol.	 2010,	 14,	 371;	 (b)	
Eckert,	H.	Molecules	2012,	17,	1074;	(c)	van	der	Heijden,	G.;	Ruijter,	E.;	Orru,	R.	V.	A.	Synlett	2013,	
24,	 666;	 (d)	 Brauch,	 S.;	 van	 Berkel,	 S.	 S.;	 Westermann,	 B.	 Chem.	 Soc.	 Rev.	 2013,	 42,	 4948.	 (e)	
Rodriguez,	 J.;	 Bonne,	 D.	 (Eds).	 Stereoselective	 Multiple	 Bond-Forming	 Transformations	 in	 Organic	
Synthesis.	John	Wiley	&	Sons,	2015.	(f)	Eckert,	H.	Molecules,	2017,	22,	349.		
26	 O’	Connor,	C.	J.;	Beckmann,	H.	S.	G.;	Spring,	D.	R.	Chem.	Soc.	Rev.	2012,	41,	4444.	
27	 Dömling,	A.;	Wang,	W.;	Wang,	K.	Chem.	Rev.	2012,	112,	3083.	
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common,	 mostly	 because	 more	 than	 60%	 of	 drugs	 and	 agrochemicals	 are	
heterocycles.28,29		
The	 IUPAC	 Compendium	 of	 Chemical	 Technology	 (“gold	 book”)	 defines	
mechanochemical	 reactions	as	 those	 induced	by	 the	direct	absorption	of	mechanical	
energy,	which	may	come	from	shear,	friction	or	compression	associated	to	grinding	or	
milling	processes.	While	ball	milling	has	been	widely	employed	 in	 industry	 to	 reduce	
particle	size	during	the	manufacturing	of	paints,	drugs	and	some	other	products,30	the	
use	of	mechanical	energy	 in	organic	synthesis	has	been	historically	almost	negligible.	
Nevertheless,	 in	 recent	 times	 the	 synthetic	 community	 is	 slowly	becoming	acquitted	
with	this	technique.	31		
Mechanochemical	activation	 is	 relevant	 in	 the	context	of	green	chemistry	because	 it	
allows	solvent-free	conditions	and,	in	most	cases,	room	temperature	processes.	Thus,	
a	 reduction	 is	 achieved	 of	 the	 use	 of	 volatile	 organic	 solvents,	 which	 represent	 the	
main	 waste	 from	 synthesis,	 both	 at	 laboratory	 and	 industrial	 scales.	 Furthermore,	
under	solid	state	conditions	very	high	concentration	of	the	reactants	 is	achieved	and	
solvation	phenomena	do	not	exist,	often	leading	to	improved	reaction	rates.32		
																																																								
28	 For	 a	 monograph,	 see:	 Ruijter,	 E.;	 Orru,	 R.	 V.	 A.	 Synthesis	 of	 heterocycles	 via	 multicomponent	
reactions,	vols.	1	and	2,	Springer	Verlag,	2010	 (Topics	 in	Heterocyclic	Chemistry	series,	volumes	23	
and	25).	
29	 For	selected	reviews	of	the	synthesis	of	heterocycles	using	multicomponent	reactions	as	key	steps,	
see:	(a)	Sapi,	J.;	Laronze,	J.-Y.	Arkivoc	2004	 (vii)	208;	(b)	D’Souza,	D.	M.;	Mueller,	T.	J.	J.	Chem.	Soc.	
Rev.	2007,	36,	1095;	(c)	 Isambert,	N.;	Lavilla,	R.	Chem.	Eur.	J.	2008,	14,	8444;	(d)	Sunderhaus,	J.	D.;	
Martin,	S.-F.	Chem.	Eur.	J.	2009,	15,	1300;	(e)	Jiang,	B.;	Rajale,	T.;	Wever,	W.;	Tu,	S.-J.;	Li,	G.	Chem.	
Asian	 J.	2010,	5,	 2318;	 (f)	 Estévez,	 V.;	 Villacampa,	M.;	Menéndez,	 J.	 C.	Chem.	 Soc.	 Rev.	2010,	39,	
4402.	 (g)	Estévez,	V.;	Villacampa,	M.;	Menéndez,	 J.	C.	Chem.	Soc.	Rev.	2014,	43,	4633;	 (h)	Khan,	 I.;	
Ibrar,	A.;	Abbas,	N.;	 Saeed,	A.	Res.	Chem.	 Intermediat.	2016,	42,	 5147.	 (i)	Haji,	M.	Beilstein	 J.	Org.	
Chem.	2016,	12,	1269.	(j)	Mamaghani,	M.;	Hossein-Nia,	R.	J.	Heterocyclic	Chem.	2017,	54,	1700.	(k)	
Ibarra,	I.	A.;	Islas-Jacome,	A.;	Gonzalez-Zamora,	E.;	Org.	Biomol.	Chem.	2018,	16,	1402.	
30	 Kaupp,	G.	CrystEngComm,	2006,	8,	794.		
31	 (a)	Rodríguez,	B.;	Bruckmann,	A.;	Rantanen,	T.;	Bolm,	C.	Adv.	Synth.	Catal.	2007,	349,	2213.	(b)	Stolle,	
A.;	 Szuppa,	 T.S.;	 Leonhardt,	 E.	 S.;	 Ondruschka,	 B.	 Chem.	 Soc.	 Rev.	 2011,	 40,	 2317.	 (c)	 Stolle,	 A.;	
Ondruschka,	B.;	Krebs,	A.;	Bolm,	C.	Catalyzed	Organic	Reactions	in	Ball	Mills,	in	P.	G.	Andersson	(Ed.),	
Innovative	 Catalysis	 in	 Organic	 Synthesis:	 Oxidation,	 Hydrogenation,	 and	 C–X	 Bond	 Forming	
Reactions,	Wiley-VCH,	Weinheim,	2012.	(d)	James,	S.	L.C.;	Adams,	J.;	Bolm,	C.;	Braga,	D.;	Collier,	P.;	
Friščić,	T.;	Grepioni,	F.;	Harris,	K.	D.	M.;	Hyett,	G.;	Jones,	W.;	Krebs,	A.;	Mack,	J.;	Maini,	L.;	Orpen,	L.	A.	
G.;	Parkin,	I.	P.;	Shearouse,	W.	C.;	J.	W.	Steed,	J.	W.;	Waddell,	D.	C.	Chem.	Soc.	Rev.	2012,	41,	413.	(e)	
Bowmaker,	G.	A.	Chem.	Commun.,	2013,	49,	334.	(f)	Wang,	G.-W.	Chem.	Soc.	Rev.	2013,	42,	7688.	(g)	
Claramunt,	 R.	 M.;	 López,	 C.;	 Sanz,	 D.;	 Elguero,	 J.	 Adv.	 Heterocycl.	 Chem.	 2014,	 112,	 117.	 (h)	
Hernández,	 J.	 G.;	 Vila-Ortiz,	 C.	 G.;	 Juaristi,	 E.	 in	 Comprehensive	Organic	 Synthesis,	 Vol.	 9,	 2nd	 ed.,	
(Eds.	 G.A.	 Molander,	 P.	 Knochel),	 Elsevier,	 Oxford,	 2014,	 p.	 287.	 (i)	 Hernández,	 J.	 G.;	 Friščić,	 T.	
Tetrahedron	Lett.	2015,	56,	4253.	(j)	Do,	J.	L.;	Friščić,	T.	ACS	Cent.	Sci.	2017,	3,	13.	(k)	Achar,	T.	K.;	A.	
Bose,	A.;	Mal,	P.	Beilstein	J.	Org.	Chem.	2017,	13,	1907.	(l)	Tan,	D.;	Friščić,	T.	Eur.	J.	Org.	Chem.	2017,	
18.	 (m)	 D.	 Margetić	 and	 V.	 Štrukil	 (Eds.),	Mechanochemical	 organic	 synthesis.	 Elsevier,	 2016.	 (n)	
Hernández,	J.	C.	Beilstein	J.	Org.	Chem.,	2017,	13,	2372.		(o)	Andersen,	J.;	Mack,	J.	Green	Chem.	2018,	
20,	 1435.	 (p)	 Howard,	 J.	 L.;	 Cao,	 Q.;	 Browne,	 D.	 L.	 Chem.	 Sci.	 2018,	 9,	 3080.	 (q)	 Leonardi,	 M.;	
Villacampa,	M.;	Menéndez,	J.	C.	Chem.	Sci.	2018,	9,	2042.	
32	 Hernández,	J.	C.;	Bolm,	C.	J.	Org.	Chem.	2017,	82,	4007.	
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The	first	mechanochemical	reaction	known	in	the	literature	was	achieved	by	grinding	
reactants	 together	 with	 a	 mortar	 and	 pestle	 (Figure	 1.7a). 33 	This	 approach	 is	
sometimes	 described	 as	 “grindstone	 chemistry”	 and	 can	 easily	 performed	 in	 any	
laboratory	 as	 it	 does	 not	 require	 specialized	 equipment.	 However,	 it	 is	 not	 easily	
reproducible	 because	 it	 depends	 on	 the	 physical	 strength	 of	 the	 operator.	 More	
recently,	 automated	 ball	 mills	 have	 been	 introduced	 for	 laboratory-scale	 synthesis.	
With	 these	 instruments	 it	 is	 possible	 to	 control	 the	 energy	 input	 by	 controlling	 the	
milling	frequency,	safety	is	improved	because	the	reactions	are	run	in	a	closed	vessel	
(if	 compared	 with	 the	 mortar).	 These	 instruments	 can	 be	 classified	 into	 two	 main	
types:	 planetary	 ball	 mills,	 where	 the	 balls	 and	 reactants	 experience	 two	 types	 of	
movements,	 namely	 friction	 with	 the	 inside	 walls	 of	 the	 jar	 as	 a	 result	 of	 the	
centrifugal	 force	 and	 impact	 when	 they	 lift	 off	 and	 collide	 with	 the	 opposite	 wall	
(Figure	1.7b)	and	mixer	(shaker)	mills,	where	the	jar	is	horizontal	and	swings	back	and	
forth	to	let	the	balls	and	reactants	collide	with	the	opposite	wall	of	the	jar	(Figure	1.7c)	
and	 is	 usually	 described	 as	 high-speed	 vibration	 milling	 (HSVM)	 or	 high-speed	 ball	
milling	(HSBM).	
	
	
Figure	1.7	
	
Besides	 the	 vibration	 frequency	 and	 the	 type	 of	 ball-mill,	 there	 are	 other	 important	
parameters	 to	 consider	 when	 planning	 a	 mechanochemical	 reaction,	 namely	 the	
material	of	the	milling	balls	and	jars,	and	the	number	of	balls	used.	The	material	that	
makes	up	the	jar	or	the	balls	sometimes	promotes	the	reaction	because	of	the	release	
of	catalytic	particles	of	metal	during	milling;	one	example	is	the	copper	ball-promoted	
click	reaction	for	the	synthesis	of	triazoles,	Scheme	3.34	Coadjuvants	are	often	useful	to	
increase	reactivity.	For	liquid	starting	materials,	an	inert	solid	such	as	NaCl,	Al2O3	and	
SiO2,	 that	 allows	 the	 transfer	of	mechanical	 energy,	 is	 normally	 included	 to	 increase																																																									
33	 For	the	historical	development	of	mechanochemistry,	see:	Takacs,	L.	Chem.	Soc.	Rev.	2013,	42,	7649.	
34	 Cook,	T.	L.;	Walker,	J.	A.;	Mack,	J.	Green	Chem.,	2013,	15,	617.	
(a) (b)
(c)
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friction.	 Furthermore,	 SiO2,	 retains	 water	 and	 generates	 mildly	 acidic	 conditions,	
thereby	 displacing	 condensation	 equilibrium	 in	 some	 cases,	 as	 in	 the	 case	 of	 the	
Strecker	 reaction. 35 	Small	 amounts	 of	 liquids	 are	 also	 sometimes	 added	 to	 solid	
starting	compounds	to	accelerate	the	reaction	under	solvent-free	conditions,	a	process	
known	as	solvent-drop	grinding	(SDG)	or	liquid-assisted	grinding	(LAG);	one	example	is	
the	acceleration	of	 the	Ugi	 reaction	by	addition	of	a	 few	drops	of	methanol.36	When	
reaction	 acceleration	 is	 promoted	by	 the	use	of	 a	 ionic	 liquid,	 it	 is	 defined	 as	 “ionic	
liquid-assisted	grinding”	(ILAG);	polymer-assisted	grinding	(POLAG)	is	another	recently	
introduced	 variation	 of	 mechanochemistry	 when	 a	 polymer	 promotes	 the	 reaction	
(Scheme	1.3).		
	
	
Scheme	1.3		
	
Reactions	 performed	 under	 mechanochemical	 conditions	 may	 show	 improved	
selectivities.	One	example	 is	the	mechanochemical	Povarov	reaction,	which	furnishes	
cis-2,4-diphenyl-1,2,3,4-tetrahydroquinoline	 derivatives	 with	 complete	
diastereoselectivity	 (Scheme	1.4).37	This	 full	cis-selectivity	 is	uncommon	when	acyclic	
olefins	are	employed	in	batch	experiments.	
	
																																																								
35	 Dabral,	S.;	Turberg,	M.;	Wanninger,	A.;	Bolm,	C.;	Hernández,	J.	G.	Molecules,	2017,	22,	146.	
36	 Polindara-García,	L.	A.;	Juaristi,	E.	Eur.	J.	Org.	Chem.,	2016,	1095.	
37	 (a)	Tan,	Y.-J.;	Zhang,	Z.;	Wang,	F.-J.;	Wu,	H.-H.;	Li,	Q.-H.	RSC	Adv.,	2014,	4,	35635.	(b)	Tan,	Y.-J.;	Wang,	
F.-J.;	Asirib,	A.	A.;	Marwanib,	H.	D.;	Zhang,	Z.		J.	Chin.	Chem.	Soc.,	2017,	64.	
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Scheme	1.4	
	
An	example	of	total	synthesis	with	a	mechanochemical	key	step	has	been	published	in	
2014	by	our	group	and	it	is	involved	a	mechanochemical	Hantzsch	pyrrole	synthesis	as	
the	key	step	for	the	preparation	of	the	antihyperlipidemic	agent	atorvastatin	(Scheme	
1.5).	 This	 compound	 can	 be	 regarded	 the	 most	 important	 pyrrole-based	 synthetic	
molecule,	having	been	the	top-selling	drug	for	more	than	a	decade.38		
	
																																																								
38	 Estévez,	V.;	Villacampa,	M.;	Menéndez,	J.	C.	Org.	Chem.	Front.,	2014,	1,	458.	
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Scheme	1.5	
	
In	 conclusion,	 we	 can	 assert	 that	 the	 synergism	 of	 MCRs	 and	 mechanochemistry	
represents	an	efficient	 tool	 for	 the	generation	of	 several	bonds	 in	a	 single	operation	
under	sustainable	conditions.	
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1.3.	The	Hantzsch	pyrrole	synthesis	and	its	evolution	
Pyrrole	was	first	isolated	in	1857	from	the	product	of	bone	pyrolysis	and	is	one	of	the	
most	 important	 and	widespread	 simple	 heterocycles	 in	 natural	 products	 and	 drugs,	
being	considered	a	privileged	structure	in	medicinal	chemistry.39	Pyrrole	is	the	central	
core	 of	 some	 key	 natural	 products	 including	 heme	 and	 chlorophyll,	 two	 pigments	
essential	 for	 life. 40 	The	 red	 pigment	 prodigiosin,	 from	 bacteria	 belonging	 to	 the	
Serratia	genus,	has	antibiotic	properties	and	acts	as	a	 transporter	of	 chloride	anions	
and	 protons	 across	 phospholipid	 membranes	 thanks	 to	 the	 association	 of	 its	
protonated	 form	 with	 chloride	 anion,	 generating	 a	 lipophilic	 species. 41 	Several	
bioactive	 secondary	 metabolites	 bear	 a	 pyrrole	 moiety,	 including	
pentabromopseudodiline	 and	 pioluteorine	 from	 bacterial	 origin,	 and	 some	 marine	
natural	 products	 that	 include	 the	 lamellarines,	 halitulin,	 nakamuric	 acid	 and	
marinopyrrole,	 the	 latter	 of	 which	 are	 important	 due	 to	 their	 activity	 against	
methicillin-resistant	 Staphillococcus	 strains.	42	A	 variety	 of	 marine	 organisms	 contain	
3,4-diarylpyrrole	 compounds	 and	 among	 them	 storniamide	 and	 its	 O-methylated	
derivatives	 have	 shown	 activity	 as	 inhibitors	 of	 the	 multidrug	 resistance	 (MDR)	
phenomenon, 43 	one	 of	 the	 main	 obstacles	 to	 anticancer	 chemotherapy.	 Many	
unnatural	 pyrrole	 derivatives	 showed	 also	 antimalarial 44 	and	 antimycobacterial 45	
activities	 and	 as	 inhibitors	 of	 HIV	 virus	 fusion46	and	 hepatoprotectors47.	 Marketed	
pyrrole-based	 drugs	 include	 the	 anti-inflammatories	 tolmetin	 and	 zomepirac,	 the	
antihypercholesterolemic	atorvastatin48	and	the	anticancer	sunitinib	(Figure	1.8).	
	
																																																								
39		 For	reviews,	see:	(a)	Bhardwaj,	V.;	Gumber,	D.;	Abbot,	V.;	Dhiman,	S.;	Sharma	P.;	RSC	Adv.	2015,	5,	
15233;	(b)	Gholap,	S.	S.;	Eur.	J.	Med.	Chem,	2016,	110,	13.	
40	 	Domagala,	T.;	Jarosz,	M.;	Lapkowski;	Eur.	J.	Med.	Chem.	2015,	100,	176.		
41	 Seganish.	J.	L.;	Davis,	J.	T.;	Chem.	Commun.,	2005,	5781.		
42	 O’Malley,	D.	P.;	Li,	K.;	Maue,	M.;	Zografos,	A.	L.;	Baran,	P.	S.;	J.	Am.	Chem.	Soc.	2007,	129,	4762.	
43	 Boger,	D.	L.;	Boyce,	C.	W.;	Labroli,	M.	A.;	Sehon,	C.	A.;	Jin,	Q.	J.	Org.	Chem.	1999,	121,	54.	
44	 Kunfermann,	 A.;	Witschel,	 M.;	 Illarionov,	 B.;	 Martin,	 R.;	 Rottmann,	M.;	 Höffken,	 H.	W.;	 Seet,	 M.;	
Eisenreich,	W.;	Knölker,	H.-J.;	Fischer,	M.;	Bacher,	A.;	Groll,	M.;	Diederich,	F.;	Angew.	Chem.	Int.	Ed.	
2014,	53,	1.	
45	 Biava,	M.;	Porretta,	G.	C.;	Poce,	G.;	Battilocchio,	C.;	Alfonso,	S.;	de	Logu,	A.;	Manetti,	F.;	Botta,	M.;	
ChemMedChem,	2011,	4,	593.	
46	 Teixeira,	C.;	Barbault,	 F.;	Rebehmed,	 J.;	 Liu,	K.;	Xie,	 L.;	 Lu,	H.;	 Jiang,	 S.;	 Fan,	B.;	Maurel,	 F.;	Bioorg.	
Med.	Chem.,	2008,	16,	3039.	
47	 Chin,	Y.	W.;	Lim,	S.	W.;	Kim,	S.-H.;	Shin,	D.-Y.;	Suh,	Y.-G.;	Kim,	Y.-B.;	Kim,	Y.	C.;	Kim,	J.	Bioorg.	Med.	
Chem.	Lett.	2003,	13,	79-81.	
48	 For	a	review	of	atorvastatin,	see:	Roth,	B.	D.	Progress	Med.	Chem.	2002,	40,	1-22.	
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Figure	1.8	
	
Pyrrole	has	also	relevance	in	materials	science	and	technology.49	For	instance,	BODIPYs	
are	 an	 organoboron-derived	 family	 of	 compounds	 whose	 most	 important	
characteristic	 is	 a	 strong	 absorption	 in	 the	 UV	 and	 the	 emission	 of	 a	 very	 intense	
fluorescence.	 These	 derivatives	 of	 the	 4,4-difluoro-4-boradipyrrin	 system	 have	 been	
employed	as	fluorescent	dyes,	among	many	other	applications.50	
Pyrrole	syntheses	are	attained	by	different	methodologies	such	as	the	classical	Knorr	
and	Paal-Knorr	reactions	(Scheme	1.6),	but	they	are	still	far	from	being	general	and	in	
many	 cases	 they	 stumble	 on	 regioselectivity	 problems	 and	 are	 not	 suitable	 for	 the	
preparation	of	polisubstituted	derivatives.																																																									
49	 For	reviews	of	pyrrole	derivatives	in	materials	science,	see:	(a)	Higgins,	S.	J.	Chem.	Soc.	Rev.	1997,	26,	
247-273.	 (b)	Maeda,	H.	Eur.	 J.	Org.	Chem.	2007,	 5313-5325.	 (c)	 Loudet,	A.;	Burgess,	K.	Chem.	Rev.	
2007,	107,	4981-4932.	(d)	Berlin,	A.;	Vercelli,	B.;	Zotti,	G.	Polym.	Rev.	2008,	48,	493-530.	
50	 For	reviews,	see:	(a)	Loudet,	A.;	Burgess,	K.	Chem.	Rev.	2007,	107,	4891.	(b)	Kamkaew,	A.;	Lim,	S.	H.;	
Lee,	H.	B.;	Kiew,	L.	V.;	Lip	Yong	Chung,	L.	Y.;	Burgess,	K.	Chem.	Soc.	Rev.	2013,	42,	77.	(c)	Kulyk,	B.;	
Taboukhat,	S.;	Akdas-Kilig,	H.;	Fillaut,	J.-L.;	Karpierz,	M.;	Sahraoui,	B.	Dyes	pigments	2017,	137,	507.	
(d)	Yuriy	S.	Marfin,	Y.	S.;	Solomonov,	A.	V.;	Timin,	A.	S.;	Rumyantsev,	E.	V.	Curr.	Med.	Chem.	2017,	24,	
2745.	(e)	Solomonov,	A.	V.;	Marfina,	Y.	S.;	Rumyantsev,	E.	V.	Dyes	pigments	2019,	162,	517.	
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Scheme	1.6	
	
The	Hantzsch	pyrrole	synthesis	was	first	described	in	1890	by	Arthur	Rudolf	Hantzsch	
in	 a	 brief	 note	 reporting	 the	 reaction	 between	 ethyl	 acetoacetate,	 ammonia	 and	 1-
chloropropan-2-one	to	yield	the	corresponding	pyrrole	derivative	(Scheme	1.7).51	
	
	
Scheme	1.7	
	
In	1970,	Roomi	and	MacDonald	published	a	paper	where	they	reported	to	have	only	
been	able	to	find	eight	additional	examples	of	pyrroles	made	by	the	Hantzsch	method	
in	the	1890-1970	literature.	Additionally,	these	reactions	proceeded	with	yields	below	
45%	and	enabled	few	structural	variations,	which	were	limited	to	alkyl	substituents	at	
C-4	and	C-5.	The	study	of	Roomi	and	MacDonald	somehow	extended	the	scope	of	the	
Hantzsch	reaction	and	they	were	able	to	prepare	compounds	with	substituents	at	C-2	
different	 from	methyl,	 and	at	C-3	with	esters	other	 than	ethyl.	Unfortunately,	 yields	
were	still	below	50%	and	the	presence	of	substituents	at	the	N-1	position	was	still	not	
possible.52	
More	 recent	versions	of	 the	Hantzsch	pyrrole	 synthesis	are	 still	hampered	by	 severe	
limitations	 in	scope.	Again,	 the	yields	generated	are	still	moderate	and	almost	never	
surpass	60%.	A	graphic	summary	of	these	precedents	is	shown	in	Scheme	1.8.	
																																																									
51	 Hantzsch,	A.	Ber.	Dtsch.	Chem.	Ges.	1890,	23,	1474.	
52	 Roomi,	M.	W.;	MacDonald,	S.	F.	Can.	J.	Chem.	1970,	48,	1689.	
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Scheme	1.8	
	
Compounds	 arising	 from	 competing	 side	 reactions	 have	 not	 been	 isolated	 often,	
although	in	some	reactions	involving	the	use	of	α-chlorocarbonyl	as	one	of	the	starting	
materials,	the	Hantzsch	reaction	competes	with	a	Feist-Benary	furan	synthesis,	with	no	
incorporation	of	the	amine	component	into	the	product	(Scheme	1.9).	
	
	
Scheme	1.9	
	
Because	of	the	 limitations	of	the	conventional	Hantzsch	pyrrole	synthesis	 in	terms	of	
low	 yields,	 harsh	 reaction	 conditions	 and	 lack	 of	 generality,	 the	 study	 and	
improvement	 of	 the	Hantzsch	 pyrrole	method	 is	 still	 challenging.	 A	 number	 of	 non-
conventional	 variations	 of	 the	 reaction	have	been	developed	 in	 recent	 years	 (Figure	
1.9)	and	will	be	briefly	summarized	below.53		
																																																								
53		 For	a	review,	see:	Leonardi,	M.;	Estévez,	V.;	Villacampa,	M.;	Menéndez,	J.	C.	Synthesis,	2019,	51,	DOI:	
10.1055/s-0037-1610320.	
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Figure	1.9	
	
Zhao	 and	 co-workers	 in	 2015 54 	reported	 that	 the	 irradiation	 of	
α-bromoacetophenones,	 ethyl	 acetoacetate	 and	 primary	 amines	 at	 500	 W	 in	 a	
pressurized	 microwave	 vial	 led	 to	 the	 generation	 of	 5-arylpyrroles	 in	 good	 yields,	
without	the	need	for	any	solvent	or	catalyst	(Scheme	1.10a).	The	main	features	of	the	
reaction	are	the	tolerance	of	both	electron-withdrawing	and	electron-releasing	groups	
in	the	α-bromoacetophenone	component	and	the	use	of	alkyl,	aryl	and	arylmethyl	or	
heteroarylmethyl	amines,	although	its	scope	was	restricted	regarding	the	β-dicarbonyl	
component.		
In	1998	a	solid-phase	version	of	the	Hantzsch	pyrrole	synthesis	was	proposed	by	Jung,	
using	an	acetoacetylated	Rink	resin	(Scheme	1.10b).	The	reaction	of	this	modified	resin	
with	primary	amines	afforded	the	corresponding	β-enaminoamides.	The	following	step	
was	 the	 reaction	with	α-halocarbonyl	 derivative	 to	 give	 desired	 pyrroles.	 In	 the	 last	
step	 the	 final	 product	 so	 obtained	 was	 liberated	 from	 the	 solid	 support	 via	 acid	
hydrolysis.	 The	 method	 only	 allows	 the	 preparation	 of	 pyrrole-3-carboxamide	
derivatives,	which	were	isolated	in	excellent	purities	but	unfortunately	no	yields	were	
reported.55	
	
	
																																																								
54		 Kan,	W.;	Jing,	T.;	Zhang,	X.-H.;	Zheng,	Y.-J.;	Chen,	L.;	Zhao,	B.	Heterocycles	2015,	91,	2367.	
55	 Trautwein,	A.	W.;	Süssmuth,	R.	D.;	Jung,	G.	Bioorg.	Med.	Chem.	Lett.	1998,	8,	2381-2384	
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Scheme	1.10	
	
Shahvelayati	et	al.	reported	an	efficient	Hantzsch	pyrrole	synthesis	under	solvent-free	
conditions	promoted	by	irradiation	using	an	ultrasonic	cleaner	(frequency,	60	kHz	and	
intensity,	 285	 W),	 and	 catalysed	 by	 ZnO	 nanoparticles	 prepared	 in	 an	 ionic	 liquid	
(Scheme	11a).	The	ZnO-NPs	employed	in	this	version	bring	both	Lewis	acid	sites	(Zn2+)	
and	Lewis	basic	sites	(O2-)	and	they	can	be	easily	recycled	and	reused	upon	three	time	
maintaining	the	same	efficiency.56	
Cosford	 showed	 that	 a	 one-pot	 synthesis	 of	 pyrrole-3-carboxylic	 acid	 derivatives	 is	
possible	by	reaction	of	tert-butyl	acetoacetate,	primary	amines	and	2-bromoketones	at	
200	°C	during	8	min	 in	continuous	 flow	(Scheme	1.11b).	The	 in	situ	hydrolysis	of	 the	
tert-butyl	 ester	 groups	 led	 to	 the	 generation	 of	 the	 corresponding	 carboxylic	 acid	
derivatives	 that	 by	 a	 subsequent	 coupling	 of	 with	 diverse	 amines	 can	 easily	 give	
pyrrole-3-carboxamide	compounds.57		
	
																																																								
56	 Shahvelayati,	A.	S.;	Sabbaghan,	M.;	Banihashem,	S.	Monatsh.	Chem.	2017,	148,	1123.	
57	 Herath,	A.;	Cosford,	N.	D.	P.	Org.	Lett.	2010,	12,	5182.	
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Scheme	1.11	
	
Finally,	our	group	has	developed	a	mechanochemical	multicomponent	reaction	based	
on	the	Hantzsch	pyrrole	synthesis	that	constitutes	the	foundation	of	this	thesis.	In	the	
context	of	our	interest	in	the	development	of	new	synthetic	methodology	based	on	the	
use	of	Ce(IV)	ammonium	nitrate	 (CAN)	as	a	 Lewis	acid	catalyst,58	we	 investigated	 the	
Hantzsch	 reaction	 in	 ethanol	 between	β-dicarbonyl	 compounds,	 primary	 amines	 and	
α-iodoketones	in	the	presence	of	CAN	and	silver	nitrate,	which	was	necessary	in	order	
to	prevent	reductive	dehalogenation	of	the	starting	iodoketones	by	the	HI	liberated	in	
the	alkylation	step.	Later,	we	discovered	that	the	reaction	could	be	also	performed	in	a	
solvent-free	fashion,	under	high-speed	vibration	milling	conditions	 (HSVM)	 in	a	mixer	
mill	working	at	20	Hz	with	the	use	of	a	single	zirconium	oxide	ball	20	mm	in	diameter.	
Furthermore,	the	mechanochemical	version	of	the	Hantzsch	pyrrole	synthesis	could	be	
telescoped	 with	 the	 synthesis	 of	 the	 starting	α-iodoketone	 from	 the	 corresponding	
ketone	 and	N-iodosuccinimide	 (NIS).	 This	 solvent-free	method	 afforded	 considerably	
higher	 yields	 of	 pyrroles	 than	 previous	 versions	 of	 the	Hantzsch	 reaction,	 in	 spite	 of	
comprising	 an	 additional	 step,	 and	 was	 far	 broader	 in	 scope	 (Scheme	 1.12).	59 	By	
starting	 from	 cyclic	 ketones,	 the	 reaction	 was	 extended	 to	 the	 synthesis	 of	 fused	
pyrrole	derivative.	60	
	
																																																								
58		 For	a	review	of	CAN	as	a	catalyst	in	organic	synthesis,	see:	Sridharan,	V.;	Menéndez,	J.	C.	Chem.	Rev.	
2010,	110,	3805.	
59	 	Estévez,	V.;	Villacampa,	M.;	Menéndez,	J.	C.	Chem.	Commun.	2013,	49,	591.	
60	 	Estévez,	V.;	Sridharan,	V.;	Sabaté,	S.;	Villacampa,	M.;	Menéndez,	 J.	C.	Asian	J.	Org.	Chem.	2016,	5,	
652.	
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Scheme	1.12	
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2.	Objectives	
This	 thesis	 is	 based	 on	 the	 use	 of	 pyrrole,	 a	well-known	 privileged	 structure,	 as	 the	
central	 core	 on	which	 to	 build	 a	 variety	 of	 DOS	 libraries	 using	 the	build-couple-pair	
approach.	 In	 this	general	context,	 the	goals	of	 the	 first	part	of	 the	 thesis	 involve	 the	
use	 of	 a	 mechanochemical	 multicomponent	 reaction	 as	 the	 couple	 phase	 and	 a	
number	 of	 cyclization	 processes	 as	 the	 pair	 phase	 to	 generate	 fused	 heterocyclic	
frameworks	 bearing	 a	 bridgehead	 nitrogen	 atom.	 The	 second	 part	 of	 the	 thesis	 is	
focused	 on	 the	 application	 of	 the	 same	 principles	 to	 the	 preparation	 of	 libraries	 of	
medium-sized	rings	and	macrocycles.		
	
	
	
More	specifically,	the	objectives	that	have	been	pursued	are:	
	
1.	 Adaptation	 of	 a	 known,	 in	 house-developed	 mechanochemical	 multicomponent	
reaction	 to	 the	 preparation	 of	 pyrrole	 derivatives	 bearing	 functional	 groups	 that	
allow	 suitable	 complexity-generating	 reactions	 at	 the	 pair	 stage	 at	 their	 N-1,	 C-2	
and	 C-5	 positions.	 The	 mechanochemical	 pyrrole	 synthesis	 also	 needed	 to	 be	
adapted	to	the	preparation	of	symmetrical	molecules	containing	two	pyrrole	units	
at	the	end	of	a	spacer.	
	
2.		Synthesis	of	fused	pyrrole	derivatives	based	on	transition	metal-catalyzed	reactions,	
including	cross-coupling	and	metathesis.	In	particular,	the	following	transformations	
were	considered	of	interest:	
a) Synthesis	of	pyrrolo[1,2-c]quinazolines	by	combination	of	C-arylation	and	N-
arylation	processes.	
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b) Synthesis	 of	 benzo[c]pyrrolo[1,2-a]azepine	 and	 frameworks	 by	
intramolecular	Heck	reactions.	
	
	
	
c) Synthesis	of	pyrrolo[1,2-a]azepine	and	pyrrolo[1,2-a]azocine	frameworks	by	
ring-closing	metathesis.	
	
	
	
3.	 Synthesis	 of	 pyrrolo[2,1-a]isoindole	 and	 pyrrolo[2,1-a]isoquinoline	 frameworks	 by	
intramolecular	Diels-Alder	reactions.	
	
	
	
4.	 Investigation	 of	 ring-formation	 processes	 on	 pyrrole-derived	 substrates	 via	 the	
generation	of	oxonium	intermediates.	Two	possibilities	were	studied:	
a) Cyclization	onto	a	C-5	aryl	substituent,	using	a	transformation	related	to	the	
Pommeranz-Fritsch	isoquinoline	synthesis.	
	
	
	
b) Cyclization	 of	 an	 oxonium	 species	 from	 an	 acetal	 under	 Noyori-type	
conditions	onto	a	C-2	active	methylene	group	adjacent	to	an	ester	via	 the	
formation	of	a	ketene	acetal	intermediate.	
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5.	 Synthesis	of	macrocycles	based	on	ring-closing	metathesis	reactions,	using	as	
starting	materials	symmetrical	bis-pyrrole	derivatives.	
	
	
	
6.	 Synthesis	 of	 diaza	 medium-sized	 rings	 by	 ring-closing	 metathesis.	 The	 starting	
pyrroles	 would	 be	 constructed	 by	 the	 Hantzsch	 method	 from	 β,δ-
diallylaminoenones,	 which	 would	 in	 turn	 be	 available	 via	 an	 enaminone	
formation/double	bond	isomerization/aza	Michael	domino	sequence.	
	
	
	
7.		Preparation	of	macrocycles	based	on	a	double	Hantzsch	pyrrole	synthesis,	with	one	
of	these	reactions	serving	as	the	macrocyclization	event.	
	
	
	
8.		Study	 of	 the	 libraries	 synthesized	 by	 the	 above	 methods	 using	 high-throughput	
screening	 methodologies.	 These	 studies	 were	 performed	 thanks	 to	 our	
collaboration	with	the	Lilly	Open	Innovation	in	Drug	Discovery	(OIDD)	program.	
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9.		Finally,	as	part	of	the	requirements	for	the	International	Ph	D	Label,	I	carried	out	a	
three-month	 stay	 at	 the	 group	 of	 Professor	 Steven	 Ley	 at	 the	 Department	 of	
Chemistry,	 Cambridge	 University,	 working	 on	 the	 use	 of	 photochemical	
homologation	 reactions	 for	 the	 preparation	 of	 aliphatic	 aldehydes	 under	 flow	
chemistry	conditions.	
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3.	The	build	phase:	Synthesis	of	starting	pyrroles	
	
3.1.	Synthesis	of	compounds	with	a	single	pyrrole	ring	
The	ability	 to	synthesize	starting	pyrroles	bearing	suitable	 functionalities	 is	 crucial	 to	
the	 success	 of	 our	 DOS	 project.	 Hence,	 we	 needed	 to	 verify	 whether	 the	
mechanochemical	 multicomponent	 pyrrole	 synthesis	 developed	 by	 our	 group	 was	
compatible	with	 the	 functionalities	 planned	 to	 be	 present	 at	 their	 N-1,	 C-2	 and	 C-5	
positions	in	order	to	carry	out	complexity-generating	reactions	at	the	final	pair	stage,	
as	summarized	in	Figure	3.1.		
	
	
Figure	3.1	
	
The	 introduction	 of	 some	 of	 these	 groups	 could	 be	 in	 principle	 troublesome	 for	 a	
variety	of	reasons	such	as	the	steric	hindrance	due	to	the	o-iodophenyl	substituent	or	
the	potential	 low	stability	of	 the	furan	ring	or	 the	acetal	 function	under	the	reaction	
conditions.61	Fortunately,	 these	 concerns	 proved	 to	 be	 largely	 unfounded	 and	 the	
usual	 reaction	 conditions	 of	 our	 previously	 established	 method	 gave	 good	 results.	
Thus,	 the	 primary	 amine	 and	 β-dicarbonyl	 components	 were	 pre-mixed	 in	 the	
presence	of	Ce(IV)	ammonium	nitrate	or	 indium	trichloride	 (5%)	as	catalysts	 to	 form	
the	 corresponding	β-enaminone	or	β-enaminoester.	 This	mixture	was	added	 to	a	20	
mL	milling	jar	containing	the	suitable	arylcarbonylmethyl	iodides,	and	after	addition	of	
an	additional	amount	of	catalyst	(5%),	one	equivalent	of	silver	nitrate	and	one	zirconia	
ball,	the	mixture	was	shaken	in	an	horizontal	ball	mill	for	1	hour	at	20	Hz,	affording	the	
target	pyrroles	1a-1x,	usually	in	good	yields	(Scheme	3.1).	In	some	cases	(pyrroles	1y-
1ag),	 the	 iodides	could	prepared	 in	situ	by	a	mechanochemical	method	 involving	the	
reaction	of	 the	 corresponding	 ketones	with	N-iodosuccinimide	 in	 the	 presence	of	p-	
toluenesulfonic	acid,	while	 for	 the	other	examples	 (pyrroles	1a-1x)	 the	 iodide	had	to	
be	synthesized	in	a	separate	step	from	the	ketone,	iodine	and	copper	oxide.62																																																											
61	 As	an	example	of	such	transformations,	CAN	is	an	excellent	catalyst	for	the	hydrolysis	of	acetals	and	
ketals.	See:	Maulide,	N.;	Vanherck,	J.-C.;	Gautier,	A.;	Markó,	I.	E.	Acc.	Chem.	Res.,	2007,	40,	381.	
62	 Yin,	G.;	Gao,	M.;	She,	N.;	Hu,	S.;	Wu,	A.;	Pan,	Y.	Synthesis,	2007,	3113.		
N
O
R3
R2
I
R1
Oxonium precursorNR5
R2
OMe
OMe
O
R3
N
O
R3
R5
R1
CO2R
Diels-Alder diene
N
O
R3
R2
R1O
Cross-coupling
N
O
R3
R5
R2
Ketene acetal precursor
Diels-Alder dienophile
Heck substrate
RCM substrate
	
	
38	 	 	 	 	 		
	 	
Scheme	3.1	
N
O OEt
CH3I
N
O OEt
I
COOEt
N
O CH3
CH3I
N
O NH2
CH3I
N
O CH3
CH3I
N
O
O
CH3I
H3C CH3
CH3
N
O OEt
I
COOEt
N
O
O
CH3I
H3C CH3
N
O OEt
CH3
I
N
O CH3
CH3
N
O OEt
COOEt
N
O O
CH3
CH3
H3C
CH3
N
O O
CH3
H3C CH3
N
O OMe
CH3
N
O CH3
CH3
N
O OEt
COOEt
N
O OMe
CH3
N
O OEt
CH3
N
O OEt
CH3
O
O
O O
O
O
O
O
OO
1a, 78% 1b, 85%
N
H
O OEt
CH3I
N
H
O OMe
CH3I
N
H
O OEt
I
CH3
N
O
R3
R2
R5
R1
NH2
R1
O
R3R2
O
1c, 78% 1d, 72% 1e, 78%
1f, 80%
1g, 65% 1h, 75% 1i, 77% 1j, 72%
1k, 70% 1m, 72%1l, 64%
1a-1ag          
(76% average)
1n, 66% 1o, 65%
1p, 75% 1q, 72% 1r, 78% 1t, 80%1s, 72%
1u, 73% 1v, 52%
N
O OEt
CH3I N
O CH3
CH3
1w, 90% 1x, 89%
CO2Et
CO2Et
O
R5 CH3
NIS, TsOH (10 mol%), 
HSVM (20 Hz), 60 min
CAN 
(5 mol%)
O
R5
I
AgNO3, HSVM, 
20 Hz, 60 min
One-pot
HN
R2
O
R3
R1
I N
COOEt
COOEt
OMe
OMe
1y, 88%
N
COOMe
COOMe
OMe
OMe
1z, 92%
N
COOMe
COOMe
OMe
OMe
Br
1aa, 75%
Cl
Cl
N
COOMe
COOMe
OMe
OMe
1ab, 90%
N
COOMe
COOMe
OMe
OMe
MeO
1ac, 78%
N
CH2
O
OtBu
CH2
1ad, 35%
N
O
OEt
CH2
CH21ae, 45%
N
CH2
O
OEt
Cl
CH2
1af, 50%
N
O
OEt
H3C
CH2
CH2
1ag, 35%
	
	
	 	 	 	 	 39		
3.2.	 Synthesis	 of	 symmetrical	 molecules	 containing	 two	 or	 three	 pyrrole	 units	 via	
mechanochemical	pseudo-five(seven)-component	reactions		
The	mechanochemical	pyrrole	synthesis	also	needed	to	be	adapted	to	the	preparation	
of	 symmetrical	molecules	containing	 two	pyrrole	units	at	 the	end	of	a	 spacer,	which	
were	necessary	for	subsequent	work	on	macrocycle	synthesis.		
Furthermore,	we	considered	such	compounds	to	be	of	interest	in	themselves	as	part	of	
our	diversity-oriented	synthesis	libraries.	Indeed,	symmetrical	molecules	consisting	of	
two	 or	 more	 pharmacophoric	 units	 joined	 by	 a	 spacer	 are	 of	 relevance	 in	 drug	
discovery,	 and	 some	 examples	 of	 therapeutic	 targets	 in	 which	 such	 bivalent	
symmetrical	ligands	have	proved	useful	include	HIV	protease,63	the	PrPc	cellular	prion	
protein 64 	and	 the	 transient	 receptor	 potential	 melastatin	 8	 (TRPM8)	 channel	
receptor.65	The	 importance	 of	 these	molecules	 can	 be	 explained	 by	 the	 existence	 of	
many	 symmetrical	 drug	 targets,	 composed	 by	 two	 or	 more	 identical	 subunits.	 The	
development	of	new	efficient	synthetic	procedures	to	obtain	this	class	of	symmetrical	
architectures	is	still	challenging	and	relies,	normally,	on	multistep	sequences.66		
We	 realized	 that	 our	 pyrrole	 synthesis	 could	 be	 adapted	 to	 this	 task	 by	 applying	 a	
pseudo-five	 component	 process	 comprising	 two	 concomitant	Hantzsch-like	 reactions	
starting	 from	 two	 equivalents	 of	β-dicarbonyl	 compounds	 I,	 two	 equivalents	 of	 aryl	
ketones	II	and	one	equivalent	of	diamine	III.	The	route	to	bis-pyrrole	derivatives	2	by	
this	disconnection	is	summarized	in	Scheme	3.2.		
	
	
Scheme	3.2	
	
																																																								
63	 Lv,	Z.;	Chu,	Y.;	Wang,	Y.	HIV	AIDS	(Auckl).,	2015,	7,	95.	
64	 Staderini,	M.;	Legname,	G.;	Bolognesi,	M.	L.;	Menéndez,	J.	C.	Curr	.Top.	Med.	Chem.,	2013,	13,	2491.	
65	 De	Petrocellis,	L.;	Arroyo,	F.	J.;	Orlando,	P.;	Schiano	Moriello,	A.;	Vitale,	R.	M.;	Amodeo,	P.;	Sánchez,	
A.;	Roncero,	C.;	Bianchini,	G.;	Martín,	M.	A.;	López-Alvarado,	P.;	Menéndez,	J.	C.	J.	Med.	Chem.,	2016,	
59,	5661.	
66	 Bitzer	J.;	Streibel	M.;	Langer	H.-J.;	Grond	S.	Org.	Biomol.	Chem.,	2009,	7,	444.	
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As	 in	 the	case	of	compounds	1,	 containing	a	single	pyrrole	 ring,	our	protocol	started	
with	the	treatment	of	aromatic	ketones	 II	with	N-iodosuccinimide	 in	the	presence	of	
toluenesulfonic	 acid	 under	 high-speed	 vibration	 milling	 during	 1	 h	 to	 afford	 the	α-
iodoketones	 IV	which	were	not	 isolated	 in	order	 to	achieve	a	 telescoped	procedure.	
The	suitable	commercial	β-dicarbonyl	compound	I	and	α,ω-diamine	III	together	with	a	
catalytic	 amount	 of	 Ce(IV)	 ammonium	 nitrate,	 which	 had	 been	 pre-mixed	 for	 30-60	
min	(monitored	by	TLC)	to	ensure	the	complete	generation	of	the	intermediate	bis-β-
enaminones	V,	were	added	 to	 the	milling	 jar	 together	with	an	additional	5%	of	CAN	
and	one	equivalent	of	silver	nitrate,	and	the	mixture	was	again	submitted	to	milling	for	
an	 additional	 hour	 to	 generate	 the	 final	 products	 (Scheme	 3.3).	 The	 proof	 for	 the	
formation	 of	 species	 IV	 and	V	 relies	 on	 the	 facts	 that:	 (i)	 they	 could	 be	 isolated	 by	
suitably	 interrupting	our	 process	 and	 (ii)	 they	 reacted	under	 our	 usual	 conditions	 to	
give	compounds	2.		
	
	
Scheme	3.3	
	
In	the	case	of	compounds	2d,	2g,	2j,	2l,	2m	and	2o,	it	was	not	possible	the	iodination	
promoted	by	the	ball	mill	and	it	has	been	achieved	with	obtaining	the	α-iodoketones	
IV	by	treatment	of	II	with	I2	and	CuO	in	a	separate	step.		
The	 scope	 of	 this	 pseudo-5CR	 is	 summarized	 in	 Figure	 3.2.	 Beyond	 the	 simple	
polymethylene	spacers,	in	order	to	increase	the	molecular	diversity	and	we	studied	the	
inclusion	 of	 spacer	 chains	 containing	 nitrogen	 atoms	 (2a-2g,	 2i).	 The	 use	 of	 N1-(2-
aminoethyl)ethane-1,2-diamine	 as	 the	 starting	 material	 was	 also	 possible,	 without	
interference	 from	 the	 secondary	 amino	 group	 in	 spite	 of	 its	 nucleophilicity,	 to	 give	
compound	 2h.	 Furthermore,	 some	 tetramethyldisiloxane	 derivatives	 (2k-2o)	 were	
prepared	 in	 view	 of	 the	 current	 interest	 in	 silicon-containing	 compounds	 for	 drug	
discovery	applications,	which	has	led	to	the	“silicon	switch”	approach,	also	defined	as	
sila-subsitution.	 It	 represents	 a	 novel	 source	 of	 chemical	 diversity	 in	 drug	 design.	
Examples	 described	 in	 literature	 for	 the	 demonstration	 of	 the	 efficiency	 of	 the	
carbon/silicon	 switch	 strategy	 are	 sila-venlafaxine,	 disila-bexarotene	 and	 sila-
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haloperidol,	 as	 well	 as	 sila-analogues	 of	 venlafaxine,	 a	 serotonin/noradrenaline	
reuptake	 inhibitor,	 haloperidol,	 a	 dopamine	 antagonist,	 and	 bexarotene,	 a	 retinoid	
agonist.67	Regarding	the	pyrrole	rings,	they	were	generally	methyl-substituted	at	C-2,		
	
	
Figure	3.2																																																									
67	 For	reviews	of	the	“silicon-switch”	approach,	see:	(a)	Mills,	J.	S.;	Showell,	G.	A.	Expert	Opin.	Investig.	
Drugs,	2004,	13,	1149;	(b)	Gately,	S.;	West,	R.	Drug	Dev.	Res.,	2007,	68,	156;	(c)	Franz,	A.	K.;	Wilson,	
S.	O.;	J.	Med.	Chem.,	2013,	56,	388.	
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but	the	attachment	of	functional	groups	to	the	methyl	substituent	was	also	possible,	
as	shown	by	the	preparation	of	compounds	2g	and	2n.	Ketone	(compounds	2f	and	2j-
2l)	and	ester	functions	(compounds	2a-2e,	2g-2i	and	2m-2o)	could	be	present	at	C-3,	
although	an	attempt	 to	 introduce	an	amide	was	unsuccessful.	At	 the	C-5	position,	 a	
variety	 of	 aromatic	 and	 heteroaromatic	 rings	 were	 tolerated.	 Furthermore,	 the	
synthesis	of	compound	2o	from	1-indanone	proved	the	possibility	to	prepare	systems	
containing	two	fused	pyrrole	moieties	linked	by	a	spacer.	
We	also	investigated	the	generation	of	a	ter-pyrrole	derivative	by	employing	triamine	
VI	as	the	starting	material.	The	synthesis	of	compound	 3	was	achieved	via	a	pseudo-
seven-component	 reaction	 between	 VI,	 three	 equivalents	 of	 1,3-pentanedione	 and	
three	equivalents	of	acetophenone,	as	 shown	 in	Scheme	3.4.	While	 the	overall	 yield	
was	only	moderate,	it	has	to	be	taken	into	account	that	the	preparation	of	3	involves	
12	individual	steps,	with	a	linear	sequence	comprising	9,	and	thus	the	average	yield	is	
89%	per	 step.	 In	 view	of	 its	 high	 functionalization,	 compound	3	 can	 be	 viewed	 as	 a	
potential	precursor	to	heterocyclic	dendrimeric		structures.	
	
	
Scheme	3.4	
	
N
H3C
Ph
O
H3C
NH3C Ph
O
H3C
N N
CH3
Ph
O
CH3
3, 35%
H2N
NH2
N NH2
NIS, 
TsOH (10 mol%), 
HSVM (20 s-1), 
60 min
O CH3
O
CH3
CAN (5 mol%)
CAN (5 mol%), 
AgNO3, HSVM, 20 s-1, 60 min
3CH3
O
O
I
3
3 Ph
Ph
H
N
NH
N
H
N
CH3
H3C O
CH3H3C
O
CH3
CH3O
VI
I
II
IV
	
	
	 	 	 	 	 43		
Finally	we	studied	an	alternative	method	for	the	generation	of	dimeric	pyrrole-based	
architectures	with	partially	 saturated	spacers	 that	are	not	accessible	by	 the	previous	
route.	 To	 this	 end,	 we	 planned	 homodimerization	 reactions	 of	 2-allyl-	 and	 2-
homoallylpyrroles	 via	 cross-metathesis.	 The	 starting	 materials	 for	 this	 study	
(compounds	 4)	 were	 readily	 prepared	 under	 the	 conditions	 for	 single-ring	 pyrrole	
derivatives	described	in	the	previous	Section	and,	as	shown	in	Scheme	3.5,	they	were	
uneventfully	 transformed	 into	 the	 target	 compounds	 5.	 The	 dimerization	 step	 took	
place	in	the	presence	of	the	second-generation	Hoveyda-Grubbs	catalyst	and	copper(I)	
iodide	 (Scheme	 3.5).	 Interestingly,	 the	 reactions	 starting	 from	 1-allylpyrroles	 gave	 a	
single	 stereoisomer	 at	 the	 central	 double	 bond,	 which	 was	 assumed	 to	 be	 E	
(compounds	 5a,	 5b	 and	 5d),	 while	 compound	 5c,	 obtained	 from	 a	 1-homoallyl	
derivative,	was	isolated	as	a	1:1	E/Z	mixture	that	could	not	be	separated.	
	
	
Scheme	3.5	
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3.3.	Experimental	section	
	
3.3.1.	General	procedure	for	the	synthesis	of	pyrroles	1a-1v,	1y-1ag	and	4a-d	
	
	
	
Method	A:	The	suitable	ketone	(1	eq.),	N-iodosuccinimide	(NIS,	1	eq.)	and	p-toluenesulphonic	
acid	(PTSA,	10	mol%)	were	added	to	a	ball	mill	vessel,	along	with	a	zirconium	oxide	ball.	The	
vessel	was	fitted	to	one	of	the	horizontal	vibratory	arms	of	the	ball	mill,	while	the	other	arm	
was	occupied	with	an	empty	vessel.	The	ball	mill	was	set	to	vibrate	at	a	frequency	of	20	s-1	for	
60	 min	 at	 room	 temperature	 to	 generate	 the	 iodinated	 product.	 Then,	 a	 mixture	 of	 the	
suitable	amine	(1.3	eq.),	the	suitable	β-dicarbonyl	compound	(1	eq.)	and	InCl3	or	CAN	(5	mol%),	
previously	stirred	at	room	temperature	during	30	min,	and	silver	nitrate	(1	eq.)	were	added	to	
the	vessel.	The	reaction	was	subjected	to	the	vibratory	movement	at	the	same	frequency	for	
60	min.	 Then,	 the	 reaction	 vessel	 was	 cleansed	with	 ethyl	 acetate	 and	 the	 suspension	was	
filtered	 to	 remove	 the	 silver	 iodide	precipitate.	 The	organic	 layer	was	washed	with	water	 (2	
mL),	 dried	 over	 anhydrous	 sodium	 sulphate	 and	 the	 solvent	 was	 removed	 under	 reduced	
pressure.	 Purification	 by	 flash	 column	 chromatography	 on	 silica	 gel	 eluting	 with	 a	 gradient	
from	 petroleum	 ether	 to	 8:2	 petroleum	 ether-ethyl	 acetate	 afforded	 the	 desired	 pyrrole	
derivatives.	Compounds	1e	and	1f	were	known	in	the	literature.68	
	
Method	 B:	 In	 some	 cases	 where	 the	mechanochemical	 protocol	 did	 not	 work	 (synthesis	 of	
pyrroles	1a-1x),	the	α-iodoketone	was	prepared	under	literature69	conditions,	as	follows:	To	a	
solution	 of	 the	 suitable	 ketone	 (1	 eq)	 in	 anhydrous	 methanol,	 iodine	 (1	 eq)	 and	 cupper(II)	
oxide	 (1	eq)	were	added.	The	mixture	was	stirred	at	 room	temperature	 for	5	min	and,	 then,	
refluxed	until	no	starting	material	was	detected	by	TLC.	The	reaction	was	cooled,	filtered	and	
the	solvent	was	removed.	The	residue	was	dissolved	in	ethyl	acetate	(10	mL)	and	washed	with	
a	10%	solution	of	Na2S2O3	(20	mL).	The	aqueous	phase	was	extracted	with	ethyl	acetate	(2	x	20	
mL)	 and	 the	 combined	 organic	 layers	 were	 dried	 over	 anhydrous	 sodium	 sulphate	 and	 the	
solvent	 was	 evaporated.	 The	 a-iodoketones	 thus	 obtained	 were	 used	 in	 the	 next	 reaction	
without	further	purification.	
	
Ethyl	5-(2-iodophenyl)-2-methyl-1H-pyrrole-3-carboxylate	(1a)	
	
Prepared	from	o-iodoacetophenone	(1	mmol)	and	ethyl	3-aminocrotonate	
(1.5	mmol);	 yield:	 277	mg	 (78%);	 dark	 orange	 solid;	 mp:	 109-111	 °C;	 1H	
NMR	(250	MHz,	CDCl3)	δ	8.65	 (br	s,	1H),	7.95	–	7.92	 (m,	1H),	7.41	–	7.33	
(m,	2H),	7.03	–	6.96	(m,	1H),	6.80	(d,	J	=	3.0	Hz,	1H),	4.30	(q,	J	=	7.1	Hz,	2H),	
2.62	 (s,	 3H),	 1.38	 (t,	 J	 =	 7.1	 Hz,	 3H);	 13C	 NMR	 (63	MHz,	 CDCl3) δ 165.5,	 140.2,	 136.9,	 135.5,																																																									
68For	reviews,	see:	(a)	Gradillas,	A.;	Pérez-Castells,	J.	Angew.	Chem.	Int.	Ed.,	2006,	45,	6086;	(b)	Gradillas,	
A.;	Pérez-Castells,	J.	Top.	Heterocycl.	Chem.,	2015,	47,	245.	
69Yin,	G.;	Gao,	M.;	She,	N.;	Hu,	S.;	Wu,	A.;	Pan,	Y.	Synthesis,	2007,	3113.	
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130.4,	 130.4,	 128.8,	 128.3,	 112.5,	 110.9,	 96.2,	 59.5,	 14.5,	 13.4;	 IR	 (neat) ν:		 	3292.2	 (N-H),	
2977.7	(C-H),	1670.6	(C=O),	1233.3	(C-O)	cm-1;	elemental	analysis	(%)	calcd.	for		C14H14INO2:	C,	
47.34;	H,	3.97;	N,	3.94;	found:	C,	47.16;	H,	3.61,	N,	4.65.	
	
Methyl	5-(2-iodophenyl)-2-methyl-1H-pyrrole-3-carboxylate	(1b)	
	
Prepared	 from	 o-iodoacetophenone	 (1	 mmol)	 and	methyl	 3-aminocrotonate	
(1.5	mmol);	yield:	289	mg	 (85%);	dark	orange	solid;	mp:	144-146	°C;	 1H	NMR	
(250	MHz,	 CDCl3) δ 8.66	 (br	 s,	 1H),	 7.95	 –	 7.92	 (m,	 1H),	 7.39	 –	 7.36	 (m,	 2H),	
7.03	–	6.96	(m,	1H),	6.79	(d,	J	=	3	Hz,	1H),	3.84	(s,	3H),	2.62	(s,	3H);	 13C	NMR	
(250	MHz,	CDCl3) δ 165.9,	140.3,	136.8,	135.7,	130.5,	130.3,	128.9,	128.3,	112.2,	110.9,	96.3,	
50.9,	 13.3;	 IR	 (neat) ν:		 3298.6,	 3292.1	 (N-H),	 2921.8	 (C-H),	 1678.9	 (C=O),	 1233.6	 (C-O)	 cm-1;	
elemental	analysis	(%)	calcd.	for	C13H12INO2:	C,	45.77;	H,	3.55;	N,	4.11;	found:	C,	45.89;	H,	3.35;	
N,	4.51.	
	
Ethyl	2-ethyl-5-(2-iodophenyl)-1H-pyrrole-3-carboxylate	(1c)	
	
Prepared	 from	 o-iodoacetophenone	 (1	 mmol),	 ammonium	 chloride	 (	 4.5	
mmol)	and	ethyl	propionylacetate	(1.5	mmol);	yield:	288	mg	(78%);	yellowish	
solid;	mp:	78-80	°C;	 1H	NMR	(250	MHz,	CDCl3) δ 8.63	(br	s,	1H),	7.96	–	7.93	
(m,	1H),	7.46	–	7.35	(m,	2H),	7.05	–	6.98	(m,	1H),	6.80	(d,	J	=	3	Hz,	1H),	4.32	
(q,	 J	 =	 7.1	 Hz,	 2H),	 3.09	 (q,	 J	 =	 7.3	 Hz,	 2H),	 1.42	 –	 1.33	 (m,	 6H);	 13C	 NMR	 (63	 MHz,	
CDCl3) δ 165.3,	141.3,	140.3,	136.9,	130.4,	130.2,	128.8,	128.4,	111.7,	110.9,	95.9,	59.4,	20.6,	
14.5,	13.4;	 IR	 (neat) ν:		3294.2	 (N-H),	2977.3,	2922.5	 (C-H),	1670.9,	 (C=O),	1233.4	 (C-O)	cm-1;	
elemental	analysis	(%)	calcd.	for	C15H16INO2:	C,	48.80;	H,	4.37;	N,	3.79;	found:	C,	49.00;	H,	4.77;	
N,	3.89.	
	
1-(1-(But-3-en-1-yl)-5-(furan-2-yl)-2-methyl-1H-pyrrol-3-yl)ethan-1-one	(1d)	
	
Prepared	 from	 2-iodo-1-(2-furyl)ethanone	 (1	 mmol),	 butenamine	 (1.95	 mmol)	
and	acetylacetone		(1.5	mmol);	yield:	175	mg	(72%);	yellowish	solid;	mp:	117°C;	
1H	NMR	(250	MHz,	CDCl3) δ 7.48	(dd,	J	=	1.9,	0.8	Hz,	1H),	6.73	(s,	1H),	6.49	(dd,	J	
=	3.3,	1.9	Hz,	1H),	6.42	(dd,	J	=	3.3,	0.8	Hz,	1H),	5.91	–	5.64	(m,	1H),	5.15	–	5.09	
(m,	1H),	5.07	–	5.06	(m,	1H),	4.11	–	4.05	(m,	2H),	2.64	(s,	3H),	2.44	(s,	3H),	2.48	–	
2.39	(m,	2H);	13C	NMR	(63	MHz,	CDCl3) δ 194.9,	146.6,	141.8,	136.6,	133.7,	123.0,	120.8,	117.6,	
111.1,	110.9,	107.2,	44.0,	34.6,	28.5,	11.8;	IR	(neat) ν:	1699.7	(C=O),	1236.6	(C-O),	1075.8	(C=C-
H)	cm-1;	elemental	analysis	(%)	calcd.	for	C15H17NO2:	C	74.05,	H	7.04,	N	5.76;	found:	C	73.07,	H	
7.14,	N	5.67.	
	
tButyl	1-allyl-5-(furan-2-yl)-2-methyl-1H-pyrrole-3-carboxylate	(1g)	
	
Prepared	from	2-iodo-1-(2-furyl)ethanone	(1	mmol),	allylamine	(1.95	mmol)	
and	tert-butyl	acetoacetate	(1.5	mmol);	yield:	186	mg	(65%);	yellowish	oil;	1H	
NMR	 (250	MHz,	 CDCl3) δ 7.45	 –	 7.44	 (m,	 1H),	 6.77	 (s,	 1H),	 6.45	 –	 6.43	 (m,	
1H),	6.38	–	6.36	(m,	1H),	6.00	–	5.89	(m,	1H),	5.20	–	5.16	(m,	1H),	4.90	–	4.82	
(m,	1H),	4.64	–	4.60	 (m,	2H),	2.55	 (s,	3H),	1.59	 (s,	9H);	 13C	NMR	 (250	MHz,	
CDCl3) δ 164.9,	146.7,	141.7,	136.9,	133.0,	123.3,	116.4,	113.8,	111.0,	110.4,	106.9,	79.4,	46.9,	
28.5,	11.0;	IR	(neat) ν:	2971.9,	2916.8,	2848.5	(C-H),	1699.3	(C=O),	1247.9,	1235.5	(C-O)	cm-1;	
elemental	analysis	(%)	calcd.	for	C17H21NO3:	C,	71.06;	H,	7.37;	N,	4.87;	found:	C,	70.82;	H,	6.99;	
N,	4.61.	
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Isopropyl	1-allyl-5-(furan-2-yl)-2-methyl-1H-pyrrole-3-carboxylate	(1h)	
	
Prepared	from	2-iodo-1-(2-furyl)ethanone	(1	mmol),	allylamine	(1.95	mmol)	
and	isopropyl	acetoacetate	(1.5	mmol);	yield:	204	mg	(75%);	yellowish	oil;	1H	
NMR	 (250	MHz,	 CDCl3) δ 7.45	 –	 7.44	 (m,	 1H),	 6.82	 (s,	 1H),	 6.46	 –	 6.44	 (m,	
1H),	6.39	–	6.38	(m,	1H),	6.01	–	5.90	(m,	1H),	5.23	–	5.17	(m,	2H),	4.90	–	4.83	
(m,	1H),	4.65	–	4.62	(m,	2H),	2.57	(s,	3H),	1.35	(d,	J	=	6.2	Hz,	6H);	13C	NMR	(63	
MHz,	CDCl3) δ 164.9,	146.6,	141.7,	137.2,	133.0,	123.6,	116.4,	112.7,	111.0,	110.2,	106.9,	66.5,	
46.9,	 22.1,	 11.0;	 IR	 (neat) ν:		 2950.5,	 2834.5	 (C-H),	 1690.7	 (C=O),	 1247.2,	 1188.9	 (C-O)	 cm-1;	
elemental	analysis	(%)	calcd.	for	C16H19NO3:	C,	70.31;	H,	7.01;	N,	5.12;	found:	C,	70.67;	H,	7.30;	
N,	5.44.	
	
Ethyl	1-(but-3-en-1-yl)-2-(2-ethoxy-2-oxoethyl)-5-(furan-2-yl)-1H-pyrrole-3-carboxylate	(1i)	
	
Prepared	 from	 2-iodo-1-(2-furyl)ethanone	 (1	 mmol),	 butenamine	 (1.95	
mmol)	 and	 diethyl	 1,3-acetonedicarboxylate	 (1.5	 mmol);	 yield:	 266	 mg	
(77%);	white	 solid;	mp:	76-78	 °C;	 1H	NMR	 (250	MHz,	CDCl3) δ 7.48	 (dd,	 J	 =	
1.9,	0.8	Hz,	1H),	6.84	(s,	1H),	6.49	(dd,	J	=	3.3,	1.9	Hz,	1H),	6.44	(dd,	J	=	3.3,	
0.8	Hz,	1H),	 5.86	–	5.62	 (m,	1H),	 5.18	–	5.01	 (m,	2H),	 4.34	–	4.07	 (m,	8H),	
2.42	(q,	J	=	7.3	Hz,	2H),	1.33	(dt,	J	=	16.2,	7.1	Hz,	6H);	13C	NMR	(63	MHz,	CDCl3) δ 169.9,	164.8,	
146.6,	141.8,	133.7,	132.4,	124.2,	117.7,	113.7,	111.1,	110.7,	107.5,	61.2,	59.6,	44.7,	34.9,	31.3,	
14.4,	14.2;	IR	(neat) ν:	2979.1,	2977.3	(C-H),	1699.7,	1696.3	(C=O),	1244.2,	1233.2	(C-O)	cm-1;	
elemental	analysis	(%)	calcd.	for	C19H23NO5:	C,	66.07;	H,	6.71;	N,	4.06;	found:	C,	66.23;	H,	6.75;	
N,	4.33.	
	
Ethyl	1-allyl-5-(2-furyl)-2-methyl-1H-pyrrole-3-carboxylate	(1j)	
	
Prepared	 from	 2-iodo-1-(2-furyl)ethanone	 (236	 mg,	 1	 mmol),	 allylamine	
(142	mg,	1.95	mmol),	ethyl	acetoacetate	(195	mg,	1.5	mmol)	and	InCl3	(11	
mg);	yield:	186	mg	(72%);	yellow	oil;	1H	NMR	(250	MHz,	CDCl3) δ 7.45	(dd,	
1H,	J	=	1.8,	0.8	Hz,	1H),	6.82	(s,	1H),	6.45	(dd,	J	=	3.3,	1.8	Hz,	1H),	6.38	(dd,	J	
=3.3,	0.8	Hz,	1H),	6.03	–	5.88	 (m,	1),	5.22	–	5.15	 (m,	1H),	4.90	–	4.81	 (m,	
1H),	4.31	(q,	J	=	7.1	Hz,	2H),	4.66	–	4.62	(m,	2H),	2.57	(s,	3H),	1.38	(t,	J	=	7.1	
Hz,	 3H);	 13C	 NMR	 (63	MHz,	 CDCl3) δ 165.3,	 146.6,	 141.7,	 137.4,	 133.0,	 123.7,	 116.4,	 112.3,	
111.0,	 110.1,	 107.0,	 59.4,	 47.0,	 14.5,	 11.0;	 IR	 (neat)	 ν:	 1700.1	 (C=O),	 1246.3	 (C-O)	 cm-1;	
elemental	analysis	(%)	calcd	for	C15H17NO3:	C	69.48,	H	6.61,	N	5.40;	found:	C	69.39,	H	6.55,	N	
5.34.	
	
1-(1-Allyl-5-(furan-2-yl)-2-methyl-1H-pyrrol-3-yl)ethan-1-one	(1k)	
	
Prepared	from	2-iodo-1-(2-furyl)ethanone	(1	mmol),	allylamine	(1.95	mmol)	and	
acetylacetone		(1.5	mmol);	yield:	160	mg	(70%);	yellowish	oil;	1H	NMR	(250	MHz,	
CDCl3)	δ	7.48	–	7.46	 (m,	1H),	6.77	 (s,	1H),	6.48	–	6.46	 (m,	1H),	6.41	–	6.39	 (m,	
1H),	6.02	–	5.89	(m,	1H),	5.24	–	5.18	(m,	1H),	4.91	–	4.82	(m,	1H),	4.66	–	4.62	(m,	
2H),	2.60	 (s,	3H),	2.46	 (s,	3H);	 13C	NMR	(63	MHz,	CDCl3)	δ		195.0,	146.4,	141.9,	
137.0,	 132.7,	 123.5,	 121.0,	 116.6,	 111.1,	 110.6,	 107.1,	 46.7,	 28.6,	 11.5;	 IR	 (neat)	 ν:	 1699.4	
(C=O),	1249.0	(C-O),	1067.8	(C=C-H)	cm-1;	elemental	analysis	(%)	calcd.	for	C14H15NO2:	C	73.34,	
H	6.59,	N	6.11;	found:	C	72.98,	H	6.40,	N	5.71.	
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Ethyl	1-(but-3-enyl)-5-(2-furyl)-2-methyl-1H-pyrrole-3-carboxylate	(1l)	
	
Prepared	 from	2-iodo-1-(2-furyl)ethanone	 (236	mg,	1	mmol),	3-butenamine	
(138	mg,	1.95	mmol),	 ethyl	 acetoacetate	 (195	mg,	1.5	mmol)	 and	 InCl3	 (11	
mg);	yield:	176	mg	(64%);	yellow	oil;	1H	NMR	(250	MHz,	CDCl3) δ 7.47	(dd,	J	=	
1.8,	0.7	Hz,	1H),	6.79	(s,	1H),	6.47	(dd,	J	=	3.3,	1.8	Hz,	1H),	6.41	(dd,	J	=	3.3,	
0.7	Hz,	1H),	5.84	–	5.66	(m,	1H),	5.14	–	5.09	(m,	1H),	5.06	–	5.05	(m,	1H),	4.30	
(q,	J	=	7.1	Hz,	2H),	4.11	–	4.05	(m,	2H),	2.61	(s,	3H),	2.48	–	2.38	(m,	2H),	1.37	(t,	J	=	7.1	Hz,	3H);	
13C	NMR	(CDCl3,	63	MHz) δ 165.3,	146.9,	141.6,	137.9,	133.9,	123.2,	117.5,	112.1,	111.1,	110.4,	
107.1,	59.4,	44.3,	34.8,	14.5,	11.3;	IR	(neat)	ν:	1699.2	(C=O),	1249.0	(C-O),	1067.2	(C=C-H)	cm-1;	
elemental	analysis	(%)	calcd	for	C16H19NO3:	C	70.31,	H	7.01,	N	5.12;	found:	C	70.23,	H	6.95,	N	
5.10.	
	
Methyl	1-(but-3-en-1-yl)-5-(furan-2-yl)-2-methyl-1H-pyrrole-3-carboxylate	(1m)	
	
Prepared	 from	2-iodo-1-(2-furyl)ethanone	 (1	mmol),	butenamine	 (1.95	mmol)	
and	methyl	acetoacetate		(1.5	mmol);	yield:	187	mg	(72%);	yellowish	oil;	mp:	1H	
NMR	(250	MHz,	CDCl3)	δ	7.47	(dd,	J	=	1.9,	0.8	Hz,	1H),	6.77	(s,	1H),	6.48	(dd,	J	=	
3.3,	1.8	Hz,	1H),	6.41	(dd,	J	=	3.3,	0.8	Hz,	1H),	6.04	–	5.56	(m,	1H),	5.11	(dd,	J	=	
6.3,	1.3	Hz,	1H),	5.06	(t,	J	=	1.3	Hz,	1H),	4.17	–	4.01	(m,	2H),	3.83	(s,	3H),	2.62	(s,	
3H),	2.50	–	2.38	(m,	2H);	13C	NMR	(63	MHz,	CDCl3) δ 165.7,	146.9,	141.7,	137.2,	133.8,	123.3,	
117.5,	 111.7,	 111.1,	 110.4,	 107.2,	 50.8,	 44.4,	 34.8,	 11.3;	 IR	 (neat) ν:		 2951.0,	 2941.4	 (C-H),	
1708.7	(C=O),	1244.2,	1182.6	(C-O)	cm-1;	elemental	analysis	(%)	calcd.	for	C15H17NO3:	C,	69.48;	
H,	6.61;	N,	5.40;	found:	C,	69.12;	H,	6.43;	N,	5.08.	
	
1-(1-(But-3-en-1-yl)-5-(2-iodophenyl)-2-methyl-1H-pyrrol-3-yl)ethan-1-one	(1n)	
	
Prepared	from	o-iodoacetophenone	(0.40	mmol),	allylamine	(0.78	mmol)	and	3-
oxobutanamide	 (0.60	mmol);	 yield:	 98	mg	 (66%);	 yellowish	 oil;	 1H	 NMR	 (250	
MHz,	CDCl3)	δ	7.97	 (m,	1H),	 7.47	–	7.35	 (m,	2H),	 7.17	–	7.10	 (m,	1H),	 6.44	 (s,	
1H),	5.63	–	5.46	(m,	1H),	5.00	–	4.91	(m,	2H),	3.84	–	3.69	(m,	2H),	2.66	(s,	3H),	
2.44	 (s,	 3H),	 2.21	 (br	 s,	 2H);	 13C	NMR	 (63	MHz,	 CDCl3)	δ 	 195.1,	 139.1,	 138.1,	
135.1,	 134.0,	 133.,	 132.4,	 130.1,	 128.0,	 120.6,	 117.6,	 110.8,	 103.0,	 43.8,	 34.7,	 28.6,	 12.1;	 IR	
(neat) ν:	1689.2	 (C=O),	 1250.0	 (C-O),	 1077.8	 (C=C-H)	 cm-1;	 elemental	 analysis	 (%)	 calcd.	 for	
C17H18INO:	C	53.84,	H	4.68,	N	3.82;	found:	C	53.75,	H	4.53,	N	3.76.	
	
tButyl	1-allyl-5-(2-iodophenyl)-2-methyl-1H-pyrrole-3-carboxylate	(1o)	
	
Prepared	from	o-iodoacetophenone	(0.40	mmol),	allylamine	(0.78	mmol)	and	
3-oxobutanamide	 (0.60	mmol);	 yield:	 111	mg	 (65%);	 yellowish	 oil;	 1H	 NMR	
(250	MHz,	CDCl3)	δ	
1H	NzMR	(250	MHz,	CDCl3) δ 7.91	–	7.88	 (m,	1H),	7.37	–	
7.26	(m,	2H),	7.08	–	7.02	(m,	1H),	6.45	(s,	1H),	5.73	–	5.59	(m,	1H),	5.06	–	5.02	
(m,	1H),	4.71	–	4.65	 (m,	1H),	4.31	–	4.18	 (m,	2H),	2.53	 (s,	3H),	1.56	 (s,	9H);	
13NMR	(63	MHz,	CDCl3) δ 165.1,	138.8,	138.1,	135.3,	134.1,	133.1,	133.0,	132.4,	129.8,	127.7,	
116.3,	 113.2,	 110.2,	 102.7,	 79.2,	 46.7,	 28.5,	 11.3;	 IR	 (neat) ν:	1689.5	 (C=O),	 	 1259.1	 (C-O),	
1068.6	 (C=C-H)	 cm-1;	 elemental	 analysis	 (%)	 calcd.	 for	 C19H22INO2:	 C	 53.91,	 H	 5.24,	 N	 3.31;	
found:	C	53.68,	H	5.40,	N	3.63.	
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Ethyl	1-(but-3-en-1-yl)-5-(2-iodophenyl)-2-methyl-1H-pyrrole-3-carboxylate	(1p)	
	
Prepared	from	o-iodoacetophenone	(0.40	mmol),	allylamine	(0.78	mmol)	and	
3-oxobutanamide	 (0.60	 mmol);	 yield:	 122	 mg	 (75%);	 yellowish	 oil;	 1H	 NMR	
(250	MHz,	CDCl3) δ 7.97	–	7.94	 (m,	1H),	7.45	–	7.33	 (m,	2H),	7.15	–	7.08	 (m,	
1H),	6.50	(s,	1H),	5.63	–	5.46	(m,	1H),	4.99	–	4.90	(m,	2H),	4.30	(q,	J	=	7.1	Hz,	
2H),	3.83	–	3.68	(m,	2H),	2.64	(s,	3H),	2.20	(br	s,	2H),	1.37	(t,	J	=	7.1	Hz,	3H);	
13C	NMR	(63	MHz,	CDCl3) δ 165.6,	139.0,	138.2,	135.5,	134.2,	133.8,	132.4,	129.9,	127.9,	117.5,	
111.6,	110.2,	102.9,	59.3,	44.0,	34.8,	14.5,	11.6;	IR	(neat) ν:	1695.4	(C=O),	1236.8	(C-O),	1070.3	
(C=C-H)	 cm-1;	 elemental	 analysis	 (%)	 calcd.	 forC18H20INO2:	 C	 52.83,	 H	 4.93,	 N	 3.42;	 found:	 C	
52.63,	H	4.84,	N	3.44.	
	
1-(1-Allyl-5-(2-iodophenyl)-2-methyl-1H-pyrrol-3-yl)ethan-1-one	(1q)	
	
Prepared	from	o-iodoacetophenone	(0.40	mmol),	allylamine	(0.78	mmol)	and	3-
oxobutanamide	(0.60	mmol);	yield:	105	mg	(72%);	yellowish	solid;	mp:	93-95	°C;	
1H	NMR	(250	MHz,	CDCl3) δ 7.97	–	7.94	(m,	1H),	7.43	–	7.29	(m,	2H),	7.15	–	7.08	
(m,	1H),	6.48	(d,	J	=	0.7	Hz,	1H),	5.79	–	5.64	(m,	1H),	5.13	–	5.07	(m,	1H),	4.76	–	
4.68	(m,	1H),	4.36	–	4.22	(m,	2H),	2.62	(s,	3H),	2.46	(s,	3H);	13C	NMR	(63	MHz,	
CDCl3) δ 195.2,	 139.0,	 137.8,	 135.6,	 134.3,	 132.7,	 132.3,	 130.1,	 127.8,	 120.6,	 116.5,	 110.7,	
102.8,	46.5,	28.6,	11.8;	IR	(neat) ν:	1697.7	(C=O),		1234.0	(C-O),	1070.3	(C=C-H)	cm-1;	elemental	
analysis	(%)	calcd.	For	C16H16INO:	C	52.62,	H	4.42,	N	3.84;	found:	C	52.99,	H	4.61,	N	3.78.	
	
Ethyl	 1-(but-3-en-1-yl)-2-(2-ethoxy-2-oxoethyl)-5-(2-iodophenyl)-1H-pyrrole-3-carboxylate	
(1r)	
Prepared	 from	 o-iodoacetophenone	 (0.40	 mmol),	 allylamine	 (0.78	 mmol)	
and	 3-oxobutanamide	 (0.60	mmol);	 yield:	 150	mg	 (78%);	 yellowish	oil;	 1H	
NMR	 (250	MHz,	 CDCl3) δ 7.97	 –	 7.94	 (m,	 1H),	 7.46	 –	 7.39	 (m,	 2H),	 7.15	 –	
7.09	(m,	1H),	6.56	(s,	1H),	5.60	–	5.44	(m,	1H),	4.98	–	4.88	(m,	2H),	4.27	–	
4.17	(m,	6H),	3.82	–	3.68	(m,	2H),	2.20	–	2.14	(m,	2H),	1.38	–	1.26	(m,	6H);	
13C	NMR	(63	MHz,	CDCl3) δ 170.0,	165.1,	139.0,	137.9,	135.1,	133.7,	132.4,	131.1,	130.1,	127.9,	
117.6,	113.2,	110.6,	102.6,	61.1,	59.5,	44.3,	34.9,	31.6,	14.4,	14.2;	 IR	(neat) ν:	1742.5,	1697.4	
(C=O),	1236.0	(C-O),	1070.3	(C=C-H)	cm-1;	elemental	analysis	(%)	calcd.	for	C21H24INO4:	C	52.20,	
H	5.03,	N	2.91;	found:	C	52.01,	H	4.94,	N	2.78.	
	
Isopropyl	1-allyl-5-(2-iodophenyl)-2-methyl-1H-pyrrole-3-carboxylate	(1s)	
	
Prepared	from	o-iodoacetophenone	(0.40	mmol),	allylamine	(0.78	mmol)	and	
3-oxobutanamide	(0.60	mmol);	yield:	118	mg	(72%);	dark	yellow	oil;	1H	NMR	
(250	MHz,	CDCl3)	δ	7.78	–	7.74	(m,	1H),	7.23	–	7.12	(m,	2H),	6.95	–	6.88	(m,	
1H),	6.37	(s,	1H),	5.59	–	5.46	(m,	1H),	5.08	–	4.98	(m,	1H),	4.93	–	4.89	(m,	1H),	
4.58	–	4.50	(m,	1H),	4.18	–	4.04	(m,	2H),	2.42	(s,	3H),	1.18	(d,	J	=	6.2	Hz,	6H);	
13C	NMR	(63	MHz,	CDCl3)	δ	165.1,	138.8,	137.9,	135.7,	134.3,	133.0,	132.4,	129.9,	127.7,	116.3,	
112.1,	110.1,	102.7,	66.4,	46.6,	22.1,	11.3;	IR	(neat) ν:	1694.4	(C=O),	1249.9	(C-O),	1067.0	(C=C-
H)	cm-1;	elemental	analysis	(%)	calcd.	for	C18H20INO2:	C	52.82,	H	4.93,	N	3.42;	found:	C	52.98,	H	
4.56,	N	3.71.	
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Ethyl	1-allyl-2-(2-ethoxy-2-oxoethyl)-5-(2-iodophenyl)-1H-pyrrole-3-carboxylate	(1t)	
	
Prepared	 from	 o-iodoacetophenone	 (0.40	mmol),	 allylamine	 (0.78	mmol)	
and	3-oxobutanamide	 (0.60	mmol);	 yield:	 149	mg	 (80%);	 yellowish	oil;	 1H	
NMR	 (250	MHz,	 CDCl3) δ 7.96	 –	 7.93	 (m,	 1H),	 7.42	 –	 7.30	 (m,	 2H),	 7.14	–	
7.07	(m,	1H),	6.59	(s,	1H),	5.79	–	5.65	(m,	1H),	5.09	–	5.04	(m,	1H),	4.77	–	
4.69	(m,	1H),	4.41	–	4.02	(m,	8H),	1.36	(t,	J	=	7.1	Hz,	3H),	1.28	(t,	J	=	7.1	Hz,	
3H);	 13C	 NMR	 (63	MHz,	 CDCl3) δ 169.9,	 165.1,	 138.9,	 137.7,	 135.5,	 133.1,	
132.4,	 131.4,	 130.1,	 127.8,	 116.5,	 113.5,	 110.3,	 102.5,	 61.1,	 59.6,	 47.1,	 31.5,	 14.4,	 14.2;	 IR	
(neat) ν:	1736.6,	1688.4	(C=O),	1236.5	(C-O),	1070.1	(C=C-H)	cm-1;	elemental	analysis	(%)	calcd.	
for	C20H22INO4:	C	51.40,	H	4.75,	N	3.00;	found:	C	51.22,	H	4.88	,	N	2.86.	
	
Ethyl	1-allyl-5-(o-iodophenyl)-2-methyl-1H-pyrrole-3-carboxylate	(1u)	
	
Prepared	 from	 2-iodo-1-(o-iodophenyl)ethanone	 (492	 mg,	 2	 mmol),	
allylamine	 (284	mg,	 3.9	mmol),	 ethyl	 acetoacetate	 (390	mg,	 3	mmol)	 and	
CAN	 (54	 mg);	 yield:	 576	 mg	 (73%);	 orange	 solid;	 mp:	 51-52	 °C;	 1H	 NMR	
(CDCl3,	250	MHz) δ 7.94	(d,	J	=	8.0	Hz,	1H),	7.41-7.29	(m,	2H),	7.09	(ddd,	J	=	
8.0,	7.1,	2.0	Hz,	1H),	6.54	(s,	1H),	5.78-5.63	(m,	1H),	5.08	(dd,	J	=	10.4,	1.0	Hz,	
1H),	4.71	(dd,	J	=	17.1,	1.0	Hz,	1H),	4.30	(q,	J	=	7.1	Hz,	2H),	4.34-4.16	(m,	2H),	2.59	(s,	3H),	1.37	
(t,	J	=	7.1	Hz,	3H);	13C	NMR	(CDCl3,	63	MHz) δ 165.6,	138.9,	137.9,	136.0,	134.5,	133.0,	132.3,	
129.9,	 127.8,	 116.3,	 111.7,	 110.0,	 102.7,	 59.3,	 46.7,	 14.5,	 11.3;	 IR	 (neat) ν:	1697.4	 (C=O),	
1236.6	(C-O),	1070.1	(C=C-H)	cm-1;	elemental	analysis	(%)	calcd	for	C17H18INO2:	C	51.66,	H	4.59,	
N	3.54;	found:	C	51.60,	H	4.50,	N	3.51.	
	
1-Allyl-5-(2-iodophenyl)-2-methyl-1H-pyrrole-3-carboxamide	(1v)		
	
Prepared	from	o-iodoacetophenone	(0.40	mmol),	allylamine	(0.78	mmol)	and	
3-oxobutanamide	 (0.60	 mmol);	 yield:	 77	 mg	 (52%);	 yellowish	 oil;	 1H	 NMR	
(250	MHz,	CDCl3) δ 7.84	–	7.77	(m,	1H),	7.32	–	7.15	(m,	2H),	6.94	–	6.86	(m,	
1H),	6.08	(s,	1H),	5.54	(dt,	J	=	6.6,	3.3	Hz,	2H),	5.02	–	4.87	(m,	1H),	4.68	–	4.47	
(m,	 2H),	 4.11	 (d,	 J	 =	 29.1	 Hz,	 2H),	 2.44	 (s,	 3H);	 13C	 NMR	 (63	 MHz,	
CDCl3) δ 168.2,	 139.0,	 137.8,	 134.9,	 134.5,	 132.9,	 132.25,	 130.0,	 127.8,	 116.4,	 113.2,	 107.5,	
102.7,	46.6,	11.26;	IR	(neat) ν:	1697.4	(C=O),	1070.3	(C=C-H)	cm-1;	elemental	analysis	(%)	calcd.	
for	C15H15IN2O:	C	49.20,	H	4.13,	N	7.65;	found:	C	49.45,	H	4.30,	N	7.72.	
	
Ethyl	1-(2,2-dimethoxyethyl)-2-(2-ethoxy-2-oxoethyl)-5-phenyl-1H-pyrrole-3-carboxylate	(1y)	
	
Prepared	from	2-iodo-acetophenone	(0.5	mmol),	2,2-dimethoxyethan-1-
amine	 (1.0	mmol)	 and	 diethyl	 3-oxopentanedioate	 (0.75	mmol);	 yield:	
171	mg	(88	%);	yellowish	oil;	1H	NMR	(250	MHz,	CDCl3)	δ	7.45	–	7.36	(m,	
5H),	6.63	(s,	1H),	4.33	–	4.25	(m,	4H),	4.25	–	4.15	(m,	2H),	4.15	–	4.05	(m,	
3H),	3.15	(s,	6H),	1.39	–	1.33	(m,	3H),	1.33	–	1.27	(m,	4H);	13C	NMR	(63	
MHz,	CDCl3)	δ	170.2,	164.9,	134.3,	133.1,	132.5,	129.6,	128.4,	127.8,	113.6,	110.2,	104.2,	60.8,	
59.4,	55.1,	46.9,	31.4,	14.3,	14.1;	 IR	 (neat) ν:		2930.2,	2844.5	 (C-H),	1695.2	 (C=O),	1257.5	 (C-
O)cm-1;	elemental	analysis	(%)	calcd.	for	C21H27NO6:	C,	64.77;	H,	6.99;	N,	3.60;	found:	C,	64.92;	
H,	6.76;	N,	3.81.	
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Methyl	 5-(4-chlorophenyl)-1-(2,2-dimethoxyethyl)-2-(2-methoxy-2-oxoethyl)-1H-pyrrole-3-
carboxylate	(1z)	
	
Prepared	 from	 p-Bromo-2-iodo-acetophenone	 (0.5	 mmol),	 2,2-
dimethoxyethan-1-amine	 (1.0	 mmol)	 and	 dimethyl	 3-
oxopentanedioate	(0.75	mmol);	yield:	202	mg	(92	%);	yellowish	oil;	
1H	NMR	(250	MHz,	CDCl3)	δ	7.49	–	7.35	(m,	2H),	7.12	–	7.08	(m,	4H),	
6.41	(s,	1H),	4.09	(s,	2H),	3.96	(d,	J	=	4.6	Hz,	1H),	3.87	(d,	J	=	5.1	Hz,	
2H),	 3.62	 (s,	 3H),	 3.56	 (s,	 3H),	 2.99	 (s,	 6H);	 13C	NMR	 (63	MHz,	 CDCl3)	 δ	 170.5,	 165.2,	 133.5,	
133.3,	131.6,	131.4,	131.1,	122.0,	113.5,	110.5,	104.0,	55.1,	52.1,	50.9,	46.9,	31.1;	IR	(neat) ν:		
3040.0,	2855.2	(C-H),	1675.2	and	1645.0	(C=O),	1244.0	(C-O)	cm-1;	elemental	analysis	(%)	calcd.	
for	C19H22BrNO6:	C,	57.65;	H,	5.60;	N,	3.54;	found:	C,	57.28;	H,	5.43;	N,	3.69.	
	
Methyl	 5-(3,4-dichlorophenyl)-1-(2,2-dimethoxyethyl)-2-(2-methoxy-2-oxoethyl)-1H-pyrrole-
3-carboxylate	(1aa)	
	
Prepared	 from	 2-iodo-3,4-dichloro-acetophenone	 (0.5	 mmol),	 2,2-
dimethoxyethan-1-amine	 (1.0	 mmol)	 and	 dimethyl	 3-
oxopentanedioate	(0.75	mmol);	yield:	161	mg	(75	%);	yellowish	oil;	
1H	NMR	(250	MHz,	CDCl3)	δ	7.34	–	7.29	(m,	2H),	7.08	–	7.04	(m,	1H),	
6.41	(s,	1H),	4.07	(s,	2H),	4.04	–	3.97	(m,	1H),	3.85	(d,	J	=	5.1	Hz,	2H),	
3.61	(s,	3H),	3.55	(s,	3H),	3.01	(s,	6H);	13C	NMR	(63	MHz,	CDCl3)	δ	170.5,	165.2,	133.9,	132.7,	
132.5,	 132.3,	 132.1,	 131.3,	 130.5,	 128.8,	 113.8,	 111.2,	 104.0,	 55.3,	 52.2,	 51.0,	 47.1,	 31.3,	 IR	
(neat) ν:		 3010.0,	 2950.2	 (C-H),	 1705.2	 and	 1675.0	 (C=O),	 1254.1	 and	 1195.9	 (C-O)	 cm-1;	
elemental	 analysis	 (%)	 calcd.	 for	C19H21Cl2NO6:	C,	53.04;	H,	4.92;	N,	3.26;	 found:	C,	53.26;	H,	
4.59;	N,	3.06.	
	
Methyl	 1-(2,2-dimethoxyethyl)-2-(2-methoxy-2-oxoethyl)-5-phenyl-1H-pyrrole-3-carboxylate	
(1ab)	
	
Prepared	 from	2-iodo-acetophenone	 (0.5	mmol),	 2,2-dimethoxyethan-
1-amine	 (1.0	 mmol)	 and	 dimethyl	 3-oxopentanedioate	 (0.75	 mmol);	
yield:	162	mg	(90	%);	transparent	oil;	1H	NMR	(250	MHz,	CDCl3)	δ	7.46	–	
7.39	(m,	5H),	6.61	(s,	1H),	4.31	(s,	2H),	4.10	(q,	J	=	3.7	Hz,	3H),	3.83	(s,	
3H),	3.76	(s,	3H),	3.15	(s,	6H);	13C	NMR	(63	MHz,	CDCl3)	δ	170.7,	165.5,	
134.6,	 133.3,	 132.6,	 129.8,	 128.6,	 128.0,	 113.4,	 110.2,	 104.3,	 55.3,	 52.2,	 50.9,	 47.0,	 31.3;	 IR	
(neat) ν:		 3110.3,	 2959.9	 (C-H),	 1772.8	 and	 1682.4	 (C=O),	 1255.1	 and	 1176.9	 (C-O)	 cm-1;	
elemental	analysis	(%)	calcd.	for	C19H23NO6:	C,	63.15;	H,	6.42;	N,	3.88;	found:	C,	63.32;	H,	6.21;	
N,	3.55.	
	
Methyl	 1-(2,2-dimethoxyethyl)-2-(2-methoxy-2-oxoethyl)-5-(4-methoxyphenyl)-1H-pyrrole-
3-carboxylate	(1ac)	
	
Prepared	 from	 2-iodo-p-methocy-acetophenone	 (0.5	 mmol),	 2,2-
dimethoxyethan-1-amine	 (1.0	 mmol)	 and	 dimethyl	 3-
oxopentanedioate	 (0.75	mmol);	 yield:	 152	mg	 (78	%);	 dark	 yellow	
oil;	1H	NMR	(250	MHz,	CDCl3)	δ	7.12	–	7.05	(m,	2H),	6.76	–	6.70	(m,	
2H),	6.31	(s,	1H),	4.05	(s,	2H),	3.90	(dd,	J	=	5.7,	4.6	Hz,	1H),	3.80	(d,	J	
=	5.1	Hz,	2H),	3.62	(s,	3H),	3.57	(s,	3H),	3.51	(s,	3H),	2.93	(s,	6H);	13C	NMR	(63	MHz,	CDCl3)	δ	
170.7,	 165.5,	 159.3,	 134.3,	 132.8,	 131.1,	 124.8,	 113.9,	 113.1,	 109.8,	 104.2,	 55.2,	 52.1,	 50.8,	
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46.9,	31.2;	IR	(neat) ν:		3050.3,	2955.5	(C-H),	1787.8	and	1680.0	(C=O),	12335.1	and	1129.2	(C-
O)	cm-1;	elemental	analysis	(%)	calcd.	for	C20H25NO7:	C,	61.37;	H,	6.44;	N,	3.58;	found:	C,	61.12;	
H,	6.8	N,	3.26.	
	
tButyl-1-allyl-2-(but-3-en-1-yl)-5-phenyl-1H-pyrrole-3-carboxylate	(1ad)	
	
Prepared	from	acetophenone	(0.5	mmol),	allylamine	(1	mmol)	and	tbutyl	3-
oxohex-5-enoate	 (0.75	mmol);	 yield:	 59	mg	 (35%);	 yellowish	 oil;	 1H	 NMR	
(250	MHz,	CDCl3)	δ	7.39	(s,	5H),	6.62	(s,	1H),	5.92	(ddd,	J	=	17.1,	10.4,	1.1	
Hz,	2H),	5.33	–	4.94	 (m,	3H),	4.85	 (dd,	1H),	4.51	 (dt,	2H),	3.10	–	2.93	 (m,	
2H),	2.40	(dt,	J	=	10.7,	6.7	Hz,	2H),	1.60	(s,	9H);	13C	NMR	(63	MHz,	CDCl3)	δ	
164.7,	139.4,	137.8,	134.3,	133.5,	132.8,	129.1,128.0,	127.4,	116.5,	115.0,	113.7,	110.3,	79.3,	
46.3,	34.1,	28.5,	25.2;	IR	(neat) ν:	1698.4	(C=O),		1236.7	(C-O),	1074.3	(C=C-H)	cm-1;	elemental	
analysis	(%)	calcd.	for	C22H27NO2:	C	78.30,	H	8.06,	N	4.15;	found:	C	77.90,	H	7.91,	N	4.00.	
Ethyl-1,2-di(but-3-en-1-yl)-5-phenyl-1H-pyrrole-3-carboxylate	(1ae)	
	
Prepared	from	acetophenone	(0.5	mmol),	butenamine	(1	mmol)	and	ethyl	
3-oxohex-5-enoate	(0.75	mmol);	yield:	73	mg	(45%);	yellowish	oil;	1H	NMR	
(250	MHz,	CDCl3)	δ	7.27	–	7.14	(m,	5H),	6.39	(s,	1H),	5.75	(dd,	J	=	17.0,	10.2	
Hz,	1H),	5.36	(dd,	J	=	17.0,	10.3	Hz,	1H),	4.97	–	4.69	(m,	4H),	4.11	(t,	J	=	7.1	
Hz,	2H),	3.84	–	3.73	(m,	2H),	2.99	–	2.86	(m,	2H),	2.29	–	2.16	(m,	2H),	1.17	
(t,	J	=	7.1	Hz,	3H);	13C	NMR	(63	MHz,	CDCl3)	δ	165.2,	140.1,	137.7,	133.7,	133.3,	132.8,	129.3,	
128.5,	127.5,	117.5,	115.2,	111.8,	110.3,	59.3,	43.6,	35.3,	34.2,	25.3,	14.5;	 IR	(neat) ν:	1699.4	
(C=O),		1236.0	(C-O),	1075.8	(C=C-H)	cm-1;	elemental	analysis	(%)	calcd.	for	C21H25NO2:	C	77.98,	
H	7.79,	N	4.33;	found:	C	77.62,	H	7.42,	N	4.53.	
	
Ethyl-1-allyl-2-(but-3-en-1-yl)-5-(4-chlorophenyl)-1H-pyrrole-3-carboxylate	(1af)	
	
Prepared	from	p-chloroacetophenone	(0.5	mmol),	allylamine	(1	mmol)	
and	 ethyl	 3-oxohex-5-enoate	 (0.75	 mmol);	 yield:	 86	 mg	 (50%);	
yellowish	solid;	mp:	190°C;	1H	NMR	(250	MHz,	CDCl3)	δ	7.42	–	7.32	(m,	
3H),	6.65	(s,	1H),	6.02	–	5.79	(m,	2H),	5.25	–	4.96	(m,	4H),	4.81	(dd,	J	=	
17.1,	0.8	Hz,	1H),	4.50	(dt,	J	=	3.9,	2.0	Hz,	2H),	4.38	–	4.24	(m,	2H),	3.09	
–	2.96	(m,	2H),	2.48	–	2.28	(m,	2H),	1.38	(t,	J	=	7.1	Hz,	3H);	13C	NMR	(63	
MHz,	 CDCl3)	 δ	 165.0,	 140.7,	 137.6,	 134.0,	 133.9,	 132.4,	 131.0,	 130.2,	 128.6,	 116.6,	 115.2,	
112.2,	110.3,	59.4,	46.3,	34.0,	25.2,	14.5;	IR	(neat) ν:	1699.4	(C=O),		1236.0	(C-O),	1075.8	(C=C-
H)	cm-1;	elemental	analysis	(%)	calcd.	for	C20H22ClNO2:	C	69.86,	H	6.45,	N	4.07;	found:	C	70.09,	
H	6.67,	N	3.88.	
	
Ethyl-1,2-di(but-3-en-1-yl)-4-methyl-5-phenyl-1H-pyrrole-3-carboxylate	(1ag)	
	
Prepared	from	acetophenone	(0.5	mmol),	butenamine	(1	mmol)	and	ethyl	
3-oxohex-5-enoate	 (0.75	mmol);	 yield:	 59	mg	 (35%);	 yellowish	 solid;	mp:	
190°C;	1H	NMR	(250	MHz,	CDCl3)	δ	7.45	–	7.29	(m,	3H),	7.24	–	7.08	(m,	2H),	
5.95	–	5.75	(m,	1H),	5.56	–	5.29	(m,	1H),	5.08	–	4.70	(m,	4H),	4.22	(q,	2H),	
3.76	–	3.65	(m,	2H),	3.03	–	2.88	(m,	2H),	2.33	(m,	2H),	2.04	(s,	5H),	1.25	(dt,	
J	=	7.1,	5.2	Hz,	3H)	ppm;	13C	NMR	(63	MHz,	CDCl3)	δ	166.0,	139.0,	137.9,	133.9,	132.4,	131.1,	
130.9,	128.4,	127.7,	118.5,	117.2,	115.0,	110.7,	59.1,	43.5,	35.3,	34.4,	25.6,	14.5,	11.8	ppm;	IR	
(neat) ν:	1698.9	 (C=O),	 	 1237.0	 (C-O),	 1075.8	 (C=C-H)	 cm-1;	 elemental	 analysis	 (%)	 calcd.	 for	
C22H27NO2:	C	78.30,	H	8.06,	N	4.15;	found:	C	77.89,	H	8.17,	N	3.52.	
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Methyl	1-allyl-5-(furan-2-yl)-2-methyl-1H-pyrrole-3-carboxylate	(4a)		
	
Prepared	from	2-furyl	methyl	ketone	(0.5	mmol),	allylamine	(1	mmol)	and	methyl	
acetoacetate	 (0.75	 mmol);	 yield:	 106	 mg	 (87%);	 dark	 yellow	 oil;	 1H	 NMR	 (250	
MHz,	CDCl3) δ 7.34	–	7.33	(m,	1H),	6.70	(s,	1H),	6.34	–	6.32	(m,	1H),	6.28	–	6.26	
(m,	1H),	5.90	–	5.77	(m,	1H),	5.10	–	5.05	(m,	1H),	4.77	–	4.69	(m,	1H),	4.54	–	4.51	
(m,	 2H),	 3.72	 (m,	 3H),	 2.46	 (s,	 3H);	 13C	 NMR	 (63	 MHz,	 CDCl3) δ 165.7,	 146.5,	 141.7,	 137.5,	
132.9,	123.7,	116.3,	111.7,	111.0,	110.0,	107.0,	50.8,	46.9,	10.9;	IR	(neat) ν:		3124.9,	2947.4	(C-
H),	 1700.8	 (C=O),	 1244.1,	 1200.2	 (C-O)	 cm-1;	 elemental	 analysis	 (%)	 calcd.	 for	 C14H15NO3:	 C,	
68.56;	H,	6.16;	N,	5.71;	found:	C,	68.59;	H,	6.13;	N,	5.76.	
	
1-(1-Allyl-5-(tert-butyl)-2-methyl-1H-pyrrol-3-yl)ethan-1-one	(4b)		
	
Prepared	 from	 3,3-dimethylbutan-2-one	 (0.5	 mmol),	 allylamine	 (1	 mmol)	 and	
acetylacetone	 (0.75)	 ;	 yield:	 65	 mg	 (60%);	 green	 oil;	 1H	 NMR	 (250	 MHz,	
CDCl3) δ 6.28	(s,	1H),	6.02	–	5.77	(m,	1H),	5.24	–	5.16	(m,	1H),	4.76	–	4.62	(m,	3H),	
2.50	 (s,	 3H),	 2.41	 (s,	 3H),	 1.36	 (s,	 9H);	 13C	 NMR	 (63	 MHz,	 CDCl3) δ 195.1,	 140.3,	
137.0,	133.3,	119.5,	116.4,	106.4,	47.1,	31.8,	30.7,	28.6,	11.6;	IR	(neat) ν:		2964.7,	2869.9	(C-H),	
1649.3	(C=O)	cm-1;	elemental	analysis	(%)	calcd.	for	C14H21NO:	C,	76.67;	H,	9.65;	N,	6.39;	found:	
C,	76.76;	H,	9.64;	N,	6.37.	
	
Methyl	1-(but-3-en-1-yl)-2-methyl-5-(thiophen-2-yl)-1H-pyrrole-3-carboxylate	(4c)		
	
Prepared	 from	 2-acetylthiophene	 (0.5	 mmol),	 3-buten-1-amine	 (1	 mmol)	 and	
methyl	 acetoacetate	 (0.75	mmol);	 yield:	 98	mg	 (71%);	 green	 oil;	 1H	 NMR	 (250	
MHz,	CDCl3)	δ	7.10	–	7.07	(m,	1H),	6.86	–	6.80	(m,	2H),	6.45	(s,	1H),	5.53	–	5.37	
(m,	1H),	4.85	–	4.78	(m,	2H),	3.81	–	3.75	(m,	2H),	3.58	(s,	3H),	2.39	(s,	3H),	2.17	–	
2.09	(m,	2H);	13C	NMR	(63	MHz,	CDCl3) δ 165.6,	137.0,	133.7,	133.4,	127.2,	126.4,	125.6,	126.0,	
117.5,	 111.6,	 111.4,	 50.7,	 43.5,	 34.7,	 11.4;	 IR	 (neat) ν:		 2977.8,	 2945.2,	 2849.5	 (C-H),	 1698.0	
(C=O),	 1240.1,	 1188.3	 (C-O)	 cm-1;	 elemental	 analysis	 (%)	 calcd.	 for	 C15H17NO2S:	 C,	 65.43;	 H,	
6.22;	N,	5.09;	found:	C,	65.45;	H,	6.29;	N,	5.06.	
	
Ethyl	1-allyl-2-(2-ethoxy-2-oxoethyl)-5-(furan-2-yl)-1H-pyrrole-3-carboxylate	(4d)		
	
Prepared	 from	 2-furyl	 methyl	 ketone	 (0.5	 mmol),	 allylamine	 (1	 mmol)	 and	
diethyl	 1,3-acetonedicarboxylate	 (0.75	 mmol);	 yield:	 136	 mg	 (80%);	 dark	
orange	oil;	 1H	NMR	(250	MHz,	CDCl3) δ 7.46	 (d,	 J	=	1.8	Hz,	1H),	6.87	 (s,	1H),	
6.46	(dd,	J	=	3.3,	1.8	Hz,	1H),	6.41	(d,	J	=	3.3	Hz,	1H),	6.07	–	5.86	(m,	1H),	5.24	
–	5.14	(m,	1H),	4.90	–	4.82	(m,	1H),	4.71	–	4.69	(m,	2H),	4.30	(q,	J	=	7.1	Hz,	2H),	4.18	(q,	J	=	7.1	
Hz,	 2H),	 4.12	 (s,	 2H),	 1.36	 (t,	 J	 =	 7.1	 Hz,	 3H),	 1.28	 (t,	 J	 =	 7.1	 Hz,	 3H);	 13C	 NMR	 (63	 MHz,	
CDCl3) δ 169.9,	164.8,	146.3,	141.9,	133.1,	132.7,	124.7,	116.5,	114.0,	111.1,	110.4,	107.5,	61.2,	
59.7,	47.2,	31.2,	14.4,	14.1;	 IR	 (neat) ν:		 	2980.5,	2924.4,	2852.3	 (C-H),	1734.7,	1704.3	 (C=O),	
1245.7,	 1181.3	 (C-O)	 cm-1;	 elemental	 analysis	 (%)	 calcd.	 for	 C18H21NO5:	 C,	 65.24;	 H,	 6.39;	 N,	
4.23;	found:	C,	65.27;	H,	6.34;	N,	4.19.	
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3.3.2.	Synthesis	of	compounds	1w	and	1x	by	cross-metathesis	
	
	
	
A	 round-bottomed	 flask	 was	 charged	 with	 second	 generation	 Hoveyda-Grubbs	 catalyst	 (2%	
mmol),	CuI	 (2%	mmol),	 the	suitable	pyrrole	1	 (0.15	mmol)	and	ethyl	acrylate	 (0.23	mmol)	 in	
dry	 diethyl	 ether	 (2	 mL),	 stirred	 and	 heated	 at	 40°C	 during	 4	 h.	 After	 completion	 of	 the	
reaction	(controlled	by	TLC)	the	solvent	was	removed	under	reduced	pressure	and	the	residue	
was	 purified	 by	 flash	 column	 chromatography	 on	 silica	 gel	 eluting	 with	 a	 gradient	 from	
petroleum	ether	to	8:2	petroleum	ether-ethyl	acetate,	affording	the	desired	pyrroles	1w	 	and	
1x.	
	
(E)-Ethyl	 1-(3-ethoxycarbonyl-2-propenyl)-5-(o-iodophenyl)-2-methyl-1H-pyrrole-3-
carboxylate	(1w)	
	
Prepared	from	pyrrole	119	(79	mg,	0.2	mmol);	yield:	84	mg	(90%);	yellow	oil;	
1H	NMR	(CDCl3,	250	MHz) δ 7.93	(dd,	J	=	8.0,	1.0	Hz,	1H),	7.36	(ddd,	J	=	7.5,	
7.2,	1.2	Hz,	1H),	7.29	(dd,	J	=	7.5,	1.9	Hz,	1H),	7.10	(ddd,	J	=	8.0,	7.2,	1.9	Hz,	
1H);	6.79	(dt,	J	=	15.6,	4.1	Hz,	1H),	6.57	(s,	1H),	5.37	(dt,	J	=	15.6,	2.0	Hz,	1H),	
4.31	 (q,	 J	=	7.1	Hz,	2H),	4.17	 (q,	 J	=	7.1	Hz,	2H),	4.59-4.30	 (m,	2H),	2.57	 (s,	
3H),	 1.38	 (t,	 J	 =	 7.1	 Hz,	 3H),	 1.28	 (t,	 J	 =	 7.1	 Hz,	 3H);	 13C	 NMR	 (CDCl3,	 63	
MHz) δ 165.6,	 165.4,	 142.7,	 139.0,	 137.5,	 135.6,	 134.4,	 132.3,	 130.2,	 128.1,	 122.3,	 112.3,	
110.5,	102.5,	60.6,	59.5,	45.2,	14.5,	14.1,	11.3;	IR	(neat)	ν: 1688.4	(C=O),	1234.6	(C-O),	1072.1	
(C=C-H)	 cm-1;	 elemental	 analysis	 (%)	 calcd	 for	 C20H22INO4:	 C	 51.40,	 H	 4.75,	 N	 3.00;	 found:	 C	
51.38,	H	4.67,	N	2.98.	
	
Ethyl	(E)-4-(3-acetyl-5-(2-iodophenyl)-2-methyl-1H-pyrrol-1-yl)but-2-enoate	(1x)	
	
Prepared	 from	 pyrrole	 xx	 (0.3	 mmol)	 foolowing	 the	 procedure	 for	 cross-
metathesis	derivatives;	yield:	78	mg	(89%);	yellowish	oil;	1H	NMR	(250	MHz,	
CDCl3) δ 7.87	–	7.83	(m,	1H),	7.30	(td,	J	=	7.4,	1.2	Hz,	1H),	7.33	–	7.27	(m,	1H),	
7.23	–	7.19	(m,	1H),	7.06	–	6.99	(m,	1H),	6.79	(dt,	J	=	15.6,	4.2	Hz,	1H),	6.41	
(s,	1H),	5.28	(dt,	J	=	15.6,	2.0	Hz,	1H),	4.43	–	4.28	(m,	2H),	4.08	(q,	J	=	7.1	Hz,	
2H),	 2.49	 (s,	 3H),	 2.37	 (s,	 3H),	 1.19	 (t,	 J	 =	 7.1	 Hz,	 3H);	 13C	 NMR	 (63	MHz,	
CDCl3) δ 195.1,	 165.5,	 142.3,	 139.1,	 137.2,	 135.1,	 134.2,	 132.2,	 130.3,	 128.1,	 122.3,	 121.0,	
111.0,	102.6,	60.6,	44.9,	28.6,	14.1,	11.7;	IR	(neat) ν:	1697.4	(C=O),	1216.0	(C-O),	1075.8	(C=C-
H)	cm-1;	elemental	analysis	(%)	calcd.	for	C19H20INO3:	C	52.19,	H	4.61,	N	3.20;	found:	C	51.98,	H	
4.39,	N	3.59.	
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3.3.3.	 General	 procedure	 for	 the	 synthesis	 of	 symmetrical	 bispyrrole	 derivatives	 2	 and	
compound	3	under	mechanochemical	conditions	
	
	
	
The	 suitable	ketone	 (1	mmol),	N-iodosuccinimide	 (NIS,	1	mmol)	and	p-toluenesulphonic	acid	
(PTSA,	10	mol%)	were	added	to	a	milling	jar,	along	with	a	zirconium	oxide	ball.	The	vessel	was	
fitted	to	one	of	the	horizontal	vibratory	arms	of	the	ball	mill,	while	the	other	arm	was	occupied	
with	an	empty	 vessel.	 The	ball	mill	was	 set	 to	 vibrate	at	 a	 frequency	of	20	 s-1	 for	60	min	at	
room	temperature.	Then,	a	mixture	of	the	corresponding	diamine	(0.85	mmol),	the	suitable	b-
dicarbonyl	 compound	 (1.3	 mmol)	 and	 cerium(IV)	 ammonium	 nitrate	 (CAN,	 10	 mol%),	
previously	 stirred	 at	 room	 temperature	 during	 30-60	min,	 and	 silver	 nitrate	 (1	mmol)	 were	
added	 to	 the	 vessel.	 The	 reaction	 was	 subjected	 to	 the	 vibratory	 movement	 at	 the	 same	
frequency	 for	 60	 min.	 Then,	 the	 reaction	 vessel	 was	 cleansed	 with	 ethyl	 acetate	 or	
dichloromethane	and	the	suspension	was	filtered	to	remove	the	silver	iodide	precipitate.	The	
organic	 layer	was	washed	with	water	 (2	mL),	dried	over	anhydrous	sodium	sulphate	and	the	
solvent	was	 removed	under	 reduced	pressure.	 Purification	 by	 flash	 column	 chromatography	
on	silica	gel	eluting	with	a	gradient	from	petroleum	ether	to	8:2	petroleum	ether-ethyl	acetate	
afforded	 the	 desired	 pyrrole	 derivatives.	 Compounds	 2h,	 2i	 and	 2j	 were	 purified	 by	 flash	
chromatography	eluting	with	a	98/2	dichloromethane/methanol	mixture.		
For	 the	 synthesis	 of	 compounds	 2d,	 2g,	 2j,	 2l,	 2m,	 2o,	 the	 required	 α-iodoketones	 were	
prepared	in	a	separate	step,	according	to	the	following	procedure:	To	a	solution	of	the	suitable	
ketone	 (1	eq)	 in	anhydrous	methanol,	 iodine	 (1	eq)	 and	 cupper(II)	 oxide	 (1	eq)	were	added.	
The	mixture	was	 stirred	at	 room	temperature	 for	5	min	and,	 then,	 refluxed	until	no	 starting	
material	was	detected	by	TLC.	The	reaction	was	cooled,	filtered	and	the	solvent	was	removed.	
The	residue	was	dissolved	in	ethyl	acetate	(10	mL)	and	washed	with	a	10%	solution	of	Na2S2O3	
(20	mL).	The	aqueous	phase	was	extracted	with	ethyl	acetate	 (2	x	20	mL)	and	the	combined	
organic	 layers	were	dried	over	anhydrous	 sodium	sulphate	and	 the	 solvent	was	evaporated.	
The	α-iodoketones	thus	obtained	were	used	in	the	next	reaction	without	further	purification.	
	
Diethyl	1,1'-(ethane-1,2-diyl)bis(2-methyl-5-phenyl-1H-pyrrole-3-carboxylate)	(2a)	
	
Prepared	 from	 acetophenone	 (1	 mmol),	 ethylenediamine	 (0.85	 mmol)	 and	
ethyl	 acetoacetate	 (1.30	mmol);	 yield:	 145	mg	 (60%);	white	 solid;	mp:	 224-
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226	°C;	1H	NMR	(CDCl3,	250	MHz) δ 7.42-7.36	(m,	6H);	7.20-7.15	(m,	4H);	6.48	(s,	2H);	4.28	(q,	J	
=	 7.1	 Hz,	 4H);	 3.88	 (s,	 4H);	 1.98	 (s,	 6H);	 1.36	 (t,	 J	 =	 7.1	 Hz,	 6H)	 ppm;	 13C	 NMR	 (CDCl3,	 63	
MHz) δ 165,	136.1,	133.0,	132.0,	129.7,	128.6,	128.0,	112.4,	110.3,	59.3,	43.1,	14.5,	10.2	ppm;	
IR	 (neat) ν:		 1701.6	 (C=O),	 1242.9	 (C-O)	 cm-1.	 Elemental	 analysis	 (%)	 calcd	 for	 C30H32N2O4:	 C	
74.36,	H	6.66,	N	5.78;	found:	C	74.31,	H	6.59,	N	5.80.	
	
Dimethyl	 1,1'-(propane-1,3-diyl)bis[5-(4-chlorophenyl)-2-methyl-1H-pyrrole-3-carboxylate]	
(2b)		
	
Prepared	 from	 4-chloroacetophenone	 (1	 mmol),	 propane-1,3-diamine	
(0.85	mmol)	 and	methyl	 acetoacetate	 (1.3	mmol);	 yield:	 178	mg	 (66%);	
white	 solid;	mp:	 84-86;	 1H	NMR	 (250	MHz,	 CDCl3) δ 7.37	–	 7.26	 (m,	 4H),	
7.13	–	7.05	(m,	4H),	6.48	(d,	J	=	0.9	Hz,	2H),	3.81	(s,	6H),	3.71	–	3.66	(m,	
4H),	 2.44	 (s,	 6H),	 1.69	–	1.60	 (m,	2H);	 13C	NMR	 (63	MHz,	CDCl3) δ 165.4,	
136.2,	 133.6,	 131.6,	 130.7,	 130.0,	 128.7,	 112.1,	 110.4,	 50.7,	 40.7,	 31.2,	 11.2;	 IR	 (neat) ν:		
2946.4	(C-H),	1689.4	(C=O),	1242.7	(C-O),	1010.9	(C-Cl)	cm-1;	elemental	analysis	(%)	calcd.	for	
C29H28Cl2N2O4:	C,	64.57;	H,	5.23;	N,	5.19;	found:	C,	64.53;	H,	5.20;	N,	5.14.	
	
Dimethyl	1,1'-(butane-1,4-diyl)bis(2-methyl-5-phenyl-1H-pyrrole-3-carboxylate)	(2c)		
	
Prepared	 from	 acetophenone	 (1	 mmol),	 butane-1,4-diamine	 (0.85	
mmol)	 and	 methyl	 acetoacetate	 (1.3mmol);	 yield:	 150	 mg	 (62%);	
yellowish	 solid;	mp:	 156-158	 °C;	1H	 NMR	 (250	MHz,	 CDCl3) δ 7.15	 (m,	
6H),	7.02	–	6.93	(m,	4H),	6.27	(s,	2H),	3.59	(s,	6H),	3.46	(m,	4H),	2.27	(s,	
6H),	 1.01	 (m,	 4H);	 13C	 NMR	 (63	 MHz,	 CDCl3) δ 165.9,	 136.2,	 133.2,	
132.8,	129.2,	128.4,	127.6,	111.6,	109.8,	50.7,	43.0,	27.1,	11.4;	IR	(neat) ν:		2953.2,	2877.8	(C-
H),	 1690.5	 (C=O),	 1243.2,	 1211.6	 (C-O)	 cm-1;	 HRMS	 (ESI)	m/z	 calcd.	 for	 [M+H]+	 485.24348,	
found	 485.24568;	 elemental	 analysis	 (%)	 calcd.	 for	 C30H32N2O4:	 C,	 74.36;	 H,	 6.66;	 N,	 5.78;	
found:	C,	74.31;	H,	6.63;	N,	5.77.	
	
Dimethyl	1,1'-(propane-1,3-diyl)bis[5-(furan-2-yl)-2-methyl-1H-pyrrole-3-carboxylate]	(2d)		
	
Prepared	 from	 2-furyl	 methyl	 ketone	 (1	 mmol),	 butane-1,4-diamine	
(0.85	mmol)	and	methyl	acetoacetate	(1.3	mmol);	yield:	158	mg	(68%);	
yellowish	oil;	1H	NMR	(250	MHz,	CDCl3) δ 7.43	(dd,	J	=	1.9,	0.8	Hz,	2H),	
6.74	(s,	2H),	6.47	(dd,	J	=	3.3,	1.9	Hz,	2H),	6.36	(dd,	J	=	3.3,	0.8	Hz,	2H),	
3.97	(m,	4H),	3.83	(s,	6H),	2.56	(s,	6H),	1.82	–	1.58	(m,	4H);	13C	NMR	(63	
MHz,	 CDCl3) δ 165.7,	 146.8,	 141.7,	 136.9,	 123.1,	 111.9,	 111.2,	 110.6,	 107.5,	 50.9,	 44.3,	 27.5,	
11.2;	 IR	 (neat) ν:		2945.0	 (C-H),	1700.5	 (C=O),	1249.1(C-O)	cm-1;	elemental	analysis	 (%)	calcd.	
for	C26H28N2O6:	C,	67.23;	H,	6.08;	N,	6.03;	found:	C,	67.13;	H,	6.01;	N,	5.99.	
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Dimethyl	1,1'-(heptane-1,7-diyl)bis(2-methyl-5-phenyl-1H-pyrrole-3-carboxylate)	(2e)		
	
Prepared	 from	acetophenone	 (1	mmol),	 heptane-1,7-diamine	 (0.85	
mmol)	 and	 methyl	 acetoacetate	 (1.3	 mmol);	 yield:	 155	 mg	 (59%);	
yellow	solid;	mp:	96-98	 °C;	 1H	NMR	(250	MHz,	CDCl3) δ 7.43	–	7.29	
(m,	10H),	6.54	(s,	2H),	3.92	–	3.81	(m,	4H),	3.87	(s,	6H),	2.61	(s,	6H),	
1.47	–1.41	 (m,	4H),	 0.99	 (s,	 6H);	 13C	NMR	 (63	MHz,	CDCl3) δ 166.0,	
136.4,	 133.4,	 133.0,	 129.3,	 128.4,	 127.4,	 111.5,	 109.6,	 50.7,	 43.8,	 30.3,	 28.2,	 26.1,	 11.5;	 IR	
(neat) ν:		2935.9,	2900.0	(C-H),	1729.0	(C=O),	1245.3	(C-O)	cm-1;	elemental	analysis	(%)	calcd.	
for	C33H38N2O4:	C,	75.26;	H,	7.27;	N,	5.32;	found:	C,	75.26;	H,	7.28;	N,	5.30.	
	
1,1'-(Octane-1,8-diyl)bis[5-(4-fluorophenyl)-2-methyl-1H-pyrrole-1,3-diyl]bis(ethan-1-one)	
(2f)		
	
Prepared	 from	1-(4-fluorophenyl)ethan-1-one	 (1	mmol),	 octane-1,8-
diamine	 (0.85	 mmol)	 and	 acetylacetone	 (1.3mmol);	 yield:	 163	 mg	
(60%);	 yellowish	 solid;	 mp:	 158-160	 °C;	 1H	 NMR	 (250	 MHz,	
CDCl3) δ 7.24	–	7.09	(m,	4H),	7.02	–	6.88	(m,	4H),	6.29	(s,	2H),	3.79	–	
3.54	(m,	4H),	2.45	(s,	6H),	2.26	(s,	6H),	1.29	–	1.25(m,	4H),	0.96	–	0.81	
(m,	 8H);	 13C	 NMR	 (63	 MHz,	 CDCl3) δ 195.0,	 162.3	 (d,	 J	 =	 252	 Hz),	
135.7,	131.9,	131.2	(d,	J	=	7.6	Hz),	129.0	(d,	J	=	3.8	Hz),	120.8,	115.4	
(d,	J	=	21.4	Hz),	110.5,	43.6,	30.4,	28.7,	28.5,	26.3,	12.0;	19F	NMR	(235	MHz,	CDCl3) δ (-114.31)	–	
(-114.43)	(m);	IR	(neat) ν:		2932.7,	2851.1	(C-H),	1649.2	(C=O),	1242.9,	1215.5	(C-O),	1152.1	(C-
F)	 cm-1;	 elemental	 analysis	 (%)	 calcd.	 for	 C34H38F2N2O2:	 C,	 74.97;	 H,	 7.03;	 N,	 5.14;	 found:	 C,	
74.91;	H,	7.00;	N,	5.10.	
	
Dimethyl	 1,1'-(dodecane-1,12-diyl)bis[5-(furan-2-yl)-2-(2-methoxy-2-oxoethyl)-1H-pyrrole-3-
carboxylate]	(2g)		
	
Prepared	from	2-furyl	methyl	ketone	(1	mmol),	dodecane-1.12-diamine	(0.85	
mmol)	and	6-methoxy-3,5-dioxohexanoate	(1.3	mmol);	yield:	207	mg	(60%)	;	
transparent	oil;	1H	NMR	(250	MHz,	CDCl3) δ 7.48	–	7.46	(m,	2H),	6.80	(s,	2H),	
6.49	–	6.47	(m,	2H),	6.42	–	6.41	(m,	2H),	4.16	(s,	4H),	4.06	–	3.96	(m,	4H),	3.82	
(s,	6H),	3.74	(s,	6H),	1.71	–	1.56	(m,	4H),	1.35	–	1.17	(m,	16H);	 13C	NMR	(63	
MHz,	 CDCl3) δ 170.3,	 165.3,	 146.6,	 141.8,	 132.3,	 124.3,	 113.2,	 111.1,	 110.6,	
107.6,	52.3,	51.0,	45.4,	31.1,	30.7,	29.5,	29.4,	29.1,	26.6;	IR	(neat) ν:		2926.0,	
2852.6	 (C-H),	 1740.8,	 1703.4	 (C=O),	 1250.1,	 1233.2	 (C-O)	 cm-1;	 elemental	
analysis	(%)	calcd.	for	C38H48N2O10:	C,	65.88;	H,	6.98;	N,	4.04;	found:	C,	65.89;	
H,	6.92;	N,	4.04.	
	
N,N-Bis[2-(3-ethoxycarbonyl-5-phenyl-2-methylpyrrol-1-yl)ethyl]amine	(2h)	
	
Prepared	 from	 acetophenone	 (1	 mmol),	 N-(2-aminoethyl)ethane-1,2-
diamine	 (0.85	mmol)	 and	ethyl	 acetoacetate	 (1.3	mmol);	 yield:	 183	mg	
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(74%);	yellowish	oil;	1H	NMR	(CDCl3,	250	MHz) δ 7.15	–	7.00	(m,	10H),	6.36	(s,	2H),	4.12	(q,	J	=	
7.1	Hz,	4H),	3.69	(t,	J	=	6.8	Hz,	4H),	2.37	(s,	6H),	2.26	(t,	J	=	6.8	Hz,	4H),	1.18	(t,	J	=	7.1	Hz,	6H);	
13C	NMR	(CDCl3,	63	MHz)	δ		165.5,	136.5,	133.3,	132.8,	129.3,	128.5,	127.6,	112.1,	110.1,	59.3,	
48.8,	43.7,	14.5,	11.6;	IR	(neat) ν:		1650	(C=O),	1250	(C-O)	cm-1;	Elemental	analysis	(%)	calcd	for	
C32H37N3O4:	C	72.84,	H	7.07,	N	7.96;	C	72.79,	H	7.03,	N	7.91.	
	
N1,N4-Bis[3-(3-ethoxycarbonyl-5-phenyl-2-methylpyrrol-1-yl)propyl]piperazine	(2i)	
	
Prepared	 from	 acetophenone	 (1	 mmol),	 1,4-
bis(aminopropyl)piperazine	(0.65	mmol)	and	ethyl	acetoacetate	(1.3	
mmol);	yield:	141	mg	(45%);	yellowish	oil;	1H	NMR	(CDCl3,	250	MHz)	
δ 	7.21-7.06	(m,	10H),	6.34	(s,	2H),	4.08	(q,	J	=	7.1	Hz,	4H),	3.73	(m,	
4H),	2.41	(s,	6H),	1.97-1.85	(m,	12H),	1.45-1.34	(m,	4H),	1.14	(t,	J	=	7.1,	6H);	13C	NMR	(CDCl3,	63	
MHz) δ 166.0,	 136.9,	 133.6,	 133.5,	 129.7,	 128.8,	 127.8,	 112.3,	 110.3,	 59.7,	 55.2,	 53.1,	 42.5,	
27.9,	 14.9,	 11.9;	 IR	 (neat) ν:	1650	 (C=O),	 1250	 (C-O)	 cm-1;	 elemental	 analysis	 (%)	 calcd	 for	
C38H48N4O4:	C	73.05,	H	7.74	N,	8.97;	found:	C	72.97,	H	7.70,	N	8.90.		
	
N1,N4-Bis[3-[3-(methylcarbonyl)-5-(furan-2-yl)-2-methylpyrrol-1-yl]propyl]piperazine	(2j)		
	
Prepared	from	2-furyl	methyl	ketone	(1	mmol),	3,3'-(piperazine-1,4-
diyl)bis(propan-1-amine)	(0.85	mmol)	and	acetylacetone	(1.3	mmol);	
yield:	152	mg	(56%);	light	brown	oil;	1H	NMR	(250	MHz,	CDCl3) δ 7.37	
(dd,	 J	 =	1.9,	0.8	Hz,	2H),	6.63	 (s,	2H),	6.39	 (dd,	 J	 =	3.3,	1.9	Hz,	2H),	
6.35	(dd,	J	=	3.3,	0.8	Hz,	2H),	4.02	–	3.95	(m,	4H),	2.54	(s,	6H),	2.41	–	
2.16	(m,	12H),	2.34	(s,	6H),	1.81	–	1.69	(m,	4H);	13C	NMR	(63	MHz,	CDCl3) δ 194.9,	146.7,	141.8,	
136.8,	123.0,	120.8,	111.1,	111.1,	107.3,	55.1,	53.0,	42.8,	28.5,	27.5,	11.7;	IR	(neat) ν:		2956.1,	
2930.9	 (C-H),	 1658.9	 (C=O),	 1256.2	 (C-O)	 cm-1;	 HRMS	 (ESI)	m/z	 calcd.	 for	 C32H41N4O4	 [M+H]
+	
545.31278,	found		545.31720.	
	
1,1'-[[(1,1,3,3-Tetramethyldisiloxane-1,3-diyl)bis(propane-3,1-diyl)]bis(2-methyl-5-phenyl-
1H-pyrrole-1,3-diyl)]bis(ethan-1-one)	(2k)	
	
Prepared	 from	 acetophenone	 (1	 mmol),	 3,3'-(1,1,3,3-
tetramethyldisiloxane-1,3-diyl)bis(propan-1-amine)	 (0.85	 mmol)	
and	acetylacetone	(1.3	mmol);	yield:	168	mg	(55%);	yellowish	oil;	1H	
NMR	(CDCl3,	250	MHz)	δ	7.46-7.36	 (m,	10H),	6.57	 (s,	2H),	3.91	 (m,	
4H),	 2.71	 (s,	 6H),	 2.51	 (s,	 6H),	 1.63-1.50	 (m,	 4H),	 0.39-0.32	 (m,	 4H),	 0.00	 (s,	 12H);	 13C	 NMR	
(CDCl3,	 63	 MHz) δ 195.0,	 135.6,	 133.0,	 132.9,	 129.2,	 128.4,	 127.5,	 120.7,	 110.3,	 46.6,	 28.4,	
24.5,	15.0,	12.0,	0.0;	IR	(neat) ν:	1650	(C=O),	1250	(C-O)	cm-1;	Elemental	analysis	(%)	calcd	for	
C36H48N2O3Si2:	C	70.54,	H	7.89,	N,	4.57;	found:	C	70.52,	H	7.82,	N	4.51.	
	
	 	
N
O
O
N
O
O
N
N
N
O
N
O
O
ON
N
N
O
N
O
Si
O
Si
	
	
58	 	 	 	 	 		
1,1'-[[(1,1,3,3-Tetramethyldisiloxane-1,3-diyl)bis(propane-3,1-diyl)]bis(2-methyl-5-
(thiophen-2-yl)-1H-pyrrole-1,3-diyl)]bis(ethan-1-one)	(2l)		
	
Prepared	 from	 2-acetylthiophene	 (1	 mmol),	 1,3-
bis(aminopropyl)tetramethyldisiloxane	 (0.85	 mmol)	 and	
acetylacetone	 (1.3	mmol);	 yield:	187	mg	 (60%);	dark	yellow	oil;	1H	
NMR	 (250	MHz,	CDCl3) δ 7.35	–	7.32	 (m,	2H),	7.09	–	7.06	 (m,	2H),	
7.03	–	7.01	(m,	2H),	6.63	(s,	2H),	3.92	–	3.86	(m,	4H),	2.62	(s,	6H),	2.43	(s,	6H),	1.67	–	1.54	(m,	
4H),	0.45	–	0.38	(m,	4H),	0.00	(s,	12H);	13C	NMR	(63	MHz,	CDCl3) δ 194.9,	136.3,	133.7,	127.3,	
126.7,	125.8,	124.9,	120.8,	112.1,	46.8,	28.5,	24.8,	15.2,	12.0,	0.1;	IR	(neat) ν:		2952.1,	2926.9	
(C-H),	 1652.7	 (C=O),	 1252.5	 (C-O)	 cm-1;	 HRMS	 (ESI)	m/z	 calcd.	 for	 [M+H]+	 625.24101,	 found	
625.24265;	elemental	analysis	(%)	calcd.	for	C32H44N2O3S2Si2:	C,	61.50;	H,	7.10;	N,	4.48;	found:	
C,	61.48;	H,	7.06;	N,	4.49.	
	
Dimethyl	 1,1'-[(1,1,3,3-tetramethyldisiloxane-1,3-diyl)bis(propane-3,1-diyl)]bis[5-(furan-2-
yl)-2-methyl-1H-pyrrole-3-carboxylate]	(2m)		
	
Prepared	 from	 2-furyl	 methyl	 ketone	 (1	 mmol),	 1,3-
bis(aminopropyl)tetramethyldisiloxane	 (0.85	 mmol)	 and	 methyl	
acetoacetate	 (1.3	mmol);	 yield:	 187	mg	 (65%);	 dark	 yellow	oil;	 1H	
NMR	(250	MHz,	CDCl3) δ 7.42	–	7.41	(m,	2H),	6.74	(s,	2H),	6.44	–	6.42	(m,	2H),	6.34	(dd,	J	=	3.3,	
0.8	Hz,	2H),	3.97	–	3.90	(m,	4H),	3.81	(s,	6H),	2.57	(s,	6H),	1.69	–	1.56	(m,	6H),	0.47	–	0.40	(m,	
4H),	0.00	(s,	12H);	13C	NMR	(63	MHz,	CDCl3)	δ	194.9,	136.3,	133.7,	127.3,	126.7,	125.8,	124.9,	
120.8,	112.1,	46.8,	28.5,	24.8,	15.2,	12.0,	0.1;	IR	(neat) ν:		2950.9	(C-H),	1705.4	(C=O),	1252.1	
(C-O)	cm-1;	elemental	analysis	(%)	calcd.	for	C32H44N2O7Si2:	C,	61.51;	H,	7.10;	N,	4.48;	found:	C,	
61.48;	H,	7.05;	N,	4.48.	
	
Diethyl	 1,1'-[(1,1,3,3-tetramethyldisiloxane-1,3-diyl)bis(propane-3,1-diyl)]bis[2-(2-ethoxy-2-
oxoethyl)-5-phenyl-1H-pyrrole-3-carboxylate]	(2n)		
	
Prepared	 from	 acetophenone	 (0.5	 mmol),	 1,3-
bis(aminopropyl)tetramethyldisiloxane	 (0.85	 mmol)	 and	 ethyl	 6-
ethoxy-3,5-dioxohexanoate	 (1.3	 mmol);	 yield:	 237	 mg	 (58%);	
yellowish	oil;	1H	NMR	(250	MHz,	CDCl3) δ 7.53	–	7.41	(m,	10H),	6.74	
(s,	2H),	4.46	–	4.28	(m,	8H),	4.29	(s,	4H),	4.09	–	3.89	(m,	4H),	1.59	–	
1.39	 (m,	 16H),	 0.51	 –	 0.28	 (m,	 4H),	 0.00	 (s,	 12H);	 13C	 NMR	 (63	MHz,	 CDCl3) δ 170.0,	 165.1,	
134.1,	132.9,	131.5,	129.2,	128.4,	127.6,	113.4,	110.2,	61.0,	59.4,	47.2,	31.5,	24.8,	15.0,	14.4,	
14.1,	-0.1;	IR	(neat) ν:		2953.6,	2933.9,	2900.7	(C-H),	1735.5,	1695.2	(C=O),	1242.4	(C-O)	cm-1;	
elemental	analysis	 (%)	calcd.	 for	C44H60N2O9Si2:	C,	64.67;	H,	7.40;	N,	3.43;	 found:	C,	64.68;	H,	
7.37;	N,	3.40.	
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Dimethyl	1,1'-[(1,1,3,3-tetramethyldisiloxane-1,3-diyl)bis(propane-3,1-diyl)]bis(2-methyl-1,4-
dihydroindeno[1,2-b]pyrrole-3-carboxylate)	(2o)		
	
Prepared	 from	 1-indanone	 (1	 mmol),	 1,3-
bis(aminopropyl)tetramethyldisiloxane	 (0.85	 mmol)	 and	 methyl	
acetoacetate	(1.3	mmol);	yield:	200	mg	(66%);	dark	yellow	oil;	1H	NMR	
(250	MHz,	CDCl3) δ 7.47	(d,	J	=	7.3	Hz,	2H),	7.29	–	7.20	(m,	4H),	7.13	–	
7.06	(m,	2H),	4.04	(m,	4H),	3.86	(s,	6H),	3.63	(s,	4H),	2.62	(s,	6H),	1.84	
–	 1.69	 (m,	 4H),	 0.61	 –	 0.48	 (m,	 4H),	 0.00	 (s,	 12H);	 13C	NMR	 (63	MHz,	 CDCl3) δ 166.2,	 146.7,	
139.2,	136.4,	135.2,	129.6,	126.3,	125.3,	123.0,	115.7,	107.9,	50.7,	47.8,	32.0,	24.8,	15.2,	11.4,	
0.1;	IR	(neat) ν:		2948.6,	2900.2	(C-H),	1702.0	(C=O),	1280.5	(C-O)	cm-1;	elemental	analysis	(%)	
calcd.	for	C38H48N2O5Si2:	C,	68.23;	H,	7.23;	N,	4.19;	found:	C,	68.17;	H,	7.22;	N,	4.14.	
	
N,N,N-tris[2-(3-acetyl-5-phenyl-2-methylpyrrol-1-yl)ethyl]amine	(3)	
	
Following	 the	 general	 procedure,	 prepared	 from	 acetophenone	 (1.8	
mmol),	 N,N-bis(2-aminoethyl)ethane-1,2-diamine	 (1.2	 mmol)	 and	
acetylacetone	 (2.7	 mmol).	 Purification	 by	 flash	 column	 chromatography	
on	 silica	 gel	 eluting	 with	 a	 gradient	 from	 dichloromethane	 to	 98:02	
dichloromethane:	 methanol	 afforded	 145	 mg	 (35%)	 of	 pyrrole	 3	 as	 a	
yellowish	oil.	1H	NMR	(CDCl3,	250	MHz) δ 7.42-7.21	(m,	15H),	6.45	(s,	3H),	
3.46	 (t,	6H,	 J	 =	7.2	Hz),	2.42	 (s,	9H),	2.39	 (s,	9H),	2.07	 (t,	6H,	 J	 =	7.2	Hz);	 13C	NMR	(CDCl3,	63	
MHz) δ 194.9,	135.4,	132.8,	132.5,	129.2,	128.6,	128.0,	120.9,	110.6,	54.2,	41.7,	28.5,	11.9;	IR	
(neat) ν:		2973.6,	2927.4	(C-H),	1650.4	(C=O)	cm-1;	Elemental	analysis	(%)	calcd.	for	C45H48N4O3:	
C	78.00,	H	6.98,	N	8.09;	found:	C	77.91,	H	6.93,	N	8.05.	
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3.3.4.	Preparation	of	compounds	5	by	cross-metathesis	reactions	
	
	
	
A	 round-bottomed	 flask	 was	 charged	 with	 second	 generation	 Hoveyda-Grubbs	 catalyst	 (2%	
mmol),	 CuI	 (2%	mmol)	 and	 the	 suitable	 pyrrole	 11	 (0.15	mmol)	 in	 dry	 diethyl	 ether	 (2	mL),	
stirred	and	heated	at	40°C	during	16	(for	compounds	5a,	5c	and	5d)	or	48	hours	(for	compound	
5b).	 After	 completion	 of	 the	 reaction	 (controlled	 by	 TLC)	 the	 solvent	 was	 removed	 under	
reduced	pressure	and	the	residue	was	purified	by	 flash	column	chromatography	on	silica	gel	
eluting	with	a	gradient	from	petroleum	ether	to	8:2	petroleum	ether-ethyl	acetate,	affording	
the	desired	pyrroles	5.	
	
Dimethyl	 1,1'-[(E)	 but-2-ene-1,4-diyl]bis[5-(furan-2-yl)-2-methyl-1H-pyrrole-3-carboxylate]	
(5a)		
	
Prepared	 from	compound	14a	 (0.25	mmol);	yield:	52	mg	 (88%);	dark	yellow	
solid;	mp:	170-172	°C;	;	1H	NMR	(250	MHz,	CDCl3) δ 7.40	–	7.39	(m,	2H),	6.80	
(s,	2H),	6.42	–	6.41	(m,	2H),	6.30	–	6.29	(m,	2H),	5.22	(t,	J	=	1.6	Hz,	2H),	4.55	
(d,	J	=	1.6	Hz,	4H),	3.84	(s,	6H),	2.51	(s,	6H);	13C	NMR	(63	MHz,	CDCl3) δ 165.6,	
146.3,	 141.7,	 137.2,	 126.4,	 123.6,	 112.1,	 111.0,	 110.1,	 107.0,	 50.87,	 45.6,	
10.9;	 IR	 (neat) ν:		 3011.6,	 2944.7,	 2849.5	 (C-H),	 1694.7	 (C=O),	 1248.4	 (C-O),	
cm-1;	HRMS	(ESI)	m/z	 calcd.	 for	 [M+Na]+	485.16886,	 found	485.17047;	elemental	analysis	 (%)	
calcd.	for	C26H26N2O6:	C,	67.52;	H,	5.67;	N,	6.06;	found:	C,	67.53;	H,	5.61;	N,	6.03.	
	
(E)-1,1'-(But-2-ene-1,4-diyl)bis[5-(tert-butyl)-2-methyl-1H-pyrrole-1,3-diyl)]bis(ethan-1-one)	
(5b)		
	
Prepared	 from	 compound	 4b	 (0.25	 mmol);	 yield:	 31	 mg	 (70%);	 green	 oil;	 1H	
NMR	(250	MHz,	CDCl3) δ 6.27	(s,	2H),	4.98	(br	s,	2H),	4.59	(br	s,	4H),	2.44	(s,	6H),	
2.41	 (s,	 6H),	 1.32	 (s,	 18H);	 13C	 NMR	 (63	 MHz,	 CDCl3) δ 195.2,	 140.3,	 136.5,	
126.8,	 119.7,	 106.5,	 45.9,	 31.8,	 30.6,	 28.6,	 11.4;	 IR	 (neat) ν:		 2964.4,	 2926.1,	
2869.9	(C-H),	1650.4	(C=O),	1245.4	(C-O)	cm-1;	elemental	analysis	(%)	calcd.	for	
C26H38N2O2:	76.06;	H,	9.33;	N,	6.82;	found:	C,	76.02;	H,	9.26;	N,	6.79.	
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(E,Z)	 Dimethyl	 1,1'-(hex-3-ene-1,6-diyl)bis[2-methyl-5-(thiophen-2-yl)-1H-pyrrole-3-
carboxylate]	(5c)		
	 	
The	reaction	from	compound	4c	(0.25	mmol)	afforded	a	1:1	mixture	of	the	E	
and	Z	isomers;	yield:	53	mg	(80%);	green	oil.	
Only	 one	 of	 the	 isomers	 could	 be	 isolated	 in	 pure	 state	 and	 its	 data	 are	
given:	1H	NMR	(250	MHz,	CDCl3) δ 7.36	–	7.33	(m,	2H),	7.11	–	7.07	(m,	2H),	
7.02	–	7.01	 (m,	2H),	6.67	 (s,	2H),	5.28	–	5.25	 (m,	2H),	3.98	–	3.92	 (m,	4H),	
3.83	 (s,	 6H),	 2.59	 (s,	 6H),	 2.28	 –	 2.25	 (m,	 4H);	 13C	 NMR	 (63	 MHz,	
CDCl3) δ 165.7,	137.0,	133.8,	128.4,	127.3,	126.6,	125.7,	125.3,	111.8,	111.6,	
50.8,	43.7,	33.7,	11.6;	 IR	 (neat) ν:		3011.6,	29944.7,	2849.5	(C-H),	1694.7	(C=O),	1241.8	(C-O)	
cm-1;	elemental	analysis	(%)	calcd.	for	C28H30N2O4S2:	C,	64.34;	H,	5.79;	N,	5.36;	found:	C,	64.29:	
H,	5.80:	N,	5.39.	
	
Diethyl	 1,1'-[(E)	 (but-2-ene-1,4-diyl)]bis[2-(2-ethoxy-2-oxoethyl)-5-(furan-2-yl)-1H-pyrrole-3-
carboxylate]	(5d)		
	
Prepared	from	compound	4d	(0.25	mmol);	yield:	70	mg	(88%);	dark	orange	
oil;	1H	NMR	(250	MHz,	CDCl3) δ 7.43	–	7.42	(m,	2H),	6.85	(s,	2H),	6.44	–	6.42	
(m,	2H),	6.34	–	6.33	(m,	2H),	5.26	(t,	J	=	1.6	Hz,	2H),	4.60	(br	s,	4H),	4.30	(q,	J	
=	7.1	Hz,	4H),	4.16	(q,	J	=	7.1	Hz,	4H),	4.02	(s,	4H),	1.37	(t,	J	=	7.1	Hz,	6H),	
1.28	 (d,	 J	 =	 7.1	 Hz,	 6H);	 13C	 NMR	 (63	MHz,	 CDCl3) δ 169.7,	 164.7,	 146.1,	
141.9,	132.5,	126.8,	124.6,	114.1,	111.1,	110.4,	107.5,	61.2,	59.7,	45.9,	31.0,	
14.4,	14.2;	IR	(neat) ν:		2973.6,	2927.4	(C-H),	1727.8,	1694.1	(C=O),	1249.8,	1225.6	(C-O)	cm-1;	
elemental	 analysis	 (%)	 calcd.	 for	 C34H38N2O10:	 C,	 64.34;	 H,	 6.04;	 N,	 4.41;	 found:	 C,	 64.31;	 H,	
6.00;	N,	4.38.	
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4.	 Synthesis	 of	 fused	 pyrrole	 derivatives	 based	 on	 transition	
metal-catalyzed	reactions	
	
4.1.	Synthesis	of	pyrrolo[1,2-c]quinazolines	by	an	Ullmann	coupling-initiated	domino	
process	
The	ready	availability	of	the	N-unsubstituted	5-(o-iodophenyl)pyrroles	1a-c	allowed	us	
to	 examine	 the	 creation	 of	 a	 fused	 pyrrole	 system	 by	 generation	 of	 two	 bonds	
involving	the	nitrogen	atom	and	the	o-position	of	a	C-5	aryl	substituent.	To	this	end,	
we	first	studied	the	reaction	of	compound	1a	with	benzylamine	 in	the	presence	of	a	
Cu(II)	 salt	 and	 potassium	 carbonate,	70	observing	 the	 formation	 of	 a	 low	 yield	 of	 a	
derivative	 of	 the	 pyrrolo[1,2-c]quinazoline	 framework	 (compound	 6c),	 as	 shown	 in	
Scheme	4.1.	
	
	
Scheme	4.1	
	
The	 architecture	 generated	 is	 the	 combination	 of	 two	 privileged	 structures,	 namely	
pyrrole	 and	 quinazoline,	 and	 is	 thus	 of	 importance	 in	 medicinal	 chemistry.71	Since	
currently	 known	 methods	 giving	 access	 to	 this	 ring	 system	 are	 often	 multistep	 in	
nature	and	do	not	always	allow	the	preparation	of	derivatives	of	 the	parent	 system,	
we	considered	this	result	of	interest	and	undertook	a	brief	optimization	study,	which	is	
summarized	in	Table	1.	
	
Table	1.	Optimization	of	the	synthesis	of	6ca	
Entry	 Catalyst	 Base	 Solvent	 Yield,	%	
1	 Cu(OAc)2	 K2CO3	 toluene	 15	
2	 Cu(OAc)2	 K2CO3	 dioxane	 traces	
3	 Cu(OAc)2	 K2CO3	 DMSO	 85	
4	 Cu(OAc)2	 Na2CO3	 DMSO	 62	
5	 CuI	 K2CO3	 DMSO	 42	
a)	The	reaction	conditions	were	110	°C,	10	h	in	all	cases.		
	
																																																									
70	 For	precedent	of	a	related	domino	sequence,	see:	Sang,	P.;	Xie,	Y.;	Zou,	J.;	Zhang,	Y.	Org.	Lett.,	2012,	
14,	3894.	
71	 For	a	review,	see:	Dumitrascu,	F.;	Popa,	M.	M.	Arkivoc,	2014	(i),	428.	
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The	 best	 conditions	 found	 involved	 the	 use	 of	 Cu(II)	 acetate	 as	 the	 copper	 source,	
K2CO3	as	the	base	and	DMSO	as	the	reaction	medium,	and	were	subsequently	applied	
to	the	preparation	of	a	library	of	compounds	6,	as	summarized	in	Scheme	4.2.		
	
	
Scheme	4.2		
We	propose	 this	 transformation	 to	 take	 place	 by	 a	 domino	process	 starting	with	 an	
initial	Ullmann	coupling,	which	is	followed	by	an	aerobic	C-H	activation	process	via	the	
dehydrogenation	 of	 the	 arylamine	 to	 an	 imine.	 This	 imine	 next	 undergoes	 a	 base-
promoted	Mannich-type	reaction	with	the	pyrrole	nitrogen	and,	finally,	a	second	aerial	
dehydrogenation	step	completes	the	sequence	(Scheme	4.3).	
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Scheme	4.3	
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4.2.	 Synthesis	 of	 pyrrolo[2,1-a]isoquinoline	 and	 benzo[c]pyrrolo[1,2-a]azepine	
frameworks	by	ring-closing	Heck	reactions	
The	availability	of	pyrrole	derivatives	decorated	both	an	allyl	(or	homoallyl)	substituent	
on	nitrogen	and	an	o-iodophenyl	 substituent	at	C-5	 (compounds	1n-1w)	afforded	an	
opportunity	to	generate	fused	pyrrole	derivatives	via	their	intramolecular	Heck	cross-
coupling	reactions.72	As	shown	in	Scheme	4.4,	the	transformation	was	achieved	under	
standard	conditions,	in	the	presence	of	palladium	acetate	and	triethylamine	in	DMF	at		
	
	
Scheme	4.4																																																									
72	 For	a	precedent	of	 the	combination	of	a	multicomponent	reaction	with	Heck	 intramolecular	cross-
couplings	to	generate	diverse	heterocyclic	scaffolds,	see:	Sunderhaus,	J.	D.;	Dockendorff,	C.;	Martin,	
S.	F.	Org.	Lett.,	2007,	9,	4223.	
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120	 °C	 for	 6	 h.	 Depending	 on	 the	 length	 of	 the	 olefin	 chain,	 two	 different	 scaffolds	
were	obtained	with	complete	regioselectivity,	namely	pyrrolo[2,1-a]isoquinolines	(7b-
7f,	7i,	7j	 and	7k)	 from	 the	 N-allylpyrroles	 and	 benzo[c]pyrrolo[1,2-a]azepine	 (7a,	7g	
and	7h)	 from	the	N-homoallylpyrroles.	The	 reaction	 tolerated	well	 the	presence	of	a	
variety	of	substituents	at	the	pyrrole	C-3	position,	including	several	esters,	ketones	and	
amides.	We	were	 also	 able	 to	 functionalize	 other	 positions	 of	 the	 final	 products	 by	
including	an	additional	ester	group	in	the	β-dicarbonyl	component	(compounds	7b,	7h)	
or	by	employing	as	starting	pyrroles	the	cross-metathesis	products	1w	and	1x,	leading	
to	compounds	7e	and	7j,	respectively.	
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4.3.	 Synthesis	 of	 pyrrolo[1,2-a]azepines	 and	 pyrrolo[1,2-a]azocines	 by	 ring-closing	
metathesis	
In	order	to	generate	fused	heterocyclic	moieties	with	a	nitrogen	bridgehead	atom,	we	
moved	 to	 the	 study	 of	 the	 ring	 closing	metathesis	 (RCM)	 reaction,	 with	 the	 aim	 of	
generating	fused	azepine	and	azocine	derivatives.	The	privileged	structure	of	azepine	is	
contained	 in	 several	 commercial	 drugs	 as	 benazepril,	 as	 ACE	 inhibitor	 employed	 for	
hypertension,	 or	 fenoldopam,	 a	 selective	 D1	 agonist.	 The	 pyrrolo[1,2-a]azepine	
scaffold	is	not	common	but	can	be	found	in	a	number	of	alkaloids	from	the	Stemona	
and	 Stichoneuron	 genera	 (Stemonaceae).73	The	 pyrrolo[1,2-a]azocine	 scaffold	 is	 also	
represented	in	nature	as	a	structural	fragment	of	the	bioactive	polycyclic	alkaloids	(–)-
nakadomarin	A	and	manzamine	A.74	A	summary	of	these	structures	 is	 represented	 in	
Figure	4.1.	
	
	
Figure	4.1	
	
The	 starting	 pyrroles	 (compounds	 1ad-1ag)	 needed	 to	 have	 suitable	 olefinic	
substituents	 both	 on	 niytrogen	 and	 in	 its	 C-1	 position.	 This	 was	 achieved	 by	 use	 of	
allylamine	 and	 homoallylamine	 as	 the	 primary	 amine	 building	 blocks,	 and	 ethyl-3-
oxohept-6-enoate	 as	 the	 β-dicarbonyl	 component,	 which	 was	 obtained	 following	 a	
procedure	previously	reported	by	our	group.75	Exposure	of	these	pyrroles	(compounds	
1ad-1ag)	to	the	Grubbs	first	generation	catalyst	afforded	the	target	heterocycles	8a-d,	
in	acceptable	to	excellent	yields	under	mild	conditions	at	room	temperature,	with	the	
liberation	of	a	molecule	of	ethylene	(Scheme	4.5).																																																									
73	 Schinnerl,	 J.;	 Kaltenegger,	 E.;	 Pacher,	 T.;	 Vajrodaya	 S.;	 Hofer,	 O.;	 Greger,	 H.	Monatsh.	 Chem.,	
2005,	136,	1671.	
74	 Bonazzi,	S.;	Cheng,	B.;	Wzorek,	J.	S.;	Evans,	D.	A.	J.	Am.	Chem.	Soc.,	2013,	(25),	9338.	
75	 Tenti,	G.;	Ramos,	M.	T.;	Méndez,	J.	C.	Curr.	Org.	Synth.,	2013,	10,	645.	
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Scheme	4.5	
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4.4.	Experimental	section	
	
4.4.1.	General	procedure	 for	 the	 synthesis	of	pyrrolo[1,2-c]quinazoline	derivatives	6a-6k	by	
an	Ullmann-initiated	domino	process	
	
	
	
A	 solution	 of	 the	 suitable	 pyrrole	 derivative	 1a-1c	 (0.2	 mmol),	 the	 suitable	 benzylamine	
derivative	 (0.4	mmol),	 K2CO3	 (0.6	mmol)	 and	 Cu(OAc)2	 (10%	mmol)	 in	 DMSO	 (10	mL/mmol)	
was	stirred	at	110	°C	for	10	h.	The	cooled	reaction	mixture	was	diluted	with	EtOAc	(20	mL)	and	
washed	 with	 saturated	 aqueous	 NaCl	 (20	 mL).	 The	 organic	 layer	 was	 separated	 and	 the	
aqueous	 one	 was	 extracted	 two	 additional	 times	 with	 EtOAc	 (2	 x	 20	 mL).	 The	 combined	
organic	 layers	 were	 dried	 over	 anhydrous	 Na2SO4	 and	 concentrated	 under	 vacuum.	 The	
residue	was	purified	by	column	chromatography	on	silica	gel	using	a	gradient	from	petroleum	
ether	to	8:2	petroleum	ether-ethyl	acetate	as	eluent.	
	
Ethyl	5-(furan-2-yl)-3-methylpyrrolo[1,2-c]quinazoline-2-carboxylate	(6a)	
	
Prepared	from	pyrrole	1a	(0.2	mmol);	yield:	45	mg	(70%);	dark	yellow	solid;	
mp:	151-153	°C;	1H	NMR	(250	MHz,	CDCl3) δ 8.00	–	7.97	(m,	1H),	7.84	–	7.81	
(m,	1H),	7.64	(dd,	J	=	1.9,	0.9	Hz,	1H),	7.56	–	7.44	(m,	2H),	7.39	(s,	1H),	6.95	
(dd,	J	=	3.4,	0.9	Hz,	1H),	6.66	(dd,	J	=	3.4,	1.9	Hz,	1H),	4.39	(q,	J	=	7.1	Hz,	2H),	
2.39	(s,	3H),	1.44	(t,	J	=	7.1	Hz,	3H);	13C	NMR	(63	MHz,	CDCl3) δ 165.2,	147.1,	
143.1,	138.6,	136.7,	130.9,	129.8,	128.7,	128.4,	127.6,	121.4,	121.2,	118.2,	112.9,	111.8,	101.9,	
60.3,	14.4,	11.7;	IR	(neat)	ν:			2983.5,	2931.7	(C-H),	1709.0	(C=O),	1241.2	(C-O)	cm-1;	elemental	
analysis	(%)	calcd.	for	C19H16N2O3:	C,	71.24;	H,	5.03;	N,	8.74;	found:	C,	70.91;	H,	5.40;	N,	8.82.	
	
Ethyl	5-(4-chlorophenyl)-3-methylpyrrolo[1,2-c]quinazoline-2-carboxylate	(6b)	
	
Prepared	 from	pyrrole	1a	 (0.2	mmol);	 yield:	52	mg	 (72%);	white	 solid;	mp:	
181-183	°C;	1H	NMR	(250	MHz,	CDCl3) δ 8.02	–	7.98	(m,	1H),	7.82	–	7.78	(m,	
1H),	7.58	–	7.43	 (m,	6H),	7.41	 (s,	1H),	4.38	 (q,	 J	=	7.1	Hz,	2H),	2.24	 (s,	3H),	
1.43	(t,	J	=	7.1	Hz,	3H);	13C	NMR	(63	MHz,	CDCl3) δ 165.1,	146.5,	136.9,	136.1,	
134.6,	 130.1,	 129.9,	 129.8,	 128.7,	 128.2,	 128.0,	 127.6,	 121.2,	 120.8,	 118.5,	
101.8,	 60.3,	 15.2,	 14.4;	 IR	 (neat) ν: 2979.6,	 2978.4	 (C-H),	 1706.2	 (C=O),	
1239.2	(C-O)	cm-1;	HRMS	(MALDI	TOF)	calcd.	for	C21H17ClN2O2:	364.0979,	found:	364.0984.	
	
Ethyl	3-methyl-5-phenylpyrrolo[1,2-c]quinazoline-2-carboxylate	(6c)		
	
Prepared	from	pyrrole	1a	 (0.2	mmol);	yield:	56	mg	(85%);	yellow	solid;	mp:	
144-146	°C;	1H	NMR	(250	MHz,	CDCl3) δ 8.04	–	8.00	(m,	1H),	7.85	–	7.81	(m,	
1H),	7.59	–	7.50	 (m,	7H),	7.41	 (s,	1H),	4.38	 (q,	 J	=	7.1	Hz,	2H),	2.20	 (s,	3H),	
1.43	(t,	J	=	7.1	Hz,	3H);	13C	NMR	(63	MHz,	CDCl3) δ 165.3,	147.7,	137.0,	136.2,	
130.6,	 130.0,	 129.9,	 128.5,	 128.4,	 128.0,	 127.6,	 121.2,	 120.9,	 118.4,	 101.7,	
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60.3,	 14.9,	 14.4;	 IR	 (neat) ν: 2978.0,	 2935.9	 (C-H),	 1705.6	 (C=O),	 1237.9	 (C-O)	 cm-1;	 HRMS	
(MALDI	TOF)	calcd.	for	C21H18N2O2:	330.1368,	found:	330.1376.	
	
Ethyl	5-(4-chlorophenyl)-3-ethylpyrrolo[1,2-c]quinazoline-2-carboxylate	(6d)	
	
Prepared	 from	 pyrrole	 1c	 (0.2	mmol);	 yield:	 53	mg	 (70%);	 yellowish	 solid;	
mp:	98-100	°C;	1H	NMR	(250	MHz,	CDCl3) δ 8.04	–	8.00	(m,	1H),	7.82	–	7.79	
(m,	1H),	7.62	–	7.46	(m,	6H),	7.45	(s,	1H),	4.39	(q,	J	=	7.1	Hz,	2H),	2.82	(q,	J	=	
7.3	Hz,	2H),	1.44	(t,	J	=	7.1	Hz,	3H),	0.83	(t,	J	=	7.3	Hz,	3H);	13C	NMR	(63	MHz,	
CDCl3) δ 164.9,	146.4,	136.9,	136.9,	136.2,	134.6,	130.4,	129.6,	128.8,	128.3,	
128.0,	 127.6,	 121.2,	 121.0,	 117.8,	 102.3,	 60.3,	 19.6,	 14.7,	 14.4;	 IR	
(neat) ν: 2977.2,	 2931.9,	 2928.6	 (C-H),	 1708.0	 (C=O),	 1233.7,	 1225.9	 (C-O)	 cm-1;	 elemental	
analysis	(%)	calcd.	for		C22H19ClN2O2:	C,	69.75;	H,	5.06;	N,	7.39;	found:	C,	69.38;	H,	5.13;	N,	7.63.	
	
Methyl	5-(2-bromophenyl)-3-methylpyrrolo[1,2-c]quinazoline-2-carboxylate	(6e)	
	
Prepared	from	pyrrole	1b	(0.2	mmol);	yield:	51	mg	(65%);	yellowish	solid;	mp:	
74-76	°C;	1H	NMR	(250	MHz,	CDCl3) δ 8.05	–	8.01	(m,	1H),	7.86	–	7.82	(m,	1H),	
7.75	–	7.71	(m,	1H),	7.63	–	7.45	(m,	5H),	7.42	(s,	1H),	3.92	(s,	3H),	2.24	(s,	3H);	
13C	 NMR	 (63	 MHz,	 CDCl3) δ 165.7,	 146.1,	 137.4,	 136.7,	 132.7,	 131.4,	 130.7,	
130.2,	 129.5,	 128.4,	 128.2,	 127.7,	 127.6,	 123.0,	 121.3,	 121.1,	 117.8,	 101.8,	
51.5,	 12.8;	 IR	 (neat) ν: 2945.4,	 2943.4	 (C-H),	 1712.3	 (C=O),	 1237.4	 (C-O)	 cm-1;	 elemental		
analysis	(%)	calcd.	for	C20H15BrN2O2:	C,	60.78;	H,	3.83;	N,	7.09;	found:	C,	61.09;	H,	4.10;	N,	7.33.	
	
Ethyl	3-ethyl-5-(furan-2-yl)pyrrolo[1,2-c]quinazoline-2-carboxylate	(6f)		
	
Prepared	 from	 pyrrole	 1c	 (0.2	 mmol);	 yield:	 40	 mg	 (60%);	 yellowish	 solid;	
mp:	85-87	°C;	1H	NMR	(250	MHz,	CDCl3) δ 8.03	–	7.99	(m,	1H),	7.84	–	7.81	(m,	
1H),	7.60	–	7.57	(m,	1H),	7.53	–	7.47	(m,	2H),	7.44	(s,	1H),	7.43	–	7.41	(m,	1H),	
7.20	–	7.17	(m,	1H),	4.40	(q,	J	=	7.1	Hz,	2H),	2.91	(q,	J	=	7.3	Hz,	2H),	1.44	(t,	J	=	
7.1	Hz,	3H),	0.94	(t,	J	=	7.3	Hz,	3H);	13C	NMR	(63	MHz,	CDCl3) δ 164.9,	141.7,	
137.5,	136.8,	136.1,	130.6,	129.1,	128.4,	128.1,	127.9,	127.6,	126.7,	121.2,	121.1,	117.8,	102.3,	
60.3,	19.7,	15.2,	14.4;	 IR	(neat) ν: 2976.1,	2975.2,	2878.6	(C-H),	1708.9	(C=O),	1231.8,	1226.1	
(C-O)	 cm-1;	 elemental	 analysis	 (%)	 calcd.	 for	C20H18N2O3:	C,	 71.84;	H,	 5.43;	N,	 8.38;	 found:	C,	
71.49;	H,	5.03;	N,	8.63.	
	
Methyl	5-(4-fluorophenyl)-3-methylpyrrolo[1,2-c]quinazoline-2-carboxylate	(6g)	
	
Prepared	from	pyrrole	1b	(0.2	mmol);	yield:	48	mg	(72%);	yellowish	solid;	mp:	
202-204	°C;	 1H	NMR	(250	MHz,	CDCl3) δ 8.01	–	7.98	(m,	1H),	7.83	–	7.79	(m,	
1H),	7.63	–	7.58	(m,	2H),	7.53	–	7.48	(m,	2H),	7.40	(s,	1H),	7.29	–	7.21	(m,	2H),	
3.92	(s,	3H),	2.22	(s,	3H);	13C	NMR	(63	MHz,	CDCl3) δ 165.6,	163.6	(d,	J	=	252	
Hz),	146.7,	136.9,	132.3	(d,	 J	=	3.6),	130.6	 (d,	J	=	8.3),	130.2	 (d,	J	=	18.9	Hz),	
128.2,	 128.0,	 127.7,	 121.2,	 120.8,	 118.2,	 115.8,	 115.5,	 101.7,	 51.5,	 15.1;	 19F	
NMR	 (235	MHz,	 CDCl3) δ (-110.11)	 –	 (-110.22)	 (m);	 IR	 (neat) ν: 3031.7,	 2932.7	 (C-H),	 1712.1	
(C=O),	1239.2	 (C-O)	cm-1;	elemental	 	analysis	 (%)	calcd.	 for	C20H15FN2O2:	C,	71.85;	H,	4.52;	N,	
8.38;	found:	C,	71.51;	H,	4.23;	N,	7.98.	
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Ethyl	3-ethyl-5-phenylpyrrolo[1,2-c]quinazoline-2-carboxylate	(6h)	
	
Prepared	 from	 pyrrole	 1c	 (0.2	 mmol);	 yield:	 52	 mg	 (75%);	 yellowish	 solid;	
mp:	 103-105	 °C;	 1H	NMR	 (250	MHz,	 CDCl3) δ 7.98	 (dd,	 J	 =	 7.4,	 1.9	Hz,	 1H),	
7.83	–	7.75	(m,	1H),	7.60	(dd,	J	=	7.4,	2.2	Hz,	2H),	7.56	–	7.43	(m,	5H),	7.39	(s,	
1H),	4.34	(q,	J	=	7.1	Hz,	2H),	2.71	(q,	J	=	7.3	Hz,	2H),	1.39	(t,	J	=	7.1	Hz,	3H),	
0.77	(t,	J	=	7.3	Hz,	3H);	13C	NMR	(63	MHz,	CDCl3) δ 165.4,	148.0,	137.7,	137.4,	
136.6,	130.8,	130.4,	129.0,	128.6,	128.5,	128.4,	128.0,	121.6,	121.5,	118.0,	102.5,	60.7,	30.1,	
20.0,	15.3,	14.8;	IR	(neat) ν: 2923.4,	2852.4	(C-H),	1730.2	(C=O),	1232.2	(C-O)	cm-1;	elemental		
analysis	(%)	calcd.	for	C22H20N2O2:	C,	76.72;	H,	5.85;	N,	8.13;	found:	C,	76.91;	H,	5.63;	N,	7.97.	
	
Methyl	3-methyl-5-(thiophen-2-yl)pyrrolo[1,2-c]quinazoline-2-carboxylate	(6i)	
	
Prepared	from	pyrrole	1b	(0.2	mmol);	yield:	49	mg	(76%);	dark	yellowish	solid;	
mp:	129-130	 °C;	1H	NMR	 (250	MHz,	CDCl3) δ 8.01	–	7.98	 (m,	1H),	7.85	–	7.81	
(m,	1H),	7.60	–	7.48	(m,	3H),	7.41	(s,	1H),	7.35	–	7.33	(m,	1H),	7.21	–	7.18	(m,	
1H),	3.93	(s,	3H),	2.38	(s,	3H);	13C	NMR	(63	MHz,	CDCl3) δ 165.7,	141.8,	136.9,	
135.9,	 131.0,	 130.3,	 129.9,	 128.4,	 128.2,	 127.9,	 127.6,	 126.8,	 121.2,	 120.9,	
118.2,	101.8,	51.5,	14.1;	IR	(neat) ν: 2921.0,	2918.8,	2851.3	(C-H),	1728.7	(C=O),	1221.1	(C-O)	
cm-1;	elemental		analysis	(%)	calcd.	for	C18H14N2O2S:	C,	67.06;	H,	4.38;	N,	8.69;	found:	C,	66.80;	
H,	3.99;	N,	8.34.	
	
Methyl	5-(furan-2-yl)-3-methylpyrrolo[1,2-c]quinazoline-2-carboxylate	(6j)	
	
Prepared	from	pyrrole	1b	(0.2	mmol);	yield:	46	mg	(75%);	dark	yellowish	solid;	
mp:	174-176	°C;	 1H	NMR	(250	MHz,	CDCl3) δ 7.99	–	7.95	 (m,	1H),	7.84	–	7.81	
(m,	1H),	7.65	–	7.64	(m,	1H),	7.55	–	7.38	(m,	2H),	7.38	(s,	1H),	6.96	–	6.95	(m,	
1H),	 6.68	 –	 6.66	 (m,	 1H),	 3.93	 (s,	 3H),	 2.39	 (s,	 3H);	 13C	 NMR	 (63	 MHz,	
CDCl3) δ 165.6,	 147.0,	 143.1,	 138.5,	 136.7,	 131.1,	 129.9,	 128.7,	 128.4,	 127.6,	
121.3,	121.2,	117.8,	113.0,	111.9,	101.8,	51.5,	11.7;	 IR	(neat) ν: 2943.9,	2946.4,	2889.7	(C-H),	
1712.3	(C=O),	1244.3	(C-O)	cm-1;	elemental	analysis	(%)	calcd.	for	C18H14N2O3:	C,	70.58;	H,	4.61;	
N,	9.15;	found:	C,	70.29;	H,	4.31;	N,	9.54.	
	
Ethyl	5-(4-methoxyphenyl)-3-methylpyrrolo[1,2-c]quinazoline-2-carboxylate	(6k)	
	
Prepared	 from	pyrrole	1a	 (0.2	mmol);	 yield:	47	mg	 (65%);	 yellowish	oil;	 1H	
NMR	(250	MHz,	CDCl3) δ 7.92	–	7.89	(m,	1H),	7.73	–	7.69	(m,	1H),	7.45	–	7.35	
(m,	4H),	7.19	(s,	1H),	6.97	–	6.94	(m,	2H),	4.28	(q,	J	=	7.1	Hz,	2H),	3.82	(s,	3H),	
2.15	(s,	3H),	1.33	(t,	J	=	7.1	Hz,	3H);	13C	NMR	(63	MHz,	CDCl3) δ 165.8,	161.3,	
148.1,	 137.6,	 131.2,	 130.5,	 130.4,	 129.0,	 128.4,	 128.3,	 128.0,	 121.6,	 121.3,	
118.7,	114.3,	102.1,	60.7,	56.0,	15.6,	14.9;	IR	(neat) ν: 2920.8,	2859.2	(C-H),	
1709.6	 (C=O),	 1219.3	 (C-O)	 cm-1;	 elemental	 	 analysis	 (%)	 calcd.	 for	 C22H20N2O3:	 C,	 73.32;	 H,	
5.59;	N,	7.77;	found:	C,	73.51;	H,	5.78;	N,	7.53.	
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4.4.2.	Preparation	of	compounds	7a-7k	by	intramolecular	Heck	reactions	
	
	
	
A	mixture	 of	 compound	 1n-1x	 (0.2	mmol),	 triethylamine	 (Et3N,	 0.5	mmol)	 and	 palladium(II)	
acetate	(5	mol%)	in	dimethylformamide	(1	mL)	was	refluxed	for	6	h	and	monitored	by	TLC.	The	
solvent	 was	 removed	 under	 reduced	 pressure	 and	 the	 purification	 of	 the	 residue	 by	 flash	
column	 chromatography	 on	 silica	 gel,	 eluting	 with	 a	 gradient	 from	 petroleum	 ether	 to	 8:2	
petroleum	ether−ethyl	acetate,	afforded	the	desired	compounds	7a-7k.	
	
Ethyl	3,7-dimethyl-5H-benzo[c]pyrrolo[1,2-a]azepine-2-carboxylate	(7a)	
	
Prepared	 from	 pyrrole	1p	 (0.2	mmol);	 yield:	 48	mg	 (85%);	 yellowish	 oil;	 1H	
NMR	(250	MHz,	CDCl3) δ 7.64	–	7.61	(m,	1H),	7.54	–	7.50	(m,	1H),	7.38	–	7.35	
(m,	2H),	6.81	(s,	1H),	6.10	–	6.04	(m,	1H),	4.31	(q,	J	=	7.1	Hz,	2H),	4.16	(d,	J	=	
7.2	Hz,	2H),	2.63	(s,	3H),	2.18	(s,	3H),	1.37	(t,	J	=	7.1	Hz,	3H);	13C	NMR	(63	MHz,	
CDCl3) δ 165.7,	141.1,	136.2,	134.0,	132.8,	131.9,	129.3,	127.8,	127.3,	126.7,	
122.9,	112.4,	108.4,	59.3,	40.2,	23.1,	14.6,	11.1;	IR	(neat) ν: 1669.0	(C=O),	1236.0	(C-O),	1066.0	
(C=C-H)	 cm-1;	 elemental	 analysis	 (%)	 calcd.	 for	 C18H19NO2;	 C	 76.84,	 H	 6.81,	 N	 4.98;	 found:	 C	
77.03,	H	7.01,	N	4.76.	
	
Ethyl	3-(2-ethoxy-2-oxoethyl)-6-methylpyrrolo[2,1-a]isoquinoline-2-carboxylate	(7b)	
	
Prepared	 from	pyrrole	1t	 (0.2	mmol);	 yield:	 56	mg	 (82%);	 yellowish	 solid;	
Mp:	115-117	°C;	1H	NMR	(250	MHz,	CDCl3) δ 8.10	–	8.06	(m,	1H),	7.71	–	7.68	
(m,	1H),	7.53	–	7.43	(m,	3H),	7.38	(s,	1H),	4.44	(s,	2H),	4.44	–	4.35	(m,	2H),	
4.21	(q,	J	=	7.1	Hz,	2H),	2.47	(s,	3H),	2.20	(s,	2H),	1.44	(t,	J	=	7.1	Hz,	3H),	1.28	
(t,	 J	 =	 7.1	 Hz,	 3H);	 13C	NMR	 (63	MHz,	 CDCl3) δ 169.7,	 165.4,	 129.2,	 127.8,	
127.5,	126.2,	123.8,	122.8,	122.4,	119.3,	119.0,	115.8,	101.0,	61.2,	60.0,	30.7,	16.8,	14.4,	14.2;	
IR	 (neat)	 ν:	1697.4,	 1669.0	 (C=O),	 1236.0	 (C-O)	 cm-1;	 elemental	 analysis	 (%)	 calcd.	 for	
C20H21NO4:	C	69.78,	H	6.94,	N	5.63;	found:	C	69.57,	H	7.00,	N	3.50.	HRMS	(MALDI	TOF)	calcd.	
for	C20H21NO4:	339,1471,	found:	339.145.	
	
tButyl	3,6-dimethylpyrrolo[2,1-a]isoquinoline-2-carboxylate	(7c)	
	
Prepared	 from	pyrrole	1o	 (0.2	mmol);	 yield:	51	mg	 (86%);	yellowish	 solid;	
mp:	86-88	°C;	 1H	NMR	(250	MHz,	CDCl3)	δ	8.07	–	8.04	(m,	1H),	7.69	–	7.66	
(m,	1H),	7.51	–	7.40	(m,	3H),	7.27	(s,	1H),	2.77	(s,	3H),	2.47	(s,	3H),	1.66	(s,	
9H);	 13C	NMR	 (63	MHz,	CDCl3)	δ		 165.4,	 127.9,	 127.6,	 127.3,	 126.7,	 126.4,	
125.8,	 123.7,	 122.2,	 119.0,	 118.4,	 116.0,	 100.8,	 79.9,	 28.5,	 16.8,	 10.5;	 IR	
(neat)	 ν:	1702.4	 (C=O),	 1247.9	 (C-O),	 1077.7	 (C=C-H)	 cm-1;	 elemental	
analysis	(%)	calcd.	for	C19H21NO2:	C	77.26,	H	7.17,	N	4.74;	found:	C	76.98,	H	6.87,	N	4.51.	
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Isopropyl	3,6-dimethylpyrrolo[2,1-a]isoquinoline-2-carboxylate	(7d)	
	
Prepared	from	pyrrole	1s	(0.2	mmol);	yield:	43	mg	(77%);	yellowish	solid;	mp:	
85-87	°C;	1H	NMR	(250	MHz,	CDCl3)	δ	7.83	–	7.80	(m,	1H),	7.44	–	7.40	(m,	1H),	
7.27	–	7.18	(m,	3H),	7.08	(s,	1H),	5.08	(p,	J	=	6.3	Hz,	1H),	2.53	(s,	3H),	2.20	(d,	J	
=	1.3	Hz,	3H),	1.21	(d,	J	=	6.3	Hz,	6H);	13C	NMR	(63	MHz,	CDCl3)	δ		165.4,	128.1,	
127.5,	 127.3,	 127.0,	 126.3,	 125.8,	 123.7,	 122.1,	 118.8,	 118.5,	 114.8,	 100.5,	
66.9,	22.6,	16.7,	10.4;	IR	(neat)	ν:	1690.4	(C=O),	1269.0	(C-O),	1100.8	(C=C-H)	cm-1;	elemental	
analysis	(%)	calcd.	for	C18H19NO2:	C	76.84,	H	6.81,	N	4.98;	found:	C	76.94,	H	6.49,	N	5.21.	HRMS	
(MALDI	TOF)	calcd.	for	C18H19NO2:	281.1416,	found:	281.1412.	
	
Ethyl	2-(2-acetyl-3-methylpyrrolo[2,1-a]isoquinolin-6-yl)acetate	(7e)	
	
Prepared	from	pyrrole	1x	(0.1	mmol);	yield:	27	mg	(80%);	white	solid;	mp:	135-
137	°C;	 1H	NMR	(250	MHz,	CDCl3) δ 8.08	–	8.05	 (m,	1H),	7.67	–	7.64	 (m,	1H),	
7.61	(br	s,	1H),	7.56	–	7.40	(m,	2H),	7.25	(s,	1H),	4.22	(q,	J	=	7.1	Hz,	2H),	3.83	(s,	
2H),	 2.81	 (s,	 3H),	 2.63	 (s,	 3H),	 1.30	 (d,	 J	 =	 7.1	 Hz,	 3H);	 13C	 NMR	 (63	 MHz,	
CDCl3) δ 196.4,	 171.0,	 128.2,	 128.0,	 126.9,	 126.6,	 126.2,	 123.7,	 122.9,	 122.2,	
121.2,	 116.7,	 100.9,	 61.3,	 36.8,	 29.1,	 14.2,	 10.7;	 IR	 (neat) ν: 	1699.4,	 1689.0	
(C=O),	1236.0	(C-O),	1066.0	(C=C-H)	cm-1;	elemental	analysis	(%)	calcd.	for	C19H19NO3:	C	73.77,	
H	6.19,	N	4.53;	found:	C	72.99,	H	6.39,	N	4.67.	
	
1-(3,6-Dimethylpyrrolo[2,1-a]isoquinolin-2-yl)ethan-1-one	(7f)	
	
Prepared	from	pyrrole	1q	(0.2	mmol);	yield:	38	mg	(80%);	yellowish	solid;	mp:	
172-174	 °C;	 1H	NMR	 (250	MHz,	CDCl3)	δ	8.08	–	8.04	 (m,	1H),	7.71	–	7.68	 (m,	
1H),	7.56	–	7.42	(m,	3H),	7.24	(s,	1H),	2.80	(s,	3H),	2.63	(s,	3H),	2.47	(d,	J	=	1.2	
Hz,	 3H);	 13C	NMR	 (63	MHz,	 CDCl3) δ 196.4,	 128.1,	 127.8,	 127.4,	 126.5,	 126.4,	
126.0,	 123.9,	 122.5,	 122.0,	 119.3,	 118.8,	 100.7,	 29.1,	 16.8,	 10.7;	 IR	
(neat) ν: 1689.0	 (C=O),	 1064.5	 (C=C-H)	 cm-1;	 elemental	 analysis	 (%)	 calcd.	 for	 C16H15NO:	 C	
80.98,	H	6.37,	N	5.90;	found:	C	80.59,	H	6.40,	N	5.84.	
	
1-(3,7-Dimethyl-5H-benzo[c]pyrrolo[1,2-a]azepin-2-yl)ethan-1-one	(7g)	
	
Prepared	from	pyrrole	1n	(0.2	mmol);	yield:	45	mg	(90%);	white	solid;	mp:	91-93	
°C;	 1H	NMR	(250	MHz,	CDCl3) δ 7.64	–	7.61	 (m,	1H),	7.55	–	7.52	 (m,	1H),	7.40	–	
7.37	(m,	2H),	6.74	(s,	1H),	6.08	(t,	J	=	7.2	Hz,	1H),	4.17	(d,	J	=	7.2	Hz,	2H),	2.66	(s,	
3H),	 2.47	 (s,	 3H),	 2.19	 (s,	 3H);13C	 NMR	 (63	 MHz,	 CDCl3) δ 195.1,	 141.2,	 136.3,	
133.7,	 132.7,	 131.7,	 129.2,	 127.9,	 127.4,	 126.9,	 122.9,	 121.4,	 108.9,	 39.9,	 28.5,	
23.1,	11.5;	IR	(neat)	ν:1702.4	(C=O),	1239.0	(C-O),	1087.6(C=C-H)	cm-1;	elemental	
analysis	(%)	calcd.	for	C17H17NO:	C	81.24,	H	6.82,	N	5.57;	found:	C	81.05,	H	6.88,	N	5.65.	
	
Ethyl	3-(2-ethoxy-2-oxoethyl)-7-methyl-5H-benzo[c]pyrrolo[1,2-a]azepine-2-carboxylate	(7h)	
	
Prepared	 from	pyrrole	1r	 (0.2	mmol);	yield:	56	mg	 (80%);	yellowish	solid;	
mp:	87-89	°C;	1H	NMR	(250	MHz,	CDCl3) δ 7.65	–	7.61	(m,	1H),	7.54	–	7.51	
(m,	1H),	7.38	–	7.36	(m,	2H),	6.85	(s,	1H),	6.10	–	6.03	(m,	1H),	4.35	–	4.16	
(m,	8H),	2.18	(d,	J	=	1.4	Hz,	3H),	1.37	(t,	J	=	7.1	Hz,	3H),	1.31	(t,	J	=	7.1	Hz,	
3H);	 13C	NMR	 (63	MHz,	 CDCl3) δ 169.9,	 165.2,	 140.9,	 136.3,	 133.9,	 131.7,	
129.4,	 129.4,	 127.8,	 127.3,	 126.9,	 123.3,	 113.7,	 108.7,	 61.2,	 59.5,	 41.1,	
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31.0,	 23.0,	 14.5,	 14.2;	 IR	 (neat)	ν:	1689.4,	 1669.0	 (C=O),	 1236.0	 (C-O),	 1066.0	 (C=C-H)	 cm-1;	
elemental	analysis	(%)	calcd.	for	C21H23NO4;	C	71.37,	H	6.56,	N	3.96;	found:	C	71.60,	H	6.43,	N	
4.01.	
	
Ethyl	3,6-dimethyl-pyrrolo[2,1-a]isoquinoline-2-carboxylate	(7i)	
	
Prepared	from	pyrrole	1u	 (100	mg,	0.25	mmol);	yield:	53	mg	(80%);	orange	
solid;	mp:	86-89	°C;	1H	NMR	(CDCl3,	250	MHz) δ 8.06	(dd,	J	=	7.6,	1.2	Hz,	1H),	
7.68	(dd,	J	=	7.7,	1.3	Hz,	1H),	7.55-7-40	(m,	3H),	7.32	(s,	1H),	4.39	(q,	J	=	7.1	
Hz,	2H),	2.79	(s,	3H),	2.47	(d,	J	=	1.2	Hz,	3H),	1.45	(t,	J	=	7.1	Hz,	3H);	13C	NMR	
(CDCl3,	 63	 MHz) δ 165.9,	 128.2,	 127.7,	 127.3,	 127.2,	 126.4,	 125.9,	 123.7,	
122.2,	118.9,	118.7,	114.5,	100.6,	59.8,	16.8,	14.5,	10.4;	 IR	 (neat) ν: 1699.9	(C=O),	1249.9	(C-
O),	1066.9	 (C=C-H)	cm-1;	elemental	analysis	 (%)	calcd	 for	C17H17NO2:	C	76.38,	H	6.41,	N	5.24;	
found:	C	76.20,	H	6.37,	N	5.20.	
	
Ethyl	6-ethoxycarbonylmethyl-3-methyl-pyrrolo[2,1-a]isoquinoline-2-carboxylate	(7j)	
	
Prepared	 from	 pyrrole	 1w	 (100	 mg,	 0.21	 mmol);	 yield:	 60	 mg	 (83%);	
yellowish	solid;	mp:	111-114	°C;	1H	NMR	(CDCl3,	250	MHz) δ 8.06	(td,	J	=	7.2,	
1.3	Hz,	1H),	7.64	(dd,	J	=	7.8,	1.1	Hz,	1H),	7.60	(s,	1H),	7.50	(td,	J	=	7.8,	1.3	Hz,	
1H),	7.41	(td,	J	=	7.2,	1.3	Hz,	1H),	7.33	(d,	J	=	0.6	Hz,	1H),	4.39	(q,	J	=	7.1	Hz,	
2H),	4.22	(q,	J	=	7.1	Hz,	2H),	3.82	(d,	J	=	0.6	Hz,	2H),	2.81	(s,	3H),	1.45	(t,	J	=	
7.1	Hz,	3H),	1.28	(t,	J	=	7.1	Hz,	3H);	13C	NMR	(CDCl3,	63	MHz) δ 171.1,	165.7,	
128.3,	 127.9,	 127.2,	 126.6,	 126.2,	 126.1,	 122.4,	 121.4,	 116.1,	 115.1,	 100.8,	
61.2,	59.9,	36.8,	14.5,	14.2,	10.4;	IR	(neat) ν: 1728.8,	1701.6	(C=O),	1248.8,	1209.2	(C-O)	cm-1;	
elemental	analysis	(%)	calcd	for	C20H21NO4:	C	70.78,	H	6.24,	N	4.13;	found:	C	70.72,	H	6.18,	N	
4.02.	
	
3,6-Dimethylpyrrolo[2,1-a]isoquinoline-2-carboxamide	(7k)	
	
Prepared	 from	pyrrole	 1v	 (0.2	mmol);	 yield:	 33	mg	 (70%);	 yellowish	 solid;	
mp:	171-173	°C;	1H	NMR	(250	MHz,	CDCl3) δ 8.04	–	8.00	(m,	1H),	7.72	–	7.69	
(m,	1H),	7.54	–	7.42	(m,	3H),	7.03	(s,	1H),	5.80	(br	s,	2H),	2.81	(s,	3H),	2.48	(d,	
J	=	1.2	Hz,	3H);	13C	NMR	(63	MHz,	CDCl3) δ 168.1,	128.3,	127.6,	127.5,	126.1,	
126.0,	 123.9,	 121.9,	 119.0,	 118.5,	 116.3,	 99.5,	 97.5,	 16.8,	 10.4;	 IR	
(neat) ν: 1689.0	 (C=O),	 1236.0	 (C-O)	 cm-1,	 1066.0	 (C=C-H)	 cm-1;	 elemental	 analysis	 (%)	 calcd.	
for	C15H14N2O:	C	75.61,	H	5.92,	N	11.76;	found:	C	75.30,	H	5.80,	N	11.89.	
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4.4.3.	Preparation	of	compounds	8	by	ring-closing-metathesis	
	
	
	
To	a	 solution	of	pyrrole	 (0.5	mmol)	 in	dry	dichloromethane,	 first	 generation	Grubbs	 catalyst	
(5%	mmol)	was	added.	 The	mixture	was	 stirred	 for	5	h	 and,	 then,	 the	 solvent	was	 removed	
under	reduced	pressure.	The	crude	residue	was	purified	by	flash	column	chromatography	on	
silica	gel	using	petroleum	ether-	ethyl	acetate	 (9:1)	as	 solvent,	 giving	 the	desired	compound	
8a-8d.	
	
tButyl-3-phenyl-8,9-dihydro-5H-pyrrolo[1,2-a]azepine-1-carboxylate	(8a)	
	
Prepared	 from	 pyrrole	1ad	 (0.2	mmol);	 yield:	 52	mg	 (67%);	 yellowish	 solid;	
mp:	87.2°C;	1H	NMR	(250	MHz,	CDCl3)	δ	7.56	–	7.17	(m,	5H),	6.50	(s,	1H),	5.90	
–	5.69	(m,	2H),	4.53	(m,	2H),	3.60	–	3.38	(m,	2H),	2.49	(br	s,	2H),	1.59	(s,	9H);	
13C	NMR	 (63	MHz,	 CDCl3)	 δ	 165.0,	 141.1,	 134.0,	 132.9,	 132.5,	 129.0,	 128.5,	
127.2,	122.4,	112.3,	108.9,	79.3,	42.1,	28.4,	22.3;	IR	(neat)	ν:	1699.4	(C=O),	1236.0	(C-O)	cm-1;	
elemental	analysis	(%)	calcd.	for	C20H23NO2:	C	77.64,	H	7.49,	N	4.53;	found:	C	77.38,	H	7.64,	N	
4.22.	
	
Ethyl-3-phenyl-5,6,9,10-tetrahydropyrrolo[1,2-a]azocine-1-carboxylate	(8b)	
	
	
Prepared	 from	pyrrole	1ae	 (0.2	mmol);	 yield:	 73	mg	 (84%);	 yellowish	 oil;	 1H	
NMR	(250	MHz,	CDCl3)	δ	7.49	–	7.31	(m,	5H),	6.56	(s,	1H),	5.73	(m,	1H),	5.47	
(m,	1H),	4.29	(q,	J	=	7.1	Hz,	2H),	4.20	(t,	J	=	6.8	Hz,	2H),	3.53	(t,	J	=	7.1	Hz,	2H),	
2.63	(q,	J	=	6.8	Hz,	2H),	2.52	(q,	J	=	6.7	Hz,	2H),	1.36	(t,	J	=	7.1	Hz,	3H);	13C	NMR	
(63	 MHz,	 CDCl3)	 δ	 165.48,	 141.2,	 133.0,	 132.9,	 131.9,	 129.5,	 128.4,	 127.4,	
125.7,	110.8,	109.7,	59.2,	44.3,	29.0,	27.0,	24.7,	14.5;	 IR	 (neat)	ν:	1689.4	(C=O),	1246.0	(C-O)	
cm-1;	 elemental	 analysis	 (%)	 calcd.	 for	C19H21NO2:	C	77.26,	H	7.17,	N	4.74;	 found:	C	75.45,	H	
7.46,	N	4.35.	
	
Ethyl-3-(4-chlorophenyl)-8,9-dihydro-5H-pyrrolo[1,2-a]azepine-1-carboxylate	(8c)	
	
Prepared	from	pyrrole	1af	(0.2	mmol);	yield:	65	mg	(81%);	yellowish	oil;	1H	
NMR	 (250	MHz,	 CDCl3)	 δ	 7.68	 –	 7.26	 (m,	 4H),	 6.70	 (s,	 1H),	 6.50	 (m,	 4H),	
5.94	–	5.62	(m,	2H),	5.16	–	4.89	(m,	2H),	4.17	–	3.55	(m,	2H),	1.24	(s,	3H);	
13C	NMR	(63	MHz,	CDCl3)	δ	165.4,	142.0,	134.2,	133.3,	131.9,	130.8,	130.1,	
128.7,	122.0,	110.8,	109.0,	59.3,	42.2,	28.3,	22.3,	14.5;	IR	(neat)	ν:	1696.4	(C=O),	1238.0	(C-O)	
cm-1;	elemental	analysis	(%)	calcd.	for	C18H18ClNO2:	C	68.46,	H	5.75,	N	4.44;	found:	C	68.08,	H	
5.96,	N	4.12.	
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Ethyl-2-methyl-3-phenyl-5,6,9,10-tetrahydropyrrolo[1,2-a]azocine-1-carboxylate	(8d)	
	
Prepared	 from	pyrrole	1ag	 (0.2	mmol);	 yield:	 36	mg	 (50%);	 yellowish	 oil;	 1H	
NMR	(250	MHz,	CDCl3)	δ	7.34	(tdd,	J	=	6.5,	5.5,	2.6	Hz,	3H),	7.20	–	7.11	(m,	2H),	
5.80	–	5.48	(m,	1H),	5.43	–	5.22	(m,	1H),	4.21	(q,	J	=	7.1	Hz,	2H),	3.94	(t,	J	=	6.8	
Hz,	2H),	3.39	(t,	J	=	7.0	Hz,	2H),	2.53	(q,	2H),	2.41	–	2.22	(q,	2H),	2.02	(s,	3H),	
1.28	(t,	J	=	7.1	Hz,	3H);	13C	NMR	(63	MHz,	CDCl3)	δ	166.3,	140.1,	132.4,	131.6,	
131.2,	130.5,	128.3,	127.6,	125.7,	117.9,	110.0,	59.0,	44.0,	29.2,	27.4,	24.8,	14.5,	12.1;	IR	(neat)	
ν:	1699.4	(C=O),	1236.0	(C-O)	cm-1;	elemental	analysis	(%)	calcd.	for	C20H23NO2:	C	77.64,	H	7.49,	
N	4.53;	found:	C	77.25,	H	7.34,	N	4.25.	
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5.	Ring	creation	based	on	intramolecular	Diels-Alder	reactions	
	
5.1.	Introduction	
Polyheterocyclic	 derivatives	 with	 a	 ring-fusion	 nitrogen	 atom	 are	 interesting	
compounds	 in	 drug	 discovery	 programs.	 For	 this	 reason,	 new	 synthetic	methods	 for	
the	 fast	 generation	 of	 5,6-dihydropyrrolo[2,1-a]isoquinoline	 and	 5H-pyrrolo[2,1-
a]isoindole	(Figure	5.1)	are	of	relevance..	
	
	
Figure	5.1	
	
These	scaffolds	are	important	structural	fragments	in	alkaloids	and	pharmacologically	
active	 compounds	 (Figure	 5.2). 76 	Lamellarine	 C	 is	 a	 member	 of	 the	 well-known	
lamellarine	 family	 of	 anticancer	 marine	 pyrrole	 alkaloids.	 Oleracein	 E	 is	 a	
neuroprotective	 tetrahydroisoquinoline.77	(_)-Chlorizidine	 A,	 a	 pyrrolo[2,1-a]isoindole	
derivative,	is	known	for	its	cytotoxic	activity.78	
	
	
Figure	5.2	
	
In	general	the	synthesis	of	these	compounds	relies	on	multistep	procedures,	involving	
the	use	of	metals	and	harsh	reaction	conditions.	Even	if	many	entries	are	known	into	
this	ring	system,	the	preparation	of	functionalized	derivatives,	particularly	at	C-7,	is	not	
trivial	and	has	been	possible	in	our	method.	
	
	 	
																																																								
76(a)	Mikhailovskii,	G.;	Shklyaev,	V.	S.	Chem.	Heterocycl.	Compd.,	1997,	33,	243;	(b)	Nelina-Nemtseva,	J.	
I.;	Gulevskaya,	A.	V.;	Pozharskii,	A.	F.;	Nguyen,	H.	T.	L.;	Filatova,	E.	A.	Tetrahedron,	2016,	72,	2327;	 (c)	
Wiest,	J.	M.;	Pöthig,	A.;	Bach,	T.	Org.	Lett.,	2016,	18,	852.	
77Sun,	H.;	He,	X.;	Liu,	C.;	Li,	L.;	Zhou,	R.;	Jin,	T.;	Yue,	S.;	Feng,	D.;	Gong,	J.;	Sun,	J.;	Ji,	J.;	Xiang,	L.	ACS	Chem	
Neurosci.,	2017,	18;8(1),	155.	
78Alvarez-Mico,	X.;	Jensen,	P.	R.;	Fenicial,	W.;	Hughes,	C.	C.	Org.	Lett.,	2013,	15	(5),	988.	
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5.2.	Synthesis	of	pyrrole	substrates	
As	 previously	 mentioned,	 one	 of	 our	 objectives	 was	 the	 exploration	 of	 the	
intramolecular	 Diels-Alder	 strategy	 as	 a	 route	 towards	 pyrrole-based	 polycyclic	
nitrogen	 heterocycles	 using	 the	 IMDAF	 (Intramolecular	 Diels–Alder	 Cycloaddition	 of	
Furans)	strategy,79	as	shown	in	Scheme	5.1.		
	
	
Scheme	5.1	
	
As	 summarized	 in	 Scheme	 5.2,	 the	 1-allyl	 (homoallyl)-5-(2-furyl)	 pyrroles	 1d-1m	
previously	synthesized	were	used	as	starting	materials	 for	 this	 study	but,	 in	order	 to	
increase	the	reactivity	of	the	olefin	as	a	dienophile,	we	first	incorporated	an		
	
	
Scheme	5.2																																																									
79	 For	a	review,	see:	Padwa,	A.;	Flick,	A.	C.	Adv.	Heterocycl.	Chem.,	2013,	110,	1.	
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unsaturated	ester	unit	at	its	end	by	a	cross-metathesis	reaction	in	the	presence	of	the	
Hoveyda-Grubbs	 second-generation	 catalyst	 and	 CuI	 in	 diethyl	 ether	 to	 furnish	
compounds	9.	
	
5.3.	Intramolecular	furan	Diels–Alder	cycloadditions	
During	our	first	experiments	of	the	IMDAF	reaction,	which	involved	heating	compound	
9a	in	refluxing	xylene,	we	obtained	a	mixture	of	10a	(40%)	and	its	7-hydroxy	derivative	
10k	 (25%),	 probably	 due	 to	 the	 existence	 of	 oxidative	 and	 dehydrative	 competing	
pathways	for	the	evolution	of	the	initial	Diels-Alder	adduct	(Scheme	5.3).		
	
	
Scheme	5.3	
	
For	 this	 reason,	 we	 carried	 out	 the	 experiment	 under	 an	 argon	 atmosphere	 and	
obtained	 compound	9a	 as	 a	 single	 product	 in	 60%	yield.	Using	 these	 conditions,	we	
carried	 out	 a	 number	 of	 additional	 intramolecular	 Diels-Alder	 reactions,	 with	 the	
results	 summarized	 in	 Scheme	 5.4.	 These	 studies	 led,	 on	 one	 hand,	 to	 pyrrolo[2,1-
a]isoindoles	 10b-10e	 and	 10g,h,	 with	 a	 good	 degree	 of	 structural	 variability	 and	
normally	in	good	to	excellent	yields.	This	framework	has	received	little	attention	in	the	
literature,	with	only	a	few	scattered	examples	having	being	described.80	On	the	other	
hand,	 by	 starting	 from	 N-homoallyl	 pyrroles	 we	 also	 obtained	 the	 pyrrolo[2,1-
a]isoquinoline	derivatives	10a,f,i,j;	 this	 framework	 represents	 an	 important	 group	of	
																																																								
80	 For	selected	more	recent	work,	see:	(a)	Jin,	R.-Z.;	Zhang,	W.-T.;	Zhou,	Y.-J.;	Wang,	X.-S.	Tetrahedron	
Lett.,	2016,	57,	2515	(b)	Zhang,	W.-T.;	Qiang,	W.-W.;	Yao,	C.-S.;	Wang,	X.-S.	Tetrahedron,	2016,	72,	
2178;	(c)	Reddy,	S.	B.	V.;	Reddy,	B.	P.;	Reddy,	V.	G.	P.;	Siriwardena,	A.	Org.	Biomol.	Chem.,	2016,	14,	
4276;	 (d)	Kazemi,	 S.	 S.;	 Keivanloo,	A.;	Nasr-Isfahani,	H.;	Bamoniri,	A.	RSC	Adv.,	2016,	6,	 92663;	 (e)	
Acosta,	P.;	Ortiz,	A.;	Insuasty,	B.;	Abonia,	R.;	Quiroga,	J.	Monatsh.	Chem.,	2017,	148,	237;	(f)	Fekete,	
B.;	Palkó,	M.;	Haukka,	M.;	Fülöp.	F.	Molecules,	2017,	22,	613.	
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pharmacologically	 active	 compounds81	and	 natural	 products.82	Even	 if	 several	 entries	
are	 known	 into	 this	 ring	 system, 83 	the	 preparation	 of	 functionalized	 derivatives,	
particularly	at	C-7,	is	not	trivial.		
	
Scheme	5.4	
																																																									
81	 For	representative	examples,	see:	(a)	Maryanoff,	B.	E.;	Maryanoff,	C.	A.;	McComsey,	D.	F.;	Sorgi,	K.	L.;	
U.S.	 Patent,	 4,837,328,	 1989.	 (b)	 Sorgi,	 K.	 L.;	 Maryanoff,	 C.	 A.;	 McComsey,	 D.	 F.;	 Graden,	 D.	W.;	
Maryanoff,	 B.	 E.	 J.	 Am.	 Chem.	 Soc.,	1990,	112,	 3567;	 (c)	 Goodman,	M.	M.;	 Shi,	 B.	 Z.;	 U.S.	 Patent,	
6,162,417,	2000;	(d)	Pla,	D.;	Albericio,	F.;	Álvarez,	M.	MedChemComm,	2011,	2,	689.	
82		 Pas̈sler,	U.;	Knölker,	H.-J.	Alkaloids	Chem.	Biol.,	2011,	70,	79.	
83		 For	a	review,	see:	(a)	Mikhailovskii,	G.;	Shklyaev,	V.	S.	Chem.	Heterocycl.	Compd.,	1997,	33,	243;	For	
selected	more	 recent	methods,	 see:	 (b)	 Su,	 S.;	Porco,	 J.	A.	 J.	Am.	Chem.	Soc.,	2007,	129,	 7744;	 (c)	
Naskar,	S.;	Banerjee,	M.;	Hazra,	A.;	Mondal,	S.;	Maity,	A.;	Paira,	R.;	Sahu,	K.	B.;	Saha,	P.;	Banerjee,	S.;	
Mondal,	 N.	 B.	 Tetrahedron	 Lett.,	 2011,	 52,	 1527;	 (d)	 Nelina-Nemtseva,	 J.	 I.;	 Gulevskaya,	 A.	 V.;	
Pozharskii,	A.	F.;	Nguyen,	H.	T.	L.;	Filatova,	E.	A.	Tetrahedron,	2016,	72,	2327;	(e)	Xu,	X.-M.;	Zhao,	L.;	
Zhu,	J.;	Wang,	M.-X.	Angew.	Chem.	Int.	Ed.,	2016,	55,	3799;	(f)	Wiest,	J.	M.;	Pöthig,	A.;	Bach,	T.	Org.	
Lett.,	2016,	18,	852.	
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5.4.	Experimental	section	
	
5.4.1.	Preparation	of	compounds	9a-9j	by	cross-metathesis	
	
	
	
A	round-bottomed	flask	was	charged	with	second-generation	Hoveyda-Grubbs	catalyst	
(2	mol%),	CuI	 (2	mol%)	and	 the	 suitable	pyrrole	1	 (0.2	mmol)	 in	dry	diethyl	ether	 (2	
mL).	Then,	ethyl	acrylate	(0.3	mmol)	was	added	to	the	mixture,	stirred	and	heated	at	
40	°C	for	3h.	After	completion,	the	solvent	was	removed	under	reduced	pressure	and	
the	residue	was	purified	by	 flash	column	chromatography	on	silica	gel	eluting	with	a	
gradient	 from	 petroleum	 ether	 to	 8:2	 petroleum	 ether-ethyl	 acetate	 afforded	 the	
desired	derivatives.	 These	derivatives	need	 to	be	 stored	 in	 a	 fridge	due	 to	 their	 low	
stability	and	should	be	used	within	a	short	time.	
	
Ethyl	(E)-5-(3-acetyl-5-(furan-2-yl)-2-methyl-1H-pyrrol-1-yl)pent-2-enoate	(9a)	
	
Prepared	from	pyrrole	1d	(0.5	mmol);	yield:	110	mg	(71%);	yellowish	
oil;	1H	NMR	(250	MHz,	CDCl3) δ 7.49	(dd,	J	=	1.9,	0.8	Hz,	1H),	6.87	(dt,	
J	=	15.7,	7.2	Hz,	1H),	6.72	(s,	1H),	6.50	–	6.48	(m,	1H),	6.43	–	6.42	(m,	
1H),	5.86	(dt,	J	=	15.7,	1.5	Hz,	1H),	4.26	–	4.11	(m,	4H),	2.63	(s,	3H),	
2.66	–	2.55	(m,	2H),	2.44	(s,	3H),	1.32	(t,	J	=	7.1	Hz,	3H);	13C	NMR	(63	
MHz,	 CDCl3) δ 194.9,	 165.9,	 146.4,	 143.3,	 142.0,	 136.4,	 123.8,	 122.9,	 121.1,	 111.2,	
107.7,	60.4,	43.1,	33.1,	28.5,	14.2,	11.7;	 IR	 (neat) ν: 1699.4,	1640.7	 (C=O),	1216.0	 (C-
O),	1065.8	(C=C-H)	cm-1;	elemental	analysis	(%)	calcd.	for	C18H21NO4:	C	68.55,	H	6.71,	N	
4.44;	found:	C	67.63,	H	6.90,	N	4.33.	
	
Methyl	 (E)-1-(4-ethoxy-4-oxobut-2-en-1-yl)-5-(furan-2-yl)-2-methyl-1H-pyrrole-3-
carboxylate	(9b)	
	
Prepared	from	pyrrole	1e	(0.5	mmol);	yield:	106	mg	(67%);	yellowish	
oil;	1H	NMR	(250	MHz,	CDCl3) δ 7.45	–	7.44	(m,	1H),	7.06	(dt,	J	=	15.6,	
4.0	Hz,	1H),	6.82	(s,	1H),	6.46	–	6.44	(m,	1H),	6.38	–	6.36	(m,	1H),	5.47	
(dt,	J	=	15.6,	2.1	Hz,	1H),	4.81	(dd,	J	=	4.0,	2.1	Hz,	2H),	4.18	(q,	J	=	7.1	
Hz,	2H),	3.85	(s,	3H),	2.55	(s,	3H),	1.28	(t,	J	=	7.1	Hz,	3H);	13C	NMR	(63	
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MHz,	 CDCl3) δ 166.2,	 166.0,	 146.6,	 143.1,	 142.4,	 137.6,	 124.1,	 122.7,	 112.9,	 111.6,	
110.8,	 107.9,	 61.1,	 51.4,	 46.1,	 14.6,	 11.4;	 IR	 (neat) ν: 2930.8,	 2859.8	 (C-H),	 1712.1	
(C=O),	 1247.0,	 1177.3	 (C-O)	 	 	 cm-1;	 elemental	 analysis	 (%)	 calcd.	 for	 C17H19NO5:	 C,	
64.34;	H,	6.04;	N,	4.41;	found:	C,	64.11;	H,	6.23;	N,	4.65.	
	
Ethyl	 (E)-2-(2-ethoxy-2-oxoethyl)-1-(4-ethoxy-4-oxobut-2-en-1-yl)-5-(furan-2-yl)-1H-
pyrrole-3-carboxylate	(9c)	
	
Prepared	from	pyrrole	1f	(0.5	mmol);	yield:	142	mg	(68%);	yellowish	
oil;	 1H	 NMR	 (250	MHz,	 CDCl3) δ 7.39	 –	 7.34	 (m,	 1H),	 6.96	 (dt,	 J	 =	
15.7,	4.0	Hz,	1H),	6.78	(s,	1H),	6.38	–	6.34	(m,	1H),	6.33	–	6.29	(m,	
1H),	5.40	(dt,	J	=	15.6,	2.1	Hz,	1H),	4.79	(dd,	J	=	4.0,	2.1	Hz,	2H),	4.22	
(q,	J	=	7.1	Hz,	2H),	4.13	–	4.06	(m,	4H),	3.99	(s,	2H),	1.28	(t,	J	=	7.1	
Hz,	 3H),	 1.21	 –	 1.15	 (m,	 6H);	 13C	NMR	 (63	MHz,	 CDCl3) δ 170.1,	 166.1,	 165.1,	 146.3,	
143.1,	 142.6,	 132.8,	 125.1,	 122.8,	 115.0,	 111.6,	 111.1,	 108.3,	 61.8,	 61.1,	 60.3,	 46.3,	
31.6,	14.8,	14.6	(x2C);	IR	(neat) ν: 2979.0,	2835.4	(C-H),	1670.2,	1667.7	(C=O),	1244.2,	
1182.6	 (C-O)	 cm-1;	 elemental	 analysis	 (%)	 calcd.	 for	 C21H25NO7:	 C,	 62.52;	 H,	 6.25;	 N,	
3.47;	found:	C,	62.23;	H,	6.65;	N,	3.73.	
	
tButyl	 (E)-1-(4-ethoxy-4-oxobut-2-en-1-yl)-5-(furan-2-yl)-2-methyl-1H-pyrrole-3-
carboxylate	(9d)	
	
Prepared	from	pyrrole	1g	(0.5	mmol);	yield:	126	mg	(70%);	yellowish	
oil;	1H	NMR	(250	MHz,	CDCl3) δ 7.44	–	7.43	(m,	1H),	7.04	(dt,	J	=	15.6,	
4.0	Hz,	1H),	6.77	(s,	1H),	6.44	–	6.43	(m,	1H),	6.36	–	6.35	(m,	1H),	5.50	
(dt,	J	=	15.6,	2.1	Hz,	1H),	4.79	(dd,	J	=	4.0,	2.1	Hz,	2H),	4.19	(q,	J	=	7.1	
Hz,	2H),	2.52	(s,	3H),	1.59	(s,	9H),	1.30	(d,	J	=	7.1	Hz,	3H);	13C	NMR	(63	
MHz,	 CDCl3) δ 165.7,	 164.6,	 146.4,	 142.7,	 141.9,	 136.4,	 123.3,	 122.3,	 114.4,	 111.1,	
110.9,	107.3,	79.6,	60.6,	45.5,	28.4,	14.1,	11.0;	IR	(neat) ν: 2976.2,	2929.9	(C-H),	1696.1	
(C=O),	1251.8,	1258.1	(C-O)	cm-1;	elemental	analysis	(%)	calcd.	for		C20H25NO5:	C,	66.84;	
H,	7.01;	N,	3.90;	found:	C,	66.57;	H,	6.90;	N,	3.62.	
	
Isopropyl	 (E)-1-(4-ethoxy-4-oxobut-2-en-1-yl)-5-(furan-2-yl)-2-methyl-1H-pyrrole-3-
carboxylate	(9e)	
	
Prepared	from	pyrrole	1h	(0.5	mmol);	yield:	117	mg	(68%);	yellowish	
oil;	 1H	NMR	 (250	MHz,	 CDCl3) δ 7.45	 –	 7.43	 (m,	 1H),	 7.06	 (ddd,	 J	 =	
15.8,	4.4,	3.4	Hz,	1H),	6.83	(s,	1H),	6.56	–	6.44	–	6.43	(m,	1H),	6.38	–	
6.36	(m,	1H),	5.53	–	5.45	(m,	1H),	5.26	–	5.16	(m,	1H),	4.82	–	4.79	(m,	
2H),	4.19	(q,	J	=	7.1	Hz,	2H,	2H),	2.54	(s,	3H),	1.36	(d,	J	=	6.2	Hz,	6H),	
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1.29	(t,	J	=	7.1	Hz,	3H);	 13C	NMR	(63	MHz,	CDCl3) δ 165.7,	164.7,	146.2,	142.7,	141.9,	
136.8,	 123.5,	 122.2,	 113.3,	 111.1,	 110.6,	 107.3,	 66.7,	 60.7,	 45.6,	 22.1,	 14.1,	 11.0;	 IR	
(neat) ν: 2944.0,	 2869.9	 (C-H),	 1699.74	 (C=O),	 1274.2,	 1162.6	 (C-O)	 cm-1;	 elemental	
analysis	(%)	calcd.	for	C19H23NO5:	C,	66.07;	H,	6.71;	N,	4.06;	found:	C,	65.83;	H,	6.35;	N,	
4.33.	
	
Ethyl	 (E)-2-(2-ethoxy-2-oxoethyl)-1-(5-ethoxy-5-oxopent-3-en-1-yl)-5-(furan-2-yl)-1H-
pyrrole-3-carboxylate	(9f)	
	
Prepared	 from	pyrrole	1i	 (0.5	mmol);	yield:	142	mg	 (68%);	yellowish	
oil;	 1H	NMR	 (250	MHz,	CDCl3) δ 7.50	–	7.44	 (m,	1H),	6.90	–	6.76	 (m,	
2H),	6.49	–	6.41	(m,	2H),	5.82	(dt,	J	=	15.7,	1.4	Hz,	1H),	4.23	(dd,	J	=	
20.5,	7.1	Hz,	10H),	2.63	–	2.48	(m,	2H),	1.36	–	1.26	(m,	9H);	13C	NMR	
(63	 MHz,	 CDCl3) δ 169.7,	 165.8,	 164.6,	 146.3,	 143.2,	 141.9,	 132.1,	
124.0,	123.7,	114.0,	111.2,	110.9,	107.9,	61.2,	60.3,	59.6,	43.6,	33.2,	
31.1,	14.3,	14.1,	14.1;	IR	(neat) ν: 2980.6,	2978.3	(C-H),	1714.4,	1709.8	(C=O),	1249.1,	
1237.1	 (C-O)	 cm-1;	 elemental	 analysis	 (%)	 calcd.	 for	 C22H27NO7:	 C,	 63.30;	 H,	 6.52;	 N,	
3.36;	found:	C,	62.91;	H,	6.75;	N,	3.62.	
	
Ethyl	 (E)-1-(4-ethoxy-4-oxobut-2-en-1-yl)-5-(furan-2-yl)-2-methyl-1H-pyrrole-3-
carboxylate	(9g)	
	
Prepared	 from	 pyrrole	 1j	 (52	 mg,	 0.2	 mmol);	 yield:	 59	 mg	 (89%);	
yellowish	 oil;	 1H	 NMR	(250	MHz,	 CDCl3) δ 7.47	 (dd,	 J	 =	 1.9,	 0.7	 Hz,	
1H),	6.83	(s,	1H),	6.44	(dd,	J	=	3.3,	1.9	Hz,	1H),	6.37	(dd,	J	=	3.3,	0.7	
Hz,	1H),	7.05	(dt,	J	=	15.6,	4.0	Hz,	1H),	5.48	(dt,	J	=	15.6,	2.1	Hz,	1H),	
4.31	(q,	2H,	J	=	7.1	Hz,	2H),	4.18	(q,	J	=	7.1	Hz,	2H),	4.81	(dd,	J	=	4.0,	
2.1	Hz,	2H),	2.55	(s,	3H),	1.38	(t,	J	=	7.1	Hz,	3H),	1.29	(t,	J	=	7.1	Hz,	3H);	13C	NMR	(CDCl3,	
63	MHz) δ 165.7,	165.1,	146.2,	142.7,	141.9,	137.0,	122.3,	123.6,	112.9,	111.1,	110.5,	
107.4,	60.7,	59.6,	45.6,	14.5,	14.1,	11.0;	IR	(neat)	ν:	1710.1	(C=O),	1246.0	(C-O),	1556.0	
(C-H,	 furyl),	 1070.7	 (C=C-H),	 773.8	 (C-H,	 furyl)	 cm-1;	 elemental	 analysis	 (%)	 calcd	 for	
C18H21NO5:	C	65.24,	H	6.39,	N	4.23;	found:	C	65.00,	H	6.24,	N	4.03.	
	
Ethyl	(E)-4-(3-acetyl-5-(furan-2-yl)-2-methyl-1H-pyrrol-1-yl)but-2-enoate	(9h)	
	
Prepared	 from	pyrrole	1k	 (0.5	mmol);	yield:	98	mg	 (65%);	yellowish	
oil;	1H	NMR	(250	MHz,	CDCl3) δ 7.46	–	7.45	(m,	1H),	7.05	(dt,	J	=	15.6,	
4.0	Hz,	1H),	6.78	(s,	1H),	6.47	–	6.45	(m,	1H),	6.38	–	6.37	(m,	1H),	5.48	
(dt,	J	=	15.6,	2.0	Hz,	1H),	4.80	(dd,	J	=	4.0,	2.0	Hz,	2H),	4.19	(q,	J	=	7.1	
Hz,	2H),	2.57	(s,	3H),	2.47	(s,	3H),	1.29	(t,	J	=	7.1	Hz,	3H);	13C	NMR	(63	
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MHz,	 CDCl3) δ 195.2,	 165.9,	 141.5,	 134.2,	 133.0,	 128.6,	 126.7,	 126.1,	 124.8,	 122.9,	
100.3,	 61.3,	 50.2,	 28.4,	 14.3,	 12.6;	 IR	 (neat) ν: 2947.0,	 2835.4	 (C-H),	 1695.7	 (C=O),	
1244.2,	1182.6	(C-O)	cm-1;	elemental	analysis	(%)	calcd.	for	C17H19NO4:	C	67.76,	H	6.36,	
N	4.65;	found:	C	67.63,	H	6.10,	N	4.31.	
	
Methyl	 (E)-1-(5-ethoxy-5-oxopent-3-en-1-yl)-5-(furan-2-yl)-2-methyl-1H-pyrrole-3-
carboxylate	(9i)	
	
Prepared	from	pyrrole	1m	(0.5	mmol);	yield:	120	mg	(72%);	yellowish	
oil;	1H	NMR	(250	MHz,	CDCl3) δ 7.45	(dd,	J	=	1.9,	0.8	Hz,	1H),	6.84	(dt,	
J	=	15.6,	7.2	Hz,	1H),	6.73	(s,	1H),	6.48	–	6.42	(m,	1H),	6.38	(dd,	J	=	3.3,	
0.8	Hz,	1H),	5.82	(dt,	J	=	15.6,	1.5	Hz,	1H),	4.26	–	4.06	(m,	4H),	3.80	(s,	
3H),	 2.57	 (s,	 5H),	 1.28	 (t,	 J	 =	 7.1	 Hz,	 3H);	 13C	 NMR	 (63	 MHz,	
CDCl3) δ 165.9,	 165.6,	 146.6,	 143.5,	 141.9,	 137.0,	 123.8,	 123.2,	 112.0,	 111.2,	 110.6,	
107.6,	 60.4,	 50.9,	 43.4,	 33.2,	 14.2,	 11.2;	 IR	 (neat) ν: 2950.4,	 2946.0	 (C-H),	 1705.7	
(C=O),	1244.2,	1182.6	(C-O)	cm-1;	elemental	analysis	(%)	calcd.	for	C18H21NO5:	C,	65.24;	
H,	6.39;	N,	4.23;	found:	C,	64.91;	H,	6.73;	N,	4.12.	
	
Ethyl	 (E)-1-(5-ethoxy-5-oxopent-3-en-1-yl)-5-(furan-2-yl)-2-methyl-1H-pyrrole-3-
carboxylate	(9j)	
	
Prepared	 from	 pyrrole	 1l	 (55	 mg,	 0.2	 mmol);	 yield:	 59	 mg	 (85%);	
yellowish	 oil;	 1H	 NMR	(250	MHz,	 CDCl3) δ 7.47	 (dd,	 J	 =	 1.8,	 0.7	 Hz,	
1H),	6.77	(s,	1H),	6.47	(dd,	J	=	3.3,	1.8	Hz,	1H),	6.41	(dd,	J	=	3.3,	0.7	Hz,	
1H),	6.87	(dt,	J	=	15.7,	7.2	Hz,	1H),	5.86	(dt,	J	=	15.7,	1.4	Hz,	1H),	4.30	
(q,	J	=	7.1	Hz,	2H),	4.20	(q,	J	=	7.1	Hz,	2H),	4.17	–	4.11	(m,	2H),	2.60	(s,	
3H),	2.64	–	2.53	(m,	2H),	1.37	(t,	J	=	7.1	Hz,	3H),	1.31	(t,	J	=	7.1	Hz,	3H);	13C	NMR	(CDCl3,	
63	MHz) δ 166.0,	165.2,	146.7,	143.5,	141.8,	136.7,	123.7,	123.1,	112.4,	111.2,	110.7,	
107.6,	 60.4,	 59.5,	 43.4,	 33.3,	 14.5,	 14.2,	 11.2;	 IR	 (neat)	ν:	1707.2	 and	 1606.8	 (C=O),	
1250.6	 and	 1194.2	 (C-O),	 1067.2	 (C=C-H)	 cm-1;	 elemental	 analysis	 (%)	 calcd	 for	
C19H23NO5:	C	66.07,	H	6.71,	N	4.06;	found:	C	66.32,	H	6.38,	N	3.80.
	
	
5.4.2.	Preparation	of	compounds	10a-10k	by	intramolecular	Diels	Alder	reactions	
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A	solution	of	the	suitable	compound	9a-9j	(0.2	mmol)	in	xylene	(1	mL)	was	refluxed	for	
36	 h	 under	 argon	 atmosphere.	 The	 solvent	 was	 removed	 under	 reduced	 pressure.	
Purification	of	the	residue	by	flash	column	chromatography	on	silica	gel,	eluting	with	a	
gradient	 from	 petroleum	 ether	 to	 8:2	 petroleum	 ether−ethyl	 acetate,	 afforded	 the	
desired	compounds	10.	
	
Ethyl	2-acetyl-3-methyl-5,6-dihydropyrrolo[2,1-a]isoquinoline-7-carboxylate	(10a)	
	
Prepared	 from	 pyrrole	 9a	 (0.2	 mmol);	 yield:	 36	 mg	 (60%);	 yellowish	
solid;	mp:	151-153	°C;	1H	NMR	(250	MHz,	CDCl3) δ 7.80	–	7.71	(m,	2H),	
7.34	(t,	J	=	7.8	Hz,	1H),	6.88	(s,	1H),	4.41	(q,	J	=	7.1	Hz,	2H),	3.99	(t,	J	=	
6.6,	Hz,	2H),	3.54	(t,	J	=	6.6	Hz,	2H),	2.63	(s,	3H),	2.49	(s,	3H),	1.44	(t,	J	=	
7.1	Hz,	3H);	13C	NMR	(63	MHz,	CDCl3) δ 194.9,	167.4,	135.2,	131.7,	130.0,	
129.6,	 128.3,	 127.8,	 126.8,	 126.2,	 121.7,	 105.7,	 61.0,	 39.9,	 28.6,	 26.0,	 14.3,	 11.4;	 IR	
(neat) ν: 1678.9	(C=O),	1234.0	(C-O)	cm-1;	elemental	analysis	(%)	calcd.	for	C18H19NO3:	
C	72.71	H	6.44,	N	4.71;	found:	C	73.03,	H	6.58,	N	4.57.	
When	 the	 reaction	 from	9a	was	performed	 in	a	 flask	open	 to	air,	 it	afforded	40%	of	
compound	10a	and	25%	of	compound	10k.		
	
6-Ethyl	2-methyl	3-methyl-5H-pyrrolo[2,1-a]isoindole-2,6-dicarboxylate	(10b)	
	
Prepared	 from	 pyrrole	 9b	 (0.2	 mmol);	 yield:	 31	 mg	 (52%);	 yellowish	
solid;	mp:	 165-167	 °C;	 1H	NMR	 (250	MHz,	 CDCl3) δ 7.87	 (d,	 J	 =	 7.6	Hz,	
1H),	7.68	(d,	J	=	7.6	Hz,	1H),	7.45	(t,	J	=	7.6	Hz,	1H),	6.73	(s,	1H),	5.16	(s,	
2H),	4.45	(q,	J	=	7.1	Hz,	2H),	3.86	(s,	3H),	2.62	(s,	3H),	1.47	(t,	J	=	7.1	Hz,	
3H);	13C	NMR	(63	MHz,	CDCl3) δ 166.0,	165.9,	141.6,	134.4,	134.3,	133.4,	
128.6,	 126.5,	 126.0,	 123.0,	 115.3,	 100.1,	 61.2,	 50.8,	 50.4,	 14.3,	 12.0;	 IR	
(neat) ν: 3056.1,	 2949.4	 (C-H),	 1696.4	 (C=O),	 1211.1,	 1202.6	 (C-O)	 cm-1;	 elemental	
analysis	(%)	calcd.	for	C17H17NO4:	C,	68.22;	H,	5.72;	N,	4.68;	found:	C,	67.94;	H,	5.99;	N,	
4.86.	
	
Diethyl	3-(2-ethoxy-2-oxoethyl)-5H-pyrrolo[2,1-a]isoindole-2,6-dicarboxylate	(10c)	
	
Prepared	from	pyrrole	9c	(0.2	mmol);	yield:	62	mg	(80%);	yellowish	
solid;	mp:	137-139	°C;	1H	NMR	(250	MHz,	CDCl3) δ 7.90	(dd,	J	=	7.6,	
1.1	Hz,	1H),	7.71	 (dd,	 J	 =	7.6,	1.1	Hz,	1H),	7.47	 (t,	 J	 =	7.6	Hz,	1H),	
6.80	(s,	1H),	5.27	(s,	2H),	4.44	(q,	J	=	7.1	Hz,	2H),	4.32	(q,	J	=	7.1	Hz,	
2H),	4.24	–	4.19	(m,	4H),	1.46	(t,	J	=	7.1	Hz,	3H),	1.40	(d,	J	=	7.1	Hz,	
3H),	 1.31	 (t,	 J	 =	 7.1	 Hz,	 3H);	 13C	 NMR	 (63	MHz,	 CDCl3) δ 169.3,	 165.8,	 165.2,	 141.6,	
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135.7,	 134.1,	 128.6,	 128.5,	 126.8,	 125.9,	 123.1,	 117.2,	 100.4,	 61.2,	 59.7,	 50.9,	 32.0,	
14.4,	 14.3,	 14.2.;	 IR	 (neat) ν: 2980.8,	 2934.1	 (C-H),	 1714.3,	 1710.1	 (C=O),	 1244.2,	
1222.6	 (C-O)	 cm-1;	 elemental	 analysis	 (%)	 calcd.	 for	 C21H23NO6:	 C,	 65.44;	 H,	 6.02;	 N,	
3.63;	found:	C,	65.21;	H,	6.32;	N,	3.96.	
	
2-(tButyl)	6-ethyl	3-methyl-5H-pyrrolo[2,1-a]isoindole-2,6-dicarboxylate	(10d)	
	
Prepared	 from	 pyrrole	 9d	 (0.2	mmol);	 yield:	 62	mg	 (90%);	 yellowish	
solid;	mp:	175-177	°C;	1H	NMR	(250	MHz,	CDCl3) δ 7.87	(dd,	J	=	7.7,	1.0	
Hz,	1H),	7.69	(dd,	J	=	7.7,	1.0	Hz,	1H),	7.46	(t,	J	=	7.7	Hz,	1H),	6.72	(s,	
1H),	5.17	(s,	2H),	4.46	(q,	J	=	7.1	Hz,	2H),	2.61	(s,	3H),	1.62	(s,	9H),	1.48	
(t,	 J	 =	 7.1	 Hz,	 3H);	 13C	 NMR	 (63	 MHz,	 CDCl3) δ 165.9,	 165.1,	 141.6,	
134.6,	 134.1,	 132.6,	 128.5,	 126.3,	 126.0,	 122.9,	 117.4,	 100.4,	 79.4,	 61.2,	 50.3,	 28.5,	
14.4,	12.0;	IR	(neat) ν: 2972.8,	2924.1	(C-H),	1686.3	(C=O),	1280.9,	1278.3	(C-O)	cm-1;	
HRMS	(MALDI	TOF)	calcd.	for	C20H23NO4:	341.16271,	found:	341.1611.	
	
6-Ethyl	2-isopropyl	3-methyl-5H-pyrrolo[2,1-a]isoindole-2,6-dicarboxylate	(10e)	
	
Prepared	 from	 pyrrole	 9e	 (0.2	mmol);	 yield:	 56	mg	 (87%);	 yellowish	
solid;	Mp:	143-145	 °C;	 1H	NMR	 (250	MHz,	CDCl3z) δ 7.88	 (dd,	 J	 =	7.6,	
1.1	Hz,	1H),	7.69	(dd,	J	=	7.6,	1.1	Hz,	1H),	7.58	–	7.40	(m,	1H),	6.76	(s,	
1H),	5.28	–	5.20	(m,	1H),	5.18	(s,	2H),	4.45	(q,	J	=	7.1	Hz,	2H),	2.63	(s,	
3H),	1.47	(t,	J	=	7.1	Hz,	3H),	1.38	(d,	J	=	6.3	Hz,	6H);	13C	NMR	(63	MHz,	
CDCl3) δ 166.0,	 165.2,	 141.6,	 134.5,	 134.3,	 133.1,	 128.6,	 126.4,	 126.0,	 122.9,	 116.1,	
100.2,	 66.5,	 61.2,	 50.3,	 22.2,	 14.4,	 12.0;	 IR	 (neat) ν: 2947.0,	 2835.4	 (C-H),	 1695.0	
(C=O),	1270.7,	1234.4	(C-O)	cm-1;	elemental	analysis	(%)	calcd.	for	C19H21NO4:	C,	69.71;	
H,	6.47;	N,	4.28;	found:	C,	69.43;	H,	6.75;	N,	4.61.	
	
Diethyl	 3-(2-ethoxy-2-oxoethyl)-5,6-dihydropyrrolo[2,1-a]isoquinoline-2,7-
dicarboxylate	(10f)	
	
Prepared	from	pyrrole	9f	 (0.2	mmol);	yield:	70	mg	(87%);	yellowish	
solid;	Mp:	 131-133	 °C;	 1H	NMR	 (250	MHz,	 CDCl3) δ 7.81	 –	 7.72	 (m,	
2H),	7.37	–	7.29	(m,	1H),	6.99	(s,	1H),	4.40	(q,	J	=	7.1	Hz,	2H),	4.32	(q,	
J	=	7.1	Hz,	2H),	4.25	–	4.16	(m,	4H),	4.01	(t,	J	=	6.6	Hz,	2H),	3.55	(t,	J	=	
6.6	Hz,	2H),	1.43	(t,	J	=	7.1	Hz,	3H),	1.39	(t,	J	=	7.1	Hz,	3H),	1.29	(t,	J	=	
7.1	Hz,	3H);	13C	NMR	(63	MHz,	CDCl3) δ 169.7,	167.3,	165.0,	131.8,	130.7,	129.9,	129.5,	
129.0,	128.4,	126.7,	126.5,	114.2,	105.7,	61.2,	61.0,	59.6,	40.8,	30.8,	26.0,	14.4,	14.3,	
14.2;	IR	(neat) ν: 2980.2,	2978.1	(C-H),	1706.7,	1702.1	(C=O),	1234.2,	1182.6	(C-O)	cm-
1;	 elemental	 analysis	 (%)	 calcd.	 for	 C22H25NO6:	 C,	 66.15;	 H,	 6.31;	 N,	 3.51;	 found:	 C,	
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65.95;	 H,	 6.75;	 N,	 3.17.	 HRMS	 (MALDI	 TOF)	 calcd.	 for	 C22H25NO6:	 399.16819,	 found:	
399.1695.	
	
Diethyl	3-methyl-5H-pyrrolo[2,1-a]isoindole-2,6-dicarboxylate	(10g)	
	
Prepared	from	pyrrole	9g	(52	mg,	0.2	mmol);	yield:	44	mg	(70%);	white	
solid;	mp:	162-164	°C;	1H	NMR	(250	MHz,	CDCl3) δ 7.88	(dd,	J	=	7.8,	0.9	
Hz,	1H),	7.69	(d,	J	=	7.6	Hz,	1H),	7.46	(t,	J	=	7.7Hz,	1H),	6.76	(s,	1H),	5.18	
(s,	2H),	4.45	(q,	J	=	7.1	Hz,	2H),	4.33	(q,	J	=	7.1	Hz,	2H),	2.63	(s,	3H),	1.47	
(t,	 J	 =	 7.1	 Hz,	 3H),	 1.40	 (t,	 J	 =	 7.1	 Hz,	 3H);	 13C	 NMR	 (63	 MHz,	
CDCl3) δ 165.9,	 165.6,	 141.6,	 134.4,	 134.3,	 133.2,	 128.5,	 126.4,	 126.0,	 122.9,	 115.6,	
100.2,	61.2,	59.4,	50.3,	14.5,	14.3,	12.0;	 IR	(neat)	ν:	1678.9	(C=O),	1233.9	(C-O)	cm-1;	
elemental	analysis	(%)	calcd	for	C18H19NO4:	C	69.00,	H	6.11,	N	4.47;	found:	C	68.76,	H	
6.00,	N	4.25.	
	
Ethyl	2-acetyl-3-methyl-5H-pyrrolo[2,1-a]isoindole-6-carboxylate	(10h)	
	
Prepared	from	pyrrole	9h	(0.2	mmol);	yield:	34	mg	(60%);	yellowish	solid;	
mp:	133-135	°C;	1H	NMR	(250	MHz,	CDCl3) δ 7.89	(d,	J	=	7.6	Hz,	1H),	7.71	
(d,	J	=	7.6	Hz,	1H),	7.48	(t,	J	=	7.6	Hz,	1H),	6.70	(s,	1H),	5.19	(s,	2H),	4.46	(q,	
J	=	7.1	Hz,	2H),	2.66	(s,	3H),	2.49	(s,	3H),	1.47	(t,	J	=	7.1	Hz,	3H);	13C	NMR	
(63	MHz,	CDCl3) δ 195.1,	165.9,	141.5,	134.3,	134.2,	132.9,	128.6,	126.6,	
126.0,	 124.8,	 122.9,	 100.3,	 61.3,	 50.2,	 28.4,	 14.3,	 12.6;	 IR	 (neat) ν: 1689.0	 (C=O),	
1236.0	(C-O)	cm-1;	elemental	analysis	(%)	calcd.	for	C17H17NO3:	C	72.07,	H	6.05,	N	4.94;	
found:	C	73.03,	H	6.26,	N	4.55.	
	
7-Ethyl	 2-methyl	 3-methyl-5,6-dihydropyrrolo[2,1-a]isoquinoline-2,7-dicarboxylate	
(10i)	
	
Prepared	 from	 pyrrole	 9i	 (0.2	 mmol);	 yield:	 50	 mg	 (80%);	 yellowish	
solid;	mp:	113-115	°C;	1H	NMR	(250	MHz,	CDCl3) δ 7.66	(dd,	J	=	7.8,	1.3	
Hz,	1H),	7.60	(dd,	J	=	7.8,	1.3	Hz,	1H),	7.25	–	7.18	(m,	1H),	6.83	(s,	1H),	
4.30	(q,	J	=	7.1	Hz,	2H),	3.88	(t,	J	=	6.6	Hz,	2H),	3.75	(s,	3H),	3.44	(t,	J	=	
6.6	 Hz,	 2H),	 2.50	 (s,	 3H),	 1.33	 (t,	 J	 =	 7.1	 Hz,	 3H);	 13C	 NMR	 (63	MHz,	
CDCl3) δ 167.4,	 165.8,	 135.7,	 131.5,	 130.1,	 129.5,	 128.1,	 128.0,	 126.7,	 126.3,	 112.4,	
105.4,	 61.0,	 50.8,	 40.1,	 26.0,	 14.3,	 10.9;	 IR	 (neat) ν: 2980.6,	 2974.7	 (C-H),	 1701.8	
(C=O),	1222.2,	1189.6	(C-O)	cm-1;	elemental	analysis	(%)	calcd.	for	C18H19NO4:	C,	69.00;	
H,	6.11;	N,	4.47;	found:	C,	69.37;	H,	6.49;	N,	4.69.	
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Diethyl	3-methyl-5,6-dihydropyrrolo[2,1-a]isoquinoline-2,7-dicarboxylate	(10j)	
	
Prepared	 from	 pyrrole	 9j	 (55	 mg,	 0.2	 mmol);	 yield:	 46	 mg	 (71%);	
yellow	solid;	mp:	89-92°C;	1H	NMR	(250	MHz,	CDCl3) δ 7.78	–	7.71	(m,	
2H),	7.32	(t,	J	=	7.8	Hz,	1H),	6.95	(s,	1H),	4.40	(q,	J	=	7.1	Hz,	2H),	4.32	
(q,	J	=	7.1	Hz,	2H),	3.99	(t,	J	=	6.5	Hz,	2H),	3.54	(t,	J	=	6.5	Hz,	2H),	2.61	
(s,	3H),	1.43	 (t,	 J	=	7.1	Hz,	3H),	1.40	 (t,	 J	=	7.1	Hz,	3H);	 13C	NMR	(63	
MHz,	 CDCl3) δ 167.4,	 165.5,	 135.5,	 131.5,	 130.2,	 129.6,	 128.0,	 128.1,	 126.4,	 126.7,	
112.9,	105.5,	61.0,	59.4,	40.1,	26.1,	14.5,	14.3,	10.9;	IR	(neat)	ν:	1695.2	(C=O),	1228.2	
(C-O)	cm-1;	elemental	analysis	(%)	calcd	for	C19H21NO4:	C	69.71,	H	6.47,	N	4.28;	found:	C	
69.65,	H	6.39,	N	4.25.	
	
Ethyl	 2-acetyl-8-hydroxy-3-methyl-5,6-dihydropyrrolo[2,1-a]isoquinoline-7-
carboxylate	(10k)	
	
Prepared	 from	pyrrole	9a	 (0.2	mmol)	under	air;	 yield:	25	mg	 (25	%);	
yellowish	oil;	1H	NMR	(250	MHz,	CDCl3) δ 10.99	(br	s,	1H),	7.66	(d,	J	=	
8.7	Hz,	1H),	6.98	(d,	J	=	8.7	Hz,	1H),	6.72	(s,	1H),	4.50	(q,	J	=	7.1	Hz,	2H),	
3.96	(t,	J	=	6.6	Hz,	2H),	3.48	(t,	J	=	6.6	Hz,	2H),	2.61	(s,	3H),	2.47	(s,	3H),	
1.48	(t,	J	=	7.1	Hz,	3H);	13C	NMR	(63	MHz,	CDCl3) δ 195.0,	170.8,	160.8,	
134.2,	 132.3,	 129.6,	 128.0,	 121.9,	 121.6,	 117.1,	 112.0,	 103.9,	 62.1,	 39.8,	 28.6,	 27.8,	
14.2,	11.3	;IR	(neat) ν: 1689.0	(C=O,	1231.0	(C-O)	cm-1;	elemental	analysis	(%)	calcd.	for	
C18H19NO4:	C	68.99,	H	6.11,	N	4.47;	found:	C	69.05,	H	6.56,	N	4.26.		
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6.	Ring	creation	via	oxonium	intermediates	
6.1	Introduction	
The	possibility	to	synthesize	pyrrole	derivatives	with	a	nitrogen	substituent	ending	 in	
an	 acetal	 group	 opens	 up	 the	 possibility	 to	 readily	 generate	 oxonium	 species	 by	
treatment	 with	 Brønsted	 or	 Lewis	 acids.	 These	 intermediates	 can	 be	 suitable	
substrates	 for	 ring-creation	processes	 leading	 to	 fused	pyrrole	systems	by	cyclization	
onto	 the	 C-2	 or	 C-5	 substituents,	 leading	 respectively,	 to	 pyrrolizine	 and	 related	
frameworks	 (route	 a	 in	 Scheme	 6.1)	 or	 pyrrolo[2,1-a]isoquinoline	 and	 related	
frameworks	(route	b).	
	
	
Scheme	6.1	
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6.2.	Cyclization	onto	a	C-2	active	methylene.	Synthesis	of	the	pyrrolizine	framework	
from	pyrrole	precursors	
	
6.2.1.	A	brief	outline	of	pyrrolizine	and	pyrrolizidine	derivatives	
Alkaloids	 derived	 from	 the	 pyrrolizine,	 dihydropyrrolizine	 and	 pyrrolizidine	 ring	
systems	(Figure	6.1)	are	very	abundant	in	the	Asteraceae,	Boraginaceae	and	Fabaceae	
families.	 They	 probably	 serve	 a	 role	 as	 plant	 chemical	 defense	 against	 insects	 and	
grazing	animals.84	
	
	
Figure	6.1	
	
As	 shown	 in	 Figure	 6.2,	 some	 other	 more	 complex	 alkaloids	 as	 for	 example	 the	
antitumor	 antibiotic	 mitomycin	 C85	contain	 the	 structural	 core	 of	 pyrrolizidine.	 The	
dihydropyrrolizine	moiety	 has	 been	 employed	 for	 the	 generation	 of	 arylacetic	 acids	
with	analgesic,	antipyretic	and	anti-inflammatory	activities.86	For	instance,	ketorolac	is	
a	 non-selective	 inhibitor	 of	 isoforms	 1	 and	 2	 of	 cyclooxygenase	 and	 licofelone	 (ML-
3000)	is	the	precursor	of	a	family	of	dual	inhibitors	of	COX	and	lipooxogenase.87	Some	
selective	inhibitors	of	COX-2	containing	a	dihydropyrrolizine	core	are	also	known,	such	
as	compound	I.88	
	
	
Figure	6.2																																																									
84	 (a)	Wiedenfeld,	H.	Food	Addit.	Contam.,	2011,	28,	282;	(b)	Flitsch,	W.	Adv.	Heterocycl.	Chem.	1984,	
37,	1.	
85	 (a)	Fukuyama,	T.;	Yang,	L.	J.	Am.	Chem.	Soc.,	1989,	111	 ,	8303;	(b)	Kovalchuk,	A.;	Kolb,	B.	Cell	Cycle	
2017,	16,	1345.	
86	 For	a	review,	see:	Gouda,	A.	M.;	Abdelazeem,	A.	H.	Eur.	J.	Med.	Chem.,	2016,	114,	257.	
87		 Laufer,		S.;	Striegel,		H.-G.;	Neher,	K.;	Zechmeister,			P.;	Donat,		C.;	Stolingwa,		K.;	Baur,		S.;	Tries,		S.;	
Kammermeier,		T.;	Dannhardt,		G.;	Kiefer,	W.	Arch.	Pharm.,	1997,	330,	307.	
88		 Striegel,	H.	G.;	Laufer,	S.;	Tollmann,	K.;	Tries,	S.;	European	Patent	EP	1246825	A1	(9	Oct	2002).	
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The	 most	 commonly	 employed	 methods	 for	 the	 synthesis	 of	 pyrrolizine	 or	
dihydropyrrolizine89	are	 based	 on	 the	 formation	 of	 the	 1-2	 bond	 by	 intramolecular	
anion	 alkylation	 reactions,	 or	 by	 intramolecular	 Wittig	 reactions.	 Other	 strategies	
involve	the	creation	of	the	4-5	bond	by	intramolecular	condensation	reactions	(Figure	
6.3).	 In	all	cases,	the	preparation	of	the	starting	pyrrole	derivative	 is	carried	out	by	a	
sequence	 of	 several	 steps,	 and	 the	 routes	 do	 not	 represent	 general	 and	 versatile	
synthetic	methods.	
	
	
Figure	6.3	
	
6.2.2.	Synthesis	of	the	pyrrolizine	ring	system	from	pyrrole	precursors	
The	 work	 presented	 in	 this	 thesis	 represents	 the	 generation	 of	 the	 pyrrolizine	
framework	in	two	steps	and	is	based	on	the	formation	of	four	bonds	and	two	rings	as	
summarized	in	Scheme	6.2.	
	
	
Scheme	6.2	
	
In	 our	 approach,	 the	 final	 stage	 is	 based	 on	 a	 5-exo-trig	 cyclization	 of	 an	 oxonium	
intermediate,	 generated	 from	 a	 starting	 acetal.	 The	 preparation	 of	 suitable	 starting	
pyrroles	 has	 been	 previously	 described	 using	 under	 our	 mechanochemical	 three-
component	 pyrrole	 synthesis	 from	 dialkoxyalkylamines,	 a	 ketone	 and	 a	 symmetrical	
1,3,5-tricarbonyl	 compound.	 To	 achieve	 the	 desrired	 cyclization,	 we	 studied	 the	
activation	of	the	aliphatic	position	at	C-2,	neighboring	the	ester	group	as	a	nucleophile,																																																									
89		 (a)	Flitsch,	W.	Adv.	Heterocycl.	Chem.,	1984,	37,	1;	(b)	Hall,	G.;	Sugden,	J.	K.;	Waghela	M.	B.	Synthesis,	
1987,	1,	10;	(c)	Gilchrist,	L.	T.;	Lemos,	A.	Tetrahedron,	1992,	48,	7655.	
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by	formation	of	the	corresponding	trimethylsilyl	enol	ether	with	trimethylsilyl	chloride,	
and	 the	 simultaneous	 generation	 of	 an	 oxonium	 cation	 by	 treatment	 of	 the	 acetal	
function	 with	 trimethylsilyl	 triflate,	 under	 Noyori	 conditions	 The	 planned	 domino	
process	proceeds	through	the	intermediacy	of	species	I,	II	and	III	(Scheme	6.3).	
	
	
Scheme	6.3	
	
Our	initial	attempts	were	carried	out	from	pyrrole	derivative	1y	using	2.5	equivalents	
of	trimethylsilyl	chloride	(X	=	Y	=	Cl)	and	triethylamine,	with	no	success.	We	changed	
the	 conditions	 to	 combine	 trimethylsilyl	 chloride	 (X	=	Cl)	 to	generate	 intermediate	 I,	
followed	 by	 a	 catalytic	 amount	 (0.2	 to	 0.4	 equivalents)	 of	 trimethylsilyl	 triflate	 (Y	 =	
OTf),	 but	 again	 these	 attempts	were	 unsuccessful.	 Finally	 we	 found	 that	 the	 use	 of	
trimethylsilyl	 chloride	 (X	 =	 Cl)	 followed	 by	 an	 over-stoichiometric	 amount	 of	
trimethylsilyl	triflate	(X	=	Y	=	OTf)	led	to	the	desired	cyclization.	It	is	important	to	note	
that	the	order	of	addition	of	the	reagents	needs	to	be	as	follows:	first	the	trimethylsilyl	
chloride	 and	 the	 triethylamine	 are	 added	 and,	 at	 least	 one	hour	 later	 to	 ensure	 the	
formation	 of	 intermediate	 II,	 trimethylsilyl	 triflate	 is	 added	 and	 the	 reaction	 left	 to	
continue	for	16	hours.	
Using	these	conditions,	we	obtained	a	small	 library	of	compounds	11,	summarized	in	
Scheme	6.4.	All	these	derivatives	were	obtained	as	a	1:1	mixture	of	the	two	possible	
diasteroisomers,	which	were	separated	and	characterized	by	NOE	experiments	for	the	
case	of	11a	as	a	representative	example	(Scheme	6.5).	Some	attempts	were	made	to	
run	 the	 reaction	 at	 lower	 temperatures,	 but	 the	 ratio	 of	 diasteroisomers	 did	 not	
significantly	change.	Work	on	this	reaction	is	ongoing	in	order	to	increase	its	scope.	
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Scheme	6.4	
	
	
Scheme	6.5	
	
Treatment	 of	 the	 crude	 compounds	 11	 with	 1.2	 equivalents	 of	 LDA	 at	 room	
temperature	 for	 2	 h	 in	 THF,	 under	 an	 argon	 atmosphere,	 led	 to	 the	 isolation	of	 the	
corresponding	pyrrolizine	derivatives	12	via	a	base-promoted	elimination	of	methanol,	
as	shown	in	Scheme	6.6.		
	
	
Scheme	6.6	
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6.3.	 Cyclization	 onto	 a	 C-5	 aryl	 substituent.	 Synthesis	 of	 pyrrolo[2,1-a]isoquinoline	
and	related	frameworks	
6.3.1.	Introduction	
Polyheterocyclic	 scaffolds,	 and	 in	 particular	 heterocycles	 with	 a	 ring-fusion	 nitrogen	
atom,	are	increasingly	attractive	in	drug	discovery	programs90	and	there	is	therefore	a	
demand	 for	 synthetic	 methods	 allowing	 their	 rapid	 and	 efficient	 construction	 from	
simple	 starting	materials.91	Among	 these	 ring	 systems,	 the	pyrrolo[2,1-a]isoquinoline	
scaffold	 constitutes	 the	 structural	 core	 of	 a	 large	 family	 of	 alkaloids, 92 	including	
lamellarine	 D,	 a	 potent	 topoisomerase	 I	 inhibitor, 93 	annosqualine,	 crispine	 A,	
antitumor	 alkaloids,	 and	 trolline,94	known	 in	 the	 traditional	 Chinese	 medicine	 for	
having	effect	against	respiratory	infections	(Figure	6.4).	Its	unnatural	derivatives	have	
shown	 interesting	 pharmacological	 properties	 such	 as	 antidepressant,95	cardiotonic96	
and	serotonin	uptake	modulating	activities.97	
	
	
Figure	6.4	
Despite	 the	 existence	 of	 several	 synthetic	 approaches	 to	 the	 fully	 unsaturated	
pyrrolo[2,1-a]isoquinoline	 system,	 most	 published	 methods	 involve	 multi-step																																																									
90	 For	representative	examples,	see:	(a)	Horton,	D.	A.;	Bourne,	G.	T.;	Smythe,	M.	L.	Chem.	Rev.,	2003,	
103,	893.	(b)	DeSimone,	R.	W.;	Currie,	K.	S.;	Mitchell,	S.	A.;	Darrow,	J.	W.;	Pippoin,	D.	A.	Comb.	Chem.	
High	Throughput	Screen.,	2004,	7,	473.	(c)	Oh,	S.;	Park,	S.	B.	Chem.	Commun.,	2011,	47,	12754.	(d)	
Collins,	I.;	Jones,	A.	M.	Molecules,	2014,	19,	17221.	(e)	Lenci,	E.;	Guarna,	A.;	Trabocchi,	A.	Molecules,	
2014,	19,	16506.	(f)	Wang,	S.;	Fang,	F.;	Dong,	G.;	Chen,	S.;	Liu,	N.;	Miao,	Z.;	Yao,	J.;	Li,	J.;	Zhang,	W.;	
Sheng,	C.	J.	Med.	Chem.,	2015,	58,	6678.	
91	 For	representative	examples,	see:	(a)	Sang,	P.;	Xie,	Y.;	Zou,	J.;	Zhang,	Y.	Org.	Lett.,	2012,	14,	3894.	(b)	
Suryavanshi,	P.	A.;	Sridharan,	V.;	Menéndez,	 J.	C.	Chem.	Eur.	 J.,	2013,	19,	13207.	 (c)	Mizoguchi,	H.;	
Oikawa,	H.;	Oguri,	H.	Nature	Chem.,	2014,	6,	57.	(d)	Zheng,	L.;	Bin,	Y.;	Wang,	Y.;	Hua,	R.	J.	Org.	Chem.,	
2016,	81,	8911.	For	representative	reviews,	see:	(e)	Cordier,	C.;	Morton,	D.;	Murrison,	S.;	Nelson,	A.;	
O’Leary-Steele,	C.	Nat.	Prod.	Rep.,	2008,	25,	719.	(f)	García-Castro,	M.;	Zimmermann,	S.;	Sankar,	M.	
G.;	Kumar,	K.	Angew.	Chem.	Int.	Ed.,	2016,	55,	7586.	
92	 Pässler,	U.;	Knölker,	H.-J.	The	Alkaloids,	2011,	70,	79.	
93	 For	 reviews,	 see:	 (a)	 Fukuda,	 T.;	 Ishibashi,	 F.;	 Iwao,	 M.	 Heterocycles,	 2011,	 83,	 491.	 (b)	 Pla,	 D.;	
Albericio,	F.;	Álvarez,	M.	Med.	Chem.	Commun.,	2011,	2,	689.	
94	 Zhao	Y.-X.;	Ding	X.-B.	Yaoxue	Xuebao,	2004,	39,	598.	
95	 Sorgi,	K.	 L.;	Maryanoff,	C.	A.;	McComsey,	D.	F.;	Graden,	D.	W.;	Maryanoff,	B.	E.	 J.	Am.	Chem.	Soc.,	
1990,	112,	3567.	
96	 Maryanoff,	B.	E.;	Maryanoff,	C.	A.;	McComsey,	D.	F.;	Sorgi,	K.	L.	U.S.	Patent,	4,837,328	(Jan	31,	1989).	
97	 Goodman,	M.	M.;	Shi,	B.	Z.	U.S.	Patent,	6,162,417	(Dec	19,	2000).	
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strategies	 and	 normally	 require	 harsh	 reaction	 conditions.98	Among	 them,	 the	 most	
general	 method	 is	 based	 on	 1,3-dipolar	 cycloadditions	 between	 isoquinolinium	 N-
ylides	and	alkynes99,	or	a	Pd(II)-catalyzed	protocol	for	the	alkylation	of	the	phenyl	ring	
2-phenylpyrroles,	followed	by	allylation	and	a	“Pd-induced	pyrrole	addition”	(Scheme	
6.7). 100 	Lamellarin	 precursors	 or	 derivatives	 are	 usually	 synthesized	 by	 multistep	
procedures	 starting	 from	 suitable	methyl	 pyrrole-2-carboxylate	 derivatives,	 including	
N-alkylation/intramolecular	 Heck	 reaction/	 dehydrogenation101	or	 N-alkylation/triflic	
acid-promoted	Pomeranz-Fritsch102	sequences	(Scheme	6.7).		
	
	
Scheme	6.7	
	
	 	
																																																								
98	 For	a	review,	see:	Mikhailovskii,	G.;	Shklyaev,	V.	S.	Chem.	Heterocycl.	Compd.,	1997,	33,	243.	
99	 Dumitrascu,	F.;	Georgescu,	E.;	Georgescu,	F.;	Popa,	M.	M.;	Dumitrescu,	D.	Molecules,	2013,	18,	2635.	
100	Wiest,	J.	M.;	Pöthig,	A.;	Bach,	T.	Org.	Lett.,	2016,	18,	852.	
101	 Pla,	D.;	Marchal,	A.;	Olsen,	C.	A.;	Albericio,	F.;	Álvarez,	M.	J.	Org.	Chem.,	2005,	70,	8231.	
102	 Dialer,	C.;	Imbri,	D.;	Hansen,	S.	P.;	Opatz,	T.	J.	Org.	Chem.,	2015,	80,	11605.	
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6.3.2.	Preparation	of	pyrrolo[2,1-a]isoquinolines	and	related	frameworks	
During	 the	 study	 for	 the	 optimization	 of	 the	 reaction	 to	 obtain	 the	 pyrrolizine	
derivative	10a,	the	generation	of	a	minor	by-product,	later	identified	as	arising	from	a	
Pomeranz-Fritsch	cyclization	and	having	the	structure	14d	was	detected	(Scheme	6.8).	
	
	
Scheme	6.8	
	
In	an	effort	to	deviate	the	reaction	towards	14a,	we	carried	out	a	similar	experiment	
with	 only	 TMSOTf	 as	 catalyst	 in	 a	 large	 excess	 of	 1.5	 equivalents	 and	 observed	 the	
presence	of	14a	as	the	only	significant	component	of	the	reaction	crude.	On	this	basis,	
we	 undertook	 an	 optimization	 study	 that	 is	 summarized	 in	 Table	 6.1.	 The	 usual	
conditions	 for	 the	Pomeranz-Fritsch	 isoquinoline	 synthesis	 require	 the	 use	 of	 strong	
Brønsted	 acids	 but,	 because	 of	 the	 success	 of	 the	 experiment	with	 TMSOTf	 and	 the	
potential	low	stability	of	pyrrole	derivatives	under	such	harsh	conditions,	we	sought	to	
perform	our	 transformation	 in	 the	presence	of	 Lewis	 acids.	Thus,	 the	preparation	of	
model	compound	14a	from	the	corresponding	pyrrole	1y	was	assayed	in	the	presence	
of	 a	 large	 excess	 of	 aluminium	 trichloride	 in	 dichloroethane,103	with	 modest	 yields	
(Table	6.1,	entries	1	and	2).	In	the	presence	of	excess	boron	trifluoride	etherate	in	1,4-
dioxane,104	the	reaction	failed	at	room	temperature	(entry	3)	but	afforded	14a	 in	69%	
yield	 at	 120	 °C.	 In	 an	 effort	 to	 improve	 this	 result,	 we	 resorted	 to	 the	 previously	
employed	 trimethylsilyl	 triflate,	 which	 is	 well	 known	 to	 activate	 acetals	 via	 the	
formation	 of	 oxonium	 species105	but	 has	 received	 very	 little	 attention	 for	 cyclization	
reactions	leading	to	heterocyclic	systems,	and	not	always	acts	as	a	catalyst	in	the	few	
examples	known.106	In	our	initial	experiment,	1y	had	been	transformed	into	14a	in	an																																																									
103	 Perchonock,	C.	D.;	Lantos,	I.;	Finkelstein,	J.	A.;	Holden,	K.	G.	J.	Org.	Chem.,	1980,	45,	1950.	
104	 Hewlins,	M.	J.	E.;	Salter,	R.	Synthesis,	2007,	2157.	
105		Murata,	S.;	Suzuki,	M.;	Noyori,	R.	Tetrahedron,	1988,	44,	4259.	
106		(a)	 Pictet-Spengler-type	 reaction:	 González,	 J.	 F.;	 Salazar,	 L.;	 de	 la	 Cuesta,	 E.;	 Avendaño,	 C.	
Tetrahedron,	2005,	61,	7447	(using	stoichiometric	TMSOTf).	(b)	 Intramolecular	Pummerer	reaction:	
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excellent	90%	yield	in	the	presence	of	TfOTMS	(1.5	eq.)	in	dry	dichloromethane	under	
an	argon	atmosphere.	The	reaction	was	very	fast,	and	was	complete	 in	only	5	min	at	
room	temperature	 (entry	5).	Subsequent	experiments	proved	that	 the	reaction	could	
be	 carried	out	open	 to	 the	 air	 (entry	 6)	 and	 in	 the	presence	of	 catalytic	 amounts	of	
trimethylsilyl	triflate	(entry	7)	without	loss	in	yield.	The	optimal	conditions	involved	the	
use	of	15%	of	the	catalyst	(entry	8).		
	
Table	6.1.	Optimization	of	the	Pommeranz-Fritzsh-type	cyclization	leading	to	
compound	14a	
Entry	 Catalyst	(%)	 Conditions	 Yield,	%	
1	 AlCl3	(400)	 DCE,	rt,	8	h	(Ar)	 30	
2	 AlCl3	(400)	 DCE,	rt,	24	h	(Ar)	 50	
3	 BF3.Et2O	(500)	 Dioxane,	rt,	4	h	(Ar)	 0	
4	 BF3.Et2O	(500)	 Dioxane,	120	°C,	0.5	h	(Ar)	 69	
5	 TfOTMS	(150)	 DCM,	rt,	5	min	(Ar)	 90	
6	 TfOTMS	(100)	 DCM,	rt,	5	min	(air)	 89	
7	 TfOTMS	(50)	 DCM,	rt,	5	min	(air)	 88	
8	 TfOTMS	(15)	 DCM,	rt,	5	min	(air)	 89	
	
In	 order	 to	 study	 the	 scope	 of	 this	 transformation,	 we	 needed	 a	 library	 of	 pyrroles	
bearing	 a	 2,2-dimethoxyethyl	 substituent	 on	 nitrogen	 (compounds	 13),	 which	 were	
prepared	under	our	usual	conditions	(Scheme	6.9).	It	is	interesting	to	highlight	that,	as	
previously	 mentioned,	 the	 mildness	 of	 the	 reaction	 conditions	 and	 the	 absence	 of	
solvent	 under	 our	 mechanochemical	 conditions	 prevented	 CAN-promoted	 side	
reactions	at	the	acetal	functional	group.107	
																																																																																																																																																																		
Komatsubara,	M.;	Umeki,	T.;	Fukuda,	T.;	Iwao,	M.	J.	Org.	Chem.,	2014,	79,	529	(requires	a	separate	
oxidative	step	for	aromatization).	(c)	Tang,	E.;	Zhao,	Y.;	Li,	W.;	Wang,	W.;	Zhang,	M.;	Dai,	X.	Org.	Lett.,	
2016,	18,	912.	
107	 As	an	example	of	such	transformations,	CAN	is	an	excellent	catalyst	for	the	hydrolysis	of	acetals	and	
ketals.	See:	Maulide,	N.;	Vanherck,	J.-C.;	Gautier,	A.;	Markó,	I.	E.	Acc.	Chem.	Res.,	2007,	40,	381.	
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Scheme	6.9	
	
Using	 the	 optimized	 conditions,	 we	 studied	 the	 scope	 of	 the	 TMSOTf-promoted	
Pommeranz-Fritzsch	reaction	on	these	structurally	varied	substrates,	which	allowed	us	
to	study	the	influence	of	the	nature	of	the	substituents	on	the	C-5	aromatic	ring	on	the	
electrophilic	 aromatic	 substitution	 step.	We	 found	 that	 the	 reaction	 allowed	 a	 wide	
range	 of	 substitutions	 working	 well	 with	 unsubstituted	 phenyl	 derivatives	 (14a-14c)	
and	 also	when	electron-releasing	 groups	were	 present	 on	 the	 C-5	 substituent	 (14d).	
Interestingly,	 the	 presence	 of	 electron-withdrawing	 groups	 did	 not	 hamper	 the	
reaction,	 allowing	 the	 preparation	 of	 fluoro-	 (14e),	 chloro-	 (14k),	 bromo-	 (14g,	 14h)	
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and	 iodo-	 (14i,	14j)	derivatives.	These	substituents	are	synthetically	 relevant	because	
they	 represent	 potential	 synthetic	 handles	 for	 additional	 functionalization	 of	 these	
compounds	using	cross-coupling	chemistry.	The	presence	of	two	Cl	substituents	in	the	
C-5	aryl	ring	was	also	well	tolerated	in	terms	of	reactivity.	Under	the	usual	conditions	at	
20	°C	this	reaction	afforded	exclusively	the	7,8-dichloro	derivative	14ka,	while	a	higher	
temperature	(40	°C)	led	to	an	8:2	14ka/14kb	mixture.	Replacement	of	the	5-phenyl	by	
other	aromatic	substituents	such	as	2-thienyl,	3-indolyl,	2-naphthyl	and	2-fluorenyl	was	
represented	by	compounds	14l,	14m,	14n	and	14o,	 respectively,	and	took	place	with	
no	 loss	 in	 efficiency	 and	 yields.	 Literature	 precedent	 for	 these	 frameworks	 is	 very	
scarce	 (14l,	 14m)	 or	 non-existent	 	 (14n,	 14o).	 The	 use	 of	 1-tetralone	 as	 the	 ketone	
component		
	
	
Scheme	6.10	
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allowed	 the	 synthesis	 of	 compounds	 14p-14s,	 derived	 from	 the	 hitherto	 unknown	
benzo[de]pyrrolo[3,2,1-ij]quinoline	framework.	
As	 a	 final	 effort	 to	 increase	 the	 structural	 complexity	 in	 the	 final	 architecture	 and	
expand	the	scope	of	the	method,	we	examined	double	TMSOTf-promoted	cyclizations.	
The	required	starting	material	13t	was	prepared	via	a	pseudo-five	component	reaction	
from	1,3-diacetylbenzene,	and	the	cyclization	proceeded	uneventfully	and	yielded	the	
angular	pentacyclic	compound	14ta	when	the	reaction	was	performed	at	20	°C,	and	a	
2:1	 mixture	 of	 14ta	 and	 its	 linear	 regioisomer	 14tb	 at	 40	 °C	 (Scheme	 6.11).	 Again,	
derivatives	14ta	and	14tb	represent	previously	unknown	frameworks.	
	
	
Scheme	6.11	
	
The	cyclization	reaction	is	assumed	to	proceed	by	the	mechanism	proposed	in	Scheme	
6.12.	The	reaction	starts	with	the	activation	of	the	acetal	by	the	TMSOTf	catalyst.	The	
acetal	so	activated	can	easily	undergo	the	attack	of	the	aromatic	ring	in	position	C-5	to	
produce	the	final	cyclization	product	with	loss	of	two	molecules	of	methanol	and	the	
generation	of	triflic	acid.	The	acid	thus	regenerates	the	TMSOTf	catalyst	from	TMSOMe	
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Scheme	6.12	
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6.4.	Experimental	section	
	
6.4.1.	General	procedure	for	the	synthesis	of	1,2-dihydro-3H-pyrrolizine	derivatives	11a-11e	
	
	
The	 required	 amount	 of	 the	 chosen	 pyrrole	1y-1ac	 (1	 eq)	 is	 added	 to	 a	 round	 bottom	 flask	
under	argon	atmosphere.	Then	1	ml	of	anhydrous	DCM	was	added	and	was	followed	by	TMS	
chloride	 (1.1	 eq)	 and	 Et3N	 (1.1	 eq),	 in	 this	 order.	 The	 reaction	 was	 stirred	 for	 1	 h	 at	 room	
temperature	and,	 then,	TfOTMS	(2.5	eq).	The	stirring	 is	maintained	for	additional	16	h,	after	
which	the	reaction	 is	controlled	by	TLC	using	ether	phase	as	mobile	phase	ethyl	acetate	8:2.	
When	the	reaction	was	finished,	the	mixture	was	washed	with	KHCO3.	The	aqueous	phase	was	
extracted	with	chloroform,	this	process	will	be	repeated	as	many	times	as	necessary	until	it	is	
well	 extracted.	 Finally,	 the	 organic	 phase	 are	 dried	 with	 anhydrous	 sodium	 sulphate	 and	
concentrated	under	vacuum.	The	product	obtained	 is	purified	by	 flash	column	using	hexane:	
ethyl	acetate	as	the	mobile	phase.	For	compounds	11b-11e	only	the	work-up	has	been	done	
because	 the	 crude	 undergoes	 directly	 to	 the	 subsequent	 reaction	 of	 elimination	 in	 order	 to	
lead	to	only	one	regioisiomer.	
	
Diethyl	2-methoxy-5-phenyl-2,3-dihydro-1H-pyrrolizine-1,7-dicarboxylate	(11a)	
	
Prepared	from	compound	1y	(0.3	mmol);	yield:	78	mg	(70	%);	yellowish	
oil;	1H	NMR	(250	MHz,	CDCl3)	δ	7.50	–	7.30	(m,	10H),	6.85	(s,	1H),	6.83	(s,	
1H),	4.78	–	4.49	(m,	4H),	4.37	–	4.12	(m,	12H),	3.55	(s,	3H),	3.48	(s,	3H),	
1.39	 –	 1.25	 (m,	 12H);	 13C	NMR	 (63	MHz,	 CDCl3)	 δ	 170.6,	 168.7,	 164.3,	
138.7,	 138.3,	 132.0,	 131.9,	 130.6,	 130.1,	 128.8,	 128.8,	 128.3,	 127.0,	
126.9,	 126.1,	 126.1,	 111.8,	 110.9,	 110.3,	 110.1,	 86.9,	 83.4,	 61.5,	 61.1,	 59.7,	 59.6,	 58.8,	 57.2,	
53.1,	 51.0,	 50.9,	 48.2,	 14.5,	 14.3,	 14.2;	 IR	 (neat) ν: 3099.9	 (C-H),	 1766.5	 and	 1733.6	 (C=O),	
1205.1	cm-1;	elemental	analysis	 (%)	calcd.	 for	C20H23NO5:	C,	67.21;	H,	6.49;	N,	3.92;	 found:	C,	
67.43;	H,	6.80;	N,	3.59.	
	
Trans-Diethyl	2-methoxy-5-phenyl-2,3-dihydro-1H-pyrrolizine-1,7-dicarboxylate	(11aa)	
	
Isolated	 from	 compound	 11a	 by	 chromatography	 1:1:0.1	
DCM/Ex/MeOH;	colorless	oil;	1H	NMR	(250	MHz,	CDCl3)	δ	7.41	–	7.28	(m,	
5H),	6.75	(s,	1H),	4.54	(dt,	J	=	5.6,	2.2	Hz,	1H),	4.44	(dd,	J	=	11.4,	5.6	Hz,	
1H),	4.27	–	3.98	(m,	6H),	3.38	(s,	3H),	1.28	–	1.19	(m,	6H);	 13C	NMR	(63	
MHz,	 CDCl3)	 δ	 170.6,	 164.3,	 138.7,	 132.0,	 130.1,	 128.8,	 126.9,	 126.0,	
111.9,	110.1,	86.9,	61.4,	59.6,	57.2,	53.1,	51.0,	14.5,	14.1;	 IR	 (neat) ν: 	 3140.2,	2955.5	 (C-H),	
1655.2	 and	 1625.2	 (C=O),	 1229.3	 (C-O)	 cm-1;	 elemental	 analysis	 (%)	 calcd.	 for	 C20H23NO5:	 C,	
67.21;	H,	6.49;	N,	3.92;	found:	C,	67.44;	H,	6.23;	N,	3.65.	
	
Cis-Diethyl	2-methoxy-5-phenyl-2,3-dihydro-1H-pyrrolizine-1,7-dicarboxylate	(11ab)	
	
Isolated	 from	 compound	 11a	 by	 chromatography	 1:1:0.1	
DCM/Ex/MeOH;	colorless	oil;	1H	NMR	(250	MHz,	CDCl3)	δ	7.51	–	7.33	(m,	
5H),	6.83	(s,	1H),	4.72	(q,	J	=	7.6	Hz,	1H),	4.58	(d,	J	=	7.6	Hz,	1H),	4.42	(dd,	
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J	=	10.3,	7.1	Hz,	1H),	4.34	–	4.19	(m,	5H),	3.55	(s,	3H),	1.34	(dd,	J	=	12.2,	7.1	Hz,	6H);	13C	NMR	
(63	MHz,	CDCl3)	 δ	 168.7,	 164.3,	 138.3,	 132.0,	 130.6,	 128.8,	 127.0,	 126.1,	 110.9,	 110.3,	 83.4,	
61.2,	 59.7,	 58.9,	 50.9,	 48.2,	 14.4,	 14.3,	 IR	 (neat) ν: 	 2993.0	 (C-H),	 1677.2	 and	 1645.2	 (C=O),	
1234.0	(C-O)	cm-1.		
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6.4.2.	General	procedure	for	the	base-promoted	elimination	affording	derivatives	12a-12d	
	
	
	
The	required	amount	of	 the	starting	pyrrole	11c-11f	 (0.1	mmol)	 is	added	 to	a	 round	bottom	
flask	under	argon	atmosphere	with	THF	and	then	LDA	(1.2	equivalents)	are	added.	The	mixture	
is	stirred	for	1	hour	and	then	controlled	by	TLC.	The	product	12	obtained	 is	purified	by	 flash	
column	using	8:2	hexane:	ethyl	acetate	as	the	mobile	phase.	
	
Dimethyl	5-(4-bromophenyl)-3H-pyrrolizine-1,7-dicarboxylate	(12a)	
	
Prepared	from	compound	11c	(0.1	mmol),	formed	from	1z;	yield:	33	
mg	(87	%);	yellowish	oil;	1H	NMR	(250	MHz,	CDCl3)	δ	7.58	(d,	J	=	8.7	
Hz,	2H),	7.45	(d,	J	=	8.7	Hz,	2H),	6.99	(d,	J	=	0.9	Hz,	1H),	6.89	–	6.86	
(m,	1H),	4.77	(d,	 J	=	2.1	Hz,	2H),	3.96	(s,	3H),	3.84	(s,	3H);	 13C	NMR	
(63	MHz,	 CDCl3)	 δ	 164.2,	 141.2,	 133.1,	 132.1,	 131.8,	 130.8,	 130.3,	
126.3,	 120.9,	 112.5,	 107.7,	 52.9,	 52.5,	 51.3;	 IR	 (neat) ν: 	 3140.2,	 2955.5	 (C-H),	 1655.2	 and	
1625.2	 (C=O),	 1229.3	 (C-O)	 cm-1;	 elemental	 analysis	 (%)	 calcd.	 for	 C17H14BrNO4:	 C,	 54.28;	 H,	
3.75;	N,	3.72;	found:	C,	54.11;	H,	3.92;	N,	3.44.	
	
Dimethyl	5-(3,4-dichlorophenyl)-3H-pyrrolizine-1,7-dicarboxylate	(12b)	
	
Prepared	from	compound	11d	(0.1	mmol),	formed	from	1aa;	yield:	
26	mg	(70	%);	transparent	oil;	1H	NMR	(250	MHz,	CDCl3)	δ	7.63	(d,	J	
=	2.1	Hz,	1H),	7.51	(d,	J	=	8.4	Hz,	1H),	7.40	(dd,	J	=	8.4,	2.1	Hz,	1H),	
7.01	(d,	J	=	0.8	Hz,	1H),	6.93	–	6.87	(m,	1H),	4.79	(d,	J	=	2.1	Hz,	2H),	
3.96	 (s,	3H),	3.84	 (s,	3H);	 13C	NMR	(63	MHz,	CDCl3)	δ	164.1,	141.6,	
133.3,	133.1,	131.7,	131.3,	130.9,	130.8,	129.4,	126.2,	123.9,	113.7,	107.9,	53.0,	52.5,	51.3;	IR	
(neat) ν: 	3111.3,	2923.1	(C-H),	1698.2	and	1675.3	(C=O),	1264.0	(C-O)	cm-1;	elemental	analysis	
(%)	calcd.	for	C17H13Cl2NO4:	C,	55.76;	H,	3.58;	N,	3.83;	found:	C,	,	55.34;	H,	3.22;	N,	3.98.	
	
Dimethyl	5-phenyl-3H-pyrrolizine-1,7-dicarboxylate	12c)	
	
Prepared	from	compound	11e	 (0.1	mmol),	 formed	from	1ab;	yield:	23	
mg	(75	%);	yellowish	oil;	1H	NMR	(250	MHz,	CDCl3)	δ	7.58	(d,	J	=	7.6	Hz,	
2H),	7.45	(t,	J	=	7.6	Hz,	3H),	7.34	(d,	J	=	7.6	Hz,	1H),	7.00	(s,	1H),	6.86	(s,	
1H),	4.79	(d,	J	=	1.9	Hz,	2H),	3.96	(s,	3H),	3.84	(s,	3H);	13C	NMR	(63	MHz,	
CDCl3)	 δ	164.4,	 140.9,	 132.9,	 131.9,	 131.7,	 131.4,	 128.9,	 127.2,	 124.9,	
112.0,	107.5,	52.9,	52.5,	51.2;	IR	(neat) ν: 2899.9	(C-H),	1777.9	and	1732.5	(C=O),	1255.5	cm-1;	
elemental	analysis	(%)	calcd.	for	C17H15NO4:	C,	68.68;	H,	5.09;	N,	4.71;	found:	C,	68.43;	H,	5.33;	
N,	4.39.	
Dimethyl	5-(4-methoxyphenyl)-3H-pyrrolizine-1,7-dicarboxylate	(12d)	
	
Prepared	from	compound	11f	(0.1	mmol),	formed	from	1ac;	yield:	
20	mg	(60	%);	dark	yellow	oil;	1H	NMR	(250	MHz,	CDCl3)	δ	7.51	(d,	J	
=	8.7	Hz,	2H),	6.99	(d,	J	=	8.7	Hz,	2H),	6.89	–	6.84	(m,	2H),	4.76	(d,	J	
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=	2.1	Hz,	2H),	3.96	(s,	3H),	3.88	(s,	3H),	3.84	(s,	3H)	;13C	NMR	(63	MHz,	CDCl3)	δ	164.5,	158.8,	
132.5,	131.9,	131.8,	128.6,	126.4,	124.2,	114.4,	114.3,	111.0,	107.3,	55.4,	52.7,	52.5,	51.2,	31.0;	
IR	(neat) ν: 	2988.3	(C-H),	1722.4	and	1677.0	(C=O),	1235.1	and	1122.9	(C-O)	cm-1;	elemental	
analysis	(%)	calcd.	for	C18H17NO5:	C,	66.05;	H,	5.23;	N,	4.28;	found:	C,	66.35;	H,	5.60;	N,	4.02.	
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6.4.3.	General	procedure	for	the	synthesis	of	pyrrole	derivatives	6	under	solvent-free	high-
speed	vibration	milling	(HSVM)	conditions	
	
	
	
The	 suitable	 ketone	 (0.5	mmol),	N-iodosuccinimide	 (NIS,	 0.5	mmol)	 and	 p-toluenesulphonic	
acid	(PTSA,	10	mol%)	were	added	to	a	ball	mill	vessel,	along	with	a	zirconium	oxide	ball.	The	
vessel	was	fitted	to	one	of	the	horizontal	vibratory	arms	of	the	ball	mill,	while	the	other	arm	
was	occupied	with	an	empty	vessel.	The	ball	mill	was	set	to	vibrate	at	a	frequency	of	20	s-1	for	
60	 min	 at	 room	 temperature.	 Then,	 a	 mixture	 of	 aminoacetaldehyde	 dimethyl	 acetal	 (1.0	
mmol),	 the	 suitable	β-dicarbonyl	 compound	 (0.75	mmol)	 and	 cerium(IV)	 ammonium	 nitrate	
(CAN,	5	mol%),	previously	stirred	at	 room	temperature	during	30	min,	and	silver	nitrate	 (0.5	
mmol)	were	added	to	the	vessel.	The	reaction	was	subjected	to	the	vibratory	movement	at	the	
same	frequency	for	60	min.	Then,	the	reaction	vessel	was	cleansed	with	ethyl	acetate	and	the	
suspension	was	filtered	to	remove	the	silver	iodide	precipitate.	The	organic	layer	was	washed	
with	water	(2	mL),	dried	over	anhydrous	sodium	sulphate	and	the	solvent	was	removed	under	
reduced	 pressure.	 Purification	 by	 flash	 column	 chromatography	 on	 silica	 gel	 eluting	 with	 a	
gradient	 from	 petroleum	 ether	 to	 8:2	 petroleum	 ether-ethyl	 acetate	 afforded	 the	 desired	
pyrrole	 derivatives	 13.	 Compounds	 6l-6o	 were	 prepared	 from	 isolated	 α-iodoketones,	
obtained	by	treatment	of	the	corresponding	ketones	with	iodine	in	the	presence	of	CuO.	
	
Ethyl	1-(2,2-dimethoxyethyl)-2-methyl-5-phenyl-1H-pyrrole-3-carboxylate	(13a)	
	
Prepared	 from	 acetophenone	 (0.5	 mmol),	 aminoacetaldehyde	 dimethyl	
acetal	 (1	mmol)	 and	 ethyl	 acetoacetate	 (0.75	mmol);	 yield:	 130	mg	 (82%);	
dark	orange	oil;	1H	NMR	(250	MHz,	CDCl3)	δ	7.59	–	7.35	(m,	5H),	6.59	(s,	1H),	
4.31	(q,	J	=	7.1	Hz,	2H),	4.15	(t,	J	=	4.8	Hz,	1H),	4.07	(d,	J	=	4.8	Hz,	2H),	3.16	(s,	
6H),	2.67	(s,	3H),	1.37	(t,	J	=	7.1	Hz,	3H);	13C	NMR	(63	MHz,	CDCl3)	δ	165.5,	137.7,	133.5,	132.9,	
129.5,	 128.4,	 127.6,	 112.0,	 110.0,	 104.1,	 59.3,	 55.1,	 46.4,	 14.4,	 11.8;	 IR	 (neat) ν: 	 	3013.5,	
2982.2,	2835.5	 (C-H),	1687.1	 (C=O),	1241.9,	1196.5	 (C-O)	cm-1;	elemental	 	 analysis	 (%)	calcd.	
for	C18H23NO4:	C,	68.12;	H,	7.30;	N,	4.41;	found:	C,	68.09;	H,	7.25;	N,	4.35.	
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Methyl	1-(2,2-dimethoxyethyl)-2-methyl-5-phenyl-1H-pyrrole-3-carboxylate	(13b)	
	
Prepared	from	acetophenone	(0.5	mmol),	aminoacetaldehyde	dimethyl	acetal	
(1	mmol)	and	methyl	acetoacetate	(0.75	mmol);	yield:	132	mg	(87%);	yellowish	
oil;	1H	NMR	(250	MHz,	CDCl3)	δ	7.43	–	7.30	(m,	5H),	6.57	(s,	1H),	4.17	–	4.13	
(m,	1H),	4.06	(d,	J	=	5.2	Hz,	2H),	3.82	(s,	3H),	3.15	(s,	6H),	2.67	(s,	3H);	13C	NMR	
(250	 MHz,	 CDCl3)	 δ	 165.8,	 137.7,	 133.6,	 132.7,	 129.4,	 128.4,	 127.5,	 111.6,	
109.9,	104.0,	55.0,	50.5,	46.4,	11.7;	IR	(neat)	ν:		2947.0	and	2835.4	(C-H),	1695.7	(C=O),	1244.2	
and	1182.6	 (C-O)	cm1;	elemental	analysis	 (%)	calcd.	 for	C17H21NO4:	C,	67.31;	H,	6.98;	N,	4.62;	
found:	C,	67.01;	H,	6.75;	N,	4.63.	
	
Methyl	 1-(2,2-dimethoxyethyl)-2-(2-methoxy-2-oxoethyl)-5-phenyl-1H-pyrrole-3-carboxylate	
(13c)	
	
Prepared	 from	 acetophenone	 (0.5	 mmol),	 aminoacetaldehyde	 dimethyl	
acetal	(1	mmol)	and	dimethyl-1,3-acetonedicarboxylate	(0.75	mmol);	yield:	
159	mg	 (88%);	 yellowish	 solid;	mp:	78-80	 °C;	 1H	NMR	 (250	MHz,	CDCl3)	δ	
7.48	–	7.37	(m,	5H),	6.61	(s,	1H),	4.31	(s,	2H),	4.10	(m,	3H),	3.83	(s,	3H),	3.76	
(s,	3H),	3.15	(s,	6H);	13C	NMR	(63	MHz,	CDCl3)	δ	170.7,	165.5,	134.6,	133.3,	
132.6,	129.8,	128.6,	127.9,	113.4,	110.2,	104.3,	55.3,	52.2,	50.9,	47.0,	31.3;	IR	(neat) ν: 	2942.3,	
2923.1,	2848.1	(C-H),	1748.9,	1695.6	(C=O),	1248.5,	1222.9	1194.9,	1163.6	(C-O)	cm-1;	ESI-MS:	
(m/z)	 320.1	 (M++Na);	 elemental	 analysis	 (%)	 calcd.	 for	 C19H23NO6:	 C,	 63.15;	H,	 6.42;	N,	 3.88;	
found:	C,	63.41;	H,	6.77;	N,	3.63.	
	
1-(1-(2,2-Dimethoxyethyl)-5-(4-methoxyphenyl)-2-methyl-1H-pyrrol-3-yl)ethan-1-one	(13d)	
	
Prepared	 from	 4 -methoxyacetophenone	 (0.5	 mmol),	
aminoacetaldehyde	 dimethyl	 acetal	 (1	 mmol)	 and	 acetylacetone	 (0.75	
mmol);	yield:	126	mg	(80%);	orange	oil;	1H	NMR	(250	MHz,	CDCl3)	δ	7.35	
–	7.30	(m,	2H),	7.00	–	6.92	(m,	2H),	6.44	(s,	1H),	4.19	(t,	J	=	5.1	Hz,	1H),	
4.01	(d,	J	=	5.1	Hz,	2H),	3.85	(s,	3H),	3.17	(s,	6H),	2.65	(s,	3H),	2.42	(s,	3H);	
13C	NMR	(63	MHz,	CDCl3)	δ	194.9,	159.1,	136.6,	133.1,	130.9,	124.9,	120.6,	113.8,	110.1,	103.8,	
55.1,	54.9,	46.0,	28.4,	12.2;	 IR	 (neat) ν: 	 	3006.1,	2936.7,	2836.5	 (C-H),	1648.3	 (C=O),	1287.3,	
1246.1	(C-O)	cm-1;	ESI-MS:	(m/z)	318.2	(M++H);	elemental		analysis	(%)	calcd.	for	C18H23NO4:	C,	
68.12;	H,	7.30;	N,	4.41;	found:	C,	68.07:	H,	7.27:	N,	4.43.	
	
	 	
N
O
O
O
O
N
O
O
O
O
O
O
N
O
O
O
O
	
	
110	 	 	 	 	 		
1-(1-(2,2-Dimethoxyethyl)-5-(4-fluorophenyl)-2-methyl-1H-pyrrol-3-yl)ethan-1-one	(13e)	
	
Prepared	 from	 4 -fluoroacetophenone	 (0.5	 mmol),	 aminoacetaldehyde	
dimethyl	 acetal	 (1	 mmol)	 and	 acetylacetone	 (0.75	 mmol);	 yield:	 127	 mg	
(79%);	 orange	 solid;	mp:	 106-108	 °C;	 1H	 NMR	 (250	MHz,	 CDCl3)	 δ	 7.46	 –	
7.33	(m,	2H),	7.23	–	7.05	(m,	2H),	6.53	(s,	1H),	4.17	(t,	J	=	5.3	Hz,	1H),	4.02	
(d,	J	=	5.3	Hz,	2H),	3.82	(s,	3H),	3.18	(s,	6H),	2.65	(s,	3H);	13C	NMR	(63	MHz,	
CDCl3)	δ	 165.8,	 164.2	 –	 160.3	 (d,	 J	 =	 248.2	Hz),	 137.6,	 132.6,	 131.4	–	 131.3	 (d,	 J	 =	 8.12	Hz),	
128.9	–	128.8	(d,	J	=	3.1	Hz),	115.6	–	115.2	(d,	J	=	21.4	Hz),	111.7,	110.1,	104.0,	55.2,	50.7,	46.4,	
11.7;	IR	(neat) ν: 2972.8,	2945.2,	2840.1	(C-H),	1691.3	(C=O),	1242.5,	1192.0	(C-O),	1129.1	(C-
F)	 cm-1;	 elemental	 	 analysis	 (%)	 calcd.	 for	 C17H20FNO4:	 C,	 63.54;	 H,	 6.27;	 N,	 4.36;	 found:	 C,	
63.32;	H,	6.19;	N,	4.29.	
	
1-(5-(4-Chlorophenyl)-1-(2,2-dimethoxyethyl)-2-methyl-1H-pyrrol-3-yl)ethan-1-one	(13f)	
	
Prepared	 from	 4 -chloroacetophenone	 (0.5	 mmol),	 aminoacetaldehyde	
dimethyl	 acetal	 (1	 mmol)	 and	 acetylacetone	 (0.75	 mmol);	 yield:	 111	 mg	
(69%);	yellowish	oil;	1H	NMR	(250	MHz,	CDCl3)	δ	7.44	–	7.33	(m,	4H),	6.50	(s,	
1H),	4.23	(t,	J	=	5.3	Hz,	1H),	4.03	(d,	J	=	5.3	Hz,	2H),	3.19	(s,	6H),	2.67	(s,	3H),	
2.43	 (s,	3H);	 13C	NMR	(63	MHz,	CDCl3)	δ	194.9,	137.2,	133.6,	132.3,	131.2,	
130.8,	128.7,	121.0,	110.9,	103.7,	55.1,	46.2,	28.5,	12.3;	IR	(neat) ν: 	2994.0,	2933.2,	2834.4	(C-
H),	 1652.6	 (C=O),	 1245.2	 (C-O),	 1011.8	 (C-Cl)	 cm-1;	 elemental	 	 	 analysis	 (%)	 calcd.	 for	
C17H20ClNO3:	C,	63.45;	H,	6.26;	N,	4.35;	found:	C,	63.35;	H,	6.20;	N,	4.29.	
	
Methyl	5-(4-bromophenyl)-1-(2,2-dimethoxyethyl)-2-methyl-1H-pyrrole-3-carboxylate	(13g)	
	
Prepared	from	4 -bromoacetophenone	(0.5	mmol),	aminoacetaldehyde	
dimethyl	 acetal	 (1	mmol)	 and	methyl	 acetoacetate	 (0.75	mmol);	 yield:	
131	mg	 (69%);	 white	 solid;	mp:	 91-93	 °C;	1H	 NMR	 (250	MHz,	 CDCl3)	 δ	
7.61	–	7.53	(m,	2H),	7.33	–	7.26	(m,	2H),	6.56	(s,	1H),	4.19	(t,	J	=	5.3	Hz,	
1H),	4.04	 (d,	 J	 =	5.3	Hz,	2H),	3.83	 (s,	3H),	3.20	 (s,	6H),	2.66	 (s,	3H);	 13C	
NMR	 (63	MHz,	 CDCl3)	 δ	 165.7,	 138.1,	 132.5,	 131.8,	 131.7,	 131.0,	 121.8,	 110.4,	 103.9,	 55.2,	
50.8,	46.6,	11.8;	IR	(neat) ν: 	2999.2,	2947.7,	2839.3	(C-H),	1691.4	(C=O),	1242.1,	1212.2	(C-O)	
cm-1;	elemental		analysis	(%)	calcd.	for	C17H20BrNO4:	C,	53.42;	H,	5.27;	N,	3.66;	found:	C,	53.35;	
H,	5.22;	N,	3.56.	
	
Methyl	 5-(4-bromophenyl)-1-(2,2-dimethoxyethyl)-2-(2-methoxy-2-oxoethyl)-1H-pyrrole-3-
carboxylate	(13h)	
	
Prepared	 from	 4 -bromoacetophenone	 (0.5	 mmol),	 aminoacetaldehyde	
dimethyl	 acetal	 (1	 mmol)	 and	 dimethyl-1,3-acetonedicarboxylate	 (0.75	
mmol);	 yield:	 165	mg	 (75%);	 yellowish	 solid;	mp:	 59-61	 °C;	1H	NMR	 (250	
MHz,	CDCl3)	δ	7.57	–	7.54	(m,	2H),	7.29	–	7.26	(m,	2H),	6.58	(s,	1H),	4.27	(s,	
2H),	4.15	(t,	 J	=	5.1	Hz,	1H),	4.04	(d,	J	=	5.1	Hz,	2H),	3.80	(s,	3H),	3.73	(s,	
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3H),	3.17	 (s,	6H);	 13C	NMR	(63	MHz,	CDCl3)	δ	170.5,	165.1,	133.4,	133.3,	131.6,	131.4,	131.1,	
122.0,	113.5,	110.5,	103.9,	55.1,	52.0,	50.8,	46.9,	31.1;	IR	(neat) ν: 	2982.1,	2952.6,	2905.6	(C-
H),	 1756.5,	 1703.4	 (C=O),	 1245.1,	 1226.3,	 1182.5,	 1149.5	 (C-O)	 cm-1;	 elemental	 	 analysis	 (%)	
calcd.	for	C19H22BrNO6:	C,	51.83;	H,	5.04;	N,	3.18;	found:	C,	51.79;	H,	4.99;	N,	3.18.	
	
1-(1-(2,2-dimethoxyethyl)-5-(4-iodophenyl)-2-methyl-1H-pyrrol-3-yl)ethan-1-one	(13i)	
	
Prepared	 from	 4 -iodoacetophenone	 (0.5	 mmol),	 aminoacetaldehyde	
dimethyl	 acetal	 (1	mmol)	 and	 acetylacetone	 (0.75	mmol);	 yield:	 149	mg	
(72%);	 orange	 solid;	mp:	 121-123	 °C;	 1H	NMR	 (250	MHz,	 CDCl3)	δ	 7.81	 –	
7.70	(m,	2H),	7.23	–	7.11	(m,	2H),	6.50	(s,	1H),	4.23	(t,	J	=	5.3	Hz,	1H),	4.04	
(d,	J	=	5.3	Hz,	2H),	3.20	(s,	6H),	2.66	(s,	3H),	2.43	(s,	3H);	13C	NMR	(63	MHz,	
CDCl3)	δ	 194.9,	 137.6,	 137.3,	 132.4,	 132.2,	 131.2,	 121.0,	 110.9,	 103.7,	 93.3,	 55.1,	 46.2,	 28.5,	
12.3;	 IR	 (neat) ν: 	 2989.4,	 2931.4,	 2834.6	 (C-H),	 1649.4	 (C=O),	 1247.6,	 1207.5	 (C-O)	 cm-1;	
elemental	analysis	(%)	calcd.	for	C17H20INO3:	C,	49.41;	H,	4.88;	N,	3.39;	found:	C,	49.39;	H,	4.80;	
N,	3.37.	
	
Methyl	1-(2,2-dimethoxyethyl)-5-(2-iodophenyl)-2-methyl-1H-pyrrole-3-carboxylate	(13j)	
	
Prepared	from	2-iodoacetophenone	(0.5	mmol),	aminoacetaldehyde	dimethyl	
acetal	 (1	mmol)	 and	methyl	 acetoacetate	 (0.75	mmol);	 yield:	 148	mg	 (69%);	
yellowish	oil;	1H	NMR	(250	MHz,	CDCl3)	δ	7.95	(dd,	J	=	8.0,	1.1	Hz,	1H),	7.46	–	
7.32	(m,	2H),	7.10	(m,	1H),	6.51	(s,	1H),	4.13	(t,	J	=	5.3	Hz,	1H),	3.95	–	3.71	(m,	
5H),	3.16	(s,	6H),	2.66	(s,	3H);	13C	NMR	(63	MHz,	CDCl3)	δ 165.9,	139.1,	137.9,	
137.2,	134.4,	132.4,	129.9,	127.9,	111.3,	110.4,	104.2,	102.7,	55.1,	50.6,	46.7,	11.6;	IR	(neat) ν: 	
2992.4,	2946.7,	2834.6	(C-H),	1697.2	(C=O),	1234.8,	1196.9	(C-O),	1067.3	(C-I)	cm-1;	elemental		
analysis	(%)	calcd.	for	C17H20INO4:	C,	47.57;	H,	4.70;	N,	3.26;	found:	C,	47.49;	H,	4.65;	N,	3.18.	
	
Methyl	 5-(3,4-dichlorophenyl)-1-(2,2-dimethoxyethyl)-2-methyl-1H-pyrrole-3-carboxylate	
(13k)	
	
Prepared	 from	3,4-dichloroacetophenone	 (0.5	mmol),	 aminoacetaldehyde	
dimethyl	acetal	(1	mmol)	and	methyl	acetoacetate	(0.75	mmol);	yield:	120	
mg	(65%);	yellowish	oil;	1H	NMR	(250	MHz,	CDCl3)	δ	7.55	(d,	J	=	2.1	Hz,	1H),	
7.50	(d,	J	=	8.3	Hz,	1H),	7.27	(dd,	J	=	8.3,	2.1	Hz,	1H),	6.58	(s,	1H),	4.25	(t,	J	=	
5.3	Hz,	1H),	4.04	(d,	J	=	5.3	Hz,	2H),	3.83	(s,	3H),	3.22	(s,	6H),	2.66	(s,	3H);	
13C	NMR	(63	MHz,	CDCl3)	δ	165.6,	138.3,	132.8,	132.5,	131.7,	131.4,	131.1,	130.4,	128.6,	112.2,	
111.0,	 103.8,	 55.2,	 50.8,	 46.7,	 11.8;	 IR	 (neat) ν: 	 2992.8,	 2848.0,	 2835.9	 (C-H),	 1699.4	 (C=O),	
1241.3,	 1196.5	 (C-O)	 cm-1;	 ESI-MS:	 (m/z)	 394.1	 (M++Na);	 elemental	 	 analysis	 (%)	 calcd.	 for	
C17H19Cl2NO4:	C,	54.85;	H,	5.15;	N,	3.76;	found:	C,	54.73;	H,	5.10;	N,	3.75.	
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Ethyl	1-(2,2-dimethoxyethyl)-2-methyl-5-(thiophen-2-yl)-1H-pyrrole-3-carboxylate	(13l)	
	
Prepared	 from	 2-acetylthiophene	 (0.5	mmol),	 aminoacetaldehyde	 dimethyl	
acetal	 (1	mmol)	 and	 ethyl	 acetoacetate	 (0.75	mmol);	 yield:	 111	mg	 (69%);	
yellowish	oil;	1H	NMR	(250	MHz,	CDCl3)	δ	7.36	–	7.34	(m,	1H),	7.14	–	7.08	(m,	
2H),	6.72	(s,	1H),	4.38	–	4.25	(m,	3H),	4.12	(d,	J	=	5.4	Hz,	2H),	3.27	(s,	6H),	2.66	
(s,	3H),	1.37	(t,	J	=	7.1	Hz,	3H);	13C	NMR	(63	MHz,	CDCl3)	δ	165.3,	138.4,	133.7,	
127.3,	127.1,	125.8,	125.5,	112.2,	111.9,	104.2,	59.4,	55.4,	46.8,	14.4,	11.8;	IR	(neat) ν: 	2934.1,	
2834.3	 (C-H),	 1693.6	 (C=O),	 1287.3,	 1246.1	 (C-O)	 cm-1;	 elemental	 	 analysis	 (%)	 calcd.	 for	
C16H21NO4S:	C,	59.42;	H,	6.55;	N,	4.33;	found:	C,	59.38;	H,	6.49;	N,	4.35.	
	
Methyl	1-(2,2-dimethoxyethyl)-5-(1H-indol-3-yl)-2-methyl-1H-pyrrole-3-carboxylate	(13m)	
	
Prepared	 from	 3-acetylindole	 (0.5	 mmol),	 aminoacetaldehyde	 dimethyl	
acetal	 (1	 mmol)	 and	 methyl	 acetoacetate	 (0.75	 mmol);	 yield:	 120	 mg	
(70%);	dark	yellow	oil;	1H	NMR	(250	MHz,	CDCl3)	δ	8.59	(brs,	1H),	7.62	(d,	J	
=	7.7	Hz,	1H),	7.45	(d,	J	=	8.1	Hz,	2H),	7.37	(d,	J	=	2.4	Hz,	1H),	7.32	–	7.14	
(m,	2H),	6.71	(s,	1H),	4.27	(t,	J	=	5.3	Hz,	1H),	4.07	(d,	J	=	5.3	Hz,	2H),	3.88	(s,	
3H),	 3.17	 (s,	 6H),	 2.72	 (s,	 3H);	 13C	NMR	 (63	MHz,	CDCl3)	δ	 166.3,	 137.3,	 135.7,	 127.6,	 126.2,	
124.1,	122.5,	120.2,	119.5,	111.6,	111.2,	110.6,	108.1,	104.3,	55.2,	50.7,	46.8,	11.9;	IR	(neat) ν: 	
3322.9	 (N-H),	 2911.2,	 2853.7	 (C-H),	 1679.8	 (C=O),	 1224.8,	 1135.3	 (C-O)	 cm-1;	 elemental		
analysis	(%)	calcd.	for	C19H22N2O4:	C,	66.65;	H,	6.48;	N,	8.18;	found:	C,	66.57;	H,	6.39;	N,	8.15.	
	
1-(1-(2,2-Dimethoxyethyl)-2-methyl-5-(naphthalen-2-yl)-1H-pyrrol-3-yl)ethan-1-one	(13n)	
	
Prepared	 from	 2-acetylnaphtalene	 (0.5	 mmol),	 aminoacetaldehyde	
dimethyl	 acetal	 (1	mmol)	 and	 acetylacetone	 (0.75	mmol);	 yield:	 121	mg	
(72%);	white	solid;	mp:	97-99	°C;	 1H	NMR	(250	MHz,	CDCl3)	δ	8.04	–	7.88	
(m,	4H),	7.66	–	7.48	(m,	3H),	6.63	(s,	1H),	4.30	–	4.21	(m,	1H),	4.16	(m,	2H),	
3.16	(s,	6H),	2.73	(s,	3H),	2.48	(s,	3H);	13C	NMR	(63	MHz,	CDCl3)	δ	195.0,	137.3,	133.4,	133.2,	
132.4,	130.1,	128.4,	128.1,	127.9,	127.6,	127.3,	126.4,	126.2,	121.0,	111.0,	103.8,	55.0,	46.3,	
28.6,	12.3;	IR	(neat) ν: 	2998.9,	2836.2,	2836.3	(C-H),	1648.0	(C=O),	1200.0,	1200.3	(C-O)	cm-1;	
elemental		analysis	(%)	calcd.	for	C21H23NO3:	C,	74.75;	H,	6.87;	N,	4.15;	found:	C,	74.71;	H,	6.80;	
N,	4.10.	
	
Ethyl	1-(2,2-dimethoxyethyl)-5-(9H-fluoren-2-yl)-2-methyl-1H-pyrrole-3-carboxylate	(13o)	
	
Prepared	 from	 2-acetylfluorene	 (0.5	 mmol),	 aminoacetaldehyde	
dimethyl	acetal	 (1	mmol)	and	ethyl	acetoacetate	 (0.75	mmol);	yield:	
162	 mg	 (80%);	 yellowish	 solid;	 mp:	 89-91	 °C;	 1H	 NMR	 (250	 MHz,	
CDCl3)	δ	7.84	(m,	3.3	Hz,	2H),	7.60	(m,	2H),	7.48	–	7.32	(m,	3H),	6.66	
(s,	1H),	4.34	(q,	J	=	7.1	Hz,	2H),	4.25	–	4.17	(m,	1H),	4.14	(m,	2H),	3.97	
(s,	 2H),	 3.17	 (s,	 6H),	 2.71	 (s,	 3H),	 1.40	 (t,	 J	 =	 7.1	Hz,	 3H);	 13C	NMR	 (63	MHz,	 CDCl3)	δ	 165.5,	
143.4,	143.2,	141.1,	141.0,	137.7,	133.9,	131.2,	128.2,	126.9,	126.8,	126.0,	125.0,	119.9,	119.8,	
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112.0,	110.1,	104.1,	59.2,	55.1,	46.5,	36.8,	14.4,	11.8;	IR	(neat) ν: 	2962.2,	2918.0,	2838.2	(C-H),	
1681.9	(C=O),	1246.3,	1194.4	(C-O)	cm-1;	elemental		analysis	(%)	calcd.	for	C25H27NO4:	C,	74.05;	
H,	6.71;	N,	3.45;	found:	C,	73.98;	H,	6.65;	N,	3.38.	
	
Methyl	1-(2,2-dimethoxyethyl)-2-methyl-4,5-dihydro-1H-benzo[g]indole-3-carboxylate	(13p)	
	
Prepared	 from	α-tetralone	 (0.5	mmol),	aminoacetaldehyde	dimethyl	acetal	
(1	mmol)	and	methyl	acetoacetate	(0.75	mmol);	yield:	130	mg	(79%);	orange	
solid;	mp:	60-62	°C;	1H	NMR	(250	MHz,	CDCl3)	δ	7.57	(d,	J	=	7.6	Hz,	1H),	7.27	
(dd,	J	=	10.6,	4.7	Hz,	2H),	7.13	(dd,	J	=	11.6,	4.2	Hz,	1H),	4.61	(t,	J	=	5.2	Hz,	
1H),	4.36	 (d,	 J	=	5.2	Hz,	2H),	3.86	 (s,	3H),	3.36	 (s,	6H),	3.02	–	2.90	 (m,	2H),	
2.90	–	2.79	(m,	2H),	2.68	(s,	3H);	13C	NMR	(63	MHz,	CDCl3)	δ	166.5,	139.1,	136.7,	129.3,	128.5,	
128.1,	126.6,	125.1,	123.9,	120.3,	109.8,	104.3,	55.4,	50.5,	48.1,	30.8,	21.6,	12.1;	IR	(neat) ν: 	
2935.2,	 2899.4,	 2834.5	 (C-H),	 1695.7	 (C=O),	 1255.0,	 1225.2,	 1194.4	 (C-O)	 cm-1;	 elemental		
analysis	(%)	calcd.	for	C19H23NO4:	C,	69.28;	H,	7.04;	N,	4.25;	found:	C,	69.22;	H,	6.98;	N,	4.23.	
	
Methyl	 1-(2,2-dimethoxyethyl)-2,4-dimethyl-4,5-dihydro-1H-benzo[g]indole-3-carboxylate	
(13q)	
	
Prepared	from	4-methyl-1-tetralone	(0.5	mmol),	aminoacetaldehyde	dimethyl	
acetal	 (1	mmol)	 and	methyl	 acetoacetate	 (0.75	mmol);	 yield:	 123	mg	 (72%);	
green	oil;	1H	NMR	 (250	MHz,	 CDCl3)	 d	 7.57	 (d,	 J	 =	 7.7	Hz,	 1H),	 7.22	 (m,	 3H),	
4.58	(t,	J	=	5.1	Hz,	1H),	4.37	(d,	J	=	5.1	Hz,	2H),	3.85	(s,	3H),	3.35	(s,	3H),	3.33	(s,	
3H),	3.10	–	2.80	 (m,	3H),	2.67	 (s,	3H),	1.26	 (d,	 J	=	7.5	Hz,	3H);	 13C	NMR	(250	
MHz,	 CDCl3)	 d	 166.5,	 141.3,	 139.2,	 128.4,	 127.3,	 127.1,	 126.3,	 125.3,	 122.3,	 120.5,	 110.3,	
104.3,	55.5,	55.4,	50.5,	48.0,	34.3,	29.1,	19.8,	12.1;	 IR	 (neat) ν: 	2947.9,	2835.7	 (C-H),	1690.8	
(C=O),	1271.7,	1248.5,	1217.3	(C-O)	cm-1;	elemental		analysis	(%)	calcd.	for	C20H25NO4:	C,	69.95;	
H,	7.34;	N,	4.08;	found:	C,	69.89;	H,	7.28;	N,	4.04.	
	
Methyl	 1-(2,2-dimethoxyethyl)-7-methoxy-2-methyl-4,5-dihydro-1H-benzo[g]indole-3-
carboxylate	(13r)	
	
Prepared	 from	 7-methoxy-1-tetralone	 (0.5	 mmol),	 aminoacetaldehyde	
dimethyl	acetal	(1	mmol)	and	methyl	acetoacetate	(0.75	mmol);	yield:	144	
mg	(80%);	dark	orange	oil;	1H	NMR	(250	MHz,	CDCl3)	δ	7.51	(d,	J	=	8.6	Hz,	
1H),	6.96	–	6.73	(m,	2H),	4.59	(d,	J	=	5.1	Hz,	1H),	4.32	(d,	J	=	5.1	Hz,	2H),	
3.84	(s,	6H),	3.36	(s,	6H),	2.99	–	2.90	(m,	2H),	2.83	(m,	2H),	2.66	(s,	3H);	13C	
NMR	 (63	MHz,	CDCl3)	δ	 166.5,	 157.0,	 138.9,	 138.1,	 128.0,	 122.5,	 121.9,	 121.5,	 114.8,	 110.9,	
109.6,	104.3,	55.4,	55.1,	50.5,	48.0,	31.3,	21.6,	12.0;	IR	(neat) ν: 	2940.4,	2905.5,	2834.4	(C-H),	
1694.5	(C=O),	1245.4,	1239.2,	1188.6	(C-O)	cm-1;	elemental	analysis	(%)	calcd.	for	C20H25NO5:	C,	
66.84;	H,	7.01;	N,	3.90;	found:	C,	66.76;	H,	6.97;	N,	3.89.	
	
Methyl	 1-(2,2-dimethoxyethyl)-2,6,8-trimethyl-4,5-dihydro-1H-benzo[g]indole-3-carboxylate	
(13s)	
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Prepared	 from	 5,7-Dimethyl-1-tetralone	 (0.5	 mmol),	 aminoacetaldehyde	
dimethyl	 acetal	 (1	mmol)	 and	methyl	 acetoacetate	 (0.75	mmol);	 yield:	 129	
mg	(72%);	yellowish	oil;	1H	NMR	(250	MHz,	CDCl3)	δ	7.30	(s,	1H),	6.88	(s,	1H),	
4.63	(t,	J	=	5.0	Hz,	1H),	4.37	(d,	J	=	5.0	Hz,	2H),	3.88	(s,	3H),	3.39	(s,	6H),	2.95	
(m,	2H),	2.81	–	2.78	(m,	2H),	2.70	(s,	3H),	2.37	(d,	J	=	2.5	Hz,	6H);	13C	NMR	(63	
MHz,	 CDCl3)	 δ	 166.4,	 139.0,	 135.3,	 134.8,	 131.7,	 129.0,	 128.3,	 128.0,	 123.5,	 119.2,	 109.4,	
104.4,	55.2,	50.4,	48.00,	25.5,	21.4,	21.2,	20.3,	12.00;	IR	(neat) ν: 	2946.8,	2832.2	(C-H),	1694.9	
(C=O),	1260.7,	1226.0,	1194.4	(C-O)	cm-1;	elemental		analysis	(%)	calcd.	for	C21H27NO4:	C,	70.56;	
H,	7.61;	N,	3.92;	found:	C,	70.51;	H,	7.55;	N,	3.92.	
	
Dimethyl	5,5'-(1,3-phenylene)bis(1-(2,2-dimethoxyethyl)-2-methyl-1H-pyrrole-3-carboxylate)	
(13t)	
	
Prepared	 from	 1,3-diacetylbenzene	 (0.5	mmol),	 aminoacetaldehyde	
dimethyl	acetal	(2	mmol)	and	methyl	acetoacetate	(1.5	mmol);	yield:	
171	mg	 (65%);	 yellowish	 solid;	mp=	122-124	 °C;	 1H	NMR	 (250	MHz,	
CDCl3)	δ	7.49	–	7.39	(m,	2H),	6.60	(s,	1H),	4.20	(d,	J	=	5.0	Hz,	1H),	4.11	
(d,	J	=	5.0	Hz,	2H),	3.84	(s,	3H),	3.18	(s,	6H),	2.68	(s,	3H);	13C	NMR	(63	
MHz,	CDCl3)	δ	165.8,	138.0,	133.2,	130.6,	128.7,	128.5,	111.9,	110.3,	
104.1,	55.1,	50.7,	46.6,	11.8;	 IR	 (neat) ν: 	2920.2,	2843.3	 (C-H),	1695.5	 (C=O),	1245.8,	1213.5	
(C-O)	 cm-1;	 HRMS	 calcd.	 for	 C28H36N2O8	 (M
++Na):	 551.2363,	 found:	 551.2390;	 elemental		
analysis	(%)	calcd.	for	C28H36N2O8:	C,	63.62;	H,	6.86;	N,	5.30;	found:	C,	63.56;	H,	6.85;	N,	5.25.	
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6.4.4.	General	procedure	for	the	Pommeranz-Fritsch	synthesis	of	pyrrolo[2,1-a]isoquinoline-
related	frameworks	14a-14t	
	
	
	
To	 a	 round	 bottom	 flask	 was	 added	 the	 corresponding	 pyrrole	 derivative	 13	 (1.0	 eq),	
trimethylsilyl	 trifluoromethanesulfonate	 (0.15-0.3	eq)	and	DCM	as	 solvent	 (4	mL/mmol).	The	
reaction	was	stirred	at	room	temperature	for	10-20	min	and	monitored	for	conversion	by	TLC.	
At	the	end	of	the	reaction,	the	solvent	was	removed	under	reduced	pressure.	The	residue	was	
purified	by	flash	chromatography	on	silica	gel	eluting	with	a	gradient	from	petroleum	ether	to	
8:2	petroleum	ether-ethyl	acetate	and	final	compound	14	is	obtained.	
	
Ethyl	3-methylpyrrolo[2,1-a]isoquinoline-2-carboxylate	(14a)	
	
Prepared	 from	 pyrrole	 13a	 (0.2	 mmol);	 yield:	 41,5	 mg	 (82%);	 dark	 yellow	
solid;	mp:	113-115	°C;	1H	NMR	(250	MHz,	CDCl3)	δ	8.03	(d,	J	=	8	Hz,	1H),	7.64	–	
7.45	(m,	3H),	7.39	(dd,	 J	=	7.5,	1.2	Hz,	1H),	7.35	(m,	1H),	6.83	(d,	 J	=	7.5	Hz,	
1H),	4.41	(q,	J	=	7.1	Hz,	2H),	2.79	(s,	3H),	1.46	(t,	J	=	7.1	Hz,	3H);	13C	NMR	(63	
MHz,	 CDCl3)	 δ	 165.8,	 128.4,	 127.8,	 127.7,	 126.9,	 126.4,	 126.3,	 126.0,	 122.0,	 120.9,	 114.9,	
112.7,	100.7,	59.9,	14.5,	10.4;	IR	(neat)	ν:		3052.8,	2980.5,	2937.8	(C-H),	1689.9	(C=O),	1296.0,	
1226.7	 (C-O)	 cm-1;	 elemental	 	 analysis	 (%)	 calcd.	 for	 C16H15NO2:	 C,	 75.87;	 H,	 5.97;	 N,	 5.53;	
found:	C,	75.80;	H,	5.89;	N,	5.50.	
	
Methyl	3-methylpyrrolo[2,1-a]isoquinoline-2-carboxylate	(14b)	
	
Prepared	from	pyrrole	13b	(0.2	mmol);	yield:	43	mg	(90%);	green	solid;	mp:	133-
135	°C;	1H	NMR	(250	MHz,	CDCl3)	δ	8.01	(d,	J	=	7.8	Hz,	1H),	7.60	–	7.44	(m,	3H),	
7.39	(dd,	J	=	7.5,	1.3	Hz,	1H),	7.35	–	7.29	(m,	1H),	6.81	(d,	J	=	7.6	Hz,	1H),	3.94	(s,	
3H),	2.78	(s,	3H);	13C	NMR	(63	MHz,	CDCl3)	δ	166.1,	128.5,	127.8,	127.8,	126.9,	
126.4,	126.3,	126.0,	121.9,	120.8,	114.6,	112.8,	100.6,	51.1,	10.3;	IR	(neat) ν: 		2992.7,	2946.6	
(C-H),	1696.8	(C=O),	1230.0	(C-O)	cm-1;	elemental		analysis	(%)	calcd.	for	C15H13NO2:	C,	75.30;	H,	
5.48;	N,	5.85;	found:	C,	75.21;	H,	5.47;	N,	5.82.	
	
Methyl	3-(2-methoxy-2-oxoethyl)pyrrolo[2,1-a]isoquinoline-2-carboxylate	(14c)	
	
Prepared	from	pyrrole	13c	(0.2	mmol);	53	mg	(90%);	yellowish	solid;	mp:	171-
173	°C;	1H	NMR	(250	MHz,	CDCl3)	δ	8.04	(d,	J	=	7.9	Hz,	1H),	7.66	(d,	J	=	7.5	Hz,	
1H),	7.61	–	7.46	(m,	2H),	7.43	(dd,	J	=	7.5,	1.2	Hz,	1H),	7.38	(s,	1H),	6.88	(d,	J	=	
7.5	Hz,	1H),	4.47	(s,	2H),	3.94	(s,	3H),	3.73	(s,	3H);	13C	NMR	(63	MHz,	CDCl3)	δ	
170.0,	165.7,	129.5,	128.0,	127.0,	126.5,	126.4,	126.2,	123.3,	122.1,	121.0,	115.9,	113.4,	101.1,	
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52.4,	 51.4,	 30.4;	 IR	 (neat)	 ν:		2994.3,	 2948.8,	 2843.1	 (C-H),	 1725.5,	 1695.5	 (C=O),	 1239.9,	
1197.1	 (C-O)	 cm-1;	 elemental	 	 analysis	 (%)	 calcd.	 for	 C17H15NO4:	 C,	 68.68;	 H,	 5.09;	 N,	 4.71;	
found:	C,	68.59;	H,	5.03;	N,	4.63.	
	
1-(8-Methoxy-3-methylpyrrolo[2,1-a]isoquinolin-2-yl)ethan-1-one	(14d)	
	
Prepared	from	pyrrole	13d	(0.2	mmol);	yield:	43	mg	(84%);	dark	orange	solid;	
mp:	126-128	°C;	1H	NMR	(250	MHz,	CDCl3)	δ	7.93	(d,	J	=	8.8	Hz,	1H),	7.60	(d,	J	
=	7.6	Hz,	1H),	7.16	–	7.09	(m,	2H),	7.00	(d,	J	=	2.6	Hz,	1H),	6.78	(d,	J	=	7.6	Hz,	
1H),	3.92	(s,	3H),	2.78	(s,	3H),	2.61	(s,	3H);	13C	NMR	(63	MHz,	CDCl3)	δ	196.5,	
158.0,	 128.6,	 127.8,	 126.3,	 123.4,	 122.8,	 121.3,	 120.3,	 116.8,	 113.0,	 108.9,	 99.1,	 55.4,	 29.1,	
10.7;	 IR	 (neat) ν: 	 2993.8,	 2899.5,	 2837.9	 (C-H),	 1656.0	 (C=O),	 1259.3,	 1223.0	 (C-O)	 cm-1;	
elemental		analysis	(%)	calcd.	for	C16H15NO2:	C,	75.87;	H,	5.97;	N,	5.53;	found:	C,	75.78;	H,	5.91;	
N,	5.44.	
	
Methyl	8-fluoro-3-methylpyrrolo[2,1-a]isoquinoline-2-carboxylate	(14e)	
	
Prepared	 from	pyrrole	13e	 (0.2	mmol);	 yield:	 41	mg	 (80%);	 yellowish	 solid;	
mp:	82-84	°C;	1H	NMR	(250	MHz,	CDCl3)	δ	8.02	–	7.96	(m,	1H),	7.66	(d,	J	=	7.6	
Hz,	1H),	7.28	–	7.18	(m,	3H),	6.79	(d,	J	=	7.6	Hz,	1H),	3.93	(s,	3H),	2.80	(s,	3H);	
13C	NMR	(63	MHz,	CDCl3)	d	166.1,	161.0	 (d,	 J	=	245.7	Hz),	128.0	 (d,	 J	=	16.4	
Hz),	124.0	(d,	J	=	8.2	Hz),	123.0	 ,	122.1,	116.3,	115.9,	114.9,	112.3,	112.0,	111.9,	100.2,	51.2,	
10.4;	 19F	 NMR	 (235	 MHz,	 CDCl3)	 δ -115.67,	 -115.72,	 -115.75,	 -115.78,	 -115.81;	 IR	 (neat) ν: 	
	2954.9,	 2855.8	 (C-H),	 1708.6	 (C=O),	 1255.5	 (C-O),	 1140.5	 (C-F)	 cm-1;	 elemental	 	 analysis	 (%)	
calcd.	for	C15H12FNO2:	C,	70.03;	H,	4.70;	N,	5.44;	found:	C,	69.91;	H,	4.63;	N,	5.39.	
	
1-(8-Chloro-3-methylpyrrolo[2,1-a]isoquinolin-2-yl)ethan-1-one	(14f)	
Prepared	 from	 pyrrole	 13f	 (0.2	mmol);	 yield:	 46	mg	 (90%);	 yellowish	 solid;	
mp:	179-181	°C;	1H	NMR	(250	MHz,	CDCl3)	δ	7.90	(d,	J	=	8.5	Hz,	1H),	7.61	(d,	J	
=	7.6	Hz,	1H),	7.51	(d,	J	=	2.0	Hz,	1H),	7.42	(dd,	J	=	8.5,	2.0	Hz,	1H),	7.20	(s,	1H),	
6.74	(d,	J	=	7.6	Hz,	1H),	2.78	(s,	3H),	2.61	(s,	3H);	13C	NMR	(63	MHz,	CDCl3)	δ	
196.2,	131.5,	128.1,	127.6,	127.6,	127.2,	126.3,	124.8,	123.2,	123.1,	121.8,	112.1,	101.1,	29.1,	
10.7;	IR	(neat) ν: 		3116.5,	3058.0,	3000.5	(C-H),	1653.3	(C=O),	1088.4	(C-Cl)	cm-1;	ESI-MS:	(m/z)	
280.0	(M++Na);	elemental		analysis	(%)	calcd.	for	C15H12ClNO:	C,	69.91;	H,	4.69;	N,	5.44;	found:	
C,	69.88;	H,	4.65;	N,	5.38.	
	
Methyl	8-bromo-3-methylpyrrolo[2,1-a]isoquinoline-2-carboxylate	(14g)	
	
Prepared	from	pyrrole	13g	(0.2	mmol);	yield:	41	mg	(65%);	white	solid;	mp:	
158-160	°C;	1H	NMR	(250	MHz,	CDCl3)	δ	7.87	(d,	J	=	8.5	Hz,	1H),	7.70	(d,	J	=	
1.9	Hz,	1H),	7.63	(d,	J	=	7.6	Hz,	1H),	7.57	(dd,	J	=	8.5,	1.9	Hz,	1H),	7.32	(s,	1H),	
6.75	(d,	J	=	7.6	Hz,	1H),	3.93	(s,	3H),	2.79	(s,	3H);	13C	NMR	(63	MHz,	CDCl3)	δ	
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166.0,	130.9,	129.3,	128.2,	128.0,	127.9,	125.2,	123.6,	122.0,	119.4,	115.0,	111.6,	101.2,	51.3,	
10.4;	 IR	 (neat) ν: 	 	2922.4,	 2852.6	 (C-H),	 1705.0	 (C=O),	 1231.9	 (C-O)	 cm-1;	 elemental	 analysis	
(%)	calcd.	for	C15H12BrNO2:	C,	56.63;	H,	3.80;	N,	4.40;	found:	C,	56.56;	H,	3.71;	N,	4.34.	
	
8-Bromo-3-(2-methoxy-2-oxoethyl)pyrrolo[2,1-a]isoquinoline-2-carboxylate	(14h)	
	
Prepared	 from	 pyrrole	 13h	 (0.2	mmol);	 yield:	 56	mg	 (75%);	 white	 solid;	
mp:	199-201	°C;	1H	NMR	(250	MHz,	CDCl3)	δ	7.90	(d,	J	=	8.5	Hz,	1H),	7.73	
(d,	J	=	1.8	Hz,	1H),	7.69	(d,	J	=	7.6	Hz,	1H),	7.60	(dd,	J	=	8.5,	1.8	Hz,	1H),	7.38	
(s,	1H),	6.80	 (d,	 J	=	7.6	Hz,	1H),	4.47	 (s,	2H),	3.94	 (s,	3H),	3.74	 (s,	3H);	13C	
NMR	 (63	MHz,	CDCl3)	δ	 169.9,	 165.5,	 131.0,	 129.3,	 128.9,	 128.1,	 125.0,	 123.7,	 123.7,	 122.1,	
119.9,	 116.3,	 112.2,	 101.5,	 52.5,	 51.5,	 30.4;	 IR	 (neat) ν: 	 3059.8,	 2951.9	 (C-H),	 1704.1	 (C=O),	
1229.4,	1198.0	(C-O)	cm-1;	elemental		analysis	(%)	calcd.	for	C17H14BrNO4:	C,	54.28;	H,	3.75;	N,	
3.72;	found:	C,	54.15;	H,	3.75;	N,	3.71.	
	
1-(8-Iodo-3-methylpyrrolo[2,1-a]isoquinolin-2-yl)ethan-1-one	(14i)	
	
Prepared	from	pyrrole	13i	(0.2	mmol);	yield:	48	mg	(69%);	yellowish	solid;	mp:	
219-221	°C;	1H	NMR	(250	MHz,	CDCl3)	δ	7.89	(s,	1H),	7.79	–	7.67	(m,	2H),	7.60	
(d,	J	=	7.6	Hz,	1H),	7.23	(s,	1H),	6.72	(d,	J	=	7.6	Hz,	1H),	2.78	(s,	3H),	2.61	(s,	3H);	
13C	 NMR	 (63	MHz,	 CDCl3)	 δ	 196.2,	 136.4,	 135.5,	 128.2,	 127.7,	 127.4,	 125.6,	
123.4,	123.1,	121.6,	111.9,	101.4,	90.5,	29.1,	10.7;	 IR	 (neat) ν: 	 	3111.1,	3001.0	 (C-H),	1655.9	
(C=O),	1073.8	(C-I)	cm-1;	elemental	analysis	(%)	calcd.	for	C15H12INO:	C,	51.60;	H,	3.46;	N,	4.01;	
found:	C,	51.55;	H,	3.45;	N,	4.00.	
	
Methyl	10-iodo-3-methylpyrrolo[2,1-a]isoquinoline-2-carboxylate	(14j)	
	
Prepared	 from	pyrrole	13j	 (0.2	mmol);	 yield:	 63	mg	 (86%);	 dark	 orange	 solid;	
mp:	155-157	°C;	1H	NMR	(250	MHz,	CDCl3)	δ	8.67	(s,	1H),	8.11	(dd,	J	=	8,	1.3	Hz,	
1H),	7.52	(d,	J	=	7.5	Hz,	1H),	7.45	(dd,	J	=	7.8,	1.3	Hz,	1H),	6.95	(m,	1H),	6.67	(d,	J	
=	7.5	Hz,	1H),	3.94	(s,	3H),	2.74	(s,	3H);	13C	NMR	(63	MHz,	CDCl3)	δ	166.0,	141.8,	
128.9,	 128.6,	 128.1,	 127.5,	 127.3,	 126.3,	 121.2,	 113.9,	 113.1,	 106.5,	 89.6,	 51.2,	 10.5;	 IR	
(neat) ν: 	 	3079.2,	 2946.4,	 2909.7	 (C-H),	 1697.4	 (C=O),	 1231.1	 (C-O),	 1056.6	 (C-I)	 cm-1;	
elemental	 	 analysis	 (%)	 calcd.	 for	 C15H12INO2:	 C,	 49.34;	 H,	 3.31;	 N,	 3.84;	 found:	 C,	 49.32;	 H,	
3.30;	N,	3.81.	
	
Methyl	7,8-dichloro-3-methylpyrrolo[2,1-a]isoquinoline-2-carboxylate	(14ka)	
	
Prepared	from	pyrrole	13k	(0.2	mmol);	yield:	49	mg	(80%);	yellow	solid;	mp:	
179-181	°C;	1H	NMR	(500	MHz,	CDCl3)	δ	7.85	(d,	J	=	8.6	Hz,	1H),	7.72	(d,	J	=	
7.9	Hz,	1H),	7.53	(d,	J	=	8.6	Hz,	1H),	7.34	(s,	1H),	7.29	(m,	2H),	3.94	(s,	3H),	
2.81	(s,	3H);	13C	NMR	(126	MHz,	CDCl3)	δ	165.8,	130.2,	129.4,	129.1,	128.3,	
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127.3,	126.2,	125.7,	122.8,	121.3,	115.7,	108.8,	101.9,	51.3,	10.4;	 IR	(neat) ν: 	2922.4,	2853.2	
(C-H),	1694.7	 (C=O),	1237.8	 (C-O)	cm-1;	ESI-MS:	 (m/z)	330.0	 (M++Na);	elemental	 	analysis	 (%)	
calcd.	for	C15H11Cl2NO2:	C,	58.47;	H,	3.60;	N,	4.55;	found:	C,	58.42;	H,	3.54;	N,	4.49.	
When	the	reaction	was	carried	out	at	40°C,	a	8:2	mixture	of	14ka	and	a	second	regioisomer	
(14kb)	 was	 detected.	 Isomer	 14kb	 (methyl	 8,9-dichloro-3-methylpyrrolo[2,1-a]isoquinoline-2-
carboxylate)	could	not	be	isolated	in	pure	state.	Its	NMR	data,	obtained	from	the	mixture,	are	
given	below:	
	
1H	NMR	 (250	MHz,	CDCl3)	δ	7.99	 (s,	 1H),	7.60	–	7.57	 (m,	2H),	7.26	 (s,	 1H),	
6.69	 (d,	 1H),	 3.94	 (s,	 3H),	 2.78	 (s,	 3H);	 13C	 NMR	 (63	MHz,	 CDCl3)	 δ	 165.7,	
131.7,	 130.1,	 129.6,	 129.0,	 128.7,	 128.2,	 128.0,	 127.2,	 126.6,	 126.1,	 125.9,	
125.9,	 125.6,	 123.4,	 122.1,	 121.2,	 115.3,	 111.0,	 109.8,	 108.7,	 101.9,	 101.9,	
51.3,	51.3,	10.4.	
	
Ethyl	7-methylthieno[3,2-g]indolizine-8-carboxylate	(14l)		
	
Prepared	 from	pyrrole	13l	 (0.2	mmol);	 yield:	 65	mg	 (85%);	 green	 solid;	mp:	
93-95	 °C;	1H	NMR	 (250	MHz,	CDCl3)	δ	 8.05	 (d,	 J	=	8	Hz,	1H),	7.68	–	7.46	 (m,	
3H),	7.41	(dd,	J	=	7.5,	1.2	Hz,	1H),	7.36	(s,	1H),	6.86	(d,	J	=	7.5	Hz,	1H),	4.41	(q,	J	
=	7.1	Hz,	2H),	2.82	(s,	3H),	1.46	(t,	J	=	7.1	Hz,	3H);	13C	NMR	(63	MHz,	CDCl3)	δ	
165.7,	130.5,	130.2,	126.5,	126.3,	124.3,	123.1,	119.6,	115.6,	108.2,	98.1,	59.9,	14.4,	10.6;	 IR	
(neat) ν: 	 3112.4,	 2971.5,	 2909.8,	 2858.4	 (C-H),	 1691.2	 (C=O),	 1228.4,	 1203.8	 (C-O)	 cm-1;	
elemental	 	 analysis	 (%)	 calcd.	 for	 C14H13NO2S:	 C,	 64.84;	 H,	 5.05;	 N,	 5.40;	 S,	 12.36;	 found:	 C,	
64.80;	H,	5.03;	N,	5.39;	S,	12.30.	
	
Methyl	3-methyl-7H-indolizino[7,8-b]indole-2-carboxylate	(14m)	
	
Prepared	from	pyrrole	13m	(0.2	mmol);	yield:	39	mg	(70%);	green	solid;	mp:	
237-239	 °C;	1H	NMR	 (250	MHz,	Acetone-d)	δ	 10.70	 (br	 s,	 1H),	 8.12	 (dd,	 J	 =	
7.9,	1.1	Hz,	1H),	8.01	(d,	J	=	7.6	Hz,	2H),	7.64	–	7.55	(m,	1H),	7.33	–	7.13	(m,	
2H),	7.07	 (s,	1H),	3.87	 (s,	3H),	2.82	 (s,	3H);	13C	NMR	 (63	MHz,	Acetone-d)	δ	
166.9,	139.2,	132.4,	128.7,	125.8,	124.7,	123.3,	123.0,	121.3,	121.1,	116.2,	112.5,	109.2,	103.1,	
96.4,	51.4,	10.9;	IR	(neat)	ν:		2962.5,	2915.9,	2839.3	(C-H),	1682	(C=O)	cm-1;	elemental	analysis	
(%)	calcd.	for	C17H14N2O2:	C,	73.37;	H,	5.07;	N,	10.07;	found:	C,	73.33;	H,	5.06;	N,	9.99.	
	
1-(3-Methylbenzo[g]pyrrolo[2,1-a]isoquinolin-2-yl)ethan-1-one	(14n)	
	
Prepared	 from	pyrrole	13n	 (0.2	mmol);	 yield:	 46	mg	 (85%);	 yellowish	 solid;	
mp:	217-219	°C;	1H	NMR	(250	MHz,	CDCl3)	δ	8.40	(d,	J	=	8.3	Hz,	1H),	8.08	(d,	J	
=	8.8	Hz,	1H),	7.94	–	7.89	(m,	2H),	7.81	(d,	J	=	7.8	Hz,	1H),	7.71	–	7.53	(m,	3H),	
7.32	(s,	1H),	2.84	(s,	3H),	2.67	(s,	3H);	13C	NMR	(63	MHz,	CDCl3)	δ	196.6,	131.9,	
129.5,	129.2,	128.8,	128.7,	127.1,	126.1,	125.8,	124.4,	123.5,	122.4,	121.5,	120.9,	120.7,	108.3,	
100.5,	29.2,	10.7;	IR	(neat) ν: 	 	2996.0,	2918.6,	2852.4	(C-H),	1654.4	(C=O),	1224.4	(C-O)	cm-1;	
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elemental		analysis	(%)	calcd.	for	C19H15NO:	C,	83.49;	H,	5.53;	N,	5.12;	found:	C,	83.42;	H,	5.51;	
N,	5.07.	
	
Ethyl	3-methyl-12H-indeno[1,2-g]pyrrolo[2,1-a]isoquinoline-2-carboxylate	(14o)	
	
Prepared	from	pyrrole	13o	(0.2	mmol);	yield:	41	mg	(70%);	dark	yellow	
solid;	mp:	189-191	°C;	1H	NMR	(250	MHz,	CDCl3)	δ	7.59	–	7.55	(m,	2H),	
7.33	–	7.28	(m,	2H),	6.57	(s,	1H),	4.20	(t,	J	=	5.3	Hz,	1H),	4.05	(d,	J	=	5.3	
Hz,	2H),	3.84	(s,	3H),	3.20	(s,	6H),	2.66	(s,	3H);	13C	NMR	(63	MHz,	CDCl3)	
δ	 165.8,	 143.4,	 143.3,	 141.1,	 140.2,	 128.9,	 127.6,	 127.0,	 126.9,	 125.6,	 125.5,	 125.1,	 120.4,	
119.9,	118.1,	117.6,	114.9,	113.2,	100.5,	59.8,	36.8,	14.5,	10.5;	IR	(neat) ν: 	2924.3,	2854.3	(C-
H),	 1695.6	 (C=O),	 1232.0	 (C-O)	 cm-1;	 HRMS	 calcd	 for	 C23H19NO2	 (M
++H):	 342.1488,	 found	
342.1519;	elemental	 	 analysis	 (%)	 calcd.	 for	 C23H19NO2:	 C,	 80.92;	 H,	 5.61;	 N,	 4.10;	 found:	 C,	
80.84;	H,	5.60;	N,	4.07.	
	
Methyl	2-methyl-9,10-dihydrobenzo[de]pyrrolo[3,2,1-ij]quinoline-1-carboxylate	(14p)	
	
Prepared	from	pyrrole	13p	(0.2	mmol);	yield:	43	mg	(82%);	red	solid;	mp:	73-75	
°C;	1H	NMR	(250	MHz,	CDCl3)	δ	7.53	(d,	J	=	7.6	Hz,	1H),	7.38	–	7.29	(m,	3H),	6.78	
(d,	 J	=	7.6	Hz,	1H),	3.95	 (s,	3H),	3.33	–	3.27	 (m,	4H),	2.80	 (s,	3H);	13C	NMR	 (63	
MHz,	 CDCl3)	 δ	 166.9,	 131.7,	 127.7,	 126.6,	 126.1,	 125.7,	 124.4,	 123.4,	 123.0,	
120.7,	 112.5,	 112.4,	 112.1,	 50.9,	 27.9,	 22.2,	 10.4;	 IR	 (neat) ν: 	 2913.5,	 2853.2	 (C-H),	 1687.1	
(C=O),	 1252.0	 (C-O)	 cm-1;	 elemental	 	 analysis	 (%)	 calcd.	 for	 C17H15NO2:	 C,	 76.96;	 H,	 5.70;	 N,	
5.28;	found:	C,	76.91;	H,	5.70;	N,	5.27.	
	
Methyl	2,10-dimethyl-9,10-dihydrobenzo[de]pyrrolo[3,2,1-ij]quinoline-1-carboxylate	(14q)	
	
Prepared	 from	pyrrole	13q	 (0.2	mmol);	 yield:	 42	mg	 (76%);	 dark	 yellow	 solid;	
mp:	77-79	°C;	1H	NMR	(250	MHz,	CDCl3)	δ	7.50	(d,	J	=	7.6	Hz,	1H),	7.40	–	7.30	(m,	
3H),	6.75	(d,	J	=	7.6	Hz,	1H),	3.93	(s,	3H),	3.51	–	3.33	(m,	2H),	3.03	–	2.95	(m,	1H),	
2.77	 (s,	 3H),	 1.47	 (d,	 J	 =	 6.7	Hz,	 3H);	13C	NMR	 (63	MHz,	CDCl3)	δ	 166.9,	 136.7,	
127.6,	126.1,	125.8,	124.8,	123.6,	123.3,	123.2,	120.6,	112.6,	111.5,	50.8,	33.1,	30.6,	21.0,	10.4;	
IR	(neat) ν: 		3057.8,	2881.8,	2835.3	(C-H),	1690.3	(C=O),	1217.3	(C-O)	cm-1;	elemental		analysis	
(%)	calcd.	for	C18H17NO2:	C,	77.40;	H,	6.13;	N,	5.01;	found:	C,	77.35;	H,	6.08;	N,	5.00.	
	
Methyl	 7-methoxy-2-methyl-9,10-dihydrobenzo[de]pyrrolo[3,2,1-ij]quinoline-1-carboxylate	
(14r)	
	
Prepared	from	pyrrole	13r	(0.2	mmol);	yield:		49	mg	(83%);	dark	yellow	solid;	
mp:	114-116	°C;	1H	NMR	(250	MHz,	CDCl3)	δ	7.45	(d,	J	=	7.6	Hz,	1H),	6.97	–	
6.86	 (m,	1H),	6.79	 (d,	 J	=	2.1	Hz,	1H),	6.65	 (d,	 J	=	7.6	Hz,	1H),	3.91	 (s,	3H),	
3.87	 (s,	 3H),	 3.34	 –	 3.12	 (m,	 4H),	 2.73	 (s,	 3H);	 13C	NMR	 (63	MHz,	 CDCl3)	δ	
166.9,	158.3,	133.5,	126.8,	126.7,	123.9,	121.1,	118.5,	115.2,	112.3,	112.2,	109.6,	105.6,	55.4,	
50.8,	28.0,	22.1,	10.3;	 IR	 (neat) ν: 	 	2935.7,	2885.4,	2843.9	 (C-H),	1694.4	 (C=O),	1255.3	 (C-O)	
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cm-1;	elemental		analysis	(%)	calcd.	for	C18H17NO3:	C,	73.20;	H,	5.80;	N,	4.74;	found:	C,	73.19;	H,	
5.73;	N,	4.76.	
	
Methyl	2,6,8-trimethyl-9,10-dihydrobenzo[de]pyrrolo[3,2,1-ij]quinoline-1-carboxylate	(14s)	
	
Prepared	 from	 pyrrole	 13s	 (0.2	mmol);	 yield:	 47	mg	 (80%);	 dark	 orange	
solid;	mp:	215-217	°C;	1H	NMR	(250	MHz,	CDCl3)	δ	7.47	(d,	J	=	7.5	Hz,	1H),	
6.97	(s,	1H),	6.84	(d,	J	=	7.5	Hz,	1H),	3.93	(s,	3H),	3.31	(m,	2H),	3.13	(m,	2H),	
2.77	 (s,	3H),	2.49	 (s,	3H),	2.38	 (s,	3H);	 13C	NMR	 (63	MHz,	CDCl3)	δ	 167.0,	
134.6,	 130.7,	 129.2,	 127.1,	 126.8,	 124.2,	 120.2,	 119.3,	 112.1,	 111.9,	 109.6,	 50.8,	 24.5,	 21.9,	
19.0,	18.1,	10.4;	IR	(neat) ν: 	2914.4,	2860.4	(C-H),	1688.4	(C=O),	1256.4	(C-O),	1056.6	(C-I)	cm-
1;	ESI-MS:	(m/z)	316.1	(M++Na);	elemental		analysis	(%)	calcd.	for	C19H19NO2:	C,	77.79;	H,	6.53;	
N,	4.77;	found:	C,	77.73;	H,	6.49;	N,	4.74.	
	
Dimethyl	4,10-dimethyldipyrrolo[2,1-a:2',1'-i][2,8]phenanthroline-5,11-dicarboxylate	(14ta)	
	
Prepared	 from	 pyrrole	 13t	 (0.2	 mmol);	 yield:	 55	 mg	 (68%);	 green	
solid;	mp:	255-257	°C;	1H	NMR	(250	MHz,	CDCl3)	δ	7.98	(t,	J	=	8.2	Hz,	
2H),	7.78	(d,	J	=	7.6	Hz,	1H),	7.68	(m,	2H),	7.61	(d,	J	=	8.2	Hz,	1H),	7.39	
(s,	1H),	6.90	(d,	J	=	7.6	Hz,	1H),	3.98	(s,	3H),	3.96	(s,	3H),	2.83	(s,	6H);	
13C	NMR	(63	MHz,	CDCl3)	δ	166.1,	166.0,	128.9,	127.5,	127.3,	127.3,	127.2,	126.6,	125.7,	122.6,	
121.4,	120.9,	120.7,	120.4,	115.2,	115.2,	113.5,	110.2,	105.9,	101.1,	51.3,	51.3,	10.6,	10.4;	IR	
(neat) ν: 	 2929.4,	 2918.6	 (C-H),	 1709.9	 (C=O),	 1237.3,	 1231.2	 (C-O)	 cm-1;	 HRMS	 calcd.	 for	
C24H20N2O4	(M
++H):	401.1496,	found	401.1549;	elemental		analysis	(%)	calcd.	for	C24H20N2O4:	C,	
71.99;	H,	5.03;	N,	7.00;	found:	C,	71.90;	H,	4.97;	N,	6.98.	
When	 the	 reaction	was	carried	out	at	40°C,	a	2:1	mixture	of	14ta	 and	a	 second	 regioisomer	
(14tb)	 was	 detected.	 Isomer	 14tb	 (dimethyl	 3,11-dimethylindolizino[7,8-g]pyrrolo[2,1-
a]isoquinoline-2,12-dicarboxylate)	could	not	be	isolated	in	pure	state.	Its	NMR	data,	obtained	
from	the	mixture,	are	given	below:	
	
1H	NMR	(250	MHz,	CDCl3)	δ	8.35	(s,	1H),	7.91	(dd,	J	=	12.4,	8.2	Hz,	1H),	
7.73	-	7.45	(m,	2H),	7.33	(s,	2H),	6.80	(d,	7.5	Hz,	2H),	3.95	(s,	3H),	2.79	-	
2.75	 (d,	 3H);	 13C	 NMR	 (63	 MHz,	 CDCl3)	 δ 166.0,	 128.8,	 128.0,	 127.5,	
125.9,	124.9,	124.6,	114.6,	114.1,	112.4,	102.0,	51.2,	10.6.				 	
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7.	Synthesis	of	pyrrole-based	macrocycles	
	
7.1.	Introduction	
Drug	 discovery	 is	 a	 highly	 inefficient	 process,	 as	 shown	 by	 the	 fact	 that	 only	 4%	 of	
research	programs	in	pharmaceutical	industry	eventually	end	with	a	drug	placed	in	the	
market.	Furthermore,	the	efficiency	of	drug	discovery	is	declining	in	terms	of	the	ratio	
between	the	number	of	new	drugs	approved	each	year	and	the	ever-increasing	costs	
of	 pharmaceutical	 development.	 This	 decline	 has	 been	 attributed	 to	 a	 number	 of	
causes,	and	there	seems	to	be	a	consensus	among	experts	that	an	improved	selection	
of	targets	is	the	most	important	factor	that	may	accelerate	and	increase	the	efficiency	
of	 the	 drug	 discovery	 process.	 In	 this	 context,	 it	 is	 relevant	 to	mention	 that	 known	
drugs	 act	 on	 about	 500	 targets,	while	 the	 number	 of	 proteins	 	 that	may	 potentially	
serve	as	therapeutic	targets	has	been	recently	estimated	to	be	about	4,500.108		Only	a	
fraction	of	 these	 targets	 are	 considered	 “druggable”,	 i.e.,	 amenable	 to	manipulation	
with	 small	 molecules	 complying	 with	 Lipinsky’s	 rule	 of	 5	 (Ro5)	 and	 are	 therefore	
considered	as	likely	to	be	cell	permeable	and	orally	bioavailable.	Less	explored	targets,	
in	 particular	 protein−protein	 and	 protein-nucleic	 acid	 interactions,	 that	 are	
“undruggable”	 using	 conventional	 small	 molecules,	 are	 expected	 to	 provide	 many	
additional	 opportunities	 for	 drug	 discovery.	 Such	 non-conventional	 targets	 contain	
binding	 sites	 that	 are	 large,	 flexible,	 often	 endowed	 with	 extreme	 polarity	 values	
(either	highly	 lipophilic	or	highly	polar)	 but	normally	 lacking	 features	 that	 are	 key	 in	
conventional	drug	design	such	as	sites	involved	in	hydrogen	bonding.	The	realization	of	
these	 problems	 has	 led	 to	 the	 concept	 of	 exploring	 the	 chemical	 space	 that	 lies	
“beyond	 Ro5”	 (bRo5),	 also	 known	 as	 “middle	 space”,	 which	 is	 expected	 to	 yield	
compounds	 that	 are	 aimed	 at	 these	 traditionally	 intractable	 targets	 while	 retaining	
significant	oral	bioavailability.109	
Macrocycles110		are	very	attractive	in	this	regard	because	they	are	pre-organized		and	
sufficiently	 rigid	 to	position	substituents	and	 functional	groups	 in	specific	 regions	 for																																																									
108		Finan	C.,	Gaulton	A.,	Kruger	F.	A.,	Lumbers	T.,	Shah	T.,	Engmann	J.,	Galver	L.,	Kelley	R.,	Karlsson	A.,	
Santos	R.,	Overington	J.	P.,	Hingorani	A.	D.,	Casas	J.	P.,	Sci.	Transl.	Med.,	2017,	9,	article	eaag1166.	
109	 (a)	 Terrett	 N.,	MedChemComm	 2013,	 4,	 474;	 (b)	 Doak	 B.	 C.,	 Over	 B.,	 Giordanetto	 F.,	 Kihlberg	 J.,	
Chem.	Biol.,	2014,	21,	1115;	(c)	Whitty	A.,	Zhou	L.,	Future	Med.	Chem.,	2015,	7,	1093;	(d)	Doak	B.	C.,	
Zheng	J.,	Dobritzsch	D.,	Kihlberg	J.,	J.	Med.	Chem.,	2016,	59,	2312.	
110	 For	representative	reviews,	see:	(a)	Diggers,	E.	M.;	Hale,	S.	P.;	Lee,	J.;	Terrett,	N.	K.;	Nat.	Rev.	Drug	
Disc.,	2008,	7,	608;	(b)	Terrett,	N.	K.;	Drug	Disc.	Today:	Technologies,	2010,	7,	97;	(c)	Levin,	J.;	(Ed.),	
Macrocycles	 in	 Drug	Discovery,	 Royal	 Society	 of	 Chemistry,	2014.	 (d)	Mallinson,	 J.;	 Collins,	 I.;	 Fut.	
Med.	 Chem.,	 2012,	 4,	 1409;	 (e)	 Yu,	 X.;	 Sun,	 D.;	Molecules,	 2013,	 18,	 6230;	 (f)	 Giordanetto,	 F.;	
Kihlberg,	J.;	J.	Med.	Che.,	2014,	57,	278;	(g)	Yudin,	A.	K.;	Chem.	Sci.,	2015,	6,	30;	(h)	Raboisson,	P.	C.;	
Wermuth,	D.;	Aldous,	P.;	Raboisson,	D.;	Rognan,	D.;	 (Eds.).	The	practice	of	medicinal	chemistry,	4th	
Ed.,	Ch.	10,	Wiley,	2015.	(i)	You,	L.	R.;	Liang,	K.;	Cui,	B.;	Wang,	X.;	Curr.	Pharm.	Des.,	2016,	22,	4086;	
(j)	Paterson,	M.	L.;	https://www.americanpharmaceuticalreview.com/Featured-Articles/343609-The-
Evolution-of-Macrocycles-in-Drug-Discovery-From-Technologies-to-Drugs/.	 (k)	 Marsault,	 E.;	
Peterson,	M.	L.;	(Eds.).	Practical	Medicinal	Chemistry	with	Macrocycles.	Wiley,	2017.	
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target	 interaction,	 while	 maintaining	 	 sufficient	 flexibility	 to	 allow	 binding	 to	 the	
extended,	 shallow	 surfaces	 that	 characterize	 the	 interaction	 between	 biomolecules.	
Furthermore,	 their	 higher	 surface	 area	 in	 comparison	 to	 small	 molecules	 and	 the	
associated	 increased	 entropic	 factor	 leads	 to	 a	 higher	 affinity	 to	 flat	 protein	
surfaces.111		
Macrocycles	 thus	 cover	 a	 unique	 region	 of	 the	 chemical	 space	 that	 is	 intermediate	
between	small	molecules	and	biological	drugs	(Figure	7.1).	Furthermore,	macrocycles	
have	 the	possibility	 to	adopt	different	 conformations,	allowing	 them	to	change	 their	
physical	 characteristics	 in	 order	 to	 gain	 cell	 permeability	 in	 spite	 of	 their	 high	
molecular	weight.	
	
	
Figure	7.1	
	
Many	 macrocyclic	 natural	 products	 are	 employed	 as	 therapeutic	 agents	 in	 spite	 of	
representing	 only	 about	 3%	 of	 natural	 products,112	and	 their	 mechanisms	 of	 action	
usually	 involve	 interference	 with	 the	 interactions	 between	 biomolecules.	
Representative	examples	include	antibacterials	such	as	the	macrolide	antibiotics	(e.g.	
erythromycin)	 and	 rifampicin,	 the	 epothilones,	 a	 family	 of	 anticancer	 compounds	
interfering	with	 tubulin.	 Fully	 synthetic	macrocycles	 such	 as	 the	 antiviral	 simeprevir,	
used	 for	 the	treatment	of	chronic	hepatitis	C,	are	also	 increasingly	 important	 (Figure	
7.2).		
	
																																																								
111		Villar,	E.	A.;	Beglov,	D.;	Chennamadhavuni,	S.;	Porco	Jr,	J.	A.;	Kozakov,	D.;	Vajda,	S.;	Whitty,	A.	Nat.	
Chem.	Biol.	2014,	10,	723.	
112	 Wessjohann	L.	A.,	Ruijter	E.,	García-Rivera	D.,	Brandt	W.,	Mol.	Divers.	2005,	9,	171.	
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Figure	7.2	
	
Despite	their	unique	characteristics,	medicinal	chemists	have	underexplored	this	class	
of	compounds	because	of	challenges	found	in	development	of	synthetic	methods	that	
are	fast	and	efficient	and	allow	the	fine-tuning	of	their	properties	(Figure	7.3).113		
	
	
Figure	7.3	
	
Some	 examples	 of	 diversity-oriented	 libraries	 of	macrocycles	 are	 known,114	but	 DOS																																																									
113	 Whitty	A.;	Zhou	L.;	Future	Med.	Chem.	2015,	7,	1093.	
114		a)	S.	Kota,	K.	Singh,	Eur.	J.	Med.	Chem.	2007,	5909–5916.	b)	A.	 Isidro-Llobet,	T.	Murillo,	P.	Bello,	A.	
Cilibrizzi,	J.	T.	Hodgkinson,	W.	R.	J.	D.	Galloway,	A.	Bender,	M.	Welch,	D.	R.	Spring,	Proc.	Natl.	Acad.	
Sci.	 USA	2011,	108,	 6793–6798.	 c)	 F.	 Kopp,	 C.	 F.	 Stratton,	 L.	 B.	 Akella,	 D.	 S.	 Tan,	Nat.	 Chem.	 Biol.	
2012,	8,	 358–365.	 d)	 A.	 Guarnieri-Ibáñez,	F.	Medina,	C.	 Besnard,	S.	 L.	 Kidd,	D.	 R.	 Spring,	 J.	 Lacour,	
Chem.	 Sci.	 2017,	 8,	 5713-5720.	 e)	 M.	 Dow,	 F.	 Marchetti,	 K.	 A.	 Abrahams,	 L.	 Vaz,	 G.	 S.	 Besra,	 S.	
Warriner,	A.	Nelson,	Chem.	Eur.	J.	2017,	23,	7207-7211.	
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libraries	of	macrocyclic	structures	with	embedded	privileged	heterocyclic	frameworks	
are	rare.115	Due	to	the	very	high	potential	of	macrocycles	 in	drug	discovery	and	their	
under-representation	 in	 currently	 available	molecular	 libraries,	 we	 decided	 to	 study	
the	preparation	of	pyrrole-based	macrocycles	by	application	of	our	mechanochemical	
pyrrole	synthesis.	
	 	
																																																								
115		H.	S.	G.	Beckmann,	F.	Nie,	C.	E.	Hagerman,	H.	Johansson,	Y.	S.	Tan,	D.	Wilcke,	D.	R.	Spring,	Nat.	Chem.	
2013,	5,	861–867.	
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7.2.	Synthesis	of	pyrrole-derived	macrocycles	by	ring-closing	metathesis		
Our	first	approach	to	macrocycles	is	based	on	the	use	of	ring-closing	metathesis	for	the	
creation	of	the	macrocycle,116	as	shown	in	Scheme	7.1	
	
	
Scheme	7.1	
	
The	pyrrole	 derivatives	 required	 as	 starting	materials	 are	 characterized	by	 a	 dimeric	
architecture	with	two	pyrrole	rings	connected	by	a	bridge	represented	by	the	diamine	
and	two	homoallyl	substituents	attached	to	their	C-2	positions.	For	the	preparation	of	
these	compounds	(15),	we	employed	the	pseudo	five-component	reaction	described	in	
Section	3.2,	in	this	case	involving	as	starting	materials	a	diamine,	two	equivalents	of	a	
phenacyl	 iodide	and	two	equivalents	of	ethyl	3-oxo-6-heptenoate	as	the	β-dicarbonyl	
component.	The	results	obtained	are	summarized	in	Scheme	7.2.		
	
																																																								
116	 For	 reviews,	 see:	 (a)	 Gradillas,	 A.;	 Pérez-Castells,	 J.;	 Angew.	 Chem.	 Int.	 Ed.,	 2006,	 45,	 6086;	 (b)	
Gradillas,	A.;	Pérez-Castells,	J.;	Top.	Heterocycl.	Chem.,	2015,	47,	245.	
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Scheme	7.2	
	
The	 ring-closing	 metathesis	 reaction	 was	 optimized	 on	 substrate	 15a,	 as	 shown	 in	
Table	 7.1.	 Although	 the	 yields	 were	 not	 very	 different	 in	 the	 various	 conditions	
assayed,	 the	 best	 result	 corresponded	 to	 the	 use	 of	 high	 dilution	 conditions,	 which	
were	 achieved	 by	 slow	 injection	 of	 the	 substrate	 via	 syringe	 pump	 to	 a	
dichloromethane	solution	of	the	catalyst,	at	room	temperature	under	an	argon		
	
Table	7.1	
Entry	 DCM	(mL)/mmol	 %	Grubbs	1st	 T	(°C)	 Atmosphere	 %	Yield	
1	 10	 5	 r.t.	 air	 65	
2*	 15	 5	 r.t.	 air	 65	
3*	 20	 10	 r.t.	 air	 65	
4*	 30	 20	 35	 argon	 60	
5	 10	 10-15	 r.t.	 argon	 75	
*Slow	injection	of	the	pyrrole	substrate	to	the	solution	of	the	catalyst	in	DCM	
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with	a	syringe	pump	over	1	h.	
atmosphere	 and	 in	 the	 presence	 of	 10-15%	 of	 the	 Grubbs	 first	 generation	
catalyst,	 depending	 on	 the	 substrate	 (entry	 5).	 Using	 these	 conditions,	 the	
macrocyclic	 compounds	 summarized	 in	 Scheme	 7.3	 were	 synthesized.	 Ring	
sizes	 varied	between	12-membered	and	18-membered	 rings.	 For	 the	 systems	
with	 a	 smaller	 size	 (12	 and	 13-membered	 rings,	 compounds	 16a-c),	 a	 single	
isomer	 was	 obtained,	 but	 in	 the	 other	 cases	 (14,	 15,	 17	 and	 18-membered	
rings,	compounds	16d-16g)	mixtures	of	E	and	Z	isomers	were	obtained.	
	
	
Scheme	7.3	
	
 Owing	 to	 the	 symmetry	of	our	 systems,	both	olefinic	protons	are	
equivalent	and	for	this	reason	the	double	bond	geometry	cannot	be	
assessed	 by	 determining	 the	 value	 of	 the	 coupling	 constant.	
Furthermore,	none	of	the	compounds	was	sufficiently	crystalline	to	
allow	 single	 crystal	 X-Ray	 studies.	 We	 assumed	 that	 the	
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predominant	 isomer	would	 be	E,	which	 is	 the	most	 common	behaviour	 observed	 in	
macrocycles	due	to	the	thermodynamic	bias	in	RCM	reactions,	and	in	order	to	confirm	
this	 assumption	 we	 carried	 out	 a	 DFT	 computational	 study	 of	 both	 isomers	 of	
compound	16a,	which	 showed	 that	 its	E	 isomer	 is	26.7	kJ/mol	more	 stable	 than	 the	
corresponding	Z	species.	
Using	 the	 same	method,	we	prepared	 compound	15h,	bearing	 a	 silicon	 atom	at	 the	
spacer	 between	 the	 two	 pyrroles,	 and	 the	 corresponding	 18-membered,	 unusual	
macrocycle	16h	 (Scheme	7.4).	As	previously	mentioned,	the	so-called	“silicon-switch”	
strategy	represents	an	interesting	recent	trend	in	medicinal	chemistry.	
	
	
Scheme	7.4	
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7.3.	Synthesis	of	pyrrole-derived	medium-sized	rings	by	ring-closing	metathesis		
The	objective	of	 this	part	of	 the	 thesis	was	 to	 complete	 the	 study	of	 a	new	domino	
reaction	 that	 allows	 the	 synthesis	 of	 1,4-diazepines	 containing	 an	 embedded	 β-
aneminoester	 moiety	 from	 1,2-diamines	 and	 alkyl	 3-oxo-5-hexenoates	 via	 the	
generation	 of	 an	 intermediate	 aza-Nazarov	 reagent	 that	 was	 discovered	 by	 Dr.	
Swarupananda	Maiti	during	his	postdoctoral	stay	in	our	group.	In	a	second	stage,	the	
conditions	 were	 established	 for	 employing	 this	 reaction	 as	 the	 initial	 step	 of	 a	
synthesis	of	pyrrole-based	medium-sided	rings,	and	some	failed	attempts	were	made	
to	use	the	heterocyclic	β-aneminoesters	as	starting	materials	for	the	synthesis	of	fused	
pyrroles.	
As	 shown	 in	 Scheme	 7.5,	 the	 reaction	 between	 1,2-diamines	 and	 alkyl	 3-oxo-5-
hexenoates	was	 initially	 performed	 in	 the	 presence	 of	 a	 catalytic	 amount	 of	 CAN	 in	
dichloromethane	 solution,	 but	 it	 was	 subsequently	 discovered	 that	 it	 could	 also	 be	
carried	 out	 in	 the	 absence	 of	 any	 solvent	 and	 catalyst.	 This	 reaction	 afforded	 the	
functionalized	 1,4-diazepines	 17a-m,	 normally	 in	 good	 to	 excellent	 yields. 117 	The	
geometry	of	the	enaminoester	unit	was	normally	Z,	as	shown	by	NOE	studies	 in	17a,	
but	became	E	for	the	N-substituted	compounds	(e.g.	17c).	A	reaction	starting	from	a		
	
	
Scheme	7.5																																																									
117		Compounds	17	were	synthesized	exclusively	by	Dr.	Maiti,	but	are	shown	here	for	completeness.		
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ketone	 (1-phenyl-4-penten-2-one)	 afforded	 compound	 17n,	 with	 an	 endocyclic	 C=N	
bond,	 and	 the	 use	 of	 urea	 as	 the	 dinucleophile,	which	 required	 reflux	 conditions	 in	
ethanol,	gave	the	pyrimidine	derivatives	17o	and	17p.	
A	mechanistic	proposal	to	account	for	the	formation	of	compounds	17	is	summarized	
in	Scheme	7.6.	The	starting	β-ketoester	was	found	to	be	stable	at	room	temperature	
as	 an	 isolated	 product	 and	 in	 CDCl3	 solution,	with	 or	without	 the	 presence	 of	 CAN.	
Therefore,	the	mechanism	does	not	start	with	the	isomerization	of	its	double	bond	to	
give	in	situ	the	conjugated	system	I.	Instead,	we	propose	that	the	domino	sequence	is	
initiated	 by	 the	 condensation	 of	 one	 of	 the	 amino	 groups	 with	 the	 ketone	 to	 give	
enaminone	II.	This	intermediate	then	undergoes	a	double	bond	isomerization,	assisted	
by	 the	 second	 amino	 group	 of	 the	 diamine,	 to	 give	 intermediate	 III.	 A	 final	
intramolecular	 vinylogous	 aza-Michael	 reaction	 completes	 the	 formation	 of	 the	
diazapine	ring.		
	
	
Scheme	7.6	
	
The	 in	situ	generation	of	intermediate	III	 is	of	interest,	since	it	can	be	regarded	as	an	
aza-Nazarov	reagent.	The	Nazarov	reagent	(methyl	or	ethyl	3-oxo-4-pentenoate)118	is	a	
densely	 functionalized	 building	 block	 that	 has	 found	 widespread	 application	 in	
synthesis,	especially	 in	annelation	reactions,	thanks	to	the	presence	of	a	vinyl	ketone	
unit	 that	 is	 activated	 as	 a	β-keto	 ester.119	The	 Nazarov	 and	 related	 reagents120	have	
some	limitations,	as	their	preparation	normally	requires	multi-step	protocols	and	they	
sometimes	 show	 low	 stability.	 For	 this	 reason,	 the	 design	 of	 domino	 processes																																																									
118		Zibuck,	R.;	Streiber,	J.	Org.	Syntheses	1993,	71,	236.	
119		For	a	review,	see:	Audran,	G.;	Brémond,	P.;	Feuerstein,	M.;	Marque,	S.	R.	A.;	Santelli,	M.	Tetrahedron	
2013,	69,	8325.	
120		For	 a	 synthetic	 equivalent	 to	 the	Nazarov	 reagent,	 see:	Amat,	M.;	Arioli,	 F.;	 Pérez,	M.;	Molins,	 E.;	
Bosch,	J.	Org.	Lett.	2013,	15,	2470.	
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involving	the	generation	of	such	reagents	from	simple	precursors,	followed	by	their	in	
situ	transformation,	would	have	considerable	advantages,	although	this	approach	has	
received	 very	 little	 attention	 in	 the	 literature.	 Furthermore,	 aza-Nazarov	 reagents,	
which	should	be	very	useful	 for	 the	preparation	of	nitrogen	heterocycles,	are	almost	
unknown.	
Since	most	 compounds	17	 contain	a	β-enaminoester	 structural	 fragment,	 they	 could	
be	 potential	 precursors	 of	 the	 pyrrolo[1,2-d][1,4]diazepine	 framework.	 However,	 all	
our	 attempts	 to	 carry	 out	 a	 mechanochemical	 Hantzsch	 reaction	 using	 17a	 as	 a	
substrate	were	unsuccessful	(Scheme	7.7).	
	
	
Scheme	7.7	
	
We	 next	 examined	 a	 reaction	 involving	 as	 starting	 materials	 two	 molecules	 of	
allylamine	rather	than	a	diamine,	aiming	at	the	generation	of	a	ring-closing	metathesis	
precursor.	When	we	mixed	methyl	3-oxo-5-hexenoate	and	diallylamine	in	the	absence	
of	 solvent	 at	 room	 temperature,	 the	 expected	 β-enaminone	 18	 was	 obtained	 in	
quantitative	 yield,	 as	 a	 1:1	mixture	 of	 Z	 and	 E	 isomers.	 This	 transformation	 can	 be	
regarded	 a	 chemo-differentiating	 ABB’	 multicomponent	 reaction,	 since	 the	 final	
product	arises	 from	one	molecule	of	one	 the	components	and	 two	molecules	of	 the	
other,	 which	 have	 different	 roles	 in	 the	 reaction.121	The	 crude	 18	 was	 added	 to	 a	
milling	 jar	where	we	had	previously	 reacted	acetophenone	and	N-iodosuccinimide	 in	
the	presence	of	toluenesulfonic	acid	under	high-speed	vibration	milling	conditions	for	
1	h,	and	the	mixture	was	treated	with	CAN	(5%)	and	silver	nitrate	(1	eq)	and	submitted	
to	 the	 same	mechanochemical	 conditions	 for	1	h.	This	 reaction	afforded	 the	desired	
pyrrole	derivative	19a,	although	 in	moderate	yield.	An	attempt	to	cyclize	19a	by	ring	
closing	metathesis	was	unsuccessful,	which	was	attributed	to	catalyst	 inactivation	by	
the	 basic	 nitrogen.122 	Therefore,	 we	 acetylated	 19a	 with	 acetic	 anhydride	 in	 the	
presence	 of	 indium	 trichloride	 to	 furnish	 the	 non-basic	 pyrrole	19b,	which	 gave	 the	
desired	 ring-closing	metathesis	 reaction	 uneventfully	 in	 the	 presence	 of	 the	 Grubbs	
first	 generation	 catalyst	 in	 dichloromethane	 at	 room	 temperature.	 The	 resulting																																																									
121		Tejedor,	D.;	García-Tellado,	F.	Chem.	Soc.	Rev.	2007,	36,	484.			
122		 For	discussions	of	the	problems	found	in	olefin	metathesis	of	compounds	containing	basic	nitrogen	
atoms,	see:	(a)	Compain,	P.	Adv.	Synth.	Catal.	2007,	349,	1829.	(b)	Lafaye,	K.;	Bosset,	C.;	Nicolas,	L.;	
Guérinot,	 A.;	 Cossy,	 J.	 Beilstein	 J.	 Org.	 Chem.	 2015,	 11,	 2223.	 See	 also:	 (c)	 Stoianova,	 D.	
http://allthingsmetathesis.com/metathesis-of-amine-containing-compounds/.	
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product	 20	 is	 a	 derivative	 of	 the	 previously	 unknown	 pyrrolo[1,2-a][1,5]diazonine	
framework.	
	
Scheme	7.8	
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7.4.	One-pot	multicomponent	macrocyclization	
As	 an	 aditional	 approach	 to	 macrocyclic	 structures,	 we	 decided	 to	 investigate	 the	
application	of	a	one-pot	process	involving	two	Hantzch	pyrrole	syntheses,	one	of	which	
acts	as	the	macrocyclization	event	(Scheme	7.9).		
	
	
Scheme	7.9	
	
In	 our	 first	 experiments,	 treatment	 of	 1,3-diacetylbenzene	 with	 N-iodosuccinimide	
under	our	previously	described	mechanochemical	 conditions	 (ball	milling	at	20	Hz	 in	
the	 presence	 of	 TsOH	 for	 1	 h),	 followed	 by	 addition	 of	 1,4-butanediamine	 and	 two	
equivalents	 of	 methyl	 acetoacetate	 (which	 had	 been	 premixed	 in	 the	 presence	 of	
InCl3),	 silver	nitrate	and	additional	ball	milling	afforded	only	a	5%	yield	of	 the	 target	
macrocycle	 21a,	 the	 main	 isolated	 products	 being	 22	 and	 23	 (Figure	 7.4).	 These	
compounds	 arose	 from	 the	 formation	 of	 one	 or	 two	 pyrrole	 rings,	 respectively,	
followed	 by	 a	 subsequent	 reductive	 dehalogenation	 of	 the	 second	 α-iodophenacyl	
moiety,	as	previously	observed	by	us	in	cases	where	the	Hantzsch	reaction	is	slow.123	
	
	
Figure	7.4	
	
We	reasoned	that	this	result	was	due	to	the	fact	that	the	high	reactant	concentrations	
that	are	prevalent	under	the	solvent-free	mechanochemical	conditions	did	not	favour	
the	 macrocyclization	 stage.	 For	 this	 reason,	 we	 resorted	 to	 a	 more	 conventional	
methodology,	carrying	out	a	slow	addition	of	the	iodoketone	to	a	solution	containing	
the	 in	 situ-prepared	 β-enaminone,	 the	 CAN	 catalyst	 and	 silver	 nitrate	 in	 order	 to	
achieve	high	dilution	conditions.	The	optimization	of	 this	process	was	carried	out	 for	
the	case	of	21a	and	is	summarized	in	Table	7.2.																																																									
123		Estévez,	V.;	 Sridharan,	V.;	 Sabaté,	S.;	Villacampa,	M.;	Menéndez,	 J.	C.	Asian	 J.	Org.	Chem.	2016,	6,	
526.	
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Table	7.2:	optimization	of	the	reaction	condition	
Vol	MeOH	
(mL/mmol)	
Eq.	Lewis	
acid	
Eq.	
AgNO3	
Injection	
time	(h)	
Yield	(%)	
10	 0,1	 2	 6	 25	
10	 0,1	 2	 2	 25	
20	 0,1	 2	 2	 traces	
15	 2	 2	 2	 traces	
15	 0,1	 2	 2	 52	
	
This	 reaction	 can	be	 viewed	as	 a	 double	Hantzsch	pyrrole	 synthesis	 telescoped	with	
the	 preparation	 of	 the	 α-haloketone	 starting	 material.	 This	 reaction	 achieves	 the	
creation	of	six	bonds	in	a	single	operation	and	has	as	the	key	step	the	formation	of	a	
macrocyclic	scaffold	during	the	formation	of	the	second	pyrrole	ring	(Scheme	7.10).	To	
our	knowledge,	this	is	the	first	example	of	the	construction	of	macrocyclic	systems	by	
one-pot	generation	of	two	heterocyclic	rings.	
	
	
Scheme	7.10	
	
The	 optimized	 conditions	 were	 used	 to	 prepare	 a	 library	 of	 compounds	 21,	 which	
cover	 a	 very	 unusual	 region	 of	 chemical	 space	 corresponding	 to	 macrocyclic	
cyclophanes	that	contain	ter-	or	quater-aryl	structural	fragments	(Figure	7.5).	Although	
yields	 were	 60%	 or	 below,	 it	 has	 to	 be	 taken	 into	 account	 that	 this	 pseudo	 four-
component	process	involves	the	creation	of	two	rings	and	six	bonds,	comprising	up	to	
11	 individual	 steps.	 In	 most	 cases,	 both	 pyrrole	 nitrogens	 were	 connected	 via	 a	
polymethylene	chain,	but	 in	 the	cases	of	compounds	21e-21g	we	employed	a	spacer	
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containing	a	tetramethyldisiloxane	moiety.		
	
	
Scheme	7.11	
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7.5.	Experimental	section		
7.5.1.	Mechanochemical	synthesis	of	bis-pyrroles	bearing	two	terminal	alkenes.	
	
	
	
The	 suitable	 acetophenone	 derivative	 (0.4	 mmol),	 N-iodosuccinimide	 (0.4	 mmol)	 and	 p-
toluenesulfonic	 acid	 (10	 mol%)	 was	 placed	 in	 a	 20	 mL	 milling	 jar	 together	 with	 a	 20	 mm	
zirconium	oxide	ball.	The	ball	mill	was	set	to	vibrate	at	a	frequency	of	20	s-1	for	60	min	at	room	
temperature.	To	this	reaction	vessel	was	added	a	mixture	of	the	suitable	diamine	(0.2	mmol),	
ethyl-3-oxohept-6-enoate,124	(0.4	mmol)	and	CAN	(5	mol%),	which	had	been	premixed	at	room	
temperature	 during	 240	 min.	 Silver	 nitrate	 (0.4	 mmol)	 and	 additional	 CAN	 (5	 mol%)	 were	
added	 and	 the	 ball	 mill	 was	 set	 to	 vibrate	 at	 a	 20	 s-1	 frequency	 for	 80	 min	 at	 room	
temperature.	 Then,	 the	 reaction	 vessel	was	 cleansed	with	 ethyl	 acetate	or	 dichloromethane	
and	the	suspension	was	filtered	to	remove	the	silver	iodide	precipitate.	The	organic	layer	was	
washed	 with	 water	 (2	 mL),	 dried	 over	 anhydrous	 sodium	 sulphate	 and	 the	 solvent	 was	
removed	under	reduced	pressure.	The	residue	was	purified	by	flash	column	chromatography	
on	silica	gel	eluting	with	a	gradient	from	petroleum	ether	to	8:2	petroleum	ether-ethyl	acetate	
and	compounds	15a-15h	are	obtained.	
	
Diethyl-1,1'-(ethane-1,2-diyl)bis(2-(but-3-en-1-yl)-5-phenyl-1H-pyrrole-3-carboxylate)	(15a)	
	
Prepared	 from	 ethyl-3-oxohept-6-enoate,	 (0.4	 mmol),	 diaminoethane	 (0.2	
mmol)	 and	 acetophenone	 (0.4	mmol);	 yield:	 72	mg	 (64%);	 yellowish	 solid;	
mp:	134-135	°C;	1H	NMR	(250	MHz,	CDCl3)	δ	7.35	–	7.31	(m,	6H),	7.19	–	7.14	
(m,	4H),	6.41	(s,	2H),	5.62	–	5.46	(m,	2H),	4.88	–	4.80	(m,	4H),	4.17	(q,	J	=	7.1	
Hz,	4H),	3.74	(s,	4H),	2.21	–	2.15	(m,	4H),	2.03	–	1.94	(m,	4H),	1.26	(d,	J	=	7.1	
Hz,	6H);	13C	NMR	(63	MHz,	CDCl3)	δ	157.9,	133.0,	130.1,	125.9,	125.2,	122.5,	
121.9,	121.1,	108.5,	105.3,	103.8,	52.4,	36.7,	27.1,	16.7,	7.5;	IR	(neat)	ν:	1699.4,	1640.7	(C=O),	
1216.0	 (C-O),	 1065.8	 (C=C-H)	 cm-1;	 elemental	 analysis	 (%)	 calcd.	 for	 C36H40N2O4	 C,	 76.57;	 H,	
7.14;	N,	4.96;	found:	C	76.45,	H	7.26,	N	4.62.	
	
	 	
																																																								
124	Tenti,	G.;	Ramos,	M.	T.;	Menéndez,	J.	C.;	Curr.	Org.	Synth.	2013,	10,	645.	
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Diethyl-1,1'-(ethane-1,2-diyl)bis(2-(but-3-en-1-yl)-5-(4-iodophenyl)-1H-pyrrole-3-
carboxylate)	(15b)	
	
Prepared	 from	 ethyl-3-oxohept-6-enoate,	 (0.4	 mmol),	 1,2-
diaminoetane	(0.2	mmol)	and	acetophenone	(0.4	mmol);	yield:	131	mg	
(80%);	yellowish	solid;	mp:	116-118	°C;	1H	NMR	(250	MHz,	CDCl3)	δ	7.73	
(d,	J	=	8.3	Hz,	4H),	6.91	(d,	J	=	8.3	Hz,	4H),	6.49	(s,	2H),	5.78	–	5.62	(m,	
2H),	5.03	–	4.94	(m,	4H),	4.29	(q,	J	=	7.1	Hz,	4H),	3.86	(br	s,	4H),	2.43	–	
2.37	(m,	4H),	2.20	–	2.10	(m,	4H),	1.36	(t,	J	=	7.1	Hz,	6H);	13C	NMR	(63	
MHz,	 CDCl3)	δ	 164.64,	 140.23,	 137.87,	 136.9,	 131.7,	 131.4,	 131.0,	 115.7,	 112.7,	 111.3,	 93.8,	
59.6,	43.8,	34.0,	24.0,	14.5;	IR	(neat)	ν:	1698.2	(C=O),	1221.7	(C-O),	1114.6	(C=C-H)	cm-1;	HRMS	
(MALDI	TOF)	calcd.	for	C36H38I2N2NaO4:,	839,0818	found:	839.0835.	
	
Diethyl-1,1'-(propane-1,3-diyl)bis(2-(but-3-en-1-yl)-5-phenyl-1H-pyrrole-3-carboxylate)	(15c)	
	
Prepared	 from	ethyl-3-oxohept-6-enoate,	 (0.4	mmol),	diaminoethane	 (0.2	
mmol)	and	acetophenone	(0.4	mmol);	yield:	83	mg	(72%);	yellowish	oil;	1H	
NMR	(250	MHz,	CDCl3)	δ	7.31	–	7.25	(m,	6H),	7.14	–	7.10	(m,	4H),	6.43	(s,	
2H),	5.81	–	5.65	(m,	2H),	4.98	–	4.85	(m,	4H),	4.19	(q,	J	=	7.1	Hz,	4H),	3.63	–	
3.56	(m,	4H),	2.79	–	2.66	(m,	4H),	2.20	–	2.10	(m,	4H),	1.57	–	1.42	(m,	2H),	
1.26	 (t,	 J	 =	7.1	Hz,	6H);	 13C	NMR	 (63	MHz,	CDCl3)	δ	 165.0,	139.7,	137.3,	133.1,	132.6,	129.0,	
128.6,	127.7,	115.3,	112.2,	110.5,	59.4,	41.0,	34.1,	32.4,	25.0,	14.5;	 IR	(neat)	ν:	1699.4	(C=O),	
1216.0	 (C-O),	 1065.8	 (C=C-H)	 cm-1;	 elemental	 analysis	 (%)	 calcd.	 for	 C37H42N2O4:	 C,	 76.79;	H,	
7.32;	N,	4.84;	found:	C	76.53,	H	7.28,	N	4.67.	
	
Diethyl-1,1'-(butane-1,4-diyl)bis(2-(but-3-en-1-yl)-5-phenyl-1H-pyrrole-3-carboxylate)	(15d)	
	
Prepared	from	ethyl-3-oxohept-6-enoate,	(0.4	mmol),	diaminoethane	(0.2	
mmol)	and	acetophenone	(0.4	mmol);	yield:	80	mg	(68%);	yellowish	solid;	
mp:	116-118	°C;	 1H	NMR	(250	MHz,	CDCl3)	δ	7.41	–	7.35	 (m,	6H),	7.25	–	
7.20	(m,	4H),	6.53	(s,	2H),	5.97	–	5.81	(m,	2H),	5.11	–	5.01	(m,	4H),	4.30	(q,	
J	=	7.1	Hz,	4H),	3.70	 (br	s,	4H),	3.00	–	2.93	 (m,	4H),	2.33	–	2.27	 (m,	4H),	
1.37	(t,	J	=	7.1	Hz,	6H),	1.21	(br	s,	4H);	13C	NMR	(63	MHz,	CDCl3)	δ	165.1,	
139.8,	137.6,	133.2,	133.0,	129.2,	128.5,	127.6,	115.2,	111.9,	110.4,	59.4,	43.2,	34.2,	27.8,	25.2,	
14.5;	IR	(neat)	ν:	1699.0	(C=O),	1216.0	(C-O),	1065.8	(C=C-H)	cm-1;	elemental	analysis	(%)	calcd.	
for	C38H44N2O4:	C,	77.00;	H,	7.48;	N,	4.73;	found:	C	76.83,	H	7.38,	N	4.66.	
	
Diethyl-1,1'-(pentane-1,5-diyl)bis(2-(but-3-en-1-yl)-5-phenyl-1H-pyrrole-3-carboxylate)	(15e)	
	
Prepared	 from	 ethyl-3-oxohept-6-enoate,	 (0.4	 mmol),	 1,5-diaminopentane	
(0.2	mmol)	and	acetophenone	(0.4	mmol);	yield:	91	mg	(75%);	yellowish	oil;	
1H	NMR	(250	MHz,	CDCl3)	δ	7.44	–	7.35	(m,	6H),	7.30	–	7.27	(m,	4H),	6.55	(s,	
2H),	6.00	–	5.84	(m,	2H),	5.13	–	5.02	(m,	4H),	4.30	(q,	J	=	7.1	Hz,	4H),	3.83	–	
3.74	(m,	4H),	3.05	–	2.99	(m,	4H),	2.41	–	2.32	(m,	4H),	1.37	(t,	J	=	7.1	Hz,	6H),	
N
O
O
N
O
O
I I
N
O
O
N
O
O
N
OO
N
O O
N
O
O
N
O
O
	
	
138	 	 	 	 	 		
1.33	–	1.19	(m,	6H),	0.93	–	0.80	(m,	2H);	13C	NMR	(63	MHz,	CDCl3)	δ	165.1,	139.9,	137.6,	133.2,	
133.1,	129.2,	128.4,	127.5,	115.2,	111.8,	110.3,	59.3,	43.7,	34.2,	30.5,	25.3,	23.3,	14.5;	IR	(neat)	
ν:	1702.0	 (C=O),	 1216.2	 (C-O),	 1064.3	 (C=C-H)	 cm-1;	 elemental	 analysis	 (%)	 calcd.	 for	
C39H46N2O4:	C,	77.20;	H,	7.64;	N,	4.62;	found:	C	72.53,	H	7.28,	N	4.36.	
	
Diethyl-1,1'-(pentane-1,5-diyl)bis(2-(but-3-en-1-yl)-5-phenyl-1H-pyrrole-3-carboxylate)	(15f)	
	
Prepared	 from	 ethyl-3-oxohept-6-enoate,	 (0.4	 mmol),	 1,7-
diaminoepthane	(0.2	mmol)	and	acetophenone	(0.4	mmol);	yield:	76	mg	
(60%);	 yellowish	 oil;	 1H	NMR	 (250	MHz,	 CDCl3)	δ	 7.43	 –	 7.33	 (m,	 10H),	
6.57	(s,	2H),	6.03	–	5.87	(m,	2H),	5.16	–	5.03	(m,	4H),	4.30	(q,	J	=	7.1	Hz,	
4H),	3.87	–	3.81	(m,	4H),	3.11	–	3.04	(m,	4H),	2.45	–	2.37	(m,	4H),	1.42	–	
1.29	 (m,	10H),	0.96	 (br	s,	6H);	 13C	NMR	(63	MHz,	CDCl3)	δ	165.2,	139.9,	
137.7,	133.3,	133.2,	129.3,	128.4,	127.5,	115.1,	111.7,	110.2,	59.3,	50.7,	
43.9,	34.2,	31.0,	28.3,	26.2,	25.3,	14.5;	IR	(neat)	ν:	1689.0	(C=O),	1211.2	(C-O),	1104.3	(C=C-H)	
cm-1;	HRMS	(MALDI	TOF)	calcd.	for	C41H50N2O4Na:,	657,3668	found:	657.3654.	
	
Diethyl-1,1'-(octane-1,8-diyl)bis(2-(but-3-en-1-yl)-5-phenyl-1H-pyrrole-3-carboxylate)	(16g)	
	
Prepared	 from	ethyl-3-oxohept-6-enoate,	 (0.4	mmol),	 1,8-diaminooctane	
(0.2	mmol)	and	acetophenone	 (0.4	mmol);	 yield:	74	mg	 (57%);	 yellowish	
oil;	1H	NMR	(250	MHz,	CDCl3)	δ	7.43	–	7.29	(m,	10H),	6.57	(s,	2H),	6.03	–	
5.87	(m,	2H),	5.16	–	5.03	(m,	4H),	4.30	(q,	J	=	7.1	Hz,	4H),	3.89	–	3.83	(m,	
5H),	3.12	–	3.05	(m,	4H),	2.46	–	2.37	(m,	4H),	1.48	–	1.34	(m,	3H),	1.37	(t,	J	
=	 7.1	Hz,	 6H),	 0.99	 (br	 s,	 8H);	 13C	NMR	 (63	MHz,	 CDCl3)	δ	 165.2,	 140.0,	
137.8,	 133.4,	 133.2,	 129.3,	 128.4,	 127.4,	 115.1,	 111.7,	 110.1,	 59.3,	 44.0,	
34.2,	31.1,	28.6,	26.3,	25.3,	14.5;	 IR	 (neat)	ν:	1700.2	 (C=O),	1222.7	 (C-O),	
1094.6	 (C=C-H)	 cm-1;	 HRMS	 (MALDI	 TOF)	 calcd.	 for	 C42H52N2O4Na:,	
671,3824	found:	671.3810.	
	
Diethyl-1,1'-((1,1,3,3-tetramethyldisiloxane-1,3-diyl)bis(propane-3,1-diyl))bis(2-(but-3-en-1-
yl)-5-phenyl-1H-pyrrole-3-carboxylate)	(15h)	
	
Prepared	 from	 ethyl-3-oxohept-6-enoate,	 (0.4	 mmol),	 1,3-
bis(aminopropyl)tetramethyldisiloxane	 (0.2	 mmol)	 and	 acetophenone	
(0.4	 mmol);	 yield:	 73	 mg	 (50	 %);	 dark	 yellow	 oil;	 1H	 NMR	 (250	 MHz,	
CDCl3)	δ	7.42	–	7.33	 (m,	10H),	6.58	 (s,	2H),	6.03	–	5.87	 (m,	2H),	5.16	–	
5.02	(m,	4H),	4.30	(q,	J	=	7.1	Hz,	4H),	3.88	–	3.81	(m,	4H),	3.12	–	3.05	(m,	
4H),	2.46	–	2.37(m,	4H),	1.37	(t,	J	=	7.1	Hz,	6H),	1.40	–	1.34	(m,	4H),	0.28	
–	0.21	(m,	4H),	-0.12	(s,	12H);	13C	NMR	(63	MHz,	CDCl3)	δ	165.2,	140.0,	
137.7,	 133.3,	 133.2,	 129.3,	 129.2,	 128.4,	 127.5,	 115.2,	 111.6,	 110.2,	
59.3,	 47.0,	 34.3,	 25.3,	 25.24,	 15.1,	 14.5,	 0.0;	 IR	 (neat)	 n:	1703.2	 (C=O),	 1223.7	 (C-O),	 1111.6	
(C=C-H)	cm-1;	HRMS	(MALDI	TOF)	calcd.	for	C44H60N2NaO5Si2:,	775,3938	found:	775,3972.	
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7.5.2.	General	procedure	of	pyrrole-based	macrocycles	16a-16h	by	RCM	reaction	
	
	
	
To	 a	 solution	 of	 the	 suitable	 pyrrole	 15a-15h	 (0.15	 mmol)	 in	 dry	 dichloromethane	 (10	 mL)	
under	 argon	 atmosphere,	 Grubbs	 1st	 generation	 catalyst	 (5-10	 mmol%)	 was	 added.	 The	
mixture	was	stirred	for	4-12	h	at	room	temperature.	Upon	completion,	as	judged	by	TLC,	the	
solvent	 was	 removed	 under	 vacuum	 and	 the	 residue	 was	 purified	 by	 flash	 column	
chromatography	on	silica	gel	eluting	with	a	gradient	 from	petroleum	ether	 to	8:2	petroleum	
ether-ethyl	acetate	affording	the	desired	macrocycle	derivatives	16a-16h.	
	
Diethyl-(E)-1,12-diphenyl-4,5,8,9,14,15-hexahydrodipyrrolo[1,2-d:2',1'-
l][1,4]diazacyclododecine-3,10-dicarboxylate	(16a)	
	
Prepared	from	pyrrole	15a	(0.1	mmol);	yield:	40	mg	(75%);	yellowish	solid;	
mp:	177-179	 °C;	 1H	NMR	 (250	MHz,	CDCl3)	δ	 7.25	–	7.19	 (m,	2H),	7.13	–	
7.05	(m,	4H),	6.96	–	6.93	(m,	4H),	6.39	(s,	2H),	5.93	–	5.80	(m,	2H),	4.25	–	
4.17	 (m,	8H),	 3.16	 (br	 s,	 4H),	 2.44	 (br	 s,	 4H),	 1.27	 (t,	 J	 =	 7.1	Hz,	 3H);	 13C	
NMR	 (63	MHz,	 CDCl3)	 δ	 164.9,	 139.5,	 133.9,	 131.8,	 130.9,	 129.1,	 128.6,	
127.8,	112.8,	110.6,	59.5,	44.4,	27.7,	27.1,	14.4;	IR	(neat)	ν:	1699.4	(C=O),	
1236.0	 (C-O)	 cm-1;	 elemental	 analysis	 (%)	 calcd.	 for	 C34H36N2O4:	 C,	 76.09;	 H,	 6.76;	 N,	 5.22;	
found:	C	75.95,	H	6.84,	N	5.16.	
	
Diethyl-(Z)-1,12-bis(4-iodophenyl)-4,5,8,9,14,15-hexahydrodipyrrolo[1,2-d:2',1'-
l][1,4]diazacyclododecine-3,10-dicarboxylate	(16b)	
	
Prepared	 from	 pyrrole	 15b	 (0.1	mmol);	 yield:	 71	mg	 (90%);	 yellowish	
solid;	mp:	124-126	 °C;	 1H	NMR	 (250	MHz,	CDCl3)	δ	7.61	 (d,	 J	 =	7.9	Hz,	
4H),	6.80	(d,	J	=	7.9	Hz,	4H),	6.48	(s,	2H),	6.02	–	5.89	(m,	2H),	4.30	(q,	J	=	
7.1	Hz,	4H),	4.18	(br	s,	4H),	3.22	(br	s,	4H),	2.52	(br	,	4H),	1.37	(t,	J	=	7.1	
Hz,	6H);	 13C	NMR	 (63	MHz,	CDCl3)	δ	 165.2,	140.2,	138.1,	133.0,	131.7,	
131.3,	 131.2,	 113.5,	 111.4,	 94.5,	 60.1,	 44.8,	 28.2,	 27.4,	 14.9;	 IR	 (neat)	
ν:	1702.4	 and	 1699.9	 (C=O),	 1276.0	 (C-O)	 cm-1;	 HRMS	 (MALDI	 TOF)	 calcd.	 for	 C34H34I2N2O4:,	
788,0607	found:	788,0622.	
	
Diethyl-(Z)-1,12-diphenyl-4,5,8,9,15,16-hexahydro-14H-dipyrrolo[1,2-e:2',1'-
m][1,5]diazacyclotridecine-3,10-dicarboxylate	(16c)	
	
Prepared	from	pyrrole	15c	 (0.1	mmol);	yield:	48	mg	(88%);	white	solid;	Mp:	
199-201	°C;	1H	NMR	(250	MHz,	CDCl3)	δ	7.45	–	7.41	(m,	5H),	7.36	–	7.29	(m,	
5H),	6.61	(s,	2H),	5.86	–	5.73	(m,	2H),	4.32	(q,	J	=	7.1	Hz,	4H),	3.85	–	3.74	m,	
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4H),	2.99	 (br	 s,	4H),	2.62	–	2.37	 (m,	6H),	1.39	 (t,	 J	=	7.1	Hz,	3H);	 13C	NMR	(63	MHz,	CDCl3)	δ	
164.9,	140.0,	133.7,	132.7,	129.4,	129.2,	128.6,	127.8,	112.2,	109.6,	59.5,	41.7,	34.1,	27.9,	27.9,	
14.5;	 IR	 (neat)	 ν:	1696.4,	 1689.9	 (C=O),	 1266.0	 (C-O)	 cm-1;	 elemental	 analysis	 (%)	 calcd.	 for	
C35H38N2O4:	C,	76.34;	H,	6.96;	N,	5.09;	found:	C	76.47,	H	7.01,	N	4.99.	
	
Diethyl	 1,12-diphenyl-4,5,8,9,14,15,16,17-octahydrodipyrrolo[1,2-f:2',1'-
n][1,6]diazacyclotetradecine-3,10-dicarboxylate	(16d)	
	
This	compound	is	a	mix	of	isomer	A	and	isomer	B	(as	8.5:1.5).	
Prepared	from	pyrrole	15d	(0.5	mmol);	yield:	36	mg	(64%);	yellowish	oil;	1H	
NMR	(250	MHz,	CDCl3)	δ 7.43	–	7.36	 (m,	6H,	 isomer	A+B),	7.33	–	7.30	 (m,	
4H,	 isomer	A+B),	6.58	(s,	2H,	 isomer	B),	6.57	(s,	2H,	 isomer	A),	5.80	–	5.68	
(m,	 2H,	 isomer	A),	 5.53	 –	 5.49	 (m,	 2H,	 isomer	 B),	 4.31	 (q,	 J	 =	 7.1	Hz,	 4H,	
isomer	A+B),	3.89	 (br	 s,	4H,	 isomer	A+B),	3.12	–	3.05	 (m,	4H),	2.62	–	2.44	
(m,	4H,	isomer	A+B),	1.52	(br	s,	4H,	isomer	A+B),	1.29	(t,	J	=	7.1	Hz,	6H);	13C	
NMR	 (63	 MHz,	 CDCl3)	 δ	 165.1,	 139.9,	 133.2,	 133.0,	 129.4,	 129.1	 (129.0	
isomer	B),	128.5,	127.6,	112.2	(112.1	 isomer	B),	110.3,	59.4,	44.1,	28.9,	27.9	(29.7	 isomer	B),	
26.2,	14.5;	 IR	 (neat)	ν:	1699.4,	1689.0	 (C=O),	1236.0	 (C-O)	cm-1;	elemental	analysis	 (%)	calcd.	
for	C36H40N2O4:	C,	76.57;	H,	7.14;	N,	4.96;	found:	C	76.21,	H	6.81,	N	4.58.	
	
Diethyl	 3,11-diphenyl-6,7,8,9,14,15,18,19-octahydro-5H-dipyrrolo[1,2-g:2',1'-
o][1,7]diazacyclopentadecine-1,13-dicarboxylate	(16e)	
	
This	compound	is	a	mix	of	isomer	A	and	isomer	B	(as	8:2).	
Prepared	from	pyrrole	15e	 (0.5	mmol);	yield:	40	mg	(70%);	yellowish	oil;	
1H	NMR	(250	MHz,	CDCl3)	δ	7.44	–	7.35	(m,	10H,	isomer	A+B),	6.59	(s,	2H,	
isomer	A+B),	5.79	–	5.66	(m,	2H,	isomer	A),	5.60	–	5.57	(m,	2H,	isomer	B),	
4.36	–	4.27	(m,	4H,	CH3CH2OCO-,	isomer	A+B),	3.96	–	3.84	(m,	4H,	isomer	
A+B),	3.11	–	3.05	 (m,	4H,	 isomer	A+B),	2.60	–	2.43	 (m,	4H,	 isomer	A+B),	
1.82	–	1.58	(m,	4H,	isomer	A+B),	1.41	–	1.34	(m,	6H,	CH3CH2OCO-,	isomer	
A+B),	1.18	–	1.10	 (m,	2,	 isomer	A+B);	 13C	NMR	 (63	MHz,	CDCl3)	δ	 165.1,	
165.0	(isomer	B),	133.3,	133.4	(isomer	B),	133.0,	133.1	(isomer	B),	111.7,	
110.3,	110.1	(isomer	B),	59.4,	50.8	(isomer	B),	43.5,	32.6	(isomer	B),	30.9	(isomer	B),	29.9,	28.2,	
26.6,	 22.8,	 14.5;	 IR	 (neat)	ν:	1701.4,	 1689.2	 (C=O),	 1233.8	 (C-O)	 cm-1;	 elemental	 analysis	 (%)	
calcd.	for	C37H42N2O4:	C,	76.79;	H,	7.32;	N,	4.84;	found:	C	76.49,	H	6.98,	N	4.58.	
	
Diethyl	 3,13-diphenyl-6,7,8,9,10,11,16,17,20,21-decahydro-5H-dipyrrolo[1,2-i:2',1'-
q][1,9]diazacycloheptadecine-1,15-dicarboxylate	(16f)	
	
This	compound	is	a	mix	of	isomer	A	and	isomer	B	(as	1:1).	
Prepared	from	pyrrole	15f	(0.5	mmol);	yield:	44	mg	(73%);	yellowish	oil;	1H	
NMR	 (250	MHz,	 CDCl3)	 δ	 7.46	 –	 7.36	 (m,	 10H,	 isomer	 A+B),	 6.60	 (s,	 2H,	
isomer	A),	6.59	(s,	2H,	 isomer	A),	5.72	–	5.66	(m,	2H,	 isomer	A+B),	4.36	–	
4.27	 (m,	4H,	CH3CH2OCO-,	 isomer	A+B),	3.94	–	3.84	 (m,	4H,	 isomer	A+B),	
3.15	–	3.05	 (m,	4H,	 isomer	A+B),	2.47	 (br	s,	4H,	 isomer	A+B),	1.68	–	1.61	
(m,	 2H,	 isomer	A),	 1.41	 –	 1.21	 (m,	 12H,	 isomer	A+B);	 13C	NMR	 (63	MHz,	
CDCl3)	δ	all	 the	picks	 refer	 to	 isomer	A	and	B:	165.2,	165.1,	140.2,	140.1,	
133.2,	133.1,	130.7,	129.5,	129.3,	129.2,	128.4,	127.5,	127.5,	111.8,	111.6,	
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110.4,	 110.1,	 59.3,	 59.3,	 50.7,	 44.0,	 43.9,	 32.7,	 30.2,	 30.1,	 28.3,	 26.9,	 26.4,	 26.1,	 26.0,	 25.6,	
24.9,	14.5,	14.5;	IR	(neat)	ν:	1698.4,	1687.2	(C=O),	1237.6	(C-O)	cm-1;	HRMS	(MALDI	TOF)	calcd.	
for	C39H46N2O4Na:	629,3355	found:	629,3333.	
	
Diethyl	 3,14-diphenyl-5,6,7,8,9,10,11,12,17,18,21,22-dodecahydrodipyrrolo[1,2-a:2',1'-
i][1,10]diazacyclooctadecine-1,16-dicarboxylate	(16g)	
	
This	compound	is	a	mix	of	isomer	A	and	isomer	B	(as	6.5:3.5).	
Prepared	from	pyrrole	15g	(0.5	mmol);	yield:	49	mg	(80%);	yellowish	oil;	1H	
NMR	 (250	 MHz,	 CDCl3)	 δ	 7.46	 –	 7.39	 (m,	 10H,	 isomer	 A+B),	 6.60	 (s,	 2H,	
isomer	A),	 6.60	 (s,	 2H,	 isomer	A+B),	 5.70	–	5.67	 (m,	2H,	 isomer	A),	 5.62	–	
5.59	 (m,	 2H,	 isomer	 B),	 4.31	 (t,	 J	 =	 7.1	Hz,	 4H,	 CH3CH2OCO-,	 isomer	A+B),	
3.94	–	3.83	(m,	4H,	isomer	A+B),	3.12	–	3.06	(m,	4H,	isomer	A+B),	2.49	(br	s,	
4H,	isomer	A+B),	1.72	–	1.50	(m,	4H,	isomer	A),	1.40	–	1.21	(m,	14H,	isomer	
A+B);	 13C	NMR	(63	MHz,	CDCl3)	δ	all	 the	picks	 refer	 to	 isomer	A	and	when	
they	refer	 to	 isomr	B	 is	 indicated:	 13C	NMR	(63	MHz,	CDCl3)	d	165.5	 (isomer	B),	165.1,	140.6	
(isomer	B),	140.3,	140.0,	133.4	(isomer	B),	133.3,	133.2,	133.1,	133.1,	133.0	(isomer	B),	130.4,	
129.6,	 129.3,	 129.2,	 128.4,	 127.5	 (isomer	 B),	 127.5,	 111.7,	 111.6,	 110.2,	 109.9,	 59.3,	 50.8	
(isomer	B),	44.3,	44.0	(isomer	B),	32.6,	30.4	(isomer	B),	30.1,	28.2	(isomer	B),	27.1	(isomer	B),	
27.0,	 26.1,	 25.8,	 25.4	 (isomer	B),	 14.5;	 IR	 (neat)	ν:	 1702.1,	 1698.0	 (C=O),	 1198.9	 (C-O)	 cm-1;	
HRMS	(MALDI	TOF)	calcd.	for	C40H48N2O4Na:	643,3512	found:	643,3506.	
	
Diethyl	 8,8,10,10-tetramethyl-3,15-diphenyl-5,6,7,8,10,11,12,13,18,19,22,23-
dodecahydrodipyrrolo[1,2-f:2',1'-n][1]oxa[6,15]diaza[2,19]disilacyclononadecine-1,17-
dicarboxylate	(16h)	
	
This	compound	is	a	mix	of	isomer	A	and	isomer	B	(as	6.5:3.5)	
Prepared	from	pyrrole	15h	(0.5	mmol);	yield:	58	mg	(80%);	white	solid;	Mp:	
134-135	°C;	1H	NMR	(250	MHz,	CDCl3)	δ	7.46	–	7.36	 (m,	10H,	 isomer	A+B),	
6.60	 (s,	 2H,	 isomer	 B),	 6.58	 (s,	 2H,	 isomer	A),	 5.69	 –	 5.64	 (m,	 2H,	 isomer	
A+B),	4.31	(t,	J	=	7.1	Hz,	4H,	CH3CH2OCO-,	isomer	A+B),	3.93	–	3.79	(m,	4H,	
isomer	A+B),	2.43	 (mbr	 s,	4H,	 isomer	A+B),	1.70	–	1.53	 (m,	4H,	 isomer	A),	
1.37	(t,	J	=	7.1	Hz,	6H,	CH3CH2OCO-,	isomer	A+B),	0.44	–	0.37	(m,	4H),	-0.01	
(s,	12H,	 isomer	A),	 -0.08	 (s,	12H,	 isomer	B);	 13C	NMR	(63	MHz,	CDCl3)	d	all	
the	 picks	 refer	 to	 isomer	A	 and	when	 they	 refer	 to	 isomr	 B	 is	 indicated:	 13C	NMR	 (63	MHz,	
CDCl3)	δ 165.2,	140.1,	133.2,	133.2,	130.5,	129.3,	128.4,	127.5,	111.6,	109.9,	59.3,	47.2,	32.7,	
26.4,	25.6,	15.	7,	14.5,	0.3,	-0.02	(isomer	B);	IR	(neat)	ν:	1700.8,	1699.8	(C=O),	1089.9	(C-O)	cm-
1;	HRMS	(MALDI	TOF)	calcd.	for	C42H56N2O5Si2:	724,3728	found:	724,3742.	
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7.5.3.	General	 experimental	 procedure	 for	 the	 synthesis	 of	 pyrrole-derived	 medium-sized	
rings	by	ring-closing	metathesis	
	
	
	
Procedure	A:	CAN	(5	mol%)	was	added	to	a	solution	of	1,2	diamine	derivative	(1	mmol)	and	the	
suitable	allyl	 ketone	or	allyl	 ketoester	 (1	mmol)	 in	CH2Cl2	 (5	ml)	at	 room	temperature	under	
argon.	 The	 solution	 was	 stirred	 until	 completion	 of	 the	 reaction,	 as	 checked	 by	 TLC.	 The	
reaction	mixture	was	diluted	with	15	ml	CH2Cl2	and	washed	with	water.	The	organic	layer	was	
dried	with	 anhydrous	Na2SO4	 and	 concentrated	 under	 vacuum.	 The	 residue	was	 purified	 by	
column	chromatography	using	as	 the	stationary	phase	neutral	Al2O3	 (activity	grade	 IV),	using	
1:10	ethyl	acetate:petroleum	ether	as	mobile	phase.	
	
Procedure	 B:	 The	 same	 procedure	was	 applied	without	 solvent,	 by	 adding	 the	 suitable	 allyl	
ketone	 or	 allyl	 ketoester	 (1	 mmol)	 onto	 the	 suitable	 1,2-diamine	 (1	 mmol)	 at	 room	
temperature.	
	
Methyl	(Z)-2-(7-methyl-1,4-diazepan-5-ylidene)acetate	(17a)	
	
Procedure	A	was	followed	using	ethane-1,2-diamine	(60	mg,	1	mmol)	and	methyl	3-
oxohex-5-enoate	(142	mg	,1	mmol).	Compound	17a	is	obtained	as	a	white	solid	(175	
mg,	95%);	mp	62	°C;	 1H	NMR	(250	MHz,	CDCl3)	δ	8.80	 (s,	1H),	4.39	 (s,	1H),	3.57	 (s,	
3H),	3.51	–	3.19	(m,	2H),	3.01	(m,	1H),	2.92	–	2.60	(m,	2H),	2.42	(dd,	J	=	14.4,	9.0	Hz,	
1H),	2.16	(dt,	J	=	14.4,	1.4	Hz,	1H),	1.82	(s,	1H),	1.12	(d,	J	=	6.5	Hz,	3H);	13C	NMR	(63	MHz,	CDCl3)	
δ	171.3,	166.1,	82.1,	52.8,	50.4,	50.1,	47.0,	45.8,	24.1;	IR	(film,	neat)	ν:	3309.1,	2950.2,	1651.3,	
1606.0,	 1506.0,	 1306.4,	 1240.3,	 1172.9,	 1050.3,	 784.1	 cm–1;	 Anal.	 Calcd.	 for	 C9H16N2O2:	 C,	
58.67;	H,	8.75;	N,	15.21.	Found:	C,	58.57;	H,	8.41;	N,	15.01.	
	
Ethyl	(7-methyl-[1,4]-diazepan-5-ylidene)acetate	(17b)	
	
Procedure	A	was	followed	using	ethane-1,2-diamine	(60	mg,	1	mmol)	and	ethyl	3-
oxohex-5-enoate	 (156	mg	 ,1	mmol).	 Compound	17b	 is	 obtained	 as	 a	white	 solid	
(178	mg,	90%),	mp	46	°C	;	1H	NMR	(250	MHz,	CDCl3)	δ	8.86	(br	s,	1H),	4.44	(s,	1H),	
4.10	 (q,	 J	=	7.1	Hz,	 	2H),	3.28-3.49	 (m,	2H),	3.03-3.10	 (m,	1H),	2.74-2.93	 (m,	2H),	
2.48	(dd,	J	=	14.4	and	9.0	Hz,	1H),	2.21	(d,	J	=	14.8	Hz,	1H),	1.77	(br	s,	1H),	1.26	(t,	J	=	7.1	Hz,	
3H),	1.17	 (d,	 J	=	6.5	Hz,	3H);	 13C	NMR	(63	MHz,	CDCl3)	δ	170.6,	165.6,	82.1,	58.4,	52.4,	49.6,	
46.5,	45.4,	23.7,	14.6;	IR	(film,	neat)	ν:	3306.0,	2973.3,	1651.5,	1606.0,	1505.6,	1304.2,	1238.4,	
1173.1,	 1103.9,	 1052.4,	 783.8	 cm–1;	 Anal.	 Calcd	 for	 C10H18N2O2:	 C,	 60.58;	 H,	 9.15;	 N,	 14.13.	
Found:	C,	60.23;	H,	9.32;	N,	14.29.	
	
Methyl	(E)-2-(1,4,7-trimethyl-1,4-diazepan-5-ylidene)acetate	(17c)	
	
Procedure	 A	 was	 followed	 using	 N,N-dimethylethane-1,2-diamine	 (88	 mg,	 1	
mmol)	 and	 methyl	 3-oxohex-5-enoate	 (142	 mg	 ,1	 mmol).	 Compound	 17c	 is	
obtained	 as	 a	 colourless,	 viscous	 liquid	 (180	 mg,	 85%);	 1H	 NMR	 (250	 MHz,	
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CDCl3)	δ	4.84	(br.	S,	1H),	4.50	(s,	1H),	3.61	(s,	3H),	3.59	–	3.42	(m,	3H),	3.42	–	3.20	(m,	1H),	2.93	
(s,	3H),	2.77	(m,	2H),	2.58	–	2.40	(m,	1H),	2.34	(s,	3H),	2.24	(s,	1H),	1.07	(d,	J	=	6.6	Hz,	3H);	13C	
NMR	 (63	MHz,	 CDCl3)	 δ	 169.8,	 164.7,	 84.8,	 57.2,	 55.0,	 54.3,	 50.5,	 43.5,	 41.2,	 34.6;	 IR	 (film,	
neat)	 ν:	 2931.3,	 2797.8,	 1682.0,	 1580.1,	 1450.0,	 1407.9,	 1144.3,	 1052.9,	 796.4	 cm-1;	 Anal.	
Calcd	for	C11H20N2O2:	C,	62.24;	H,	9.50;	N,	13.20.	Found:	C,	62.01;	H,	9.13;	N,	9.39.	
	
Ethyl	(E)-2-(1,4,7-trimethyl-1,4-diazepan-5-ylidene)acetate	(17d)	
	
Procedure	 A	was	 followed	 using	N,N-dimethylethane-1,2-diamine	 (88	 mg,	 1	
mmol)	 and	 Ethyl	 3-oxohex-5-enoate	 (156	 mg	 ,1	 mmol).	 Compound	 17d	 is	
obtained	 as	 a	 colourless,	 viscous	 liquid	 (188	mg,	 83%);	 1H	 NMR	 (CDCl3,	 250	
MHz)	δ	4.47	(s,	1H),	4.04	(q,	J	=	7.1	Hz,		2H),	3.58	-	3.51	(m,	3H),	3.49	–	3.27	(m,	
1H),	2.90	(s,	3H),	2.78	-	2.73	(m,	2H),	2.72	-	2.38	(m,	1H),	2.31	(s,		3H),	1.25	(t,	J	
=	7.1	Hz,	 	3H),	1.04	 (d,	 J	=	6.6	Hz,	 	3H);	 13C	NMR	 (CDCl3,	63	MHz)	δ	168.9,	164.0,	84.7,	58.2,	
56.8,	 54.5,	 53.8,	 43.0	 (2c),	 34.0,	 14.5;	 IR	 (neat)	 ν:	 2972.3,	 2930.6,	 1679.4,	 1578.9,	 1449.5,	
1409.8,	 1140.2,	 1054.3,	 796.5	 cm-1;	 Anal.	 Calcd	 for	 C12H22N2O2:	 C,	 63.69;	 H,	 9.80;	 N,	 12.38.	
Found:	C,	63.39;	H,	9.45;	N,	12.66.	
	
Methyl	 (Z)-2-((4R,5aS,9aR)-4-methyldecahydro-2H-benzo[b][1,4]diazepin-2-ylidene)acetate	
(17ea)		
	
1H	NMR	(250	MHz,	CDCl3)	δ	8.88	(br	s,	1H),	4.34	(d,	J	=	1.7	Hz,	1H),	3.60	(d,	J	=	2.0	
Hz,	4H),	3.01	(q,	J	=	6.3	Hz,	1H),	2.96	–	2.86	(m,	1H),	2.64	(dd,	J	=	14.8,	5.1	Hz,	
1H),	2.18	(dd,	J	=	14.9,	6.4	Hz,	1H),	2.12	–	1.98	(m,	1H),	1.73	–	1.20	(m,	9H),	1.13	
(d,	J	=	6.6	Hz,	3H);	13C	NMR	(63	MHz,	CDCl3)	δ	171.3,	164.3,	82.6,	57.6,	54.9,	50.4,	
49.2,	44.5,	31.6,	28.6,	25.3,	23.5,	22.8;	IR	(film,	neat)	ν:	3290.8,	2932.1,	2856.0,	1651.3,	1607.1,	
1445.3,	 1243.3,	 1173.8,	 1108.7,	 1046.7,	 786.0	 cm-1;	 Anal.	 Calcd	 for	 C13H22N2O2:	 C,	 65.52;	 H,	
9.30;	N,	11.75.	Found:	C,	63.87;	H,	9.66;	N,	11.44.	
	
Methyl	(Z)-2-((4S,5aS,9aR)-4-methyldecahydro-2H-benzo[b][1,4]diazepin-2-ylidene)acetate	
(17eb)		
	
1H	NMR	(250	MHz,	CDCl3)	δ	8.64	(br	s,	1H),	4.40	(s,	1H),	4.05	–	3.84	(m,	1H),	
3.63	(s,	3H),	3.04	(dd,	J	=	9.3,	6.4	Hz,	1H),	2.84	(m,	1H),	2.43	(dd,	J	=	14.3,	9.3	
Hz,	1H),	2.10	(d,	J	=	14.3	Hz,	1H),	2.02	–	1.73	(m,	3H),	1.73	–	1.47	(m,	4H),	1.47	
–	 1.22	 (m,	 2H),	 1.10	 (d,	 J	 =	 6.4	 Hz,	 3H);	 13C	 NMR	 (63	MHz,	 CDCl3)	 δ	 171.6,	
165.6,	81.5,	58.2,	55.0,	50.4,	46.5,	46.1,	32.3,	27.2,	26.1,	24.9,	20.2;	 IR	(film,	neat)	ν:	3290.8,	
2932.1,	2856.0,	1651.3,	1607.1,	1445.3,	1243.3,	1173.8,	1108.7,	1046.7,	786.0	cm-1;	Anal.	Calcd	
for	C13H22N2O2:	C,	65.52;	H,	9.30;	N,	11.75.	Found:	C,	63.87;	H,	9.66;	N,	11.44.	
	
	
Methyl	(Z)-2-(4-methyl-1,3,4,5-tetrahydro-2H-benzo[b][1,4]diazepin-2-ylidene)acetate	(17f)	
	
Procedure	 A	 was	 followed	 using	 benzene-1,2-diamine	 (108	 mg,	 1	 mmol)	 and	
Methyl	 3-oxohex-5-enoate	 (142	mg,	 1	 mmol).	 Compound	 17f	 is	 obtained	 as	 a	
colourless,	 viscous	 liquid	 (139	 mg,	 60	 %)	 or	 procedure	 B	 was	 followed	 using	
benzene-1,2-diamine	(108	mg,	1	mmol)	and	Methyl	3-oxohex-5-enoate	(142	mg	,	
1	mmol).	Compound	17f	 is	obtained	as	a	 colourless,	 viscous	 liquid	 (213	mg,	92	
%);	1H	NMR	(CDCl3,	250	MHz)	δ	7.29	-	6.87	(m,	3H),	6.78	(d,	J	=	7.6	Hz,		1H),	4.72	(s,	1H),	3.97	-	
3.89	(m,	1H),	3.72	(s,		3H),	2.79	(br	s,	1H),	2.51	(dd,	J	=	13.8	and	4.7	Hz,		1H),	2.26	(dd,	J	=	13.8	
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and	7.1	Hz,		1H),	1.31	(d,	J	=	6.3	Hz,		3H);	13C	NMR	(CDCl3,	63	MHz)	δ	170.9,	159.8,	138.5,	130.7,	
125.2,	122.8,	122.1,	121.4,	84.3,	56.3,	50.7,	39.8,	23.6;	IR	(film,	neat)	ν:	3346.0,	2966.0,	1651.6,	
1614.6,	 1588.4,	 1497.8,	 1309.5,	 1163.6,	 1041.8,	 750.2	 cm-1;	 Anal.	 Calcd	 for	 C13H16N2O2:	 C,	
67.22;	H,	6.94;	N,	12.06.	Found:	C,	67.71;	H,	6.49;	N,	12.42.	
	
Ethyl	(Z)-2-(4-methyl-1,3,4,5-tetrahydro-2H-benzo[b][1,4]diazepin-2-ylidene)acetate	(17g)	
	
Procedure	 B	 was	 followed	 using	 benzene-1,2-diamine	 (108	 mg,	 1	 mmol)	 and	
Ethyl	 3-oxohex-5-enoate	 (156	 mg	 ,	 1	 mmol).	 Compound	 17g	 is	 obtained	 as	 a	
colourless,	viscous	liquid	(224	mg,	91	%);	1H	NMR	(CDCl3,	250	MHz)	δ	10.24	(br	s,	
1H),	7.00	-	6.90	(m,	3H),	6.76	(d,	J	=	7.7	Hz,		1H),	4.18	(q,	J	=	7.1	Hz,		2H),	3.96	-	
3.89	(m,	1H),	3.45	(br	s,	1H),	2.50	(dd,	J	=	13.6	and	4.3	Hz,		1H),	2.26	(dd,	J	=	13.7	
and	7.0	Hz,		1H),	1.32	(t,	J	=	6.5	Hz,		3H),	1.30	(d,	J	=	7.1	Hz,		3H);	13C	NMR	(CDCl3,	63	MHz)	δ	
170.6,	 159.7,	 138.5,	 130.7,	 125.2,	 122.7,	 122.0,	 121.4,	 84.7,	 59.2,	 56.3,	 39.8,	 23.9,	 15.0;	 IR	
(film,	neat)	ν:	3346.8,	2973.6,	1651.2,	1614.3,	1497.3,	1307.0,	1273.8,	1158.9,	1044.8,	751.5	
cm-1;	Anal.	Calcd	for	C14H18N2O2:	C,	68.27;	H,	7.37;	N,	11.37.	Found:	C,	67.97;	H,	7.11;	N,	10.99.	
	
Ethyl	 (Z)-2-(7-chloro-4-methyl-1,3,4,5-tetrahydro-2H-benzo[b][1,4]diazepin-2-
ylidene)acetate	(17h)		
	
Procedure	B	was	followed	using	4-chlorobenzene-1,2-diamine	(142	mg,	1	mmol)	and	Ethyl	3-
oxohex-5-enoate	 (156	mg	 ,	 1	mmol).	 Compound	17his	 obtained	 as	 3:1	mixture	 (17ha:17hb)	
(244	 mg,	 87	 %)	 of	 diasteroisomers	 that	 has	 been	 possible	 to	 separate	 with	 column	
chromatography.	
	
Ethyl	 (Z)-2-(8-chloro-4-methyl-1,3,4,5-tetrahydro-2H-benzo[b][1,4]diazepin-2-
ylidene)acetate	(17ha)	
	
White	solid,	m.p	87	°C;	1H	NMR	(CDCl3,	250	MHz)	δ	10.22	(br	s,	1H),	6.84	(d,	J	
=	1.0	Hz,		2H),	6.76	(s,	1H),	4.72	(s,		1H),	4.18	(q,	J	=	7.1	Hz,		2H),	3.97	-	3.85	(m,	
1H),	2.49	(dd,	J	=	13.9	and	4.1	Hz,		1H),	2.27	(dd,	J	=	13.8	and	7.2	Hz,		1H),	1.32	
(t,	J	=	7.0	Hz,	3H),	1.29	(d,	J	=	7.1	Hz,	 	3H).	One	NH	proton	missing;	13C	NMR	
(CDCl3,	63	MHz)	δ	170.6,	159.2,	139.4,	129.7,	128.9,	123.6,	121.5,	120.6,	85.2,	59.4,	55.8,	39.7,	
23.9,	 14.9;	 IR	 (film,	neat)	ν:	 3353.7,	 2974.8,	 1651.0,	 1614.4,	 1493.5,	 1307.1,	 1274.9,	 1229.7,	
1160.7,	1044.4	cm-1;	Anal.	Calcd	for	C14H17ClN2O2:	C,	59.89;	H,	6.10;	N,	9.98.	Found:	C,	59.56;	H,	
5.88;	N,	10.16.	
	
Ethyl	 (Z)-2-(7-chloro-4-methyl-1,3,4,5-tetrahydro-2H-benzo[b][1,4]diazepin-2-
ylidene)acetate	(17hb)		
	
Colourless	viscous	 liquid;	 1H	NMR	 (CDCl3,	250	MHz)	δ	 10.21	 (br	 s,	1H),	6.94-
6.83	(m,	2H),	6.67	(d,	J	=	8.2	Hz,	 	1H),	4.73	(s,	 	1H),	4.18	(q,	J	=	7.2	Hz,	 	2H),	
3.95-3.85	(m,	1H),	3.38	(br	s,	1H),	2.49	(dd,	J	=	13.9	and	4.4	Hz,		1H),	2.23	(dd,	
J	=	13.8	and	7.0	Hz,	1H),	1.31	(t,	J	=	7.1	Hz,		3H),	1.28	(d,	J	=	6.3	Hz,		3H);	13C	
NMR	(CDCl3,	63	MHz)	δ	170.5.	158.9,	136.9,	131.8,	126.6,	124.4,	122.4,	122.2,	85.8,	59.4,	56.1,	
39.7,	23.8,	14.9;	 IR	 (neat)	ν:	3354.0,	2972.6,	1651.4,	1621.3,	1494.9,	1366.3,	1305.5,	1268.8,	
1162.6,	1044.4	cm-1;	Anal.	Calcd	for	C14H17ClN2O2:	C,	59.89;	H,	6.10;	N,	9.98.	Found:	C,	60.07;	H,	
6.54;	N,	10.22.	
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Methyl	 (Z)-2-(4,7,8-trimethyl-1,3,4,5-tetrahydro-2H-benzo[b][1,4]diazepin-2-ylidene)acetate	
(17i)	
	
Procedure	 B	 was	 followed	 using	 4,5-dimethylbenzene-1,2-diamine-1,2-
diamine	 (136	 mg,	 1	 mmol)	 and	 methyl	 3-oxohex-5-enoate	 (142	 mg,	 1	
mmol).	Compound	17i	is	obtained	as	a	colourless	viscous	liquid	(234	mg,	90	
%);	 1H	NMR	(CDCl3,	250	MHz)	δ	10.13	(br	s,	1H),	6.70	(s,	1H),	6.54	(s,	1H),	
4.90	(br	s,	1H),	4.68	(s,	1H),	3.88	-	3.81	(m,	1H),	3.69	(s,	3H),	2.54	–	2.40	(m,	
1H),	2.22	 -	2.15	 (m,	7H),	 	 1.24	 (d,	 J	 =	6.3	Hz,	 	 3H);	 13C	NMR	 (CDCl3,	 63	MHz)	δ	 170.2,	159.5,	
135.4,	132.8,	129.6,	127.8,	123.1,	122.1,	83.0,	55.9,	50.0,	39.1,	23.1,	18.8,	18.6;	IR	(film,	neat)	
ν:	 3344.8,	 2966.2,	 1651.7,	 1614.3,	 1515.6,	 1311.4,	 1244.5,	 1165.7,	 1037.4,	 783.7	 cm-1;	 Anal.	
Calcd	for	C15H20N2O2:	C,	69.20;	H,	7.74;	N,	10.76.	Found:	C,	69.47;	H,	7.91;	N,	10.36.	
	
Ethyl	 (Z)-2-(4,7,8-trimethyl-1,3,4,5-tetrahydro-2H-benzo[b][1,4]diazepin-2-ylidene)acetate	
(17j)	
	
Procedure	 B	 was	 followed	 using	 4,5-dimethylbenzene-1,2-diamine-1,2-
diamine	(136	mg,	1	mmol)	and	methyl	3-oxohex-5-enoate	(142	mg,	1	mmol).	
Compound	17j	 is	 obtained	as	 a	 colourless	 viscous	 liquid	 (247	mg,	 91	%);	 1H	
NMR	 (CDCl3,	 250	MHz)	δ	 10.16	 (br	 s,	 1H),	 6.74	 (s,	 1H),	 6.58	 (s,	 1H),	 4.68	 (s,	
1H),	4.18	(q,	J	=	7.1	Hz,	2H),	3.92-3.85	(m,	1H),	2.46	(dd,	J	=	13.7	and	4.4	Hz,	1H),	2.26-2.18	(m,	
1H),	2.18	(s,	7H),	1.31	(t,	J	=	7.1	Hz,	3H),	1.28	(d,	 J	=	6.3	Hz,	3H);	 13C	NMR	(CDCl3,	63	MHz)	δ	
170.6,	159.9,		135.9,	133.4,	130.4,	128.6,		123.8,		122.7,	84.2,	59.2,	56.5,	39.9,	23.8,	19.5,	19.2,	
15.0;	IR	(neat)	ν:	3342.0,	2970.2,	1651.3,	1613.4,	1514.5,	1308.5,	1242.5,	1163.8,	1046.3,	782.9	
cm-1;	Anal.	Calcd	for	C16H22N2O2:	C,	70.04;	H,	8.08;	N,	10.21.	Found:	C,	69.71;	H,	7.77;	N,	9.94.	
	
Methyl	3,5-bis(allylamino)hex-2-enoate	(18)	
	
Procedure	B	was	followed	using	allylamine	(228	mg,	4	mmol)	and	methyl	
3-oxohex-5-enoate	(284	mg,	2	mmol).	Compound	18	 is	obtained	as	a	3:1	
mixture	 of	 diasteroisomers,	 yellowish	 viscous	 liquid	 in	 a	 full	 conversion	
that	has	not	been	purified	and	used	for	the	subsequent	step	as	a	crude;	
1H	NMR	(250	MHz,	CDCl3)	δ	8.57	(br	s,	1H),	5.87	–	5.62	(m,	2H),	5.25	–	4.88	(m,	4H),	4.40	(s,	
1H),	3.88	–	3.66	 (m,	2H),	3.48	 (s,	3H),	3.26	–	2.99	 (m,	2H),	2.88	–	2.68	 (m,	1H),	2.26	 (dd,	 J	=	
13.9,	7.0	Hz,	1H),	2.01	 (dd,	 J	 =	13.9,	6.7	Hz,	1H),	1.00	 (d,	 J	 =	7.5	Hz,	3H);	 13C	NMR	 (63	MHz,	
CDCl3)	δ	170.4,	162.5,	136.3,	134.4,	115.6,	115.5,	83.0,	50.7,	49.6,	49.4,	44.7,	39.5,	20.0.	
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7.5.4.	Mechanochemical	synthesis	of	compound	19a	and	its	N-acetylation	to	19b	
	
	
	
Acetophenone	 (0.5	 mmol),	 N-iodosuccinimide	 (NIS,	 0.5	 mmol)	 and	 p-toluenesulphonic	 acid	
(PTSA,	10	mol%)	were	added	to	a	ball	mill	vessel,	along	with	a	zirconium	oxide	ball.	The	vessel	
was	 fitted	 to	 one	of	 the	 horizontal	 vibratory	 arms	of	 the	 ball	mill,	while	 the	 other	 arm	was	
occupied	with	an	empty	vessel.	The	ball	mill	was	set	to	vibrate	at	a	frequency	of	20	s-1	for	60	
min	at	room	temperature.	Then,	a	mixture	of	prop-2-en-1-amine	(2.0	mmol),	methyl	3-oxohex-
5-enoate	(0.75	mmol)	and	cerium(IV)	ammonium	nitrate	(CAN,	5	mol%),	previously	stirred	at	
room	temperature	during	30	min,	and	silver	nitrate	(0.5	mmol)	were	added	to	the	vessel.	The	
reaction	was	 subjected	 to	 the	vibratory	movement	at	 the	 same	 frequency	 for	60	min.	Then,	
the	reaction	vessel	was	cleansed	with	ethyl	acetate	and	the	suspension	was	filtered	to	remove	
the	 silver	 iodide	 precipitate.	 The	 organic	 layer	 was	 washed	 with	 water	 (2	 mL),	 dried	 over	
anhydrous	sodium	sulphate	and	the	solvent	was	removed	under	reduced	pressure.	Purification	
by	flash	column	chromatography	on	silica	gel	eluting	with	a	gradient	from	petroleum	ether	to	
8:2	petroleum	ether-ethyl	acetate	afforded	the	desired	pyrrole	derivatives	19a.	
	
Methyl	1-allyl-2-(2-(allylamino)propyl)-5-phenyl-1H-pyrrole-3-carboxylate	(19a)	
	
Prepared	 from	 acetophenone	 (0.5	 mmol)	 and	 compound	 18	 (0.75	
mmol)	and	obtained	as	a	yellowish	oil	(84	mg	,	50%);	1H	NMR	(250	MHz,	
CDCl3)	δ	7.38	(s,	6H),	6.63	(s,	1H),	6.07	–	5.70	(m,	2H),	5.40	–	5.04	(m,	
5H),	4.85	–	4.43	(m,	3H),	3.83	(s,	4H),	3.56	–	2.93	(m,	5H),	2.00	(s,	1H),	
1.17	(d,	J	=	6.0	Hz,	4H);	13C	NMR	(63	MHz,	CDCl3)	δ	165.6,	137.9,	135.1,	
134.2,	133.9,	132.4,	129.0,	128.3,	127.6,	116.9,	116.1,	112.5,	110.0,	53.1,	50.8,	49.2,	46.4,	32.2,	
19.4;	 IR	 (film,	 neat)	ν:	 3252.2,	 3113.5,	 2951.5,	 1711.3,	 1667.9,	 1647.0,	 1237.6,	 1157.3	 cm-1;	
Anal.	Calcd	for	C21H26N2O2:	C,	74.53;	H,	7.74;	N,	8.28.	Found:	C,	74.90;	H,	7.99;	N,	8.02.	
	
Methyl	1-allyl-2-(2-(N-acetylallylamino)propyl)-5-phenyl-1H-pyrrole-3-carboxylate	19b	
	
	
	
H2C
O
CO2Me
H2C
NH22 Neat, rt, 1h NH
O
MeO Me
N
H
N NH
Ph
Me
O
OMe
CH3
O
Ph
O
Ph
I
NIS, TsOH, HSVM, 
20 Hz, 1 h
CAN (5%), AgNO3 (1 eq), 
HSVM, 20 Hz, 1 h 
(30% overall)
18
19a
N NH
Ph
Me
O
OMe
N N
Ph
Me
Ac
O
OMeInCl3 10%, Ac2O,
rt, 45 min (99%)
19b19a
N
N
H
H3C
O OMe
	
	
	 	 	 	 	 147		
Pyrrole	 19a	 (68	 mg,	 0.2	 mmol)	 was	 treated	 with	 Ac2O	 (0.03	 mL,	 0.3	 mmol)	 at	 room	
temperature	 for	 30	 min	 under	 magnetic	 stirring	 in	 the	 presence	 of	 InCl3	 (10%	 mol).125	No	
solvent	was	used.	The	reaction	was	monitored	by	TLC.	The	crude	mixture	was	extracted	with	
Et2O	 to	 afford	 final	 product	 in	 a	 full	 conversión	 monitored	 by	 1H-NMR.	 The	 mixture	 was	
employed	with	no	further	purification	for	the	subsequent	reaction.	
	
	 	
																																																								
125	Chakraborti,	A.	K.;	Gulhane,	R.;	Tetrahedron	Letters,	2003,	44,	6749.	
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7.5.5.	Synthesis	of	compound	20	by	ring	closing	metathesis	reaction	
	
	
	
To	a	solution	of	compound	19b	 (0.15	mmol)	 in	dry	dichloromethane,	first	generation	Grubbs	
catalyst	 (5%	mmol)	was	added.	 The	mixture	was	 stirred	 for	24	h	 and,	 then,	 the	 solvent	was	
removed	 under	 reduced	 pressure.	 The	 crude	 residue	 was	 purified	 by	 flash	 column	
chromatography	on	silica	gel	using	9:1	petroleum	ether-ethyl	acetate	as	solvent.	
	
Methyl	1-allyl-2-(2-(N-allylacetamido)propyl)-5-phenyl-1H-pyrrole-3-carboxylate	(20)	
	
Final	compound	20	 is	obtained	giving	the	desired	compound	as	a	dark	
yellow	oil;	yield:	38	mg	(50	%)	;	1H	NMR	(250	MHz,	CDCl3)	δ	7.41	(dd,	J	=	
3.9,	2.5	Hz,	6H),	6.51	(s,	1H),	6.26	(dt,	J	=	9.8,	7.6	Hz,	1H),	5.49	–	5.21	(m,	
1H),	4.73	(ddd,	J	=	23.4,	13.0,	7.4	Hz,	2H),	4.26	(dd,	J	=	14.8,	7.2	Hz,	1H),	
3.84	(s,	4H),	3.74	(d,	J	=	7.3	Hz,	2H),	3.57	(dd,	J	=	15.0,	4.5	Hz,	1H),	3.41	–	
3.08	 (m,	1H),	 1.92	 (s,	 3H),	 1.37	 (d,	 J	 =	6.6	Hz,	3H);	 13C	NMR	 (63	MHz,	CDCl3)	δ	 171.3,	166.2,	
136.6,	 134.4,	 133.8,	 133.1,	 130.5,	 128.7,	 128.4,	 127.0,	 112.23,	 110.4,	 54.5,	 51.3,	 39.3,	 37.4,	
31.5,	22.5,	20.3;	IR	(neat)	ν:	3102.3	(CAr),	1702.2	(C=O),	1236.0	(C-O)	cm-1;	HRMS	(MALDI	TOF)	
calcd.	for	C21H26N2O2:	338.1994,	found:	338.1985.	
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7.5.6.	 General	 procedure	 of	 pyrrole-based	 macrocycles	 21a-21h	 by	 two	 concomitant	
Hantzsch	pyrrole	syntheses	
	
	
	
A	mixture	of	the	corresponding	diamine	(0.33	mmol),	the	suitable	dicarbonyl	compound	(0.66	
mmol)	 and	 CAN	 (5	 mol%)	 in	 methanol	 (10	 mL/mmol	 of	 diamine)	 was	 stirred	 at	 room	
temperature	 for	 12	 h.	 A	 solution	 of	 the	 suitable	 a-iodoketone	 (0.23	 mmol)	 in	 methanol	 (5	
mL/mmol),	silver	nitrate	(0.5	mmol)	and	indium	trichloride	(InCl3,	5	mol%)	were	slowly	added	
by	 1	 hour	 injection	 to	 the	 flask	 containing	 the	 non-isolated	 enaminone,	 and	 stirred	 for	
additional	 5	 h.	 Then,	 washed	with	water	 and	 dry	with	 Na2SO4.	 Purification	 by	 flash	 column	
chromatography	 on	 silica	 gel	 eluting	 with	 a	 gradient	 from	 dichloromethane	 to	 9.5:0.5	
dichloromethane-methanol	afforded	the	desired	macrocycle	derivatives	21a-21h.	
	
Dimethyl	3,10-dimethyl-5,6,7,8-tetrahydro-13,17-(metheno)dipyrrolo[1,2-f:2',1'-
m][1,6]diazacyclotridecine-2,11-dicarboxylate	(21a)	
	
Prepared	 from	 1,3-diacetylbenzene,	 (0.23	 mmol),	 methyl	
acetoacetate	 (0.66	 mmol)	 and	 1,4-diaminobutane	 (0.33	 mmol);	
yield:	 50	 mg	 (52%);	 white	 solid;	 mp	 >	 210	 °C;	 1H	 NMR	 (250	
MHz,CDCl3)	δ	7.49	–	7.45	(m,	2H),	7.38	–	7.35	(m,	2H),	6.70	(s,	2H),	
3.85	(s,	10H),	2.68	(s,	6H),	2.32	–	2.14	(m,	4H);	13C	NMR	(63	MHz,	CDCl3)	δ	165.9,	139.1,	134.9,	
131.7,	131.6,	129.7,	126.3,	111.8,	107.8,	50.9,	41.8,	26.7,	12.0;	IR	(neat)	ν:		2958.7	and	2943.4	
(Ar	 C-H),	 1699.4	 (C=O),	 1231.6	 and	 1177.5	 (C-O)	 cm-1;	 elemental	 analysis	 (%)	 calcd.	 for	
C24H26N2O4:	C,	70.92;	H,	6.45;	N,	6.89;	found:	C,	70.61;	H,	6.15;	N,	6.57.	
	
Dimethyl	15,35-dimethyl-11H,31H-1,3(2,1)-dipyrrola-2(1,3)-benzenacyclooctaphane-14,34-
dicarboxylate	(21b)		
	
Prepared	 from	 1,3-diacetylbenzene	 (0.23	 mmol),	 methyl	
acetoacetate	 (0.66	 mmol)	 and	 1,5-diaminopentane	 (0.33	 mmol);	
yield:	 53	mg	 (53%);	white	 solid;	mp	>	210	 °C;	 1H	NMR	 (250	MHz,	
CDCl3)	d				7.63	(br	s,	1H),	7.43	–	7.42	(m,	3H),	6.82	(s,	2H),	4.03	(d,	J	
=	8.5	Hz,	4H),	3.85	(s,	6H),	2.66	(s,	6H),	2.06	(s,	4H),	1.62	(s,	2H);	13C	NMR	(63	MHz,	CDCl3)	d	
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165.8,	137.2,	132.4,	132.3,	129.6,	127.6,	124.7,	111.6,	109.5,	50.8,	43.6,	21.6,	11.5;	IR	(neat)	ν:	
2945.8	(Ar	C-H),	1699.2.6	(C=O),	1232.0	and	1177.6	(C-O)	cm-1;	elemental	analysis	(%)	calcd.	for	
C25H28N2O4:	C,	71.41;	H,	6.71;	N,	6.66;	found:	C,	71.09;	H,	6.38;	N,	6.24.	
	
Dimethyl	15,35-dimethyl-11H,31H-1,3(2,1)-dipyrrola-2(1,3)-benzenacyclodecaphane-14,34-
dicarboxylate	(21c)	
	
Prepared	 from	 1,3-diacetylbenzene	 (0.23	 mmol),	 methyl	
acetoacetate	 (0.66	 mmol)	 and	 1,7-diaminoheptane	 (0.33	 mmol);	
yield:	 43	mg	 (40%);	 light	 yellow	 solid;	mp	 =	 182-184	 °C;	 1H	 NMR	
(250	MHz,	CDCl3)	δ	7.53	–	7.42	(m,	2H),	7.33	–	7.25	(m,	2H),	6.57	(s,	
2H),	3.84	–	3.78	(m,	10H),	2.61	(s,	6H),	1.62	–	1.46	(m,	4H),	0.98	(br	
s,	4H),	0.69	–	0.57	(m,	2H);	13C	NMR	(63	MHz,	CDCl3)	δ	166.0,	136.0,	133.8,	133.6,	133.3,	129.9,	
128.0,	111.6,	108.4,	50.7,	42.1,	29.2,	26.4,	24.4,	11.6;	IR	(neat)	ν:	2931.7	and	2855.5	(Ar	C-H),	
1698.1	 (C=O),	 1438.9	 and	 1234.0	 and	 1193.5	 (C-O)	 cm-1;	 HRMS	 (MALDI	 TOF)	 calcd.	 for	
C27H32N2O4:	448,2362,	found:	448.2368.	
	
Dimethyl	15,35-dimethyl-11H,31H-1,3(2,1)-dipyrrola-2(1,3)-benzenacycloundecaphane-14,34-
dicarboxylate	(21d)		
	
Prepared	 from	 1,3-diacetylbenzene	 (0.23	 mmol),	 methyl	
acetoacetate	 (0.66	 mmol)	 and	 1,8-diaminooctane	 (0.33	 mmol);	
yield:	44	mg	 (40%);	 yellow	solid;	mp	=	148-150	 °C;	 1H	NMR	 (250	
MHz,	 CDCl3)	δ	 7.47	 –	 7.33	 (m,	 2H),	 7.30	 –	 7.18	 (m,	 2H),	 6.48	 (s,	
2H),	3.89	–	3.83	(m,	4H),	3.73	(s,	6H),	2.53	(s,	6H),	1.48	–	1.28	(m,	
4H),	1.11	–	0.83	(m,	8H);	13C	NMR	(63	MHz,	CDCl3)	δ	166.0,	136.5,	
133.5,	 132.8,	 130.5,	 129.1,	 128.5,	 111.6,	 109.7,	 50.8,	 43.1,	 28.7,	
26.0,	24.6,	11.5;	IR	(neat)	ν:	2924.7	and	2851.5	(Ar	C-H),	1700.4	(C=O),	1440.8	and	1192.3	(C-O)	
cm-1;	elemental	analysis	(%)	calcd.	for		C28H34N2O4:	C,	72.70;	H,	7.41;	N,	6.06;	found:	C,	72.31;	
H,	7.20;	N,	5.85.	
	
Dimethyl	15,35,7,7,9,9-hexamethyl-11H,31H-8-oxa-7,9-disila-1,3(2,1)-dipyrrola-2(1,3)-
benzenacyclododecaphane-14,34-dicarboxylate	(21e)	
	
Prepared	from	1,3-diacetylbenzene	(0.23	mmol),		methyl	acetoacetate	(0.66	
mmol)	and	1,3-bis(aminopropyl)tetramethyldisiloxane	(0.33	mmol);	yield:	81	
mg	(60%);	white	solid;	mp	>	210	°C;	1H	NMR	(250	MHz,	CDCl3)	δ	7.51	–	7.42	
(m,	2H),	7.38	–	7.31	(m,	2H),	6.60	(s,	2H),	3.98	(t,	J	=	7.3	Hz,	4H),	3.84	(s,	6H),	
2.63	(s,	6H),	1.43	–	1.28	(m,	4H),	0.26	–	0.14	(m,	4H),	-0.07	(s,	12H);	13C	NMR	
(63	 MHz,	 CDCl3)	 δ	 166.0,	 136.6,	 133.8,	 132.7,	 130.9,	 128.2,	 127.9,	 111.5,	
110.1,	 50.7,	 46.6,	 24.3,	 15.2,	 11.5,	 0.2;	 IR	 (neat)	ν:	 2948.5	 (Ar	C-H),	 1701.9	
(C=O),	 1438.8	 and	 1253.1	 and	 1207.6	 and	 1069.0	 (C-O)	 cm-1;	 elemental	
analysis	(%)	calcd.	for	C30H42N2O5Si2:	C,	63.57;	H,	7.47;	N,	4.94;	found:	C,	63.19;	H,	7.09;	N,	4.58.	
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1,1'-(15,45,8,8,10,10-hexamethyl-11H,41H-9-oxa-8,10-disila-1,4(2,1)-dipyrrola-2(1,3),3(1,4)-
dibenzenacyclotridecaphane-14,44-diyl)bis(ethan-1-one)	(21f)	
	
Prepared	from	4,4’-diacetylbiphenyl	 (0.23	mmol),	acetylacetone	(0.66	mmol)	
and	 1,3-bis(aminopropyl)tetramethyldisiloxane	 (0.33	 mmol);	 yield:	 51	 mg	
(35%);	white	solid;	mp	>	210	°C;	1H	NMR	(250	MHz,	CDCl3)	δ	7.86	(d,	J	=	8.3	Hz,	
4H),	7.48	(d,	J	=	8.3	Hz,	4H),	6.70	(s,	2H),	3.85	(s,	6H),	3.78	(t,	J	=	7.8	Hz,	4H),	
2.60	(s,	6H),	1.07	–	0.95	(m,	4H),	0.17	–	0.08	(m,	4H),	-0.25	(s,	12H);	13C	NMR	
(63	 MHz,	 CDCl3)	 δ	 166.0,	 138.4,	 136.1,	 132.5,	 132.4,	 130.6,	 126.2,	 110.9,	
108.6,	50.8,	47.2,	24.0,	16.2,	11.3,	-0.1;	IR	(neat)	ν:	3095.5	and	2965.1	(Ar	C-
H),	1700.3	(C=O),	1248.6	and	1203.2	(C-O)	cm-1;	elemental	analysis	(%)	calcd.	
for	C36H46N2O3Si2:	C,	70.77;	H,	7.59;	N,	4.59;	found:	C,	70.49;	H,	7.25;	N,	4.35.	
	
	
1,1'-(15,35,7,7,9,9-hexamethyl-11H,31H-8-oxa-7,9-disila-1,3(2,1)-dipyrrola-2(1,3)-
benzenacyclododecaphane-14,34-diyl)bis(ethan-1-one)	(21g)	
	
Prepared	from	1,3-diacetylbenzene	(0.23	mmol),	acetylacetone	(0.66	mmol)	
and	 1,3-bis(aminopropyl)tetramethyldisiloxane	 (0.33	 mmol);	 yield:	 64	 mg	
(50%);	white	 solid;	mp:	164-166	 °C;	 1H	NMR	 (250	MHz,	CDCl3)	d	7.54	 (br	 s,	
2H),	7.45	–	7.35	(m,	2H),	6.63	(s,	2H),	4.04	(t,	J	=	7.0	Hz,	4H),	2.72	(s,	6H),	2.53	
(s,	 6H),	 1.44	 (s,	 4H),	 0.36	–	0.21	 (m,	4H),	 -0.00	 (s,	 12H);	 13C	NMR	 (63	MHz,	
CDCl3)	δ	195.1,	136.0,	133.8,	132.4,	131.0,	128.4,	128.2,	120.8,	110.8,	46.4,	
28.6,	24.3,	15.2,	12.0,	0.2;	IR	(neat)	ν:	2955.2	(Ar	C-H),	1711.6	(C=O),	1252.6	
and	1090.9	(C-O)	cm-1;	HRMS	(MALDI	TOF)	calcd.	for	C30H42N2O3Si2:	534,2734,	
found:	534.2744.	
	
1,1'-(15,45-dimethyl-11H,41H-1,4(2,1)-dipyrrola-2(1,3),3(1,4)-dibenzenacyclotetradecaphane-
14,44-diyl)bis(ethan-1-one)	(21h)	
	
Prepared	 from	 4,4’-diacetylbiphenyl	 (0.23	 mmol),	 acetylacetone	
(0.66	 mmol)	 and	 1,10-diaminodecane	 (0.33	 mmol);	 yield:	 38	 mg	
(30%);	yellow	oil;	1H	NMR	(250	MHz,	CDCl3)	δ	7.84	(d,	J	=	8.3	Hz,	4H),	
7.49	(d,	J	=	8.3	Hz,	4H),	6.63	(s,	2H),	3.81	–	3.75	(m,	4H),	2.64	(s,	6H),	
2.49	(s,	6H),	1.31	–	1.20	(m,	6H),	1.01	(br	s,	4H),	0.62	(br	s,	6H);	13C	
NMR	 (63	 MHz,	 CDCl3)	 δ	 195.1,	 139.0,	 135.6,	 132.3,	 131.0,	 126.4,	
120.4,	109.3,	76.5,	42.9,	30.4,	29.0,	28.7,	28.6,	26.5,	11.8;	IR	(neat)	ν:	
2924.3	 and	 2852.2	 (Ar	 C-H),	 1679.4	 and	 1602.5	 (C=O),	 1422.5	 and	
1265.5	 and	 1179.9	 (C-O)	 cm-1;	 HRMS	 (MALDI	 TOF)	 calcd.	 for	 C36H42N2O2:	 534.3246,	 found:	
534.3235.	
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8.	 Chemometric	 study	 and	 high-throughput	 screening	 of	 the	
libraries	synthesized		
	
8.1.	Chemometric	study	
We	also	undertook	a	brief	chemoinformatic	study	of	our	compounds	in	order	to	assess	
their	 diversity	 in	 terms	 of	 molecular	 shape,	 as	 judged	 by	 the	 distribution	 of	 their	
principal	moments	of	inertia	for	each	molecule	in	its	minimum	energy	conformer.	The	
study	 was	 carried	 out	 with	 the	 open-access	 LLAMA	 platform	 for	 Diversity-Oriented	
Synthesis	from	the	University	of	Leeds	(UK).126,127	This	study	showed	(Figure	8.1)	that	
the	DOS	library	has	a	broad	shape	distribution	that	was	comparable	to	a	library	formed	
by	60	 structurally	diverse	natural	products	 and	another	of	40	high-selling	drugs	 that	
are	summarized	in	Figure	8.2.	
	
																																																									
126		 Colomer,	 I.;	Empson,	C.	 J.;	Craven,	P.;	Owen,	Z.;	Doveston,	R.	G.;	Churcher,	 I.;	Marsden,	S.	P.;	
Nelson,	A.	Chem.	Commun.	2016,	52,	7209.		
127		 The	address	of	the	LLAMA	web	site	is:	https://llama.leeds.ac.uk.	
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Figure	8.1	
	
Figure	8.2	
	
	
	
	 	
1.Rapamycin
2.Mizoribine
3.Penicillin G 
4.Erythromycin A 
5.Discodermolide 
6.Streptomycin 
7.Validamycin 
8.Actinonin
9.Echinocandin B
10.Sperguallin 
11.Calyculin A 
12.Taxol 
13.Coformycin 
14.Monensin 
15.Arglabin 
16.Ginkgolide B 
17.Staurosporine 
18.Vancomycin 
19.Forskolon 
20.Amphotericin B
41.Talaromycin B 
42.Zaragozic acid A
43.Brevetoxin B 
44.Compactin
45.Mycobactin S 
46.Duocarmycin A 
47.Quinine
48.Trichostatin A 
49.Calicheamicin ÔÅß1
50.Brefeldin A 
51.Pseudomonic acid A 
52.Cytochalasin B  
53.Daptomycin 
54.Epothilone A 
55.Bestatin 
56.Artemisinin
57.Plaunotol 
58.Lipstatin
59.Geldanamycin 
60. Lactacystin
Reference compounds for the Principal Moments of Inertia (PMI) study
Natural products
21.SQ 26180 
22.Radicicol 
23.Cephamycin C 
24.Salicylihalamide A 
25.Telomestatin 
26.Rifamycin B 
27.Thienamycin
28.Avermectin B1a 
29.FK506 
30.Phorbolmyristate acetate
31.Apoptolidin 
32.Cyclosporin A 
33.Adriamycin
34.Trapoxin B 
35.Vincristine 
36.Colchicine 
37.Bleomycin A2
38.Fumagillin 
39.Midecamycin A1 
40.Spongistatin 1
Drugs
1.Montelukast (Singulair®)
2.Esomeprazole (Nexium®)
3.Simvastatina (Zocor®)
4.Fluticasona (Flonase®)
5.Salmeterol (Servent®)
6.Atorvastatin (Lipitor®)
7.Zolpidem (Ambien®)
8.Clopidogrel (Plavix®)
9.Lansoprazol (Prevacid®)
10.Amlodipine (Norvasc®)
11.Bupropion (Wellbutrin®)
12.Quetiapine (Seroquel®)
13.Pantoprazole (Protonix®)
14.Venlafaxine (Effexor®)
15.Pioglitazone (Actos®)
16.Sertraline (Zoloft®)
17.Escitalopram (Lexapro®)
18.Rosiglitazone (Avandia®)
19.Risperidone (Risperdal®)
20.Olanzapine (Zyprexa®)
21.Fenofibrate (Tricor®)
22.Topiramate (Topomax®)
23.Metoprolol (Toprol®)
24.Benazepril (Benazepril®)
25.Alendronic acid (Fosamax®)
26.Aripiprazol (Abilify®)
27.Levofloxacin (Levaquin®)
28.Lamotrigine (Lamictal®)
29.Colecoxib (Celebrex®)
30.Ezetimibe (Zetia®)
31.Cetirizine (Zyrtec®)
32.Valsartan (Diovan®)
33.Valaciclovir (Valtrex®)
34.Amphetamine (four salts of its two     
      enantiomers) (Adderall®)
35.Rabeprazole (Aciphex®)
36.Sumatriptan (Imitrex®)
37.Rosuvastatin (Crestor®)
38.Carvedilol (Coreg®)
39.Bupropion (Wellbutrin®)
40.Duloxetine (Cymbalta®)
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8.2.	Introduction	to	the	OIDD	program	
The	high-throughput	study	of	our	 libraries	was	done	 in	collaboration	with	Lilly	via	 its	
Open	 Innovation	Drug	Discovery	 (OIDD)	 Program.	 This	 is	 a	 platform	 to	 facilitate	 the	
collaboration	between	big	pharma	and	academic	researchers	for	early	drug	discovery.	
The	main	advantage	of	this	collaboration	for	academic	research	group	is	the	possibility	
to	access	 to	 cutting-edge	 research	 tools	and	data	aimed	at	 improving	 their	 scientific	
work	for	the	discovery	of	novel	therapeutics	for,	possibly,	novel	targets.	Participants	of	
the	OIDD,	 to	 specify,	 can	 be	 universities	 (as	 our	 case),	 research	 institutes	 and	 small	
biotechnology	companies.		
Once	 affiliated,	 registered	 and	 accepted	 the	 agreement,	 participants	 have	 to	 upload	
molecular	structures	to	Lilly’s	web	page	for	an	initial	in	silico	evaluation.	At	this	point,	
molecular	 descriptors	 are	 created	 by	 the	 program	 and	 a	 first	 evaluation	 of	 the	
molecular	parameters	is	done	(as	metabolic	stability,	structural	novelty,	drug-likeness	
properties,	 molecular	 weight…)	 to	 identify	 which	 compounds	 are	 eligible	 for	 the	
second	step	of	biological	evaluation.	If	a	compound	is	chosen	and	approved,	the	OIDD	
program	 provides	 vials	 as	 an	 in-kind	 service	 to	 participants.	 The	 whole	 process	 is	
driven	 in	 a	 structure-blinded	 fashion,	 where	 the	 results	 of	 the	 in	 silico	 analysis	 are	
considered	and	become	available	to	Lilly	or	Elanco.	Compounds	accepted	for	biological	
evaluation	can	belong	to	 fragment-like	molecules,	 small	molecules,	natural	products,	
larger	molecules	or	small	peptides.	The	following	step,	when	the	physical	samples	have	
been	received,	is	the	beginning	of	the	biological	evaluation	in	several	different	assays	
modules	 for	 different	 therapeutic	 diseases	 using	 High	 Throughput	 Screening	 (HTS)	
technology.	 All	 the	 biological	 results	 are	 provided	 to	 the	 researcher	 through	 their	
personal	 OIDD	 account.	 All	 the	 accepted	 compounds	 will	 further	 undergo	 in	 vitro	
screening	 in	 both	 Lilly	 active	 and	 emerging	 projects,	 neglected	 and	 tropical	 disease	
screening	(summary	of	all	diseases	considered	in	the	OIDD	program	in	Figure	8.3).	The	
OIDD	 team	 may	 decide	 to	 discuss	 further	 steps	 with	 investigator	 for	 specific	
compounds	with	a	promising	profile.	
	
	
Figure	8.3	
	
In	vitro	screening	process	consists	of	a	primary	screening	assay	followed	by	secondary	
biochemical	 and/or	 cell-based	 follow-up	 screen	 to	 define	 the	 activity	 profile	 of	 the	
compound.	In	this	phase	both	phenotypic	and	target-based	approaches	are	employed.	
For		
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In	the	first	case,	complex	cellular	systems	are	required	instead	of	specific	targets	of	the	
target-based	approaches.	Finally	the	biological	results	are	provided	to	the	participating	
investigators	and	they	are	allowed	to	export	results	to	create	personalized	reports,	as	
the	case	of	this	thesis.	Data	reported	include	the	single	point	(SP)	of	concentration	at	
which	the	compound	was	tested	to	a	specific	assay	to	measure	biological	activity,	plus	
the	results	associated	with	the	subsequent	concentration-response	curve	(CRC),	where	
applicable.	In	addition,	the	exportable	report	includes	molecular	properties	such	as	the	
atomic	molecular	weight	 (AMW),	 a	measure	of	 the	 compound's	 lipophilicity	 (cLogP),	
and	heavy	atom	count	(HA).	
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8.3.	Biological	results	of	our	DOS	libraries	
Following	the	initial	in	silico	testing,	the	majority	of	our	molecules	were	been	accepted	
and	approved	for	biological	screening.	The	structures	of	all	the	compounds	assayed	is	
given	in	Figure	8.4,	with	the	codes	used	in	this	thesis	and	also	with	the	code	assigned	
by	OIDD.	
	
	
Figure	8.4	
	
The	results	obtained	are	reported	below,	organized	by	targets	and	diseases.	
	
1-Protein	Translation	Inhibition	for	Alzheimer’s	disease:	neurodegeneration	and	pain	
scope.		
The	 accumulation	 in	 the	 extracellular	 space	 of	 amyloid	 plaques	 and	 intracellular	
formation	 of	 neurofibrillary	 tangles	 (NFTs)	 it	 basically	 features	 the	 Alzheimer’s	
pathology,	also	defined	as	Alzheimer’s	disease	(AD).	Amyloid	plaques	are	composed	of	
Aβ	protein	and	the	NFTs	of	tau	protein.	Modern	strategies	for	the	AD	treatment	are	to	
target	 this	 association	 of	 proteins	 by	 preventing	 their	 accumulation	 and,	 or,	 their	
removal	once	deposited.	For	this	reason,	acting	at	the	level	of	protein	translation	could	
regulate	or	inhibit	the	expression	of	such	proteins	as	a	new	possible	valid	target.	
	
In	 the	 following	 all	 the	biological	 results	 that,	 in	 some	 cases,	 have	 shown	promising	
preliminary	activity,	are	reported.	
	
	
	
This	assays	have	been	done	in	Huh7	cell-line,	widely	employed	in	laboratory	due	to	its	
facility	 condition	 growth.	 Their	 origin	 is	 from	 human	 liver,	 derived	 from	 a	 well-
differentiated	hepatocyte-derived	carcinoma	cell-line.	With	the	 intention	of	 interpret	
all	 the	 data	 furnish	 by	 Lilly,	we	 have	 to	 introduce	 the	 role	 of	 the	 targets	 studied	 in	
these	assays:		
- ANGPTL8	(also	known	as	lipasin	or	Betatrophin)	is	a	protein	encoded	in	humans	by	
the	C19orf80	gene	(gene	19).	Human	betatrophine,	olso	the	one	from	mice,	is	not	
able	to	increase	beta-cell	division.	Deletion	of	betatrophin/Angptl8	does	not	seem	
Neuroscience:	
Tau	
Primary	assays:	
•  Tau	target-based	reporter	inhibition	assay	Huh7	SP	(%	Inhibition)	CRC(IC50)		
•  Profiling	Target-based	reporter	inhibition	assay	Huh7	SP	
•  Target-less	reporter	assay	Huh7	CRC	Inhibition	(IC50)	
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to	 impact	 glucose	 and	 insulin	 tolerance	 in	mice.128	This	 protein	 is	 able	 to	 inhibit	
the	 enzyme	 Lipoprotein	 lipase	 (LPL)	 and	 consequently,	 when	 overexpressed,	 an	
increment	of	circulating	triglyceride	levels	is	detected.129	
- APOC3	or	apolipoprotein	C-III	(known	also	as	apo-CIII)	is	a	human	protein	encoded	
by	APOC3	gene.	 Its	 secretion	 is	at	 level	of	 liver	and	small	 intestine.	 Its	 role	 is	 to	
inhibit	 lipoprotein	 and	 hepatic	 lipase	 and,	 for	 example,	 it	 blocks	 the	 uptake	 of	
triglyceride	 rich	 particles.	When	 apoC-III	 levels	 increases,	 hypertriglyceridemia	 is	
produced.130	
- Nav1.7	is	a	voltage-gated	sodium	ion	channel	encoded	by	SCN94	gene	in	humans.	
Its	 expression	 is	 at	 neuronal	 level:	 in	 the	 sympathetic	 ganglion	 neurons	 in	 the	
involuntary	nervous	system	and	in	the	nociceptive	(pain)	neurons	at	level	of	dorsal	
root	 ganglion	 (DRG). 131 	Nav1.7	 is	 located	 at	 the	 pain-sensing	 nerves,	 the	
nociceptors,	 close	 to	 the	 region	 where	 the	 impulse	 is	 initiated.	 This	 channel	 is	
relevant	in	the	early	phases	of	neuronal	electrogenesis	and	its	acts	by	a	transition	
of	the	channel	into	an	inactive	state	when	it	is	depolarized	also	under	little	electric	
changes.	It	 is	relevant	in	several	diseases	as	primary	erythromelalgia,	paroxysmal	
extreme	pain	disorder,	congenital	insensitivity	to	pain,	clinical	analgesics	and	itch.	
- PCSK9	will	be	further	discussed.	
- 	
The	Lilly	assay	oriented	 to	 targets	different	 from	hTau	are	employed	as	 reference	 in	
order	 to	 find	 selective	 TAU-inhibition.	 All	 the	 targets	 described	 before	 are	 proteins	
overexpressed	in	the	Huh7	cell-line	and,	for	these	reason,	evaluated	in	this	experiment	
as	controls.	
	
Cmpd	 OIDD	ID	
Primary	SP	
hTau	Huh7	
TT	Inhib	SP	
hAngptl8	
Huh7	TT	
Inhib	SP	
hAPOC3	
Huh7	TT	
Inhib	SP	
hNav1.7	
Huh7	TT	
Inhib	SP	
hPCSK9	
Huh7	TT	
Inhib	SP	
%Inhib	
@40µM	
%Inhib@	
40µM	
%Inhib@	
40µM	
%Inhib@	
40µM	
%Inhib@	
40µM	
	 2351663277	 63,06	 77,21	 52,36	 60,05	 49,06	
	 2351663279	 62,51	 57,3	 34,06	 36,16	 39,62	
	 2351663280	 -259,6	 38,24	 20,68	 -22,55	 7,541	
	 2351663281	 85,52	 85,7	 78,74	 71,81	 73,58	
	 2351663285	 93,33	 98,51	 90,66	 85,76	 72,46																																																									
128	 Wang	Y.;	Quagliarini	F.;	Gusarova	V.;	Gromada	J.;	Valenzuela	D.	M.;	Cohen	J.	C.;	Hobbs	H.	H.;	Proc.	
Natl.	Acad.	Sci.	U.S.A.,	2013,	110,	16109.		
129	 Zhang	R.;	Biochem.	Biophys.	Res.	Commun.,	2012,	424,	786.	
	
131	 Rush	A.M.;	Dib-Hajj	S.	D.;	Liu	S.;	Cummins	T.	R.;	Black	J.	A.;	Waxman	S.	G.;	Proc.	Natl.	Acad.	Sci.	U.S.A.	
2006,	103,	8245.	
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Cmpd	 OIDD	ID	
Primary	SP	
hTau	Huh7	
TT	Inhib	SP	
hAngptl8	
Huh7	TT	
Inhib	SP	
hAPOC3	
Huh7	TT	
Inhib	SP	
hNav1.7	
Huh7	TT	
Inhib	SP	
hPCSK9	
Huh7	TT	
Inhib	SP	
%Inhib	
@40µM	
%Inhib@	
40µM	
%Inhib@	
40µM	
%Inhib@	
40µM	
%Inhib@	
40µM	
	 2351663286	 -100,3	 24,36	 12,46	 7,08	 8,571	
	 2351663287	 20,75	 22,76	 31,88	 -33,47	 29,76	
	 2351663288	 -38,62	 -41,67	 -14,32	 -29,6	 -3,39	
	 2351663289	 12,45	 19,24	 13,2	 -14,71	 20,24	
	 2351663291	 99,43	 97,56	 98,62	 96,66	 94,34	
	 2351663292	 90,28	 99,25	 82,87	 91,44	 77,36	
	 2351663341	 -64,16	 -1,764	 2,086	 -2,828	 12,86	
	 2351663342	 -19,17	 -0,8819	 3,493	 -1,471	 -2,857	
	 2351663343	 28,34	 51,22	 16,73	 13,35	 28,3	
	 2351663344	 -13,55	 0	 -13,54	 -3,055	 -2,143	
	 2351663345	 60,12	 -749,5	 44,53	 15,99	 40,48	
	 2351663348	 99,53	 96,95	 98,62	 101,1	 98,11	
	 2351663349	 2,643	 14,55	 18,73	 -15,95	 8,571	
	 2351663350	 98,15	 97,07	 95,58	 80,38	 94,75	
	 2351663368	 58,06	 49,86	 35,43	 48,07	 43,4	
	 2351663369	 61,35	 62,79	 58,71	 42,88	 50	
	 2351663370	 32,78	 -152,6	 25,28	 -22,97	 21,43	
	 2351663371	 74,09	 -749	 68,7	 51,89	 64,15	
	 2351663372	 68,22	 70,28	 58,35	 49,68	 67,86	
	 2351663373	 -1,833	 16,23	 13,72	 -18,55	 27,38	
	 2351663375	 17,5	 32,62	 29,53	 18,4	 18,87	
	 2351663376	 -33,79	 -1,764	 12,18	 -27,04	 -12,14	
	 2351663378	 9,553	 -12,88	 21,18	 32,62	 28,57	
	 2351663379	 10,56	 39,72	 41,34	 28,51	 37,74	
	 2351663381	 61,42	 43,43	 42,42	 42,81	 65,25	
	 2351663388	 -3,889	 55,27	 24,61	 17,68	 30,19	
	 2351663390	 21,55	 -34,19	 40,58	 37,25	 40,95	
	 2351663391	 -71,43	 -24,95	 5,966	 -56,34	 8,571	
	 2351663393	 66,1	 66,6	 53,16	 39,87	 88,1	
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2-PCSK9-inhibition:	cardiovascular	and	endocrine	scope.		
	
Proprotein	convertase	subtilisin	kexin	type	9	(PCSK9)	is	a	proteinase	K	belonging	to	the	
family	 of	 secretory	 proteases.	 Its	 major	 role	 is	 in	 the	 regulation	 of	 cholesterol	
homeostasis	 and,	 specifically,	 this	 protein	 drives	 LDL	 receptor	 (LDL-R)	 to	 lysosomal	
degradation	 in	 order	 to	 regulate	 plasma	 LDL-cholesterol	 (LDL-C).	 When	 mutated,	
PCSK9	 provokes	 hyperlipidemia	 and	 premature	 coronary	 artery	 disease	 (CAD)	 in	
humans.	Its	important	to	highlight	that	if	this	proporotein	is	absent	of	mutation,	it	lows	
LDL	levels	and	acts	as	protector	from	CAD.	As	therapy,	antibodies	have	recently	been	
approved	by	FDA	and	have	shown	to	be	impressive	efficient	in	lowering	LDL	levels,	in	
some	cases,	in	combination	with	statins.	Small	molecules	able	to	inhibit	PCSK9	are	now	
being	 studied.	 The	 expression	 of	 protein	 PCSK9	 is	 strictly	 regulated	 at	 level	 of	
transcription	and	post	transcription.	PCSK9	SI	is	a	phenotypic	module	employed	in	the	
identification	of	organic	molecules	able	to	inhibit	expression	of	this	protein	in	multiple	
cell	 systems	 (including	 human	 hepatoma	 cell	 lines	 Huh7,	 Hela	 cells	 and	 primary	
hepatocytes).	 In	 Lilly’s	 screen	 also	 all	 the	 compounds	 inhibiting	 PCSK9	 protein	
secretion	with	 no	 suppression	 of	 cell	 viability	 and	 Apo-A1	 protein	 secretion,	 will	 be	
considered	of	interest.	
	
	
	
Cmpd	 OIDD	ID	
Primary	SP	 Primary	CRC	
PCSK9	
AlphaLisa	
Huh7	SP	
PCSK9	Huh7	
Viability	
CellTiter-Glo	SP	
PCSK9	
AlphaLisa	
Huh7	CRC	
PCSK9	Huh7	
Viability	CellTiter	
Glo	CRC	
%Inhib@	
5mM	
%Inhib@	
5mM	
Rel	IC50	
(mM)	
Rel	IC50	
(mM)	
	 2351663277	 -1,304	 -3,942	 		 		
	 2351663279	 -34,93	 -0,5383	 		 		
	 2351663280	 -41,87	 -1,434	 		 		
	 2351663281	 -39,32	 -3,283	 		 		
	 2351663285	 -55,43	 0,4058	 		 		
	 2351663286	 -29,52	 -14,83	 		 		
Endocrine/Cardiovascular:	
PCSK9	Inhibition	
PCSK9	Alphalisa	
	Viabily	VellTiter-Glo	
	Huh7	
SP/CRC	
Primary	assays	
•  PCSK9	Alphalisa	Huh7	SP/CRC	(%	Inhibition/IC50)	
•  PCSK9	Viability	CellTiter-Glo	SP/CRC		(%	Inhibition/IC50)	
	
	
	
	 	 	 	 	 161		
Cmpd	 OIDD	ID	
Primary	SP	 Primary	CRC	
PCSK9	
AlphaLisa	
Huh7	SP	
PCSK9	Huh7	
Viability	
CellTiter-Glo	SP	
PCSK9	
AlphaLisa	
Huh7	CRC	
PCSK9	Huh7	
Viability	CellTiter	
Glo	CRC	
%Inhib@	
5mM	
%Inhib@	
5mM	
Rel	IC50	
(mM)	
Rel	IC50	
(mM)	
	 2351663287	 -38,66	 -7,866	 		 		
	 2351663288	 -25,54	 3,125	 		 		
	 2351663289	 -18,73	 0,5016	 		 		
	 2351663291	 -49,02	 -9,354	 		 		
	 2351663292	 -24,46	 -1,556	 		 		
	 2351663341	 -16,88	 6,037	 		 		
	 2351663342	 -25,61	 0,3128	 		 		
	 2351663343	 -6,146	 5,744	 		 		
	 2351663344	 -10,69	 3,458	 		 		
	 2351663345	 -38,92	 -1,07	 		 		
	 2351663348	 -32,28	 4,072	 		 		
	 2351663349	 -30,6	 2,449	 		 		
	 2351663350	 -8,828	 -5,803	 		 		
	 2351663368	 -63,61	 -1,31	 		 		
	 2351663369	 -29,34	 0,2424	 		 		
	 2351663370	 -16,36	 -14,18	 		 		
	 2351663371	 -9,555	 -1,093	 		 		
	 2351663372	 -24,59	 3,424	 		 		
	 2351663373	 -33,94	 -2,3	 		 		
	 2351663375	 -20,01	 -2,68	 		 		
	 2351663376	 -34,35	 0,6228	 		 		
	 2351663378	 -14,79	 1,733	 		 		
	 2351663379	 -17,89	 1,091	 		 		
	 2351663381	 -6,583	 -1,682	 		 		
	 2351663388	 -17,33	 -2,739	 		 		
	 2351663390	 -23,71	 -1,009	 		 		
	 2351663391	 -33,24	 -0,3974	 		 		
	 2351663393	 -28,86	 -5,535	 		 		
	 2351677024	 -74,09	 2,97	 		 		
	 2351677025	 75,6	 36,7	 		 		
	 2351677124	 31,39	 29,61	 		 		
	 2351677125	 -20,11	 32,61	 		 		
	 2351677126	 -2,254	 -6,219	 		 		
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Cmpd	 OIDD	ID	
Primary	SP	 Primary	CRC	
PCSK9	
AlphaLisa	
Huh7	SP	
PCSK9	Huh7	
Viability	
CellTiter-Glo	SP	
PCSK9	
AlphaLisa	
Huh7	CRC	
PCSK9	Huh7	
Viability	CellTiter	
Glo	CRC	
%Inhib@	
5mM	
%Inhib@	
5mM	
Rel	IC50	
(mM)	
Rel	IC50	
(mM)	
	 2351677128	 44,66	 23,81	 		 		
	 2351677148	 -44,62	 -2,247	 		 		
	 2351677149	 -41,39	 1,303	 		 		
	 2351677151	 -64,93	 3,32	 		 		
	 2351677152	 -52,35	 4,029	 		 		
	 2351677153	 -40,78	 3,89	 		 		
	 2351677271	 -58,4	 0,1916	 		 		
	 2351677274	 -74,57	 42,27	 		 		
	 2351677276	 -33,54	 -5,759	 		 		
	 2351677278	 -36,98	 -8,298	 		 		
	 2351677280	 22,03	 24,56	 		 		
	 2351677282	 46,05	 28,8	 		 		
	 2351677284	 -39,45	 -15,64	 		 		
	 2351677286	 -68,69	 -2,654	 		 		
	 2351677287	 74,23	 30,62	 		 		
	 2351677289	 -19,5	 -12,25	 		 		
	 2351677290	 37,68	 27,44	 		 		
	 2351677291	 44,83	 35,53	 		 		
	 2351677292	 -73,44	 19,76	 		 		
	 2351677293	 -47,19	 6,961	 		 		
	 2351677294	 75,65	 21,82	 30,43	 >40.0	
	 2351677295	 -67,26	 -6,597	 		 		
	 2351677296	 -37,78	 31,48	 		 		
	 2351677304	 -101,6	 30,4	 		 		
	 2351692808	 -65,82	 36,08	 		 		
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Compound	 OIDD	ID	
Primary	SP	
hPCSK9	Huh7	TT	Inhib	SP	
%Inhib@	
40mM	
	 2351663277	 49,06	
	 2351663279	 39,62	
	 2351663280	 7,541	
	 2351663281	 73,58	
	 2351663285	 72,46	
	 2351663286	 8,571	
	 2351663287	 29,76	
	 2351663288	 -3,39	
	 2351663289	 20,24	
	 2351663291	 94,34	
	 2351663292	 77,36	
	 2351663341	 12,86	
	 2351663342	 -2,857	
	 2351663343	 28,3	
	 2351663344	 -2,143	
	 2351663345	 40,48	
	 2351663348	 98,11	
	 2351663349	 8,571	
	 2351663350	 94,75	
	 2351663368	 43,4	
	 2351663369	 50	
	 2351663370	 21,43	
	 2351663371	 64,15	
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	 2351663372	 67,86	
	 2351663373	 27,38	
	 2351663375	 18,87	
	 2351663376	 -12,14	
	 2351663378	 28,57	
	 2351663379	 37,74	
	 2351663381	 65,25	
	 2351663388	 30,19	
	 2351663390	 40,95	
	 2351663391	 8,571	
	 2351663393	 88,1	
	
3-Arginase:	oncology	scope.	
	
Arginase	 is	 an	 enzyme	 placed	 in	 the	 intracellular	 space.	 Its	 role	 is	 to	 hydrolyse	 L-
arginine	to	ornithine	and	urea.	The	Arginase	isoenzymes	are	characteristic	of	mammals	
and	 their	 difference	 is	 related	 in	 their	 location:	 ARG1	 is	 cytoplasmic	 and	 RG2	 is	
mitochondrial.	The	major	activity	of	Arginase	is	at	the	level	of	immune	response.	When	
high	ARG1	 levels	are	detected,	 its	activity	 is	expressed	 in	both	M2	macrophages	and	
myeloid-derived	 suppressor	 cells	 (MDSC).	 The	 reason	 why	 Arginase	 is	 a	 target	 of	
interest	 for	 oncology	 is	 to	 stimulate	 the	 same	 immune	 system	 when	 used	 in	
combination	with	checkpoint	inhibitors.	
	
	
	
Compound	 OIDD	ID	
Primary	SP	
hARG1	MassSpec_No	Metal	or	BSA_384	SP	
%Inhib@100mM	
	 2351663277	 35,49	
	 2351663279	 13,92	
	 2351663280	 28,12	
	 2351663281	 		
	 2351663285	 38,23	
	 2351663286	 22,64	
Oncology:	
Arginase	Inhibition	
•  hArginase	LC-MS	SP	
•  hArginase	LC-MC	CRC	
Primary	assays	
•  Human	Arginase	LC-MS	SP	(%	Inhibition)	
•  Human	Arginase	LC-MC	CRC	(%	Inhibition)	
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Compound	 OIDD	ID	
Primary	SP	
hARG1	MassSpec_No	Metal	or	BSA_384	SP	
%Inhib@100mM	
	 2351663287	 19,64	
	 2351663288	 49,65	
	 2351663289	 10,04	
	 2351663291	 40,61	
	 2351663292	 56,65	
	 2351663341	 3,496	
	 2351663342	 16,58	
	 2351663343	 		
	 2351663344	 6,946	
	 2351663345	 7,179	
	 2351663348	 0,9942	
	 2351663349	 		
	 2351663350	 35,76	
	 2351663368	 31,4	
	 2351663369	 		
	 2351663370	 12,18	
	 2351663371	 17	
	 2351663372	 -0,4162	
	 2351663373	 25,57	
	 2351663375	 14,46	
	 2351663376	 7,302	
	 2351663378	 6,174	
	 2351663379	 26,67	
	 2351663381	 -11,53	
	 2351663388	 10,17	
	 2351663390	 2,035	
	 2351663391	 13,64	
	 2351663393	 1,875	
	 2351677024	 15,31	
	 2351677025	 8,392	
	 2351677124	 3,589	
	 2351677125	 -13,11	
	 2351677126	 -13,09	
	 2351677128	 16,84	
	 2351677148	 17,57	
	 2351677149	 40,15	
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Compound	 OIDD	ID	
Primary	SP	
hARG1	MassSpec_No	Metal	or	BSA_384	SP	
%Inhib@100mM	
	 2351677151	 49,08	
	 2351677152	 52,24	
	 2351677153	 37,48	
	 2351677271	 15,57	
	 2351677274	 0,9057	
	 2351677276	 1,341	
	 2351677278	 -7,016	
	 2351677280	 55,32	
	 2351677282	 14,6	
	 2351677284	 -15,7	
	 2351677286	 3,211	
	 2351677287	 -1,025	
	 2351677289	 73,1	
	 2351677290	 52,97	
	 2351677291	 50,19	
	 2351677292	 83,03	
	 2351677293	 47,43	
	 2351677294	 32,46	
	 2351677295	 54,43	
	 2351677296	 52,46	
	 2351677304	 27,6	
	 2351692808	 30,56	
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4-IL-17	Protein	Protein	Interaction:	immunology	and	inflammation	scope.	
	
IL-17A	 is	 an	proinflammatory	 cytokine	produced	by	activated	T	 cells	 (a	 subset	 called	
Th17)	 at	 inflammatory	 site.	 This	 IL	 acts	 in	 three	 different	 manners:	 first,	 as	 host	
defense	against	extracellular	bacteria	and	 fungi;	 secondly,	as	promoter	of	neutrophil	
homeostasis;	thirdly,	 it	has	a	role	in	the	chronic	pathogenic	inflammation.	The	IL-17A	
can	exists	as	a	homodimer	A/A	or	heterodimer	A/F	with	IL-17F.	Cells	able	to	respond	to	
the	local	production	of	IL-17A	are	that	ones	that	express	the	IL-17A	receptors	(IL-17RC	
and	IL-17RC).	Its	mechanism	is	to	stimulate	the	cytokine	and	chemokine	cascade	that	
are	 able	 to	 recruit	 and	 activate	 neutrophils	 and	 memory	 T	 cells	 to	 maintain	 a	
proinflammatory	 state.	 In	 some	 cases,	 IL-17A	 produce	 pathogenic	 T	 cells	 which	 are	
responsible	 of	 pathogenesis	 and	 autoimmune	 diseases	 (psoriasis,	 psoriatic	 arthritis,	
rheumatoid	arthritis	and	anklyosing	spondylitis).	Efficient	treatment	for	patients	with	
plaques	psoriasis	is,	demonstrated,	the	employment	of	neutralizing	antibodies.	
In	 Lilly	 assay	 is	 evaluated	 the	 ability	 of	 our	molecules	 to	 inhibit	 the	 protein-protein	
interaction	in	order	to	avoid	the	dimer	formation	A/A	or	A/F.	
	
	
	
Compound	 OIDD	ID	
Primary	SP	 Primary	CRC	
IL-17A	AlphaLisa	SP	 IL-17A	AlphaLisa	CRC	
%Inhib@100mM	 Abs	IC50	(mM)	
	 2351663277	 62,34	 		
	 2351663279	 36,1	 		
	 2351663280	 3,144	 		
	 2351663281	 45,49	 		
	 2351663285	 4,259	 		
	 2351663286	 38,39	 		
	 2351663287	 15,15	 		
	 2351663288	 40,43	 		
	 2351663289	 28,46	 		
	 2351663291	 32,44	 		
	 2351663292	 63,57	 		
Autoimmune:	
IL-17A	
•  IL-17A	Alphalisa	SP	
•  IL-17A	Alphalisa		
IL	17_IL17R	TR-FRET	CRC	
Primary	assays	
•  IL-17A	Alphalisa	SP/CRC	(%	Inhibition/IC50)	
•  IL-17_IL17R	TR-FRET	Inhibition	CRC	(IC50)	
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Compound	 OIDD	ID	
Primary	SP	 Primary	CRC	
IL-17A	AlphaLisa	SP	 IL-17A	AlphaLisa	CRC	
%Inhib@100mM	 Abs	IC50	(mM)	
	 2351663341	 49,46	 		
	 2351663342	 24,26	 		
	 2351663343	 51,77	 		
	 2351663344	 15,96	 		
	 2351663345	 73,53	 37,95	
	 2351663348	 73,89	 40,37	
	 2351663349	 31,93	 		
	 2351663350	 67,28	 		
	 2351663368	 65,44	 		
	 2351663369	 74,04	 35,62	
	 2351663370	 69,49	 		
	 2351663371	 71	 55,93	
	 2351663372	 49,27	 		
	 2351663373	 11,2	 		
	 2351663375	 18,2	 		
	 2351663376	 50,78	 		
	 2351663378	 31,38	 		
	 2351663379	 48,96	 		
	 2351663381	 24,61	 		
	 2351663388	 39,19	 		
	 2351663390	 36,31	 		
	 2351663391	 49,55	 		
	 2351663393	 29,43	 		
	 2351677024	 47,33	 		
	 2351677025	 76,06	 45,77	
	 2351677124	 -17,63	 		
	 2351677125	 -1,197	 		
	 2351677126	 36,34	 		
	 2351677128	 34,17	 		
	 2351677148	 13,6	 		
	 2351677149	 22,2	 		
	 2351677151	 7,943	 		
	 2351677152	 23,07	 		
	 2351677153	 14,69	 		
	 2351677271	 67,03	 		
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Compound	 OIDD	ID	
Primary	SP	 Primary	CRC	
IL-17A	AlphaLisa	SP	 IL-17A	AlphaLisa	CRC	
%Inhib@100mM	 Abs	IC50	(mM)	
	 2351677274	 32,54	 		
	 2351677276	 -6,638	 		
	 2351677278	 -0,7617	 		
	 2351677280	 37,87	 		
	 2351677282	 16,32	 		
	 2351677284	 24,37	 		
	 2351677286	 0,9793	 		
	 2351677287	 26,44	 		
	 2351677289	 55,71	 		
	 2351677290	 46,35	 		
	 2351677291	 67,9	 		
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5-GPR120	Agonist:	endocrine	and	cardiovascular	scope.	
	
GPR120	 is	 a	 receptor	 for	 long-chain	 fatty	 acids,	 Omega-3	 included.	 Its	 expression	 is	
related	 in	 all	 the	 tissues	 affected	 by	 metabolic	 disease	 and	 diabetes,	 including	
pancreas,	adipose	tissue,	gastrointestinal	tract	and	the	pituitary	gland.	When	GPR120	
is	 activated	 it	 acts	 with	 the	 important	 role	 to	 regulate	 body	 weight	 and	 glucose	
homeostasis.	For	example	in	human	the	R270H	mutation	of	GPR120	is	correlated	with	
obesity	and	high	glucose	levels.	GPR120	knockout	mice	are	obese	and	insulin	resistant		
and	intolerant	to	glucose.	 In	recent	years	have	been	discovered	small	molecules	able	
to	 act	 as	 GPR120	 agonists	 and	 so	 able	 to	 low	 glucose	 levels,	 improving	 insulin	
sensitivity	 and	 reduction	 the	 inflammation	 in	 obese	 people.	 For	 this	 reason,	 the	
activation	of	 this	 receptor	 is	 seen	as	a	new	 frontier	 in	 the	 treatment	of	 this	 class	of	
diseases.	
Lilly	 assay	 is	 made	 in	 HEK293	 cell-line	 that	 are	 human	 embryonic	 kidney.	 Calcium	
mobilization	 FLIPR	 test	 is	 able	 to	 determine	 concentration-depending	 changes	 of	
calcium	 levels	 through	 a	 fluorescent	 detection.	 More	 exactly,	 calcium-extracellular	
level	is	evaluated.	
	
	
	
	
	
	
	
Endocrine/Cardiovascular:	
GPR120	Agonist	
Primary	assays:	
•  hGPR120,	Calcium	Mobilization	FLIPR,	HEK293	Clone	22,	SP	(%	Inhibition)		
•  Calcium	Mobilization	FLIPR,	HEK293	un-transfected,	SP	(%	Inhibition)	
•  hGPR120,	Calcium	Mobilization	FLIPR,	HEK293	cells,	Clone	20/22	cells,	CRC	(IC50)		
	
	
Secondary	assays:	
•  hGPR40,	hGPR120,	Calcium	Mobilization	FLIPR,	HEK293	cells,	CRC	(IC50)		
•  FFAR	selectivity,	CRC	(IC50)	
•  mGPR120,	Receptor	Binding,	CRC	(IC50)		
•  hGPR120	FLIPR	HEK293	SP	
•  	hGPR120	FLIPR	HEK293	Clone	22/20	CRC		
•  hGPR40	FLIPR	HEK293	CRC	
•  	FFAR	selectivity	panel		
•  mGRP120	Receptor	Binding	HEK293		
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Cmpd	 OIDD	ID	
Primary	SP	 Primary	CRC	 Secondary	
hGPR120	Clone	
22	Ca	Moblzn	
Ag	SP	
HEK293	Ca	
Moblzn	Ag	
SP	
hGPR120	Clone	
20	Ca	Moblzn	
Ag	CRC	
mGPR120	Clone	
24	Ca	Moblzn	
Ag	CRC	
%Stim@	
30mM	
%Stim@	
30mM	
Rel	EC50	
(mM)	
Rel	EC50	
(mM)	
	 2351663277	 7,064	 		 		 		
	 2351663279	 0,3347	 		 		 		
	 2351663280	 0,7606	 		 		 		
	 2351663281	 0,3955	 		 		 		
	 2351663285	 0,9431	 		 		 		
	 2351663286	 -0,213	 		 		 		
	 2351663287	 0,3955	 		 		 		
	 2351663288	 1,917	 		 		 		
	 2351663289	 20,35	 		 		 		
	 2351663291	 2,221	 		 		 		
	 2351663292	 0,03042	 		 		 		
	 2351663341	 1,917	 		 		 		
	 2351663342	 0,3955	 		 		 		
	 2351663343	 1,1	 		 		 		
	 2351663344	 0,4563	 		 		 		
	 2351663345	 13,17	 		 		 		
	 2351663348	 14,21	 		 		 		
	 2351663349	 0,03042	 		 		 		
	 2351663350	 1,065	 		 		 		
	 2351663368	 0,6997	 		 		 		
	 2351663369	 28,81	 		 		 		
	 2351663370	 3,803	 		 		 		
	 2351663371	 0,4563	 		 		 		
	 2351663372	 4,837	 		 		 		
	 2351663373	 1,065	 		 		 		
	 2351663375	 7,758	 		 		 		
	 2351663376	 0,6389	 		 		 		
	 2351663378	 3,438	 		 		 		
	 2351663379	 0,9431	 		 		 		
	 2351663381	 1,917	 		 		 		
	 2351663388	 0,3955	 		 		 		
	 2351663390	 0,8823	 		 		 		
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Cmpd	 OIDD	ID	
Primary	SP	 Primary	CRC	 Secondary	
hGPR120	Clone	
22	Ca	Moblzn	
Ag	SP	
HEK293	Ca	
Moblzn	Ag	
SP	
hGPR120	Clone	
20	Ca	Moblzn	
Ag	CRC	
mGPR120	Clone	
24	Ca	Moblzn	
Ag	CRC	
%Stim@	
30mM	
%Stim@	
30mM	
Rel	EC50	
(mM)	
Rel	EC50	
(mM)	
	 2351663391	 0,1521	 		 		 		
	 2351663393	 1,004	 		 		 		
	 2351677024	 3,653	 		 		 		
	 2351677025	 4,566	 		 		 		
	 2351677124	 -1,37	 		 		 		
	 2351677125	 -5,023	 		 		 		
	 2351677126	 7,763	 		 		 		
	 2351677128	 9,589	 		 		 		
	 2351677148	 10,5	 		 		 		
	 2351677149	 2,74	 		 		 		
	 2351677151	 3,653	 		 		 		
	 2351677152	 -2,74	 		 		 		
	 2351677153	 5,479	 		 		 		
	 2351677271	 3,196	 		 		 		
	 2351677274	 3,196	 		 		 		
	 2351677276	 10,5	 		 		 		
	 2351677278	 -3,653	 		 		 		
	 2351677280	 0	 		 		 		
	 2351677282	 -10,96	 		 		 		
	 2351677284	 5,936	 		 		 		
	 2351677286	 -3,196	 		 		 		
	 2351677287	 4,11	 		 		 		
	 2351677289	 -0,9132	 		 		 		
	 2351677290	 14,16	 		 		 		
	 2351677291	 0,4566	 		 		 		
	 2351677292	 -7,763	 		 		 		
	 2351677293	 1,826	 		 		 		
	 2351677294	 -1,826	 		 		 		
	 2351677295	 2,74	 		 		 		
	 2351677296	 10,96	 		 		 		
	 2351677304	 7,306	 		 		 		
	
2351692808	 73,52	 0	
>100.0	
EC50	is	not	
>100.0	
EC50	is	not	
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Cmpd	 OIDD	ID	
Primary	SP	 Primary	CRC	 Secondary	
hGPR120	Clone	
22	Ca	Moblzn	
Ag	SP	
HEK293	Ca	
Moblzn	Ag	
SP	
hGPR120	Clone	
20	Ca	Moblzn	
Ag	CRC	
mGPR120	Clone	
24	Ca	Moblzn	
Ag	CRC	
%Stim@	
30mM	
%Stim@	
30mM	
Rel	EC50	
(mM)	
Rel	EC50	
(mM)	
reached	till	
100mM	
reached	till	
100mM	
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Compound	 OIDD	ID	
Primary	SP	
hPCSK9	Huh7	TT	Inhib	SP	
%Inhib@40mM	
	 2351663277	 49,06	
	 2351663279	 39,62	
	 2351663280	 7,541	
	 2351663281	 73,58	
	 2351663285	 72,46	
	 2351663286	 8,571	
	 2351663287	 29,76	
	 2351663288	 -3,39	
	 2351663289	 20,24	
	 2351663291	 94,34	
	 2351663292	 77,36	
	 2351663341	 12,86	
	 2351663342	 -2,857	
	 2351663343	 28,3	
	 2351663344	 -2,143	
	 2351663345	 40,48	
	 2351663348	 98,11	
	 2351663349	 8,571	
	 2351663350	 94,75	
	 2351663368	 43,4	
	 2351663369	 50	
	 2351663370	 21,43	
	 2351663371	 64,15	
	 2351663372	 67,86	
	 2351663373	 27,38	
	 2351663375	 18,87	
	 2351663376	 -12,14	
	 2351663378	 28,57	
	 2351663379	 37,74	
	 2351663381	 65,25	
	 2351663388	 30,19	
	 2351663390	 40,95	
	 2351663391	 8,571	
	 2351663393	 88,1	
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6-Tuberculosis	 (TB):	 is	 an	 infectious	 disease	 caused	 by	Mycobacterium	 tuberculosis	
(MTB)	bacteria	and	generally	affects	the	lungs.	In	the	Lilly’s	screen	is	tested	the	ability	
ot	 new	 compounds	 to	 prevent	 the	 growth	 of	 a	 virulent	 strain	 of	 Mycobacterium	
tuberculosis	(H37Rv)	in	liquid	medium.	More	specifically,	the	primary	assay	tests,	at	a	
single	concentration,	compound	by	their	inhibition	against	a	genetically-modified	and	
fluorescent	reporter	strain	of	the	bacteria.		
	
	
	
Compound	 OIDD	ID	
Primary	SP	
TB	MIC	SP	IDRI	OIDD	
%Inhib@20mM	
	
2351663277	
15.3	
5.5	
	
2351663279	
2.2	
-16.7	
	
2351663280	
7.0	
-0.8	
	
2351663281	
2.7	
0.2	
	
2351663285	
11.5	
2.9	
	
2351663286	
6.3	
-6.3	
	
2351663287	
10.0	
-1.7	
	
2351663288	
-2.7	
-9.5	
	
2351663289	
1.2	
4.4	
	
2351663291	
10.0	
10.5	
	
2351663292	
72.7	
74.3	
Tuberculosis-	
Primary	assays:	
Whole	cellular	activity	H37Rv	cells	at	SP	(%	Inhibition)	
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Compound	 OIDD	ID	
Primary	SP	
TB	MIC	SP	IDRI	OIDD	
%Inhib@20mM	
	
2351663341	
4.5	
5.5	
	
2351663342	
3.8	
6.1	
	
2351663343	
3.6	
-15.8	
	
2351663344	
3.3	
3.8	
	
2351663345	
2.2	
0.8	
	
2351663348	
1.6	
-1.3	
	
2351663349	
4.9	
3.9	
	
2351663350	
22.3	
15.8	
	
2351663368	
11.8	
6.9	
	
2351663369	
26.6	
5.0	
	
2351663370	
-9.2	
-5.4	
	
2351663371	
2.5	
3.5	
	
2351663372	
4.7	
4.7	
	
2351663373	
6.1	
2.3	
	
2351663375	
9.7	
6.3	
	
2351663376	
5.2	
4.3	
	
2351663378	
4.1	
0.7	
	
2351663379	
2.3	
-17.2	
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Compound	 OIDD	ID	
Primary	SP	
TB	MIC	SP	IDRI	OIDD	
%Inhib@20mM	
	
2351663381	
20.9	
20.0	
	
2351663388	
5.2	
0.8	
	
2351663390	
5.6	
3.4	
	
2351663391	
3.3	
2.2	
	
2351663393	
13.9	
6.9	
	
2351677024	
4.9	
-8.1	
	
2351677025	
-0.9	
-0.9	
	
2351677124	
9.4	
5.1	
	
2351677125	
10.9	
-2.1	
	
2351677126	
9.4	
9.8	
	
2351677128	
11.1	
8.8	
	
2351677148	
-1.9	
-8.5	
	
2351677149	
11.5	
5.8	
	
2351677151	
8.3	
11.5	
	
2351677152	
2.6	
2.8	
	
2351677153	
6.4	
-4.4	
	
2351677271	
1.1	
6.2	
	
2351677274	
8.7	
12.0	
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Compound	 OIDD	ID	
Primary	SP	
TB	MIC	SP	IDRI	OIDD	
%Inhib@20mM	
	
2351677276	
7.2	
15.3	
	
2351677278	
4.4	
-3.3	
	
2351677280	
11.1	
14.0	
	
2351677282	
4.2	
-9.4	
	
2351677284	
7.4	
11.1	
	
2351677286	
-15.2	
0.5	
	
2351677287	
10.7	
-0.6	
	
2351677289	
12.6	
-2.7	
	
2351677290	
4.4	
-1.0	
	
2351677291	
7.6	
0.2	
	
2351677292	
21.4	
15.3	
	
2351677293	
10.4	
-0.8	
	
2351677294	
5.8	
-7.2	
	
2351677295	
12.6	
-4.8	
	
2351677296	
12.0	
3.9	
	
2351677304	
13.4	
4.2	
	
2351692808	
12.0	
-7.2	
	 2351786662	 2,46	
	 2351786663	 -4,15	
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Compound	 OIDD	ID	
Primary	SP	
TB	MIC	SP	IDRI	OIDD	
%Inhib@20mM	
	 2351786664	 -1,22	
	 2351786669	 -1,58	
	 2351786670	 5,23	
	 2351786671	 5,76	
	 2351791156	 3,73	
	 2351798652	 0,62	
	 2351798653	 -0,48	
	 2351798654	 3,56	
	 2351798655	 -1,22	
	 2351798657	 6,5	
	 2351798658	 0,99	
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7-Leishmania:	Leishmania	parasite	is	the	responsible	of	the	so-called	kala-azar	disease.		
The	 global	 disease	 reported	 by	Neglected	 Tropical	 Diseases	 (NTDs)	 is	 always	 higher.	
The	World	Health	Organization	(WHO)	reports	that	half	a	billion	people	are	at	risk	of	
contracting	 Chagas	 disease,	 African	 trypanosomiasis	 and	 several	 different	 forms	 of	
lehismaniasis	(almost	20	million	persons	are	infected	and	every	year	a	number	around	
95	 thousands	 deaths	 are	 registered).	 Kinetoplastid	 therapies	 are	 far	 from	 being	
efficient	 and	 safe.	 In	 2012	 these	 three	 diseases	 have	 been	 included	 in	 the	 London	
Declaration	of	private	and	public	partners	 to	 focus	 the	attention	 in	10	NTDs,	as	new	
perspective	for	WHO.	
The	disease	 is	presented	with	 cutaneous,	mucocutaneous	or	 visceral	manifestations.	
The	 parasites	 are	 flagellated	 protozoans	 and	 are	 characterized	 by	 the	 presence	 of	 a	
DNA-containing	 region	 called	 kinetoplast	 in	 the	 mitochondrion	 (only	 one	 present).	
When	 hosted	 in	 a	 vehicle	 they	 undergo	 morphological	 changes	 during	 their	 all	 life	
cycle.	 Its	 genomes	 encode	 for	 several	 proteins	 that	 are	 not	 contained	 in	 human	
proteome.	For	this	reason	researcher	think	about	the	possibility	to	identify	and	target	
this	different	proteins	in	order	to	find	a	more	efficient	therapy.	
In	Lilly	assay	is	tested	and	so	evaluated	the	ability	to	inhibit	the	growth	of	the	parasite.	
	
	
	
Compound	 OIDD	ID	
Primary	SP	 Primary	CRC	
Viability	L.	
donovani	
Cytotox	SP		
NV-
Basal_Viabilit
y	L.	donovani	
Cytotox	CRC	
Tres	Cantos	
NV-L.	
donovani	
THP-1	FBS	
Dead	Cells	
CRC	Tres	
Cantos	
NV-L.	
donovani	
THP-1	FBS	
Parasites	
per	Cell	CRC	
Tres	Cantos	
NV-L.	
donovani	
THP-1	FBS	
Infected	
Cells	CRC	
Tres	Cantos	
%Inhib@	
5uM	
pIC50	
(M)	
pIC50	
(M)	
pIC50	
(M)	
pIC50	
(M)	
	 235166327
7	
1,78	 		 		 		 		
	 235166327
9	
-18,9	 		 		 		 		
	 235166328
0	
-5,27	 		 		 		 		
Leishmania-	
Primary	assays:	
•  L.donovani	Axenic	Assay	growth	Inhibition	SP/CRC	(%	Inhibition/IC50)	
•  L.donovani	Imaging	CRC,	infected	THP-1	macrophage	intracellular	Imaging	assay.	
•  HepG2	cytotoxicity	Assay	CRC	(IC50).	
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Compound	 OIDD	ID	
Primary	SP	 Primary	CRC	
Viability	L.	
donovani	
Cytotox	SP		
NV-
Basal_Viabilit
y	L.	donovani	
Cytotox	CRC	
Tres	Cantos	
NV-L.	
donovani	
THP-1	FBS	
Dead	Cells	
CRC	Tres	
Cantos	
NV-L.	
donovani	
THP-1	FBS	
Parasites	
per	Cell	CRC	
Tres	Cantos	
NV-L.	
donovani	
THP-1	FBS	
Infected	
Cells	CRC	
Tres	Cantos	
%Inhib@	
5uM	
pIC50	
(M)	
pIC50	
(M)	
pIC50	
(M)	
pIC50	
(M)	
	 235166328
1	
-0,07	 		 		 		 		
	 235166328
5	
13,04	 		 		 		 		
	 235166328
6	
-7,76	 		 		 		 		
	 235166328
7	
-0,65	 		 		 		 		
	 235166328
8	
23,01	 		 		 		 		
	 235166328
9	
10,97	 		 		 		 		
	 235166329
1	
95,99	
4.43	
4.43	
<4.3	
4.34	
<4.3	
<4.3	
<4.3	
<4.3	
	 235166329
2	
-5,86	 		 		 		 		
	 235166334
1	
12,62	 		 		 		 		
	 235166334
2	
-34,84	 		 		 		 		
	 235166334
3	
-23,89	 		 		 		 		
	 235166334
4	
10,71	 		 		 		 		
	 235166334
5	
0,88	 		 		 		 		
	 235166334
8	
-42,27	 		 		 		 		
	 235166334
9	
7,31	 		 		 		 		
	 235166335 -12,45	 		 		 		 		
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Compound	 OIDD	ID	
Primary	SP	 Primary	CRC	
Viability	L.	
donovani	
Cytotox	SP		
NV-
Basal_Viabilit
y	L.	donovani	
Cytotox	CRC	
Tres	Cantos	
NV-L.	
donovani	
THP-1	FBS	
Dead	Cells	
CRC	Tres	
Cantos	
NV-L.	
donovani	
THP-1	FBS	
Parasites	
per	Cell	CRC	
Tres	Cantos	
NV-L.	
donovani	
THP-1	FBS	
Infected	
Cells	CRC	
Tres	Cantos	
%Inhib@	
5uM	
pIC50	
(M)	
pIC50	
(M)	
pIC50	
(M)	
pIC50	
(M)	
0	
	 235166336
8	
1,64	 		 		 		 		
	 235166336
9	
-0,04	 		 		 		 		
	 235166337
0	
-6,37	 		 		 		 		
	 235166337
1	
7,45	 		 		 		 		
	 235166337
2	
-10,65	 		 		 		 		
	 235166337
3	
-11,54	 		 		 		 		
	 235166337
5	
10,8	 		 		 		 		
	 235166337
6	
3,72	 		 		 		 		
	 235166337
8	
-5,2	 		 		 		 		
	 235166337
9	
12,84	 		 		 		 		
	 235166338
1	
-17	 		 		 		 		
	 235166338
8	
-12,63	 		 		 		 		
	 235166339
0	
-8,93	 		 		 		 		
	 235166339
1	
-4,91	 		 		 		 		
	 235166339
3	
5,42	 		 		 		 		
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Compound	 OIDD	ID	
Primary	SP	 Primary	CRC	
Viability	L.	
donovani	
Cytotox	SP		
NV-
Basal_Viabilit
y	L.	donovani	
Cytotox	CRC	
Tres	Cantos	
NV-L.	
donovani	
THP-1	FBS	
Dead	Cells	
CRC	Tres	
Cantos	
NV-L.	
donovani	
THP-1	FBS	
Parasites	
per	Cell	CRC	
Tres	Cantos	
NV-L.	
donovani	
THP-1	FBS	
Infected	
Cells	CRC	
Tres	Cantos	
%Inhib@	
5uM	
pIC50	
(M)	
pIC50	
(M)	
pIC50	
(M)	
pIC50	
(M)	
	 235167702
4	
-3,56	 		 		 		 		
	 235167702
5	
3,56	 		 		 		 		
	 235167712
4	
-4,87	 		 		 		 		
	 235167712
5	
-0,36	 		 		 		 		
	 235167712
6	
-0,26	 		 		 		 		
	 235167712
8	
-1,66	 		 		 		 		
	 235167714
8	
4,58	 		 		 		 		
	 235167714
9	
10,57	 		 		 		 		
	 235167715
1	
8,4	 		 		 		 		
	 235167715
2	
6,52	 		 		 		 		
	 235167715
3	
0,03	 		 		 		 		
	 235167727
1	
4,25	 		 		 		 		
	 235167727
4	
-23,18	 		 		 		 		
	 235167727
6	
-13,84	 		 		 		 		
	 235167727
8	
-4,38	 		 		 		 		
	 235167728 0,41	 		 		 		 		
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Compound	 OIDD	ID	
Primary	SP	 Primary	CRC	
Viability	L.	
donovani	
Cytotox	SP		
NV-
Basal_Viabilit
y	L.	donovani	
Cytotox	CRC	
Tres	Cantos	
NV-L.	
donovani	
THP-1	FBS	
Dead	Cells	
CRC	Tres	
Cantos	
NV-L.	
donovani	
THP-1	FBS	
Parasites	
per	Cell	CRC	
Tres	Cantos	
NV-L.	
donovani	
THP-1	FBS	
Infected	
Cells	CRC	
Tres	Cantos	
%Inhib@	
5uM	
pIC50	
(M)	
pIC50	
(M)	
pIC50	
(M)	
pIC50	
(M)	
0	
	 235167728
2	
-3,5	 		 		 		 		
	 235167728
4	
-16,03	 		 		 		 		
	 235167728
6	
0,26	 		 		 		 		
	 235167728
7	
5,37	 		 		 		 		
	 235167728
9	
4,17	 		 		 		 		
	 235167729
0	
-17,67	 		 		 		 		
	 235167729
1	
2,82	 		 		 		 		
	 235167729
2	
-11,71	 		 		 		 		
	 235167729
3	
-34,98	 		 		 		 		
	 235167729
4	
5,77	 		 		 		 		
	 235167729
5	
-31,07	 		 		 		 		
	 235167729
6	
-6,36	 		 		 		 		
	 235167730
4	
2,21	 		 		 		 		
	 235169280
8	
-9,38	 		 		 		 		
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8-Chagas	Disease:	known	as	American	trypanosomiasis,	is	a	tropical	parasitic	disease.	
Spread	 by	 blood-sucking	 insects	 called	 Triatominae	 or	 kissing	 bug.	 Symptoms	 are	
different	 during	 the	 infection:	 at	 the	 begining	 no	 or	 mild	 symptoms	 as	 fever,	 are	
shown.	 At	 the	 stage	 of	 8-12	 weeks	 the	 chronic	 phase	 is	 detected.	 In	 the	 succesive	
cases	 two	 different	 behaviours	 can	 be	 presented:	 for	 the	 60-70%	 of	 the	 cases	 the	
patient	never	presents	 the	 symptoms,	 and	on	 the	other	 side,	 the	 resting	30-40%	sill	
develop	further	symptoms	in	the	next	10-30	years.	
	
	
	
Cmpd	 OIDD	ID	
Primary	SP	
T.cruzi	
Growth	
Inhibitio
n	SP	
NV-
Basal_Viab
ility	T.cruzi	
CTG	Inhib	
SP	Tres	
Cantos	
NV-T.cruzi	
myocardioc
yte	Dead	
Cells	SP	Tres	
Cantos	
NV-T.cruzi	
myocardiocy
te	Parasites	
per	Cell	SP	
Tres	Cantos	
NV-T.cruzi	
myocardiocy
te	Infected	
Cells	SP	Tres	
Cantos	
%Inhib
@	
5mM	
%Inhib@	
5mM	
%Inhib@	
5mM	
%Inhib@	
5NA	
%Inhib@	
5mM	
	 2351663277	 6,03	 		 		 		 		
	
2351663279	
2.3	
2.3	
		 		 		 		
	
2351663280	
-20.78	
-20.78	
		 		 		 		
	 2351663281	 6,79	 		 		 		 		
	 2351663285	 9,76	 		 		 		 		
	 2351663286	 3,88	 		 		 		 		
	 2351663287	 5,32	 		 		 		 		
	
2351663288	
9.36	
9.36	
		 		 		 		
	
2351663289	
8.03	
8.03	
		 		 		 		
Chagas	Disease-	
Primary	assays:	
•  T.	cruzi	NIH-3T3	growth	inhibition	assay	SP/CRC	(%	Inhibition/IC50)		
•  T.	cruzi	H9C2	intracellular	Imaging	assay	CRC	(IC50)		
•  Trypomastigote	luciferin-based	assay	(IC50)	
•  HepG2	cytotoxicity	Assays	CRC	(IC50)		
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Cmpd	 OIDD	ID	
Primary	SP	
T.cruzi	
Growth	
Inhibitio
n	SP	
NV-
Basal_Viab
ility	T.cruzi	
CTG	Inhib	
SP	Tres	
Cantos	
NV-T.cruzi	
myocardioc
yte	Dead	
Cells	SP	Tres	
Cantos	
NV-T.cruzi	
myocardiocy
te	Parasites	
per	Cell	SP	
Tres	Cantos	
NV-T.cruzi	
myocardiocy
te	Infected	
Cells	SP	Tres	
Cantos	
%Inhib
@	
5mM	
%Inhib@	
5mM	
%Inhib@	
5mM	
%Inhib@	
5NA	
%Inhib@	
5mM	
	
2351663291	
8.18	
8.18	
		 		 		 		
	
2351663292	
-17.31	
-17.31	
		 		 		 		
	
2351663341	
6.47	
6.47	
		 		 		 		
	
2351663342	
2.9	
2.9	
		 		 		 		
	
2351663343	
0.11	
0.11	
		 		 		 		
	
2351663344	
4.76	
4.76	
		 		 		 		
	
2351663345	
-7.53	
-7.53	
		 		 		 		
	
2351663348	
-7.41	
-7.41	
		 		 		 		
	
2351663349	
-7.23	
-7.23	
		 		 		 		
	
2351663350	
-8.18	
-8.18	
		 		 		 		
	 2351663368	 -13,26	 		 		 		 		
	 2351663369	 -3,52	 		 		 		 		
	 2351663370	 -1,21	 		 		 		 		
	 2351663371	 0,22	 		 		 		 		
	 2351663372	 -24,26	 		 		 		 		
	 2351663373	 2,76	 		 		 		 		
	 2351663375	 -0,53	 		 		 		 		
	 2351663376	 8,92	 		 		 		 		
	 2351663378	 -6,79	 		 		 		 		
	 2351663379	 10,56	 		 		 		 		
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Cmpd	 OIDD	ID	
Primary	SP	
T.cruzi	
Growth	
Inhibitio
n	SP	
NV-
Basal_Viab
ility	T.cruzi	
CTG	Inhib	
SP	Tres	
Cantos	
NV-T.cruzi	
myocardioc
yte	Dead	
Cells	SP	Tres	
Cantos	
NV-T.cruzi	
myocardiocy
te	Parasites	
per	Cell	SP	
Tres	Cantos	
NV-T.cruzi	
myocardiocy
te	Infected	
Cells	SP	Tres	
Cantos	
%Inhib
@	
5mM	
%Inhib@	
5mM	
%Inhib@	
5mM	
%Inhib@	
5NA	
%Inhib@	
5mM	
	 2351663381	 6,13	 		 		 		 		
	 2351663388	 -0,76	 		 		 		 		
	 2351663390	 18,67	 		 		 		 		
	 2351663391	 -1,75	 		 		 		 		
	 2351663393	 -7,02	 		 		 		 		
	
2351677024	
-18.87	
-18.87	
		 		 		 		
	
2351677025	
2.64	
2.64	
		 		 		 		
	
2351677124	
-2.79	
-2.79	
		 		 		 		
	
2351677125	
9.98	
9.98	
		 		 		 		
	
2351677126	
8.69	
8.69	
		 		 		 		
	
2351677128	
-13.77	
-13.77	
		 		 		 		
	
2351677148	
16.92	
16.92	
		 		 		 		
	
2351677149	
4.41	
4.41	
		 		 		 		
	
2351677151	
-5.87	
-5.87	
		 		 		 		
	
2351677152	
-6.4	
-6.4	
		 		 		 		
	
2351677153	
-4.49	
-4.49	
		 		 		 		
	
2351677271	
-8.26	
-8.26	
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Cmpd	 OIDD	ID	
Primary	SP	
T.cruzi	
Growth	
Inhibitio
n	SP	
NV-
Basal_Viab
ility	T.cruzi	
CTG	Inhib	
SP	Tres	
Cantos	
NV-T.cruzi	
myocardioc
yte	Dead	
Cells	SP	Tres	
Cantos	
NV-T.cruzi	
myocardiocy
te	Parasites	
per	Cell	SP	
Tres	Cantos	
NV-T.cruzi	
myocardiocy
te	Infected	
Cells	SP	Tres	
Cantos	
%Inhib
@	
5mM	
%Inhib@	
5mM	
%Inhib@	
5mM	
%Inhib@	
5NA	
%Inhib@	
5mM	
	
2351677274	
7.22	
7.22	
		 		 		 		
	
2351677276	
16.08	
16.08	
		 		 		 		
	
2351677278	
5.11	
5.11	
		 		 		 		
	
2351677280	
19.93	
19.93	
		 		 		 		
	
2351677282	
1.83	
1.83	
		 		 		 		
	
2351677284	
-9.61	
-9.61	
		 		 		 		
	
2351677286	
4.55	
4.55	
		 		 		 		
	
2351677287	
-1.32	
-1.32	
		 		 		 		
	
2351677289	
16.86	
16.86	
		 		 		 		
	
2351677290	
2.87	
2.87	
		 		 		 		
	
2351677291	
-11.72	
-11.72	
		 		 		 		
	
2351677292	
-40.37	
-40.37	
		 		 		 		
	
2351677293	
-13.17	
-13.17	
		 		 		 		
	
2351677294	
8.24	
8.24	
		 		 		 		
	
2351677295	
0.53	
0.53	
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Cmpd	 OIDD	ID	
Primary	SP	
T.cruzi	
Growth	
Inhibitio
n	SP	
NV-
Basal_Viab
ility	T.cruzi	
CTG	Inhib	
SP	Tres	
Cantos	
NV-T.cruzi	
myocardioc
yte	Dead	
Cells	SP	Tres	
Cantos	
NV-T.cruzi	
myocardiocy
te	Parasites	
per	Cell	SP	
Tres	Cantos	
NV-T.cruzi	
myocardiocy
te	Infected	
Cells	SP	Tres	
Cantos	
%Inhib
@	
5mM	
%Inhib@	
5mM	
%Inhib@	
5mM	
%Inhib@	
5NA	
%Inhib@	
5mM	
	
2351677296	
-0.28	
-0.28	
		 		 		 		
	
2351677304	
15.0	
15.0	
		 		 		 		
	
2351692808	
82.96	
82.96	
81.97	
83.36	
55.35	
57.63	
8.78	
12.55	
5.94	
40.05	
-1.91	
18.4	
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9.	 Mild	 and	 versatile	 synthesis	 of	 aliphatic	 aldehydes	 in	 a	
photochemical-promoted	process	in	flow	
	
9.1.	Introduction	
	
The	 reactions	 between	 carbonyl	 compounds	 and	 diazo	 compounds	 have	 been	
extensively	 studied 132 	since	 the	 description	 of	 the	 Buchner-Curtius-Schlotterbeck	
reaction,133	almost	a	century	ago.		
This	type	of	reactivity	represents	an	efficient	synthetic	tool	 for	the	generation	of	C-C	
bond,	which	 have	 been	mostly	 employed	 for	 the	 construction	 of	 ketones	 or	 fro	 the	
extenxion	of	 carbon	chains.134	However,	 the	 controlled	 formation	of	aldehydes	using	
diazo	chemistry	does	not	represent	an	easy	task	due	to	the	high	coupling	reactivity	of	
diazo	 compounds	 with	 carbonyl	 groups.	 Kingsbury	 reported	 a	 double	 homologation	
reaction	catalyzed	by	a	Lewis	acid	which	combines	ex-situ	prepared	diazo	compounds	
and	the	flash-pyrolyzed	preparation	of	anhydrous	formaldehyde	(Scheme	9.1,	a)135	and	
Hu	described	an	interesting	three-component	coupling	of	aryldiazoacetate,	aniline	and	
aqueous	 formaldehyde	(Scheme	9.1,	b).136	In	both	cases,	 the	authors	were	unable	to	
stop	the	reaction	at	the	aldehyde-generating	step	on	the	way	to	a	final	product	either	
the	doubly	homologated	ketone	or	the	α-aryl	serine	derivative.	
	
	
Scheme	9.1	
																																																								
132	 (a)	 Candeias,	 N.	R.;	 Paterna,	 R.;	 Gois,	 P.	M.	 P.	 Chem.	 Rev.,	 2016,	 116,	 2937;	 (b)	 Guttenberger,	 N.;	
Breinbauer,	R.	Tetrahedron,	2017,	73,	6815.	
133	 (a)	 Buchner,	 E.;	 Curtius,	 T.	Ber.	Dtsch.	 Chem.	Ges.,	1885,	18,	 2377.	 (b)	Schlotterbeck,	 F.	Ber.	Dtsch.	
Chem.	Ges.,	1885,	40,	1826.	
134	 (a)	Mock,	W.	L.;	Hartman,	M.	E.	J.	Org.	Chem.,	1977,	42,	459;	 (b)	Allwood,	D.	M.;	Blakemore,	D.	C.;	
Ley,	S.	V.	Org.	Lett.	2014,	16,	3064;	(c)	Moebius,	D.	C.;	Kingsbury,	J.	S.	J.	Am.	Chem.	Soc.,	2009,	131,	
878.	
135	 Wommack,	A.	J.;	Kingsbury,	J.	S.	J.	Org.	Chem.,	2013,	78,	10573.	
136	 Wang,	C.;	Liu,	S.;	Xing,	D.;	Wang,	X.;	Wu,	X.;	Hu,	W.	Tetrahedron,	2013,	69,	11203.	
R1 R2
N2
+ H H
O
produced by Pyrolysis 
of paraformaldehyde
5-10 mol% Sc(OTf)3
toluene, -20 °C R
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b) Hu - 2013
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H H
O 1 mol%, Rh2(OAc)4
THF, 30 °C
Ar2 N
H
Ar1 COOMe
OH
Formalin
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Based	 on	 the	 previous	 experience	 in	 the	 Ley	 group	 on	 the	 use	 of	 oxadiazolines	 as	
benchstable,	 nonstabilized	 diazo	 compound	 precursors	 under	 flow	 conditions,137	we	
set	 up	 to	 study	 the	 controlled	 homologation	 of	 diazo	 compounds	 generated	 from	
bench-stable	precursors	in	flow	to	form	aldehydes	and	their	derivatives.	
	
9.2.	 Synthesis	 of	 aliphatic	 aldehydes	 and	 their	 corresponding	 alcohols	 and	
benzimidazoles	derivatives	
Due	 to	 the	 lack	 of	 a	 general	method	 for	 the	 preparation	 of	 aliphatic	 aldehydes,	we	
were	encouraged	to	further	 investigate	this	kind	of	transformation	by	controlling	the	
aldehyde	formation	step	and	with	no	use	of	protecting	group	chemistry.	The	planned	
synthetic	strategy	is	described	in	Scheme	9.2.	
	
	
Scheme	9.2	
	
We	selected	2-tetralone	oxadiazoline	as	the	reference	compound	for	the	optimization	
study	and	we	combined	it	with	different	sources	of	formaldehyde	under	UV	irradiation	
(Table	 9.1).	 Formaldehyde	 surrogates	 trioxane	 and	 dioxolane,	 which	 are	 usually	
employed	as	formaldehyde	source,	gave	only	traces	of	desired	aldehyde	22a	although	
almost	 all	 the	 oxadiazoline	 starting	 material	 was	 converted	 into	 the	 diazo	 specie	
(entries	1	and	2).138	
The	use	of	a	stock	solution	of	monomeric	formaldehyde,	generated	via	thermolysis	of	
paraformaldehyde,139	gave	 a	 55%	 yield	 of	 the	 desired	 aldehyde	 (entry	 3)	 but	 the	
tendency	of	the	stock	solution	to	polymerize	without	warning	on	warming	above	-78	
°C,	made	 this	 strategy	no	worthy.	 Then,	we	attempted	 the	 reaction	with	 formalin,	 a	
37%	aqueous	solution	of	formaldehyde,	and	the	target	aldehyde	22a	was	obtained	in	a	
modest	48%	yield	(entry	4).	After	several	modifications	of	the	reaction	conditions,	we	
found	an	improvement	of	the	conversion	(87%)	and	the	yield	(60%)	when	the	reaction	
was	carried	out	with	0.4	mmol	of	oxadiazoline,	0.4	mmol	of	formalin	(0.3	mL,	37	wt%)	
in	2-methyltetrohydrofuran	(4	mL)	and	elongating	the	residence	time	up	to	80,	with	an	
(entry	 7).	 Other	 ajustments	 such	 as	 formaldehyde	 ratio	 changes	 or	 switching	 to	
tetrahydrofuran	or	dichloromethane	were	ineffective	(entry	8,	9,	10	and	11).																																																									
137	 (a)	Movsisyan,	M.;	Delbeke,	E.	I.	P.;	Berton,	J.	K.	E.	T.;	Battilocchio,	C.;	Ley,	S.	V.;	Stevens,	C.	V.	Chem.	
Soc.	Rev.,	2016,	45,	4892;	(b)	Greb,	A.;	Poh,	J.	S.;	Greed,	S.;	Battilocchio,	C.;	Pasau,	P.;	Blakemore,	D.	
C.;	 Ley,	 S.	 V.	Angew.	 Chem.	 Int.	 Ed.,	2017,	56,	 16602;	 (c)	 Dingwall,	 P.;	 Greb,	 A.;	 Crespin,	 L.	 N.	 S.;	
Labes,	R.;	Musio,	B.;	Poh,	J.S.;	Pasau,	P.;	Blakemore	D.	C.;	Ley	S.	V.	Chem.	Comm.,	2018,	54,	11685;	
(d)	Chen,	Y.;	Blakemore,	D.C.;	Pasau	P.;	Ley	S.V.	Org.	Lett.,	2018,	20,	6569.	
138	 Hamilton,	J.	Y.;	Morandi,	B.;	Carreira,	E.	M.	Synthesis,	2013,	45,	1857.	
139	 Gilman,	H.;	Catlin,	W.	E.	Org.	Synth.,	1926,	6,	22.	
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Table	9.1:	optimization	of	the	reaction	conditions.	
Entrya	 Fomaldehyde	source	 Ox./M	 tR/min	 T/°C	 Conv.	 Yield	
1	 Dioxolane	 0.1	 40	 20	 99%	 0%	
2	 Trioxane	 0.1	 40	 20	 96%	 2%	
3	 Thermolysed		
Paraformaldheyde	
0.1	 40	 20	 67%	 55%	
4	 37%	aq	 0.1	 40	 20	 78%	 48%	
5	 37%	aq	 0.1	 40	 10	 72%	 41%	
6	 37%	aq	 0.05	 40	 10	 80%	 39%	
7	 37%	aq	 0.1	 80	 20	 87%	 60%	
(50%)b	
8c	 37%	aq	 0.1	 80	 20	 86%	 58%	
9d	 37%	aq	 0.1	 80	 20	 87%	 56%	
10e	 37%	aq	 0.1	 80	 20	 78%	 41%	
11f	 37%	aq	 0.1	 80	 20	 79%	 12%	
aNMR	 yields	 calculated	 with	 1,3,5-trimethoxybenzene	 as	 an	 internal	 standard.	 bIsolated	 yield.	 c100	
equiv.	 of	 formaldehyde	was	 used.	 d5.0	 equiv.	 of	 formaldehyde	was	 used.	 eTetrahydrofuran	was	 used	
instead	of	2-methyltetrahydrofuran.	fDichloromethane	was	used	instead	of	2-methyltetrahydrofuran.	
	
It	is	interesting	to	remark	that	even	if	the	conversion	of	the	oxadiazoline	increased,	the	
aldehyde	was	 recovered	only	 in	50%	yield	after	 column	chromatography.	A	 carefully	
study	of	the	crude	sample	showed	that	a	significant	amount	of	the	aldehyde	hydrate	
form	was	also	present,	but	no	more	than	10%	of	the	doubly	homologated	ketone.		
The	formation	of	the	hydrate	derivative	could	be	due	to	the	presence	of	large	amount	
of	 water	 in	 the	 reaction	 media,	 that	 acts	 as	 an	 in	 situ	 protecting	 group.	 This	 fact,	
together	with	a	very	low	concentration	of	diazo	compound	during	the	progression	of	
the	reaction,	hinder	double	homologation.	It	was	also	observed	in	same	cases,	over	an	
extended	period	of	time,	the	presence	of	the	corresponding	carboxylic	acid,	probably	
proceeding	from	an	aerobic	oxidation	process.	
In	order	 to	better	handle	 the	unstable	aldehydes,	we	explored	 two	methods	 to	 trap	
the	desired	products.	The	 first	one	was	 to	 reduce	 the	crude	mixture	 reaction	with	a	
solution	 of	 sodium	 borohydride	 (NaBH4)	 to	 convert	 the	 aldehyde	 into	 the	
corresponding	 alcohol.	 This	 strategy	 can	be	 also	 considered	 a	way	 to	 store	unstable	
aldehydes,	 which	 can	 be	 used	 again	 via	 a	 secondary	 oxidation.	 The	 second	 one	
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consisted	in	subjecting	the	crude	mixture	reaction	to	an	oxidative	condensation	with	o-
phenylenediamine,	based	on	a	modified	procedure	originally	reported	by	Jiao	et.	al.140		
The	 scope	 of	 the	 aldehyde	 synthesis	 and	 their	 derivatization	 to	 alcohols	 and	
benzimidazoles	is	summarized	in	Table	9.2.	
	
	
Table	9.2:	Scope	of	the	aldehyde	synthesis	and	their	derivatization	into	alcohols	
and	benzimidazoles	
Entry	 Aldehyde	22a	–	pa	 Alcohol	23a	–	pb	 Benzimidazole	24a	–	pc	
	
1	 	
22a,	60%d	
(50%)	
	
23a,	60%	
	
24a,	72%	
	
2	 	
22b,	48%	
	
23b,	53%	
	
24b,	76%	
	
3	 	
22c,	56%	
	
23c,	72%	
	
24c,	55%	
	
4	 	
22d,	85%d	
(75%)	
	
23d,	89%d	(77%)	
	
24d,	60%	
	
5	
	
22e,	65%	
	
23e,	75%	
	
24e,	80%	
	
6	
	
22f,	58%d	
(49%)	
	
23f,	53%	
	
24f,	49%	
																																																								
140Zhang,	C.;	Zhang,	L.;	Jiao,	N.	Green	Chem.,	2012,	14,	3273.	
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Entry	 Aldehyde	22a	–	pa	 Alcohol	23a	–	pb	 Benzimidazole	24a	–	pc	
	
7	
	
22g,	55%d	
	
23g,	68%d	
	
24g,	72%	
	
8	
	
22h,	68%	
	
23h,	75%	
	
24h,	79%	
	
9	 	
22i,	n.d.e	
	
23i,	n.d.e	
	
24i,	59%	
	
10	
	
22j,	57%	
	
23j,	75%	 	
24j,	n.d.e	
	
11	 	
22k,	85%f	
	
23k,	66%	
	
24k,	n.d.e	
	
12	 	
22l,	35%d	
	
23l,	50%	
	
24l,	48%	
	
13	 	
22m,	25%d	
	
23m,	60%	
	
24m,	75%	
	
14	
	
22n,	58%d	
	
23n,	88%d	
(69%)	
	
24n,	73%	
	
15	
	
22o,	18%d	
	
23o,	n.d.e	 	
24o,	39%	
	
16	
	
22p,	8%d	
	
23p,	58%d	
	
24p,	69%	
aReaction	conditions:	oxadiazoline	(1.0	equiv.,	0.1	M),	formaldehyde	(10	equiv.,	37	wt%	in	H2O,	1.0	M)	in	
2-methyltetrahydrofuran.	 bAldehyde	 reduced	 directly	 with	 NaBH4	 (10	 equiv.,	 0.5	 M)	 in	 ethanol.	
cAldehyde	 reacted	with	o-phenylenediamine	 (1.5	 equiv.,	 0.075	M)	 in	 toluene.	 dNMR	 yield,	 calculated	
using	 1,3,5-trimethoxybenzene	 as	 an	 internal	 standard.	 eNot	 determined	 due	 to	 volatility	 or	 product	
contamination.	f81%	of	the	product	identified	as	the	hydrated	form.	
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In	general,	 yields	of	 compounds	23	 and	24	 are	better	 than	 the	 isolated	yields	of	22,	
reflecting	that	the	aldehyde	was	present	in	the	crude	mixture	reaction.	The	obtention	
of	benzimidazole	derivatives	 in	much	higher	 isolated	yields	represents	a	proof	of	 the	
robustness	 of	 the	 method	 and	 of	 the	 good	 production	 of	 the	 desired	 aliphatic	
aldehydes,	and	their	stability	problems	make	difficult	their	isolation.	Functional	groups	
as	 alkene,	 alkyne,	 nitrogen-based	 functional	 groups,	 Boc-protected	 amine	 and	 bulky	
substituents	were	well	tolerated.	For	compounds	22i	and	23i	isolated	yields	were	not	
determined	 due	 to	 their	 volatility,	 a	 common	 problem	 with	 these	 low	 molecular	
weight	 molecules.	 Even	 thought,	 the	 formation	 of	 2-cyclobutylbenzimidazole	 was	
possible	in	59%	yield	(24i)	as	a	proof	for	the	aldehyde	formation.	Generally,	α-methyl	
aldehydes	 displayed	 a	 tendency	 towards	 hydration	 or	 aerobic	 oxidation,	 resulting	 in	
low	 crude	 NMR	 yields	 and	 difficulty	 in	 their	 isolation	 their	 isolation,	 being	 this	
behaviour	known	for	similar	materials.		
Many	of	these	products	can	be	thought	of	as	branched	or	iso	aldehydes,	which	would	
be	 difficult	 to	 prepare	 through	 traditional	 methods	 such	 as	 hydroformylation,	
particularly	in	the	presence	of	an	alkene	or	alkyne	
We	can	conclude	that	have	developed	a	mild,	operationally	straightforward	procedure	
for	 the	 homologation	 of	 ketones	 and	 aryl	 aldehydes	 via	 non-stabilised	 diazo	
compounds	in	flow	avoiding	expensive	and	reactive	transition	metal	catalysts	and	uses	
formalin	as	a	cheap	and	readily	available	homologation	reagent.	
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9.3.	Experimental	section	
	
9.3.1.	General	procedure	A:	synthesis	of	aliphatic	aldehydes	22	
	
	
	
A	solution	of	the	appropriate	oxadiazoline	(1.0	equiv.,	0.05	mmol/mL)	and	formaldehyde	(10	
equiv.	aqueous	solution,	37%	w/w)	in	2-MeTHF	(0.5	mol/mL)	was	pumped	(0.125	mL	min-1,	tR	=	
80	 min)	 through	 a	 Vapourtec	 UV-150	 photochemical	 reactor	 (10	 mL,	 FEP	 tubing)	 while	
irradiate	 by	 a	 310	 nm	UV	 lamp	 (output	 power:	 9W)	 held	 at	 20	 °C.	 The	 reactor	 output	 was	
monitored	using	a	Mettler	Toledo	FlowIR®	 instrument	 (SiComp	head,	bands	of	 interest:	C=O	
stretch	 signal	 at	 1750-1700	 cm-1	 for	 methyl	 acetate,	 generated	 by	 the	 decomposition	 of	
oxadiazoline).	Once	 the	FlowIR®	detector	 showed	 the	 signal	of	 the	 reaction	 slug,	 the	output	
stream	was	collected	in	a	sealed	sample	vial	containing	a	biphasic	solution	of	dichloromethane	
and	brine	with	 stirring	 to	 separate	 excess	 formaldehyde	 and	other	 potential	 impurities.	 The	
collected	material	was	rested,	and	the	organic	phase	was	separated	and	con-	centrated	under	
reduced	 pressure.	 The	 remaining	 residue	 was	 purified	 via	 flash	 silica	 gel	 column	
chromatography	with	appropriate	eluent	combination	to	give	the	desired	product.		
	
1,2,3,4-Tetrahydronaphthalene-2-carbaldehyde	(22a)		
	
General	 procedure	 A	 was	 followed	 using	 5'-methoxy-5'-methyl-3,4-dihydro-
1H,5'H-spiro(naphthalene-2,2'-[1,3,4]oxadiazole)	 (92	 mg,	 0.4	 mmol,	 1.0	 eq.)	
and	formaldehyde	(0.3	mL,	37	wt%	in	H2O,	4	mmol,	10	eq.).	The	crude	mixture	
was	purified	via	flash	column	chromatography	(0	-	20%	EtOAc	in	petroleum	ether)	to	give	the	
titled	product	as	a	transparent	oil	(32	mg,	50%).	1H	NMR	(600	MHz,	CDCl3)	δ	9.80	(d,	J	=	1.2	Hz,	
1H,	HCO),	7.13	(dt,	J	=	6.3,	3.5	Hz,	3H,	HAr),	7.10	(q,	J	=	4.1,	3.5	Hz,	1H,	HAr),	3.04	–	2.95	(m,	2H,	
ArCH2CH2),	2.94	–	2.82	(m,	2H,	ArCH2),	2.75	–	2.68	(m,	1H,	HCOCH),	2.26	–	2.19	(m,	1H,	ArCHa),	
1.84	–	1.75	 (m,	1H,	ArCHa’);	
13C	NMR	(151	MHz,	CDCl3)	δ	203.9	 (HCO),	136.1	 (CAr),	134.4(CAr),	
129.4(CArH),	 129.0(CArH),	 126.2(CArH),	 126.1(CArH),	 47.0	 (HCOCH),	 28.6	 (ArCH2CH2),	 28.2	
(ArCH2CH),	23.1	(Ca).	HRMS	(ESI)	calcd	for	C11H12ONa
+	[M+Na]+	183.0780,	 found	183.0775.	 IR	
max	 (film)	 ν:	 2904,	 2851,	 1723,	 1702,	 1432,	 1110,	 1042	 cm-1.	 The	 data	 presented	 are	
consistent	with	literature	precedent.141	
	 	
																																																								
141Shi,	Z.-C.;	Devasagayaraj,	A.;	Gu,	K.;	Jin,	H.;	Marinelli,	B.;	Samala,	L.;	Scott,	S.;	Stouch,	T.;	Tunoori,	A.;	
Wang,	 Y.;	 Zang,	 Y.;	 Zhang,	C.;	 Kimball,	 S.	D.;	Main,	A.	 J.;	 Sun,	W.;	 Yang,	Q.;	Nouraldeen,	A.;	 Yu,	 X.-Q.;	
Buxton,	E.;	Patel,	S.;	Nguyen,	N.;	Swaffield,	J.;	Powell,	D.	R.;	Wilson,	A.;	Liu,	Q.	J.	Med.	Chem.,	2008,	51,	
3684.	
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Tetrahydro-2H-pyran-4-carbaldehyde	(22b)	
	
General	 procedure	 A	 was	 followed	 using	 3-methoxy-3-methyl-4,8-dioxa-1,2-
diazaspiro[4.5]-	 dec-1-ene	 (74	mg,	 0.4	mmol,	 1.0	 equiv)	 and	 formaldehyde	 (0.3	
mL,	37	wt	%	in	H2O,	4	mmol,	10	equiv).	The	crude	mixture	was	purified	via	flash	
column	 chromatography	 (0−15%	 EtOAc	 in	 petroleum	 ether)	 to	 give	 the	 titled	 product	 as	 a	
volatile	transparent	oil	(23	mg,	48%):	1H	NMR	(600	MHz,	CDCl3)	δ	9.68	(d,	J	=	1.0	Hz,	1H,	HCO),	
4.00−	 3.92	 (m,	 2H,	 OCHa+OCHb),	 3.48	 (ddd,	 J	 =	 11.5,	 10.7,	 2.6	 Hz,	 2H,	 OCHa′	 +	 OCHb′),	
2.55−2.36	(m,	1H,	HCOCH),	1.89−1.83	(m,	2H,	OCHc	+	OCHd),	1.70	(dtd,	J	=	13.7,	10.7,	4.2	Hz,	
2H,	OCHc′	+	OCHd′);	
13C{1H}	NMR	(151	MHz,	CDCl3)	δ	203.0	(HCO),	66.8	(Ca+Cb),	46.9	(HCOCH),	
25.8	 (Cc+Cd);	 LRMS	(ESI,	m/z)	115.2	 ([M	+	H]
+,	100);	 IR	max	 (film)	ν:	2968,	1879,	1720,	1279,	
1201,	1135,	1080,	924	cm−1.	The	data	presented	are	consistent	with	literature	precedent.142	
	
	Tetrahydro-2H-thiopyran-4-carbaldehyde	(22c)	
	
General	 procedure	 A	 was	 followed	 using	 3-methoxy-3-methyl-4-oxa-8-thia-1,2-
diazaspiro[4.5]dec-1-ene	 (81	mg,	0.4	mmol,	1.0	 	eq.)	and	 formaldehyde	(0.3	mL,	
37	wt%	in	H2O,	4	mmol,	10	eq.).		The	crude	mixture	was	purified	via	flash	column	
chromatography	 (0	 –	 20%	EtOAc	 in	 petroleum	ether)	 to	 give	 the	 titled	product	 as	 a	 volatile	
transparent	oil	(29	mg,	56%).	1H	NMR	(600	MHz,	CDCl3)	δ	9.59	(s,	1H,	HCO),	2.67	(dt,	J	=	10.2,	
3.6	Hz,	4H,	SCH2),	2.34	–	2.22	(m,	3H,	HCOCH	+	CHa	+	CHb),	1.75	(dtd,	J	=	14.3,	10.2,	4.5		Hz,	2H,	
CHa’+	CHb’);	
13C	NMR	(151	MHz,	CDCl3)	δ	203.3		(HCO),	49.3	(HCOCH),	27.6	(SCH2),	27.2	(Ca	+	Cb);	
HRMS	(ESI)	calcd	for	C6H11OS
+	[M+H]+:	131.0528,	found	131.0531.	IR	max	(film)	ν:	2918,	2849,	
2369,	 1724,	 1239,	 1130,	 1088,	 983	 cm-1.	 The	 data	 presented	 are	 consistent	with	 literature	
precedent.143	
	
Tetrahydrothiophene-3-carbaldehyde	(22d)	
	
General	 procedure	 A	 was	 followed	 using	 3-methoxy-3-methyl-4-oxa-7-thia-1,2-
diazaspiro[4.4]non-1-ene	(37	mg,	0.2	mmol,	1.0		eq.)	and	formaldehyde	(0.16	mL,	
37	wt%	 in	H2O,	2.0	mmol,	10	 	eq.).	A	NMR	85%	yield	was	calculated	using	1,3,5-
trimethoxybenzene	(11mg,	0.066	mmol,	0.33	eq.)	as	an	internal	standard.	The		crude	mixture	
was	purified	via	flash	column	chromatography	(0	–		20%	EtOAc	in	petroleum	ether)	to	give	the	
titled	product	as	a	colourless	volatile	oil	(17	mg,	75%)	with	less	than	10%	of	dichloromethane.	
1H	NMR	(600	MHz,	CDCl3)	δ	9.63	(d,	J	=	1.3	Hz,	1H,	HCO),	3.16	(dd,	J	=	10.9,	5.0	Hz,	1H,	SCHcCH),	
3.09	 –	 3.04	 (m,	 1H,	 HCOCH),	 2.98	 (dd,	 J	 =	 10.9,	 7.0	 Hz,	 1H,	 SCHcCH),	 2.91	 –	 2.85	 (m,	 1H,	
SCHbCH2)	J	=	12.7,	5.9	Hz,	1H,	CHCHa),	2.12	(dq,	J	=	13.4,	6.9	Hz,	1H,	 	CHCHa’);	 	
13C	NMR	(151	
MHz,	CDCl3)	δ	201.3	(HCO),	55.1		(HCOCH),	31.1	(Cc),	30.9	(Cb),	30.5	(Ca).	LRMS	(ESI,	m/z)	117.1	
																																																								
142	 Kazem	Shiroodi,	R.;	Dudnik,	A.	S.;	Gevorgyan,	V.	J.	Am.	Chem.	Soc.	2012,	134,	6928.		
143	 Cabrera-Pardo,	J.	R.;	Trowbridge,	A.;	Nappi,	M.;	Ozaki,	K.;	Gaunt,	M.	J.	Angew.	Chem.	Int.	Ed.,	2017,	
56,	11958.		
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	([M+H]+,	100%).	IR	max	(film)	ν:	2944,	1720,	1416,	1235,	1028,		956	cm-1.	The	data	presented	
are	consistent	with	literature	precedent.144	
	
1,4-Dioxaspiro[4.5]decane-8-carbaldehyde	(22e)	
	
General	 procedure	 A	 was	 followed	 using	 3-methoxy-3-methyl-4,9,12-trioxa-
1,2-diazadispiro[4.2.48.25]tetradec-1-ene	 (102	 mg,	 	0.4	 mmol,	 1.0	 eq.)	 and	
formaldehyde	 (0.3	mL,	 37	wt%	 in	H2O,	 4	 	mmol,	 10	 eq.).	 The	 crude	mixture	
was	purified	via	flash	column		chromatography	(0	–	20%	EtOAc	in	petroleum	ether)	to	give	the	
	titled	product	as	a	colourless	volatile	oil	(44	mg,	65%)		1H	NMR		(600	MHz,	CDCl3)	δ	9.64	(d,	J	=	
1.3	Hz,	1H,	HCO),	3.94	(dd,	J	=		5.3,	3.4	Hz,	4H,	OCH2CH2O),	2.25	(ttd,	J	=	9.7,	4.1,	1.4	Hz,	1H,	
	HCOCH),	1.97	–	1.91	(m,	2H,	CHc	+	CHd),	1.80	–	1.71	(m,	4H,	 	CHc’	+	CHd’	+	CHe	+	CHf),	1.61	–	
1.56	(m,	2H,	CHe	+	CHf);		
13C	NMR	(151	MHz,	CDCl3)	δ	204.2	(HCO),	108.2	(OCO),		64.5	(Ca),	64.5	
(Cb),	48.4	(HCOCH),	33.5	(Cc	+	Cd),	23.4	(Ce	+	Cf).		LRMS	(ESI,	m/z)	171.4	([M+H]
+,	100%).	IR	max	
(film)	ν:	2949,	1722,	1447,	1362,	1239,	1142,	1104,	1033,	948,	881	cm-1.		The	data	presented	
are	consistent	with	literature	precedent.145	
	
tButyl	4-formylpiperidine-1-carboxylate	(22f)	
	
General	 procedure	 A	 was	 followed	 using	 tert-butyl	 3-meth-oxy-3-methyl-4-
oxa-1,2,8-triazaspiro[4.5]dec-1-ene-8-carboxylate	 (57	mg,	 0.2	mmol,	 1.0	 eq.)	
and	formaldehyde	(0.16	mL,	37	wt%	 in	 	H2O,	2.0	mmol,	10	eq.).	A	NMR	58%	
yield	was	calculated	using		1,3,5-trimethoxybenzene	(11mg,	0.066	mmol,	0.33	
eq.)	as	an	internal	standard.	The	crude	mixture	was	purified	via	flash	column	chromatography	
(0	–	20%	EtOAc	in	petroleum	ether)	to	give	the	titled	product	as	a	colourless	oil	(21	mg,	49%).	
1H	NMR	(600	MHz,	CDCl3)	δ	9.65	(s,	1H,	HCO),	3.97	(br	s,	2H,	NCHc	+	NCHd),	3.02	–	2.81	(m,	2H,	
NCHc’	+	NCHd’),	2.47	–	2.36	(m,	1H,	HCOCH),	1.98	–	1.80	(m,	2H,	CHa	+	CHb),	1.59	–	1.50	(m,	2H,	
CHa’	+	CHb’),	1.44	(s,	9H,	C(CH3)3);	
13C	NMR	(151	MHz,	CDCl3)	δ	203.1	(HCO),	154.8	(NCOO),	79.8	
(C(CH3)3),	48.1	(HCOCH),	43.0	(br,	Cc	+	Cd),	28.5	(C(CH3)3),	25.3	(Ca	+	Cb).	LRMS	(ESI,	m/z)	214.3	
([M+H]+,	100%).	 IR	max	(film)	ν:	2927,	1726,	1688,	1418,	1365,	1273,	1232,	1168,	1128,	958,	
864,	769	cm-1.	The	data	presented	are	consistent	with	literature	precedent.146	
Adamantane-2-carbaldehyde	(22h)	
	
General	 procedure	 A	 was	 followed	 using	 5′ -methoxy-5′ -methyl-5′H-
spiro[adamantane-2,2′-	 [1,3,4]oxadiazole]	 (94	 mg,	 0.4	 mmol,	 1.0	 equiv)	 and	
formaldehyde	 (0.3	mL,	37	wt	%	 in	H2O,	4	mmol,	 10	equiv).	 The	 crude	mixture	
was	purified	via	flash	column	chromatography	(0	−	20%	EtOAc	in	petroleum	ether)	to	give	the																																																									
144	 Boehm,	J.,	Charles;	Busch-Petersen,	J.;	Fu,	W.;	Jin,	Q.;	Kerns,	J.	K.;	Li,	H.;	Lin,	G.;	Lin,	X.;	Neipp,	C.	E.	
Indole	Carboxamides	as	IKK2	Inhibitors.	WO2008118724	(A1),	2008.	
145	 Tseng,	C.-C.;	Noordali,	H.;	Sani,	M.;	Madhani,	M.;	Grant,	D.	M.;	Frenneaux,	M.	P.;	Zanda,	M.;	Greig,	I.	
R.	J.	Med.	Chem.,	2017,	60,	2780.	
146	 Vallone,	A.;	D’Alessandro,	S.;	Brogi,	S.;	Brindisi,	M.;	Chemi,	G.;	Alfano,	G.;	Lamponi,	S.;	Lee,	S.	G.;	Jez,	
J.	M.;	Koolen,	K.	 J.	M.;	Dechering,	K.	 J.;	Saponara,	S.;	Fusi,	F.;	Gorelli,	B.;	Taramelli,	D.;	Parapini,	S.;	
Caldelari,	R.;	Campiani,	G.;	Gemma,	S.;	Butini,	S.	Eur.	J.	Med.	Chem.,	2018,	150,	698.	
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titled	product	 as	 a	white	 solid	 (45	mg,	68%):	 1H	NMR	 (600	MHz,	CDCl3)	δ	 9.73	 (s,	 1H,	HCO),	
2.44−2.37	 (m,	3H,	HCOCH	+	HCOCHCH),	2.01−1.67	 (m,	12H,	CHb	+	CHc	+	CHd);	
13C	NMR	 (151	
MHz,	CDCl3)	δ	206.1	 (HCO),	56.7	 (HCOCH),	38.0	 (Cb),	37.2	 (Cd),	33.7	 (Cb′),	28.3	 (Ca),	28.0	 (Cc),	
27.6	(Cc′);	HRMS	(ESI)	calcd	for	C11H17O
+	[M	+	H]+	165.1274,	found	165.1271;	IR	max	(film)	ν:	
2936,	 2896,	 1752,	 1463,	 1190,	 1076,	 912	 cm−1;	 mp	 164−166	 °C.	 The	 data	 presented	 are	
consistent	with	literature	precedent.147	
	
4-(6-Methoxynaphthalen-2-yl)-2-methylbutanal	(22j)	
	
General	 procedure	 A	 was	 followed	 using	 2-methoxy-5-(2-(6-
methoxynaph-thalen-2-yl)ethyl)-2,5-dimethyl-2,5-dihydro-1,3,4-
oxadiazole	(126	mg,	0.4	mmol,	1.0	equiv)	and	formaldehyde	(0.3	mL,	
37	 wt	 %	 in	 H2O,	 4	 mmol,	 10	 equiv).	 The	 crude	 mixture	 was	 purified	 via	 flash	 column	
chromatography	(0	−	20%	EtOAc	in	petroleum	ether)	to	give	the	titled	product	as	a	transparent	
oil	(55	mg,	57%)	together	with	7%	of	oxidized	carboxylic	acid:	1H	NMR	(600	MHz,	CDCl3)	δ	9.65	
(d,	J	=	1.8	Hz,	1H,	HCO),	7.68	(dd,	J	=	8.5,	3.4	Hz,	2H,	HAr),	7.55	(d,	J	=	1.8	Hz,	1H,	HAr),	7.30	(dd,	J	
=	8.4,	1.8	Hz,	1H,	HAr),	7.16−7.10	(m,	2H,	HAr),	3.92	(s,	3H,	OCH3),	2.88−2.75	(m,	2H,	HCOCH	+	
ArCHa),	2.41	(qd,	J	=	6.9,	1.8	Hz,	1H,	ArCHa′),	2.19−2.10	(m,	1H,	ArCH2CHb),	1.78−1.70	(m,	1H,	
ArCH2CHb′),	1.18	(d,	 J	=	7.1	Hz,	3H,	CHCH3);	
13C	NMR	(151	MHz,	CDCl3)	δ	205.0	 (HCO),	157.4	
(CAr),	136.6	(CAr),	133.2	(CAr),	129.2	(CAr),	129.0	(CArH),	127.7	(CArH),	127.1	(CArH),	126.5	(CArH),	
119.0	(CArH),	105.8	(CArH),	55.3	(OCH3),	45.6	(HCOCH),	33.0	(Ca),	32.1	(Cb),	13.4	(CHCH3);	HRMS	
(ESI)	 calcd	 for	 C16H19O2+	 [M	 +	H]+	 243.1385,	 found	 243.1386;	 IR	max	 (film)	ν:	 2933,	 1721,	
1634,	1606,	1483,	1390,	1264,	1229,	1031,	850	cm−1.	
	
	 	
																																																								
147Madder,	 A.;	 Sebastian,	 S.;	 Van	Haver,	D.;	De	Clercq,	 P.	 J.;	Maskill,	 H.	 J.	 Chem.	 Soc.,	 Perkin	 Trans.	 2	
1997,	2,	2787.	
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9.3.2.	General	procedure	B:	synthesis	of	alcohol	derivatives	23	
	
	
	
The	reaction	slug	 from	general	procedure	A	was	directly	collected	 into	a	 round-bottom	flask	
containing	NaBH4	(10	equiv)	in	EtOH	(0.5	mmol/mL)	and	stirred	for	a	further	1	h.	The	resulting	
mixture	 was	 then	 quenched	 with	 ice−water,	 extracted	 with	 ethyl	 acetate	 (2	 ×	 20	 mL),	 and	
washed	with	brine	(2	×	20	mL).	The	organic	phase	was	combined,	dried	over	MgSO4,	filtered,	
and	 concentrated	 under	 reduced	 pressure.	 The	 remaining	 residue	 was	 purified	 via	 flash	
column	chromatography	with	appropriate	eluents	to	give	the	desired	alcohol.		
	
(1,2,3,4-Tetrahydronaphthalen-2-yl)methanol	(23a)	
	
General	procedure	B	was	followed	using	5-methoxy-5-methyl-3,4-dihydro-1H,5′
H-spiro[naphthalene-2,2-[1,3,4]oxadiazole]	 (92	 mg,	 0.4	 mmol,	 1.0	 equiv),	
formaldehyde	(0.3	mL,	37	wt	%	in	H2O,	4	mmol,	10	equiv),	and	sodium	borohydride	(153	mg,	
4.0	mmol,	10	equiv).	The	crude	mixture	was	purified	via	 flash	column	chromatography	 (10	−	
40%	EtOAc	in	petroleum	ether)	to	give	the	titled	product	as	a	transparent	oil	(39	mg,	60%):	1H	
NMR	(600	MHz,	CDCl3)	δ	7.09	(app.	p,	J	=	2.2	Hz,	4H,	HAr),	3.69−3.59	(m,	2H,	HOCH2),	2.93−2.79	
(m,	 3H,	 ArCH2CH	 +	 ArCHa),	 2.52	 (dd,	 J	 =	 16.3,	 10.7	 Hz,	 1H,	 ArCHa′),	 2.06−1.95	 (m,	 2H,	
ArCH2CH2),	 1.55−	1.39	 (m,	 2H,	HOCH2CH	+	CH2OH);	
13C	NMR	 (151	MHz,	 CDCl3)	δ	 136.8	 (CAr),	
136.0	 (CAr),	 129.3	 (CArH),	 128.9	 (CArH),	 125.7	 (CArH),	 125.7	 (CArH),	 67.8	 (HOCH2),	 37.1	
(HOCH2CH),	32.5	(ArCH2),	28.8	(Ca),	26.0	(ArCH2CH2);	HRMS	(ESI)	calcd	for	C11H14ONa
+	[M	+	Na]+	
185.0937,	 found	 185.0931;	 IR	max	 (film)	ν:	 3370,	 2918,	 1494,	 1453,	 1436,	 1065,	 1022,	 900	
cm−1.	The	data	presented	are	consistent	with	literature	precedent.148	
	
(Tetrahydro-2H-pyran-4-yl)methanol	(23b)	
	
General	 procedure	 B	 was	 followed	 using	 3-methoxy-3-methyl-4,8-dioxa-1,2-
diazaspiro[4.5]-dec-1-ene	(74	mg,	0.4	mmol,	1.0	equiv),	formaldehyde	(0.3	mL,	37	
wt	%	in	H2O,	4	mmol,	10	equiv),	and	sodium	borohydride	(153	mg,	4.0	mmol,	10	
equiv).	The	crude	mixture	was	purified	via	 flash	column	chromatography	(10	−	40%	EtOAc	 in	
petroleum	ether)	 to	 give	 the	 titled	product	 as	 a	 transparent	oil	 (25	mg,	 53%):	 1H	NMR	 (600	
MHz,	 CDCl3)	 δ	 3.99	 (ddt,	 J	 =	 11.5,	 4.6,	 1.1	 Hz,	 2H,	 OCHa	 +	 OCHb),	 3.51	
(d,J=6.5Hz,2H,HOCH2),3.41(td,J=11.5,2.1Hz,2H,	OCHa′	+	OCHb′),	1.79−1.73	(m,	1H,	HOCH2CH),	
1.68−1.64	 (m,	2H,	CHc	+	CHd),	 1.38−1.32	 (m,	2H,	CHc′	 +	CHd′);	
13C	NMR	 (151	MHz,	CDCl3)	δ	
68.1	(HOCH2),	67.8	(Ca	+	Cb),	37.7	(HOCH2CH),	29.4	(Cc	+	Cd);	LRMS	(ESI,	m/z)	115.3	([M	−	H]
−,	
																																																								
148	 Jones,	G.	B.;	Wright,	J.	M.;	Plourde,	G.	W.;	Hynd,	G.;	Huber,	R.	S.;	Mathews,	J.	E.	J.	Am.	Chem.	Soc,.	
2000,	122,	1937.	
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100);	 IR	max	 (film)	ν:	3368,	2918,	2847,	1652,	1443,	1235,	1140,	1031,	1012,	984,	849	cm−1.	
The	data	presented	are	consistent	with	literature	precedent.149	
	
(Tetrahydro-2H-thiopyran-4-yl)methanol	(23c)	
	
General	 procedure	 B	 was	 followed	 using	 3-methoxy-3-methyl-4-oxa-8-thia-1,2-
diazaspiro[4.5]dec-1-ene	(81	mg,	0.4	mmol,	1.0	equiv),	 formaldehyde	(0.3	mL,	37	
wt	%	in	H2O,	4	mmol,	10	equiv),	and	sodium	borohydride	(153	mg,	4.0	mmol,	10	
equiv).	The	crude	mixture	was	purified	via	 flash	column	chromatography	(10	−	40%	EtOAc	 in	
petroleum	ether)	 to	 give	 the	 titled	product	 as	 a	 transparent	oil	 (38	mg,	 72%):	 1H	NMR	 (600	
MHz,	CDCl3)	δ	3.47	(d,	J	=	6.4	Hz,	2H,	HOCH2),	2.70	(ddd,	J	=	14.3,	11.9,	2.6	Hz,	2H,	SCHa	+	SCHb),	
2.64−2.58	(m,	2H,	SCHa′	+	SCHb′),	2.07	(dd,	J	=	13.5,	3.5	Hz,	2H,	CHc	+	CHd),	1.59	(br	s,	1H,	OH),	
1.57−1.48	(m,	1H,	HOCH2CH),	1.39	(dtd,	J	=	13.1,	11.8,	3.5	Hz,	1H,	CHc′	+	CHd′);	
13C	NMR	(151	
MHz,	CDCl3)	δ	68.4	(HOCH2),	40.2	(HOCH2CH),	30.8	(Ca	+	Cb),	28.3	(Cc	+	Cd);	HRMS	(ESI)	calcd	for	
C6H13O32S
+	[M	+	H]+	133.0682,	found	133.0681;	IR	max	(film)	ν:	3584,	2924,	1454,	1422,	1273,	
1036	cm−1.	The	data	presented	are	consistent	with	literature	precedent.150	
		
(Tetrahydrothiophene-3-yl)methanol	(23d)	
	
General	 procedure	 B	 was	 followed	 using	 3-methoxy-3-methyl-4-oxa-7-thia-1,2-
diazaspiro[4.4]non-1-ene	(37	mg,	0.2	mmol,	1.0	equiv),	formaldehyde	(0.16	mL,	37	
wt	%	in	H2O,	2.0	mmol,	10	equiv),	and	sodium	borohydride	(76	mg,	2.0	mmol,	10	
equiv).	An	89%	NMR	yield	was	calculated	using	1,3,5-trimethoxybenzene	(11	mg,	0.066	mmol,	
0.33	 equiv)	 as	 an	 internal	 standard.	 The	 crude	 mixture	 was	 purified	 via	 flash	 column	
chromatography	(0	−	40%	EtOAc	in	petroleum	ether)	to	give	the	titled	product	as	a	colorless	oil	
(18	mg,	77%)	with	less	than	5%	of	ethyl	acetate:	1H	NMR	(600	MHz,	CDCl3)	δ	3.64	(dt,	J	=	6.8,	
3.5	Hz,	2H,	HOCH2),	2.94	(dd,	J	=	10.6,	6.8	Hz,	1H,	SCHcCH),	2.87	(ddd,	J	=	7.2,	5.9,	1.6	Hz,	2H,	
SCHbCH2	+	SCHb′CH2),	2.65	(dd,	J	=	10.6,	7.2	Hz,	1H,	SCHc′CH),	2.44	(dpd,	J	=	8.3,	6.8,	5.5	Hz,	
1H,	HOCH2CH),	 2.12	 (dq,	 J	 =	 11.9,	 5.7	Hz,	 1H,	 CHCHa),	 1.85−1.71	 (m,	 2H,	OH	+	 CHCHa′);	
13C	
NMR	 (151	MHz,	CDCl3)	δ	 64.8	 (HOCH2),	46.7	 (HOCH2CH),	33.8	 (Cc),	33.4	 (Cd),	30.9	 (Ca);	 LRMS	
(ESI,	m/z)	117.3	 ([M	−	H]−,	 100);	 IR	max	 (film)	ν:	 3336,	2928,	2860,	2355,	1438,	1264,	1210,	
1079,	1049,	1028,	967,	945,	885,	684	cm−1.	The	data	presented	are	consistent	with	literature	
precedent.151	
	
(1,4-Dioxaspiro[4.5]decan-8-yl)metanol	(23e)	
	
General	procedure	B	was	followed	using	3-methoxy-3-methyl-4,9,12-trioxa-1,2-
diazadispiro[4.2.48.25]tetradec-1-ene	 (102	 mg,	 0.4	 mmol,	 1.0	 equiv),	
formaldehyde	 (0.3	 mL,	 37	 wt	 %	 in	 H2O,	 4	 mmol,	 10	 equiv),	 and	 sodium																																																									
149	 Kazem	Shiroodi,	R.;	Dudnik,	A.	S.;	Gevorgyan,	V.	J.	Am.	Chem.	Soc.,	2012,	134,	6928.	
150	 Callahan,	J.	F.;	Kerns,	J.	K.;	Li,	P.;	Li,	T.;	McCleland,	B.	W.;	Nie,	H.;	Pero,	J.	E.;	Davies,	T.	G.;	Grazia	Carr,	
M.;	Griffiths-Jones,	C.	M.;	Heightman,	T.	D.;	Norton,	D.;	Verdonk,	M.	L.;	Woolford,	A.	J.-	A.;	Willems,	
H.	M.	G.	Biaryl	Pyrazoles	as	NRF2	Regulators.	WO2017/60854,	2017.	
151	 Della,	E.	W.;	Graney,	S.	D.	J.	Org.	Chem.,	2004,	69,	3824.	
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borohydride	 (152	mg,	4.0	mmol,	10	equiv).	 The	crude	mixture	was	purified	via	 flash	 column	
chromatography	 (10	 −	 40%	 EtOAc	 in	 petroleum	 ether)	 to	 give	 the	 titled	 product	 as	 a	
transparent	oil	(52	mg,	75%):	1H	NMR	(600	MHz,	CDCl3)	δ	4.09−3.78	(m,	4H,	OCH2CH2O),	3.46	
(d,	J	=	6.5	Hz,	2H,	HOCH2),	1.86	(br	s,	1H,	HO),	1.78−1.73	(m,	4H,	CHc	+	CHd),	1.52	(td,	J	=	13.5,	
12.8,	4.6	Hz,	3H,	HOCH2CH	+	OCCHa	+	OCCHb),	1.26	(dtd,	J	=	13.5,	12.8,	11.7,	4.0	Hz,	2H,	OCCHa
′	+	OCCHb′);	
13C	NMR	(151	MHz,	CDCl3)	δ	109.1	(OCO),	67.8	(HOCH2),	64.2	(OCH2CH2O),	39.2	
(HOCH2CH),	34.2	(Ca	+	Cb),	26.7	(Cc	+	Cd);	HRMS	(ESI)	calcd	for	C9H16O3Na
+	[M	+	Na]+	195.0992,	
found	 195.0987;	 IR	 max	 (film)	 ν:	 3460,	 2928,	 2863,	 1106,	 1032,	 928,	 890	 cm−1.	 The	 data	
presented	are	consistent	with	literature	precedent.152	
		
tButyl	4-(Hydroxymethyl)piperidine-1-carboxylate	(23f)	
	
General	procedure	B	was	followed	using	tert-butyl	3-methoxy-3-methyl-4-oxa-
1,2,8-triazaspiro[4.5]dec-1-ene-8-carboxylate	 (57	 mg,	 0.2	 mmol,	 1.0	 equiv),	
formaldehyde	 (0.16	 mL,	 37	 wt	 %	 in	 H2O,	 2.0	 mmol,	 10	 equiv),	 and	 sodium	
borohydride	 (76	mg,	 2.0	mmol,	 10	 equiv).	 The	 crude	mixture	was	 purified	 via	 flash	 column	
chromatography	(10−	50%	EtOAc	in	petroleum	ether)	to	give	the	titled	product	as	a	colorless	
oil	(23	mg,	53%):	1H	NMR	(600	MHz,	CDCl3)	δ	4.12	(br	s,	2H,	NCHc	+	NCHd),	3.56−3.44	(m,	2H,	
HOCH2CH),	2.69	(br	s,	2H,	NCHc′	+	NCHd′),	1.75−1.68	(m,	2H,	CHa	+	NCHb),	1.66−1.59	(m,	1H,	
HOCH2CH),	1.45	(s,	9H,	C(CH3)3),	1.20−1.05	(m,	2H,	CHa′	+	CHb′);	
13C	NMR	(151	MHz,	CDCl3)	δ	
155.0	(NCOO),	79.5	(C(CH3)3),	67.8	(HOCH2),	43.8	(br,	Cc	+	Cd),	39.0	(HOCH2CH),	28.7	(br,	Ca	+	
Cb),	28.6	(C(CH3)3);	HRMS	(ESI)	calcd	for	C11H22O3N+	[M	+	H]
+	216.1594,	found	216.1591;	 IR	
max	(film)	ν:	3455,	2974,	2924,	2857,	2355,	1693,	1669,	1424,	1366,	1313,	1274,	1247,	1168,	
1087,	 1039,	 962,	 864,	 769	 cm−1.	 The	 data	 presented	 are	 consistent	 with	 literature	
precedent.153	
	
(Adamantan-2-yl)methanol	(23h)	
	
General	 procedure	 B	 was	 followed	 using	 5-methoxy-5-methyl-5 ′ H-
spiro[adamantane-2,2-[1,3,4]oxadiazole]	 (94	 mg,	 0.4	 mmol,	 1.0	 equiv),	
formaldehyde	 (0.3	 mL,	 37	 wt	 %	 in	 H2O,	 4	 mmol,	 10	 equiv),	 and	 sodium	
borohydride	 (153	mg,	2.0	mmol,	10	equiv).	 The	crude	mixture	was	purified	via	 flash	 column	
chromatography	 (10	 −	 40%	 EtOAc	 in	 petroleum	 ether)	 to	 give	 the	 titled	 product	 as	 a	
transparent	 oil	 (50	mg,	 75%):	 1H	 NMR	 (600	MHz,	 CDCl3)	 δ	 3.74	 (d,	 J	 =	 7.1	 Hz,	 2H,	 HOCH2),	
1.94−1.90	(m,	1H,	HOCH2CH),	1.89−1.84	(m,	4H,	CHb),	1.83−1.79(m,	3H,	CHb′	+	CHa),	1.79−1.77	
(m,	1H,	CHa′),	1.75−1.72	(m,	2H,	CHb′′),	1.57	(br	s,	1H,	CHc),	1.55	(br	s,	3H,	CHc′	+	CHd),	1.25	
(br	s,	1H,	HO);	13C	NMR	(151	MHz,	CDCl3)	δ	65.3	(HOCH2),	47.3	(HOCH2CH),	39.1	(Cb),	38.2	(Cd),	
31.9	(Cb′),	29.2	(Ca),	28.4	(Cc),	27.9	(Cc′);	HRMS	(ESI)	calcd	for	C11H18ONa+	[M	+	Na]
+	189.1250,	
																																																								
152	 Kitbunnadaj,	R.;	Hoffmann,	M.;	Fratantoni,	S.	A.;	Bongers,	G.;	Bakker,	R.	A.;	Wieland,	K.;	Jilali,	A.	e.;	
De	Esch,	I.	J.	P.;	Menge,	W.	M.	P.	B.;	Timmerman,	H.;	Leurs,	R.	Bioorg.	Med.	Chem.,	2005,	13,	6309.	
153	 Renou,	 J.;	 Dias,	 J.;	 Mercey,	 G.;	 Verdelet,	 T.;	 Rousseau,	 C.;	 Gastellier,A.-J.;Arboleás,M.;Touvrey-
Loiodice,M.;Baati,R.;Jean,	L.;	Nachon,	F.;	Renard,	P.-Y.	RSC	Adv.,	2016,	6,	17929.	
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found	189.1247;	 IR	max	 (film)	ν:	3260,	2861,	2849,	1466,	1452,	1066,	1033,	1007,	971	cm−1.	
The	data	presented	are	consistent	with	literature	precedent.154	
	
4-(6-Methoxynaphthalen-2-yl)-2-methylbutan-1-ol	(23j)	
	
General	 procedure	 B	 was	 followed	 using	 2-methoxy-5-(2-(6-
methoxynaph-thalen-2-yl)ethyl)-2,5-dimethyl-2,5-dihydro-1,3,4-
oxadiazole	 (98	mg,	 0.4	mmol,	 1.0	 equiv),	 formaldehyde	 (0.3	mL,	 37	
wt	%	in	H2O,	4	mmol,	10	equiv),	and	sodium	borohydride	(153	mg,	2.0	mmol,	10	equiv).	The	
crude	mixture	was	purified	 via	 flash	 column	chromatography	 (10	−	40%	EtOAc	 in	petroleum	
ether)	to	give	the	titled	product	as	a	yellow	oil	(73	mg,	75%):	1H	NMR	(600	MHz,	CDCl3)	δ	7.66	
(d,	J	=	8.4	Hz,	2H,	HAr),	7.55	(s,	1H,	HAr),	7.33	(dd,	J	=	8.3,	1.8	Hz,	1H,	HAr),	7.14−7.09	(m,	2H,	HAr),	
3.91	 (s,	 3H,	 OCH3),	 3.56	 (br	 s,	 1H,	 HOCHc),	 3.54−3.51	 (m,	 1H,	 HOCHc′),	 2.89−2.79	 (m,	 1H,	
ArCHa),	2.78−2.68	(m,	1H,	ArCHa′),	1.91−1.80	(m,	1H,	CHb),	1.76−1.66	(m,	1H,	CHb′),	1.61−1.50	
(m,	2H,	HOCH2CH	+	OH),	1.02	 (d,	 J	 =	6.7	Hz,	3H,	CHCH3);	
13C	NMR	 (151	MHz,	CDCl3)	δ	 157.3	
(CAr),	137.9	(CAr),	133.1	(CAr),	129.2	(CAr),	129.0	(CArH),	127.9	(CArH),	126.9	(CArH),	126.3	(CArH),	
118.6	 (CArH),	 105.6	 (CArH),	 68.2	 (Cc),	 55.3	 (OCH3),	 35.3	 (Ca),	 34.9	 (Cb),	 33.2	 (HOCH2CH),	 16.5	
(CHCH3);	HRMS	 (ESI)	 calcd	 for	C16H20O2
+	 [M	+	H]+	244.1467,	 found	244.1463;	 IR	max	 (film)	ν:	
3342,	2961,	2926,	2850,	1634,	1604,	1484,	1462,	1391,	1263,	1228	cm−1.		
	
2-Methylpentane-1,5-diol	(23k)	
	
General	 procedure	 B	 was	 followed	 using	 3-(5-methoxy-2,5-dimethyl-2,5-
dihydro-1,3,4-oxadiazol-2-yl)-propan-1-ol	 (37	 mg,	 0.2	 mmol,	 1.0	 equiv),	
formaldehyde	 (0.16	mL,	 37	wt	%	 in	 H2O,	 2.0	mmol,	 10	 equiv),	 and	 sodium	
borohydride	 (76	mg,	 2.0	mmol,	 10	 equiv).	 The	 crude	mixture	was	 purified	 via	 flash	 column	
chromatography	(2%	MeOH	in	dichloromethane)	to	give	the	titled	product	as	a	colorless	oil	(16	
mg,	66%):	 1H	NMR	(600	MHz,	CDCl3)	δ	3.60	 (t,	 J	=	6.1	Hz,	2H,	HOCH2CH2),	3.48−3.36	 (m,	2H,	
HOCH2CH),	 3.16	 (br	 s,	 2H,	 OH),	 1.66−1.56	 (m,	 2H,	 HOCH2CH2),	 1.54−1.45	 (m,	 2H,	
CH2CH2CHCH3),	 1.16−1.06	 (m,	 1H,	 CHCH3),	 0.88	 (d,	 J	 =	 6.7	Hz,	 3H,	 CH3);	
13C	NMR	 (151	MHz,	
CDCl3)	 δ	 67.8	 (HOCH2CH2),	 62.8	 (HOCH2CH),	 35.4	 (HOCH2CH2),	 29.7	 (CH2CH2CHCH3),	 29.1	
(CHCH3),	16.7	(CH3);	HRMS	(ESI)	calcd	for	C6H15O2
+	[M	+	H]+	119.1067,	found	119.1066;	IR	max	
(film)	ν:	3291,	2932,	2869,	1652,	1455,	1418,	1377,	1104,	1038,	940,	897,	731	cm−1.	The	data	
presented	are	consistent	with	literature	precedent.155	
	
2-Methyl-3-(pyridin-4-yl)propan-1-ol	(23l)	
	
General	procedure	B	was	followed	using	2-methoxy-2,5-dimethyl-5-(pyridin-4-
ylmethyl)-2,5-dihydro-1,3,4-oxadiazole	 (88	 mg,	 0.4	 mmol,	 1.0	 equiv),	
formaldehyde	 (0.3	 mL,	 37	 wt	 %	 in	 H2O,	 4	 mmol,	 10	 equiv),	 and	 sodium	
borohydride	 (153	mg,	2.0	mmol,	10	equiv).	 The	crude	mixture	was	purified	via	 flash	 column																																																									
154	 Kawamoto,	T.;	Fukuyama,	T.;	Ryu,	I.	J.	Am.	Chem.	Soc.,	2012,	134,	875.	
155	 Jackson,	W.;	Moffat,	M.;	Perlmutter,	P.;	Tasdelen,	E.	J.	Chem.,	1992,	45,	823.	
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chromatography	 (30	 −	 70%	 EtOAc	 in	 petroleum	 ether)	 to	 give	 the	 titled	 product	 as	 a	
transparent	oil	(30	mg,	50%):	1H	NMR	(600	MHz,	CDCl3)	δ	8.51	(br	s,	2H,	HAr),	7.12	(d,	J	=	4.9	Hz,	
2H,	HAr),	3.51	(dd,	J	=	5.9,	1.0	Hz,	2H,	HOCH2),	2.81	(dd,	J	=	13.4,	6.0	Hz,	1H,	CHa),	2.40	(dd,	J	=	
13.4,	8.4	Hz,	1H,	CHa′),	2.03−1.93	(m,	1H,	HOCH2CH),	1.75	(br	s,	1H,	OH),	0.91	(d,	J	=	6.8	Hz,	
3H,	 CHCH3);	
13C	NMR	 (151	MHz,	 CDCl3)	δ	 150.2	 (CpyridineH),	 149.6	 (CpyridineH),	 124.8	 (CpyridineH),	
67.2	(HOCH	),	39.0	(Ca),	7.2	(HOCH2CH),	16.4	(CHCH3);	HRMS	(ESI)	calcd	for	C9H14NO
+	[M	+	H]+	
152.1071,	found	152.1075;	IR	max	(film)	ν:	3353,	2924,	2348,	2185,	1605,	1043	cm−1.	The	data	
presented	are	consistent	with	literature	precedent.156	
	
3-(Furan-2-yl)-2-methylpropan-1-ol	(23m)	
	
General	 procedure	 B	 was	 followed	 using	 2-(furan-2-ylmethyl)-5-methoxy-2,5-
dimethyl-2,5-dihydro-1,3,4-oxadiazole	 (84	 mg,	 0.4	 mmol,	 1.0	 equiv),	
formaldehyde	 (0.3	 mL,	 37	 wt	 %	 in	 H2O,	 4	 mmol,	 10	 equiv),	 and	 sodium	
borohydride	 (152	mg,	4.0	mmol,	10	equiv).	 The	crude	mixture	was	purified	via	 flash	 column	
chromatography	 (10	 −	 40%	 EtOAc	 in	 petroleum	 ether)	 to	 give	 the	 titled	 product	 as	 a	
transparent	 oil	 (34	 mg,	 60%):	 1H	 NMR	 (600	 MHz,	 CDCl3)	 δ	 7.31	 (dd,	 J	 =	 1.9,	 0.9	 Hz,	
1H,HFuran),6.29(dd,J=3.2,1.9Hz,1H,	HFuran),	6.02(dd,J=3.2,	0.9	Hz,	1H,	HFuran),	3.50	 (d,	 J	=	6.0	Hz,	
2H,	HOCH2),	2.73	(dd,	J	=	14.9,	6.4	Hz,	1H,	CHa),	2.54	(dd,	J	=	14.9,	7.4	Hz,	1H,	CHa′),	2.03	(dq,	J	
=	13.2,	6.4	Hz,	1H,	HOCH2CH),	1.46	(br	s,	1H,	OH),	0.94	(d,	J	=	6.8	Hz,	3H,	CHCH3);	
13C	NMR	(151	
MHz,	CDCl3)	δ	154.7	(CFuran),	141.2	(CFuranH),	110.3	(CFuranH),	106.3	(CFuranH),	67.6	(HOCH2),	35.4	
(Ca),	 31.5	 (HOCH2CH),	 16.5	 (CHCH3);	HRMS	 (ESI)	 calcd	 for	C8H11O2
−	 [M	−	H]−	 139.0754,	 found	
139.0753;	IR	max	(film)	ν:	3342,	2919,	1595,	1507,	1460,	1381,	1146,	1033,	927	cm−1.	The	data	
presented	are	consistent	with	literature	precedent.157	
	
2-Methylhex-5-en-1-ol	(23n)	
	
General	 procedure	 B	 was	 followed	 using	 2-(but-3-en-1-yl)-5-methoxy-2,5-
dimethyl-2,5-dihydro-1,3,4-ox-adiazole	 (37	 mg,	 0.2	 mmol,	 1.0	 equiv),	
formaldehyde	 (0.16	 mL,	 37	 wt	 %	 in	 H2O,	 2.0	 mmol,	 10	 equiv),	 and	 sodium	
borohydride	 (76	 mg,	 2.0	 mmol,	 10	 equiv).	 An	 88%	 NMR	 yield	 was	 calculated	 using	 1,3,5-
trimethoxybenzene	 (11	 mg,	 0.066	 mmol,	 0.33	 equiv)	 as	 an	 internal	 standard.	 The	 crude	
mixture	was	purified	via	flash	column	chromatography	(0	−	40%	EtOAc	in	petroleum	ether)	to	
give	the	titled	product	as	a	colorless	oil	(16	mg,	69%):	1H	NMR	(600	MHz,	CDCl3)	δ	5.81	(ddt,	J	=	
17.0,	10.2,	6.6	Hz,	1H,	CH2=CH),	5.02	(dd,	J	=	17.0,	1.9	Hz,	1H,	Hb),	4.95	(dd,	J	=	10.2,	1.9	Hz,	1H,	
Ha),	3.48	(ddd,	J	=	45.3,	10.5,	6.1	Hz,	2H,	CHCH2OH),	2.18−2.09	(m,	1H,	CH2=CHCHc),	2.09−1.99	
(m,	1H,	CH2=CHCHc′),	 1.70−1.60	 (m,	1H,	CH2CHdCHCH3),	 1.58−1.47	 (m,	1H,	CH2CHd′CHCH3),	
1.33	(br	s,	1H,	OH),	1.28−1.16	(m,	1H,	CHCH3),	0.93	(d,	J	=	6.7	Hz,	3H,	CH3);	
13C	NMR	(151	MHz,	
CDCl3)	δ	 139.0	 (CH2=CH),	114.6	 (CH2=CH),	68.3	 (CHCH2OH),	35.4	 (Cc),	32.4	 (Cd),	31.3	 (CHCH3),	
																																																								
156	 Nacsa,	E.	D.;	MacMillan,	D.	W.	C.	J.	Am.	Chem.	Soc.,	2018,	140,	3322.		
157	 Harmata,	M.;	Gamlath,	C.	B.;	Barnes,	C.	L.;	Jones,	D.	E.	J.	Org.	Chem.,	1995,	60,	5077.	
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16.6	 (CH3);	 LRMS	 (ESI,	m/z)	 113.5	 ([M	 +	 H]
+,	 100);	 IR	max	 (film)	ν:	 3436,	 2969,	 2355,	 2316,	
1448,	1329,	1046	cm−1.	The	data	presented	are	consistent	with	literature	precedent.158	
	
9.3.3.	General	procedure	C:	synthesis	of	benzimidazoles	derivatives	24	
	
	
	
The	reaction	slug	from	general	procedure	A	was	collected	into	a	round-bottom	flask	containing	
a	 biphasic	 solution	 of	 brine	 and	 toluene	with	 stirring.	 Upon	 resting,	 the	 toluene	 phase	was	
syringed	out	and	injected	into	another	open	round-bottom	flask	charged	with	freshly	activated	
4	Å	molecular	 sieves.	The	mixture	was	stirred	 for	another	1	min	before	o-phenylenediamine	
(1.5	equiv)	was	added.	The	reaction	mixture	was	then	bubbled	with	one	O2	balloon	and	stirred	
at	room	temperature	(30	°C)	for	12	h.	Molecular	sieves	were	filtered	over	filter	paper,	and	the	
filtrate	was	concentrated	under	vacuum	before	being	purified	via	flash	chromatography	with	
appropriate	eluent	combinations	to	afford	the	final	benzimidazole	derivatives.	
	
2-(1,2,3,4-Tetrahydronaphthalen-2-yl)-1H-benzimidazole	(24a)	
	
General	 procedure	 C	 was	 followed	 using	 5-methoxy-5-methyl-3,4-
dihydro-1H,5′H-spiro[naphthalene-2,2-[1,3,4]oxadiazole]	 (46	 mg,	 0.2	
mmol,	 1.0	 equiv),	 formaldehyde	 (0.15	mL,	 37	wt	%	 in	H2O,	 2	mmol,	 10	
equiv),	and	o-phenylenediamine	(32	mg,	0.3	mmol,	1.5	equiv).	The	crude	mixture	was	purified	
via	 flash	 column	 chromatography	 (10	 −	 40%	 EtOAc	 in	 petroleum	 ether)	 to	 give	 the	 titled	
product	as	a	white	solid	(36	mg,	72%):	1H	NMR	(600	MHz,	CDCl3)	δ	9.06	(br	s,	1H,	NH),	7.76	(br	
s,	1H,	HAr),	7.40	(br	s,	1H,	HAr),	7.24	(d,	J	=	5.5	Hz,	2H,	HAr),	7.29−7.13	(m,	4H,	HAr),	3.41	(tdd,	J	=	
10.3,	 5.5,	 3.1	 Hz,	 1H,	 CCH),	 3.35−3.20	 (m,	 2H,	 ArCH2CH),	 2.97	 (qp,	 J	 =	 10.3,	 5.5	 Hz,	 2H,	
ArCH2CH2),	2.48−	2.37	(m,	1H,	CHCHa′),	2.14	(dtd,	J	=	13.0,	10.3,	6.2	Hz,	1H,	CHCHc′);	
13C	NMR	
(151	MHz,	methanol-d4)	δ	159.8	(CAr),	136.8	(CAr),	136.1	(CAr),	130.0	(CArH),	129.9	(CArH),	127.1	
(CArH),	126.9	(CArH),	123.3	(CArH),	115.4	(br,	CArH),	36.7	(CCH),	35.4	(ArCH2CH),	30.0	(ArCH2CH2),	
29.6	 (Ca);	 One	 aromatic	 carbon	 is	 not	 seen	 in	 the	
13C{1H}	 NMR	 spectrum	 due	 to	 peak	
broadening;	HRMS	(ESI)	calcd	for	C17H17N2
+	[M	+	H]+	249.1387,	found	249.1392;	IR	max	(film)	ν:	
2921,	1423,	1275,	1009,	993,	932,	743	cm−1.	mp:	239−241	°C.	
	
2-(Tetrahydro-2H-pyran-4-yl)-1H-benzimidazole	(24b)	
	
General	procedure	C	was	followed	using	3-methoxy-3-methyl-4,8-dioxa-1,2-
diazaspiro[4.5]dec-1-ene	(37	mg,	0.2	mmol,	1.0	equiv),	 formaldehyde	(0.15	
mL,	37	wt	%	 in	H2O,	2	mmol,	10	equiv),	and	o-	phenylenediamine	 (32	mg,																																																									
158	 Peram,	P.	S.;	Vences,	M.;	Schulz,	S.	Org.	Biomol.	Chem.,	2017,	15,	6967.		
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0.3	mmol,	1.5	equiv).	The	crude	mixture	was	purified	via	flash	column	chromatography	(10	−	
40%	EtOAc	in	petroleum	ether)	to	give	the	titled	product	as	a	transparent	oil	(31	mg,	76%):	1H	
NMR	(600	MHz,	methanol-d4)	δ	7.51	(dd,	J	=	6.1,	3.2	Hz,	2H,	HAr),	7.19	(dd,	J	=	6.1,	3.2	Hz,	2H,	
HAr),	4.06	(dt,	J	=	11.5,	3.3	Hz,	2H,	OCHc	+	OCHd),	3.65−3.53	(m,	2H,	OCHc′	+	OCHd′),	3.24−3.15	
(m,	1H,	CCH),	2.04−1.92	(m,	4H,	CHa	+	OCHb);	
13C	NMR	(151	MHz,	Methanol-d4)	δ	 	159.0	(CAr),	
123.3	(CArH),	115.2	(br,	CArH),	68.6	(Cc	+	Cd),	36.8	(CCH),	32.4	(Ca	+	Cb);	one	aromatic	carbon	is	
not	 seen	 in	 the	 13C{1H}	 NMR	 spectrum	 due	 to	 peak	 broadening;	 HRMS	 (ESI)	 calcd	 for	
C12H15N2O
+	[M	+	H]+	203.1181,	found	203.1184;	IR	max	(film)	ν:	2958,	2922,	2852,	1457,	1427,	
1128,	739	cm−1.	mp:	225−227	°C.	
	
2-(Tetrahydro-2H-thiopyran-4-yl)-1H-benzimidazole	(24c)	
	
General	procedure	C	was	 followed	using	3-methoxy-3-methyl-4-oxa-8-thia-
1,2-diazaspiro[4.5]dec-1-ene	 (40	 mg,	 0.2	 mmol,	 1.0	 equiv),	 formaldehyde	
(0.16	mL,	37	wt	%	in	H2O,	2.0	mmol,	10	equiv),	and	o-	phenylenediamine	(32	
mg,	0.3	mmol,	1.5	equiv).	The	crude	mixture	was	purified	via	flash	column	chromatography	(10	
−	40%	EtOAc	in	petroleum	ether)	to	give	the	titled	product	as	a	white	solid	(24	mg,	55%):	1H	
NMR	(600	MHz,	methanol-d4)	δ		7.51	(br	s,	2H,	HAr),	7.20	(dd,	J	=	6.1,	3.1	Hz,	2H,	HAr),	4.59	(s,	
1H,	NH),	3.00	(ddd,	J	=	12.0,	8.7,	3.3	Hz,	1H,	CCH),	2.92−2.85	(m,	2H,	SCHc	+	SCHd),	2.73	(d,	J	=	
14.0	Hz,	2H,	SCHc′	+	SCHb′),	2.37	(dd,	J	=	13.6,	3.1	Hz,	2H,	CHa	+	CHb),	2.06	(qd,	J	=	12.5,	3.2	Hz,	
2H,	 CHa	 +	 CHb);	
13C	NMR	 (151	MHz,	methanol-d4)	δ	 159.7	 (CAr),	 123.3	 (br,	 CArH),	 39.5	 (CCH),	
33.8	(Ca	+	Cb),	29.2	(Cc	+	Cd);	two	aromatic	carbons	are	not	seen	in	the	
13C	NMR	spectrum	due	
to	 peak	 broadening;	HRMS	 (ESI)	 calcd	 for	 C12H15N2S
+	 [M	+	H]+	 219.0956,	 found	 219.0955;	 IR	
max	(film)	ν:	3394,	2924,	1709,	1432,	1274,	1047,	951,	744	cm−1;	mp	220−222	°C.	
	
2-(Tetrahydrothiophene-3-yl)-1H-benzimidazole	(24d)	
	
General	 procedure	 C	 was	 followed	 using	 3-methoxy-3-methyl-4-oxa-7-thia-
1,2-diazaspiro[4.4]non-1-ene	 (38	 mg,	 0.2	 mmol,	 1.0	 equiv),	 formaldehyde	
(0.15	mL,	37	wt	%	 in	H2O,	2	mmol,	10	equiv),	and	o-	phenylenediamine	(32	
mg,	0.3	mmol,	1.5	equiv).	The	crude	mixture	was	purified	via	flash	column	chromatography	(10	
−	40%	EtOAc	in	petroleum	ether)	to	give	the	titled	product	as	a	white	solid	(29	mg,	72%):	 1H	
NMR	(600	MHz,	methanol-d4)	δ	 	7.55−7.38	(m,	2H,	HAr),	7.21−7.13	(m,	2H,	HAr),	3.60	(ddd,	J	=	
15.8,	9.7,	6.3	Hz,	1H,	CCH),	3.23	(dd,	J	=	10.4,	6.9	Hz,	1H,	CCHCHa),	3.14	(dd,	J	=	10.4,	9.3	Hz,	
1H,	CCHCHa′),	2.98	(dd,	J	=	8.4,	5.0	Hz,	2H,	SCH2CH2),	2.52	(dt,	J	=	10.4,	5.1	Hz,	1H,	CCHCHb),	
2.36−2.26	 (m,	 1H,	 CCHCHb′);	
13C	 NMR	 (151	MHz,	methanol-d4)	 δ	 	 156.4	 (CAr),	 123.4	 (CArH),	
115.4	 (br,	 CArH),	 45.0	 (CCH),	 37.0	 (Cb),	 36.0	 (Ca),	 31.2	 (SCH2CH2);	 one	 aromatic	 carbon	 is	 not	
seen	in	the	13C{1H}	NMR	spectrum	due	to	peak	broadening;	HRMS	(ESI)	calcd	for	C11H13N2S
+	[M	
+	 H]+	 205.0805,	 found	 205.0799;	 IR	max	 (film)	 ν:	 2923,	 2356,	 2348,	 2158,	 2034,	 1420,	 740	
cm−1;	mp	242−244	°C.	
	
	 	
	
	
210	 	 	 	 	 		
2-(1,4-Dioxaspiro[4.5]decan-8-yl)-1H-benzimidazole	(24e)	
	
General	procedure	C	was	followed	using	3-methoxy-3-methyl-4,9,12-trioxa-
1,2-diazadispiro[4.2.48.25]tetradec-1-ene	 (51	 mg,	 0.2	 mmol,	 1.0	 equiv),	
formaldehyde	(0.15	mL,	37	wt	%	in	H2O,	2	mmol,	10	equiv),	and	o-phenylenediamine	(32	mg,	
0.3	mmol,	1.5	equiv).	The	crude	mixture	was	purified	via	flash	column	chromatography	(10	−	
40%	EtOAc	 in	 petroleum	ether)	 to	 give	 the	 titled	 product	 as	 a	white	 solid	 (41	mg,	 80%):	 1H	
NMR	(600	MHz,	CDCl3)	δ	7.57−7.51	(m,	2H,	HAr),	7.20	(dd,	 J	=	6.1,	3.1	Hz,	2H,	HAr),	4.01−3.90	
(m,	 4H,	OCH2CH2O),	 3.02	 (tt,	 J	 =	 11.8,	 3.7	Hz,	 1H,	 CCH),	 2.21−2.13	 (m,	 2H,	 CHCHa	 +	 CHCHb),	
2.07−1.97	(m,	2H,	CHCHa′	+	CHCHb′),	1.90−1.83	(m,	2H,	CCHc	+	CCHd),	1.68	(td,	J	=	13.2,	4.3	Hz,	
2H,	 CCHc′	+	 CCHd′);	
13C	NMR	 (151	MHz,	 CDCl3)	δ	 157.9	 (CAr),	 122.4	 (CArH),	 114.8	 (br,	 CArH),	
108.1	(OCO),	64.5	(Ce),	64.4	(Cf),	37.3	(CCH),	34.4	(Cc	+	Cd),	29.2	(Ca	+	Cb);	one	aromatic	carbon	
is	 not	 seen	 in	 the	 13C{1H}	 NMR	 spectrum	 due	 to	 peak	 broadening;	 HRMS	 (ESI)	 calcd	 for	
C15H19N2O2
+	[M	+	H]+	259.1457,	found	259.1447;	IR	max	(film)	ν:	2988,	2945,	1678,	1588,	1402,	
1344,	1249,	1219,	1089,	1013,	967,	838,	735	cm−1;	mp	230−232	°C.	
	
tButyl	4-(1H-Benzimidazol-2-yl)piperidine-1-carboxylate	(24f)	
	
General	procedure	C	was	followed	using	tert-butyl	3-methoxy-3-methyl-
4-oxa-1,2,8-triazaspiro[4.5]dec-1-ene-8-carboxylate	 (57	 mg,	 0.2	 mmol,	
1.0	equiv),	formaldehyde	(0.16	mL,	37	wt	%	in	H2O,	2.0	mmol,	10	equiv),	
and	 o-phenylenediamine	 (32	mg,	 0.3	mmol,	 1.5	 equiv).	 The	 crude	mixture	 was	 purified	 via	
flash	column	chromatography	(10	−	40%	EtOAc	in	petroleum	ether)	to	give	the	titled	product	
as	a	white	solid	(30	mg,	49%):	1H	NMR	(600	MHz,	CDCl3)	δ		10.02	(br	s,	1H,	NH),	7.71	(br	s,	1H,	
HAr),	7.41	(br	s,	1H,	HAr),	7.22	(dd,	J	=	6.0,	3.1	Hz,	2H,	HAr),	4.23	(br	s,	2H,	NCHc	+	NCHd),	3.10	(tt,	
J	=	11.8,	3.8	Hz,	1H,	CCH),	2.89	(br	s,	2H,	NCHc′	+	NCHd′),	2.13−2.04	(m,	2H,	CHa	+	CHb),	1.85	
(qd,	J	=	12.2,	4.3	Hz,	2H,	CHa′	+	CHb′),	1.47	(s,	9H,	C(CH3)3);	
13C	NMR	(151	MHz,	CDCl3)	δ	157.0	
(CAr),	154.9	 (NCOOC(CH3)3),	143.2	 (br,	CAr),	122.5	 (br,	CArH),	119.1	 (br,	CArH),	110.7	 (br,	CArH),	
80.0	(C(CH3)3),	44.1	(br,	Cc	+	Cd),	37.1	(CCH),	30.9	(br,	Ca	+	Cb),	28.6	(C(CH3)3);	HRMS	(ESI)	calcd	
for	C17H24O2N3
+	 [M	+	H]+	302.1869,	 found	302.1869;	 IR	max	(film)	ν:	2976,	1692,	1536,	1425,	
1366,	1272,	1231,	1166,	1123,	980,	861,	768,	742	cm−1;	mp	226−228	°C.	
	
2-[1-(Pyrimidin-2-yl)piperidin-4-yl]-1H-benzimidazole	(24g)	
	
General	 procedure	 C	 was	 followed	 using	 3-methoxy-3-methyl-8-
(pyrimidin-2-yl)-4-oxa-1,2,8-triazaspiro[4.5]dec-1-ene	 (55	 mg,	 0.2	
mmol,	1.0	equiv),	formaldehyde	(0.16	mL,	37	wt	%	in	H2O,	2.0	mmol,	
10	 equiv),	 and	 o-phenylenediamine	 (32	 mg,	 0.3	 mmol,	 1.5	 equiv).	 The	 crude	 mixture	 was	
purified	 via	 flash	 column	 chromatography	 (10	 −	 40%	 EtOAc	 in	 petroleum	 ether)	 to	 give	 the	
titled	product	as	a	white	solid	(40	mg,	72%):	1H	NMR	(600	MHz,	CDCl3)	δ	9.75	(br	s,	1H,	NH),	
8.30	(d,	J	=	4.6	Hz,	2H,	Hpyrimidine),	7.54	(br	s,	2H,	HAr),	7.22	(dd,	J	=	5.9,	3.1	Hz,	2H,	HAr),	6.47	(t,	J	
=	4.6	Hz,	1H,	Hpyrimidine),	 4.86	 (d,	 J	=	13.5	Hz,	2H,	NCHc	+	NCHd),	3.22	 (tt,	 J	 =	11.8,	3.7	Hz,	1H,	
CCH),	3.10−2.99	(m,	2H,	NCHc′	+	NCHd′),	2.19	(d,	J	=	11.3	Hz,	2H,	CHa	+	CHb),	1.92	(qd,	J	=	12.4,	
3.9	 Hz,	 2H,	 CHa′	 +	 CHb′);	
13C	 NMR	 (151	MHz,	 CDCl3)	 δ	 161.7	 (Cpyrimidine),	 157.9	 (CpyrimidineH),	
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157.2	 (CAr),	 122.6	 (br,	CArH),	 110.0	 (CpyrimidineH),	 43.9	 (Cc	 +	Cd),	 37.3	 (CCH),	 30.7	 (Ca	+	Cb);	 two	
aromatic	 carbons	are	not	 seen	 in	 the	 13C{1H}	NMR	spectrum	due	 to	peak	broadening;	HRMS	
(ESI)	calcd	for	C16H18N5
+	[M	+	H]+	280.1557,	found	280.1546;	IR	max	(film)	ν:	2936,	2346,	1982,	
1584,	1541,	1518,	1481,	1456,	1426,	1358,	1304,	1272,	1233,	1105,	1050,	977,	798,	741	cm−1;	
mp	222−224	°C.	
	
2-(Adamantan-2-yl)-1H-benzimidazole	(24h)	
	
General	 procedure	 C	 was	 followed	 using	 5-methoxy-5-methyl-5′ H-
spiro[adamantane-2,2-[1,3,4]oxadiazole]	 (47	 mg,	 0.2	 mmol,	 1.0	 equiv),	
formaldehyde	 (0.15	 mL,	 37	 wt	 %	 in	 H2O,	 2	 mmol,	 10	 equiv),	 and	 o-
phenylenediamine	 (32	 mg,	 0.3	 mmol,	 1.5	 equiv).	 The	 crude	 mixture	 was	 purified	 via	 flash	
column	chromatography	(10	−	40%	EtOAc	 in	petroleum	ether)	to	give	the	titled	product	as	a	
dark	yellow	solid	(40	mg,	79%):	1H	NMR	(600	MHz,	CDCl3)	δ	7.57	(br	s,	2H,	HAr),	7.21	(dd,	J	=	
6.0,	 3.1	Hz,	 2H,	HAr),	 3.27	 (s,	 1H,	CCH),	 2.66−2.59	 (m,	 2H,	CHa),	 2.08−1.94	 (m,	 7H,	CHc	 +	Cb),	
1.87−1.86	(m,	1H,	CHc′),	1.83	(br	s,	2H,	Cd),	1.77−1.70	(m,	2H,	Cb);	
13C	NMR	(151	MHz,	CDCl3)	δ	
157.2	(CAr),	122.3	(CArH),	44.6	(CCH),	38.4	(Cb),	37.6	(Cd),	33.1	(Cb′),	31.0	(Ca),	27.8	(Cc),	27.7	(Cc
′);	two	aromatic	carbons	are	not	seen	in	the	
13C{1H}	NMR	spectrum	due	to	peak	broadening;	
HRMS	(ESI)	calcd	for	C17H21N2
+	[M	+	H]+	253.1705,	found	253.1700;	IR	max	(film)	ν:	2922,	1422,	
1275,	1009,	993,	743	cm−1;	mp	244−246	°C.	
	
2-Cyclobutyl-1H-benzimidazole	(24i)	
	
General	 procedure	 C	 was	 followed	 using	 7-methoxy-7-methyl-8-oxa-5,6-
diazaspiro[3.4]oct-5-ene	 (31	 mg,	 0.2	 mmol,	 1.0	 equiv),	 formaldehyde	 (0.16	
mL,	37	wt	%	in	H2O,	2.0	mmol,	10	equiv),	and	o-phenylenediamine	(32	mg,	0.3	
mmol,	1.5	equiv).	The	crude	mixture	was	purified	via	flash	column	chromatography	(10	−	40%	
EtOAc	 in	petroleum	ether)	 to	give	 the	 titled	product	as	a	white	 solid	 (20	mg,	59%):	 1H	NMR	
(600	MHz,	CDCl3)	δ	7.56	(dd,	J	=	6.0,	3.2	Hz,	2H,	HAr),	7.21	(dd,	J	=	6.0,	3.1	Hz,	2H,	HAr),	3.80	(p,	J	
=	8.7	Hz,	1H,	CCH),	2.58−2.47	(m,	2H,	CHa	+	CHb),	2.47−2.38	(m,	2H,	CHa′	+	CHb′),	2.14−2.01	
(m,	1H,	CHc),	1.99−1.91	(m,	1H,	CHc′);	
13C	NMR	(151	MHz,	CDCl3)	δ	158.1	(CAr),	138.6	(br,	CAr),	
122.3	(CArH),	114.8	(br,	CArH),	34.3	(CCH),	28.2	(Ca	+	Cb),	18.8	(Cc);	HRMS	(ESI)	calcd	for	C11H13N2
+	
[M	+	H]+	173.1073,	found	173.1069;	IR	max	(film)	ν:	2942,	1537,	1455,	1419,	1328,	1272,	982,	
740	cm−1;	mp	186−188	°C.	The	data	presented	are	consistent	with	literature	precedent.159	
	
2-[1-(Pyridin-4-yl)propan-2-yl]-1H-benzimidazole	(24l)	
	
General	 procedure	 C	 was	 followed	 using	 2-methoxy-2,5-dimethyl-5-
(pyridin-4-ylmethyl)-2,5-dihydro-1,3,4-oxadiazole	 (44	mg,	 0.2	mmol,	 1.0	
equiv),	formaldehyde	(0.16	mL,	37	wt	%	in	H2O,	2.0	mmol,	10	equiv),	and																																																									
159	 Genovino,	J.;	Lian,	Y.;	Zhang,	Y.;	Hope,	T.	O.;	Juneau,	A.;	Gagne,́	Y.;	Ingle,	G.;	Frenette,	M.	Org.	Lett.,	
2018,	20,	3229.	
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o-phenylenediamine	 (32	mg,	 0.3	mmol,	 1.5	 equiv).	 The	 crude	mixture	was	 purified	 via	 flash	
column	chromatography	(10	−	100%	EtOAc	in	petroleum	ether)	to	give	the	titled	product	as	a	
yellow	solid	(23	mg,	48%):	1H	NMR	(600	MHz,	CDCl3)	δ	10.14	(br	s,	1H,	NH),	8.40−8.36	(m,	2H,	
HPyridine),	7.73	 (br	 s,	1H,	HAr),	7.34	 (br	 s,	1H,	HAr),	7.23	 (s,	2H,	HAr),	7.00−6.98	 (m,	2H,	HPyridine),	
3.35	(p,	J	=	7.0	Hz,	1H,	CCH),	3.28	(dd,	J	=	13.4,	7.5	Hz,	1H,	CHCHa),	3.00	(dd,	J	=	13.4,	6.8	Hz,	
1H,	 CHCHa′),	 1.47	 (d,	 J	 =	 6.9	 Hz,	 3H,	 CH3);	
13C	 NMR	 (151	MHz,	 CDCl3)	 δ	 157.3	 (CAr),	 149.5	
(CPyridineH),	 148.8	 (CPyridine),	 143.1	 (br,	 CAr),	 124.5	 (CPyridineH),	 122.3	 (br,	 CArH),	 110.5	 (br,	 CArH),	
41.8	 (Ca),	 35.9	 (CCH),	 19.4	 (CH3).	 HRMS	 (ESI)	 calcd	 for	 C15H16N3
+	 [M	 +	 H]+	 238.1344,	 found	
238.1344;	IR	max	(film)	ν:	3051,	2969,	1603,	1559,	1535,	1484,	1454,	1419,	1328,	1272,	1219,	
1110,	1070,	1043,	993,	907,	843,	795,	768,	747	cm−1;	mp	188−	190	°C.	
	
2-[1-(Furan-2-yl)propan-2-yl]-1H-benzimidazole	(24m)	
	
General	procedure	C	was	 followed	using	2-(furan-2-ylmethyl)-5-methoxy-
2,5-dimethyl-2,5-dihydro-1,3,4-oxadiazole	 (42	 mg,	 0.2	 mmol,	 1.0	 equiv),	
formaldehyde	 (0.15	 mL,	 37	 wt	 %	 in	 H2O,	 2	 mmol,	 10	 equiv),	 and	 o-
phenylenediamine	 (32	 mg,	 0.3	 mmol,	 1.5	 equiv).	 The	 crude	 mixture	 was	 purified	 via	 flash	
column	chromatography	(10	−	40%	EtOAc	 in	petroleum	ether)	to	give	the	titled	product	as	a	
white	 solid	 (34	 mg,	 75%):	 1H	 NMR	 (600	 MHz,	 CDCl3)	 δ	 7.53	 (dd,	 J	 =	 6.1,	 3.2	 Hz,	 2H,	 HAr),	
7.30−7.27	(m,	1H,	HFuran),	7.23−7.18	(m,	2H,	HAr),	6.24	(dd,	J	=	3.2,	1.9	Hz,	1H,	HFuran),	5.96	(d,	J	=	
3.2	Hz,	1H,	HFuran),	3.51	(h,	J	=	7.1	Hz,	1H,	CCH),	3.24	(dd,	J	=	15.0,	7.2	Hz,	1H,	CHCHa),	3.06	(dd,	J	
=	15.0,	7.2	Hz,	1H,	CHCHa′),	1.48	(d,	J	=	7.0	Hz,	3H,	CHCH3);	
13C	NMR	(151	MHz,	CDCl3)	δ	158.1	
(CFuran),	153.3	(CAr),	141.5	(CFuranH),	122.4	(CArH),	115.1	(br,	CArH),	110.5	(CFuranH),	107.1(CFuranH),	
34.6	(Ca),	34.1	(CCH),	19.3	(CH3);	one	aromatic	carbon	is	not	seen	in	the	
13C{1H}	NMR	spectrum;	
HRMS	 (ESI+):	m/z	 calcd	 for	 C14H15N2O
+	 [M	 +	H]+	 227.1177,	 found	 227.1184;	 IR	max	 (film)	ν:	
2921,	1423,	1275,	1009,	993,	932,	743	cm−1;	mp	180−182	°C.	
	
2-(Hex-5-en-2-yl)-1H-benzimidazole	(24n)	
	
General	 procedure	 C	 was	 followed	 using	 2-(but-3-en-1-yl)-5-methoxy-2,5-
dimethyl-2,5-dihydro-1,3,4-oxadiazole	 (37	 mg,	 0.2	 mmol,	 1.0	 equiv),	
formaldehyde	 (0.16	 mL,	 37	 wt	 %	 in	 H2O,	 2.0	 mmol,	 10	 equiv)	 and	 o-	
phenylenediamine	 (32	 mg,	 0.3	 mmol,	 1.5	 equiv).	 The	 crude	 mixture	 was	 purified	 via	 flash	
column	chromatography	(10	−	40%	EtOAc	 in	petroleum	ether)	to	give	the	titled	product	as	a	
white	solid	(29	mg,	73%).	1H	NMR	(600	MHz,	CDCl3)	δ	10.18	(br	s,	1H,	NH),	7.55	(br	s,	2H,	HAr),	
7.21	(dd,	 J	=	6.0,	3.1	Hz,	2H,	HAr),	5.75	(ddt,	 J	=	17.0,	10.2,	6.6	Hz,	1H,	CH2=CH),	4.97	(dd,	 J	=	
17.0,	1.8	Hz,	1H,	Ha),	4.93	(dd,	J	=	10.2,	1.8	Hz,	1H,	Hb),	3.14	(h,	J	=	7.0	Hz,	1H,	CCH),	2.14−2.05	
(m,	2H,	CH2=CHCH2),	2.04−1.97	(m,	1H,	CCHCHc),	1.85−1.77	(m,	1H,	CCHCHc′),	1.45	(d,	J	=	7.1	
Hz,	 3H,	 CH3);	
13C	 NMR	 (151	 MHz,	 CDCl3)	 δ	 159.3	 (CAr),	 137.9	 (CH2=CH),	 122.3	 (CArH),	 115.3	
(CH2CH),	 35.6	 (Cc),	 34.2	 (CCH),	 31.6	 (CH2=CHCH2),	 19.8	 (CH3);	 two	 aromatic	 carbons	 are	 not	
seen	 in	 the	 13C	 NMR	 spectrum;	 HRMS	 (ESI)	 calcd	 for	 C13H17N2
+	 [M	 +	 H]+	 201.1386,	 found	
201.1379;	IR	max	(film)	ν:	3074,	2968,	2932,	2736,	1818,	1640,	1538,	1454,	1426,	1330,	1272,	
989,	906,	745,	729	cm−1;	mp	182−185	°C.	
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2-(4,4-Dimethylhept-6-yn-2-yl)-1H-benzimidazole	(24o)	
	
General	procedure	C	was	 followed	using	2-(2,2-dimethylpent-4-yn-1-yl)-5-
methoxy-2,5-dimethyl-2,5-dihydro-1,3,4-oxadiazole	 (45	mg,	 0.2	mmol,	 1.0	
equiv),	formaldehyde	(0.16	mL,	37	wt	%	in	H2O,	2.0	mmol,	10	equiv),	and	o-
phenylenediamine	 (32	mg,	 0.3	mmol,	 1.5	 equiv).	 The	 crude	mixture	 was	
purified	 via	 flash	 column	 chromatography	 (10	 −	 40%	 EtOAc	 in	 petroleum	 ether)	 to	 give	 the	
titled	product	as	a	white	solid	(19	mg,	39%):	1H	NMR	(600	MHz,	CDCl3)	δ	9.68	(br	s,	1H,	NH),	
7.71	 (br	 s,	1H,	HAr),	7.38	 (br	 s,	1H,	HAr),	7.21	 (dd,	 J	=	6.2,	2.9	Hz,	2H,	HAr),	3.29−3.21	 (m,	1H,	
CCHCH3),	 2.12	 (dd,	 J	 =	 14.4,	 8.9	 Hz,	 1H,	 CHCCHb),	 2.07	 (dd,	 J	 =	 16.2,	 3.2	 Hz,	 1H,	 CHCCHa),	
2.02−1.93	(m,	2H,	CHCCH2	+	CHCCHa′),	1.72	(dd,	J	=	14.4,	4.0	Hz,	1H,	CHCCHb′),	1.44	(d,	J	=	7.1	
Hz,	3H,	CHCH3),	0.92	(d,	J	=	17.9	Hz,	6H,	C(CH3)2);	
13C	NMR	(151	MHz,	CDCl3)	δ	159.7	(CAr),	122.3	
(br,	 CArH),	 110.7	 (br,	CArH),	 82.6	 (CHCCH2),	 70.5	 (CHCCH2),	 47.1	 (Cb),	 34.0	 (C(CH3)2),	 31.9	 (Ca),	
31.2	(CCHCH3),	27.3	(C(CH3)2),	27.1	(C(CH3)2),	23.3	(CCHCH3);	one	aromatic	carbon	is	not	seen	in	
the	13C	NMR	spectrum;	HRMS	(ESI)	calcd	for	C16H21N2
+	[M	+	H]+	241.1699,	found	241.1690;	IR	
max	 (film)	 ν:	 3311,	 2965,	 2752,	 2367,	 1538,	 1453,	 1424,	 1335,	 1269,	 994,	 746	 cm−1;	 mp	
191−192	°C.	
	
2-(1-Cyclopropylethyl)-1H-benzimidazole	(24p)	
	
General	 procedure	 C	 was	 followed	 using	 2-cyclopropyl-5-methoxy-2,5-
dimethyl-2,5-dihydro-1,3,4-oxadiazole	 (34	 mg,	 0.2	 mmol,	 1.0	 equiv),	
formaldehyde	 (0.16	 mL,	 37	 wt	 %	 in	 H2O,	 2.0	 mmol,	 10	 equiv),	 and	 o-	
phenylenediamine	 (32	 mg,	 0.3	 mmol,	 1.5	 equiv).	 The	 crude	 mixture	 was	 purified	 via	 flash	
column	 chromatography	 (10−40%	 EtOAc	 in	 petroleum	 ether)	 to	 give	 the	 titled	 product	 as	 a	
white	solid	(26	mg,	69%):	1H	NMR	(600	MHz,	CDCl3)	δ	9.49	(br	s,	1H,	NH),	7.73	(br	s,	1H,	HAr),	
7.41	(br	s,	1H,	HAr),	7.22	(dd,	J	=	6.1,	3.1	Hz,	2H,	HAr),	2.36	(dq,	J	=	9.6,	7.0	Hz,	1H,	CCH),	1.56	(d,	
J	=	7.0	Hz,	3H,	CH3),	1.10	(dddd,	J	=	13.0,	9.6,	8.0,	4.9	Hz,	1H,	CHCHCH2),	0.71−0.63	(m,	2H,	CHa	
+	CHa′),	0.44−0.38	(m,	1H,	CHb),	0.36−0.30	(m,	1H,	CHb′);	
13C	NMR	(151	MHz,	CDCl3)	δ	158.7	
(CAr),	143.4	(br,	CAr),	133.5	(br,	CAr),	122.3	(CArH),	119.4	(br,	CArH),	110.4	(br,	CArH),	39.5	(CCH),	
19.0	(CH3),	16.6	(CCHCH),	4.8	(Ca),	4.4	(Cb);	HRMS	(ESI)	calcd	for	C12H15N2
+	[M	+	H]+	187.1230,	
found	 187.1221;	 IR	max	 (film)	 ν:	 2969,	 2317,	 2135,	 1456,	 1414,	 1274,	 1076,	 744	 cm−1;	 mp	
187−189	°C.	
	
	 	
	
	
214	 	 	 	 	 		
		 	
	
	
	 	 	 	 	 215		
10.	Conclusions	
	
1. As	a	general	conclusion,	this	thesis	has	proved	that	the	build-couple-pair	approach	
is	 suitable	 to	 construct	 DOS	 libraries	 using	 pyrrole,	 a	 well-known	 privileged	
structure,	 as	 the	 central	 core	 on	 which	 to	 generate	 molecular	 diversity	 and	
complexity.	
	
2. A	 mechanochemical	 multicomponent	 pyrrole	 synthesis	 related	 to	 the	 Hantzsch	
reaction	is	suitable	for	the	preparation	of	pyrrole	derivatives	bearing	at	their	N-1,	C-
2	 and	 C-5	 positions	 functional	 groups	 allowing	 suitable	 complexity-generating	
reactions	 at	 a	 later	 (pair)	 stage.	 The	mechanochemical	 pyrrole	 synthesis	was	 also	
suitable	for	the	preparation	of	symmetrical	molecules	containing	two	pyrrole	units	
at	the	end	of	a	spacer.	
	
	
	
3. Some	 transition	metal-catalyzed	 reactions	 were	 suitable	 to	 generate	 rings	 at	 the	
pair	 stage	 of	 our	 strategy,	 giving	 rise	 to	 pyrrolo[1,2-c]quinazoline,	 pyrrolo[2,1-
a]isoquinoline	and	benzo[c]pyrrolo[1,2-a]azepine	 frameworks	by	application	of	 an	
Ullmann-initiated	 domino	 process,	 ring-closing	 Heck	 reactions	 and	 ring-closing	
metathesis	reactions,	respectively.		
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4.	 Pyrrolo[2,1-a]isoindole	 and	 pyrrolo[2,1-a]isoquinoline	 frameworks	 are	 readily	
available	 by	 intramolecular	 Diels-Alder	 reactions	 from	 1-allyl(homoallyl)-5-(2-
furyl)pyrroles.	
	
	
	
5.	 The	 generation	of	 intermediate	oxonium	 species	 from	acetals	via	 their	 treatment	
with	 Brønsted	 or	 Lewis	 acids	 is	 a	 good	 strategy	 to	 generate	 fused	 pyrroles	 by	
Pommeranz-Fritsch	 type	 cyclizations	 onto	 C-5	 aryl	 substituents	 or	 by	 attack	 of	 a	
ketene	acetal	function	concomitantly	generated	at	C-2.		
	
	
	
6.	 Ring-closing	 metathesis	 reactions,	 using	 as	 starting	 materials	 symmetrical	 bis-
pyrrole	 derivatives	 bearing	 homoallyl	 chains	 or	 1-allyl-2-allylaminoethylpyrroles	
allow	 the	 efficient	 construction	 of	 pyrrole-derived	 macrocycles	 or	 medium-sided	
rings.	
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7.		Structurally	 unusual	 pyrrole-related	 macrocycles,	 including	 cyclophane	 structural	
fragments,	 are	 also	 readily	 available	 by	 means	 of	 double	 Hantzsch	 pyrrole	
syntheses,	where	one	of	these	reactions	serves	as	the	macrocyclization	event.	
	
	
	
8.		The	 DOS	 libraries	 synthesized	 by	 the	 above	 methods	 were	 assayed	 using	 high-
throughput	 screening	 methodologies	 via	 the	 Lilly	 Open	 Innovation	 in	 Drug	
Discovery	(OIDD)	program	and	generated	some	interesting	hit	compounds	that	will	
be	further	studied	in	the	future.	
	
9.		Photochemical	 homologation	 reactios	 under	 flow	 conditions	 are	 suitable	 for	 the		
synthesis	of	aliphatic	aldehydes,	This	part	of	the	thesis	was	carried	at	the	laboratory	
of	Professor	Steven	Ley	at	the	Department	of	Chemistry,	Cambridge	University.	
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11.	Representative	spectra	
	
Ethyl	2-ethyl-5-(2-iodophenyl)-1H-pyrrole-3-carboxylate	(1c)	
1H	NMR	(250	MHz,	CDCl3)	
	
13C	NMR	(63	MHz,	CDCl3)
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	 	 	 	 	 221		
tButyl	1-allyl-5-(furan-2-yl)-2-methyl-1H-pyrrole-3-carboxylate	(1g)	
1H	NMR	(250	MHz,	CDCl3)	
	
13C	NMR	(63	MHz,	CDCl3)	
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222	 	 	 	 	 		
1-(1-(but-3-en-1-yl)-5-(2-iodophenyl)-2-methyl-1H-pyrrol-3-yl)ethan-1-one	(1n)	
1H	NMR	(250	MHz,	CDCl3)	
	
13C	NMR	(63	MHz,	CDCl3)
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	 	 	 	 	 223		
Ethyl	(E)-4-(3-acetyl-5-(2-iodophenyl)-2-methyl-1H-pyrrol-1-yl)but-2-enoate	(1x)	
1H	NMR	(250	MHz,	CDCl3)	
	
13C	NMR	(63	MHz,	CDCl3)
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224	 	 	 	 	 		
Ethyl	 1-(2,2-dimethoxyethyl)-2-(2-ethoxy-2-oxoethyl)-5-phenyl-1H-pyrrole-3-
carboxylate	(1y)	
1H	NMR	(250	MHz,	CDCl3)	
	
13C	NMR	(63	MHz,	CDCl3)	
	
	 	
	
	
	 	 	 	 	 225		
Ethyl-1,2-di(but-3-en-1-yl)-4-methyl-5-phenyl-1H-pyrrole-3-carboxylate	(1ag)	
1H	NMR	(250	MHz,	CDCl3)	
	
13C	NMR	(63	MHz,	CDCl3)	
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226	 	 	 	 	 		
Dimethyl	1,1'-(propane-1,3-diyl)bis[5-(4-chlorophenyl)-2-methyl-1H-pyrrole-3-
carboxylate]	(2b)	
1H	NMR	(250	MHz,	CDCl3)		
	
13C	NMR	(63	MHz,	CDCl3)	
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	 	 	 	 	 227		
N1,N4-Bis[3-(3-ethoxycarbonyl-5-phenyl-2-methylpyrrol-1-yl)propyl]piperazine	(2i)	
1H	NMR	(250	MHz,	CDCl3)		
13C	NMR	(63	MHz,	CDCl3)	
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228	 	 	 	 	 		
1,1'-[[(1,1,3,3-Tetramethyldisiloxane-1,3-diyl)bis(propane-3,1-diyl)]bis(2-methyl-5-
(thiophen-2-yl)-1H-pyrrole-1,3-diyl)]bis(ethan-1-one)	(2l)	
1H	NMR	(250	MHz,	CDCl3)	
	
13C	NMR	(63	MHz,	CDCl3)	
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	 	 	 	 	 229		
N,N,N-Tris[2-(3-acetyl-5-phenyl-2-methylpyrrol-1-yl)ethyl]amine	(3)		
1H	NMR	(250	MHz,	CDCl3)		
	
13C	NMR	(63	MHz,	CDCl3)	
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230	 	 	 	 	 		
(E)-1,1'-(But-2-ene-1,4-diyl)bis[5-(tert-butyl)-2-methyl-1H-pyrrole-1,3-diyl)]bis(ethan-
1-one)	(5b)	
1H	NMR	(250	MHz,	CDCl3)		
	
13C	NMR	(63	MHz,	CDCl3)	
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	 	 	 	 	 231		
Ethyl	5-(furan-2-yl)-3-methylpyrrolo[1,2-c]quinazoline-2-carboxylate	(6a)	
1H	NMR	(250	MHz,	CDCl3)	
	
13C	NMR	(63	MHz,	CDCl3)	
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232	 	 	 	 	 		
Methyl	5-(2-bromophenyl)-3-methylpyrrolo[1,2-c]quinazoline-2-carboxylate	(6e)	
1H	NMR	(250	MHz,	CDCl3)	
	
13C	NMR	(63	MHz,	CDCl3)
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	 	 	 	 	 233		
1-allyl-5-(2-iodophenyl)-2-methyl-1H-pyrrole-3-carboxamide	(5a)	
1H	NMR	(250	MHz,	CDCl3)
	
13C	NMR	(63	MHz,	CDCl3)
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234	 	 	 	 	 		
tbutyl	3,6-dimethylpyrrolo[2,1-a]isoquinoline-2-carboxylate	(7c)	
1H	NMR	(250	MHz,	CDCl3)	
	
13C	NMR	(63	MHz,	CDCl3)
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	 	 	 	 	 235		
Ethyl-2-methyl-3-phenyl-5,6,9,10-tetrahydropyrrolo[1,2-a]azocine-1-carboxylate	(8d)	
1H	NMR	(250	MHz,	CDCl3)	
	
13C	NMR	(63	MHz,	CDCl3)
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236	 	 	 	 	 		
Ethyl	(E)-5-(3-acetyl-5-(furan-2-yl)-2-methyl-1H-pyrrol-1-yl)pent-2-enoate	(9a)	
1H	NMR	(250	MHz,	CDCl3)	
	
13C	NMR	(63	MHz,	CDCl3)	
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	 	 	 	 	 237		
tButyl	(E)-1-(4-ethoxy-4-oxobut-2-en-1-yl)-5-(furan-2-yl)-2-methyl-1H-pyrrole-3-
carboxylate	(3d)	
1H	NMR	(250	MHz,	CDCl3)	
	
13C	NMR	(63	MHz,	CDCl3)
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238	 	 	 	 	 		
Ethyl	2-acetyl-3-methyl-5,6-dihydropyrrolo[2,1-a]isoquinoline-7-carboxylate	(10a)	
1H	NMR	(250	MHz,	CDCl3)	
	
13C	NMR	(63	MHz,	CDCl3)
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	 	 	 	 	 239		
2-(tButyl)	6-ethyl	3-methyl-5H-pyrrolo[2,1-a]isoindole-2,6-dicarboxylate	(4d)	
1H	NMR	(250	MHz,	CDCl3)	
	
13C	NMR	(63	MHz,	CDCl3)
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240	 	 	 	 	 		
Diethyl	2-methoxy-5-phenyl-2,3-dihydro-1H-pyrrolizine-1,7-dicarboxylate	(11a)	
1H	NMR	(250	MHz,	CDCl3)		
	
13C	NMR	(63	MHz,	CDCl3)	
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	 	 	 	 	 241		
Trans-Diethyl	2-methoxy-5-phenyl-2,3-dihydro-1H-pyrrolizine-1,7-dicarboxylate	
(11aa)	
1H	NMR	(250	MHz,	CDCl3)	
	
13C	NMR	(63	MHz,	CDCl3)	
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242	 	 	 	 	 		
Dimethyl	5-(4-bromophenyl)-3H-pyrrolizine-1,7-dicarboxylate	(12a)	
1H	NMR	(250	MHz,	CDCl3)	
	
13C	NMR	(63	MHz,	CDCl3)	
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	 	 	 	 	 243		
Methyl	1-(2,2-dimethoxyethyl)-2,6,8-trimethyl-4,5-dihydro-1H-benzo[g]indole-3-
carboxylate	(13s)	
1H	NMR	(250	MHz,	CDCl3)	
	
13C	NMR	(63	MHz,	CDCl3)	
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244	 	 	 	 	 		
Dimethyl	5,5'-(1,3-phenylene)bis(1-(2,2-dimethoxyethyl)-2-methyl-1H-pyrrole-3-
carboxylate)	(6t)	
1H	NMR	(250	MHz,	CDCl3)	
	
13C	NMR	(63	MHz,	CDCl3)	
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	 	 	 	 	 245		
Diethyl-1,1'-(ethane-1,2-diyl)bis(2-(but-3-en-1-yl)-5-(4-iodophenyl)-1H-pyrrole-3-
carboxylate)	(15b)	
P1H	NMR	(250	MHz,	CDCl3)
	
13C	NMR	(63	MHz,	CDCl3)
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246	 	 	 	 	 		
Diethyl-1,1'-((1,1,3,3-tetramethyldisiloxane-1,3-diyl)bis(propane-3,1-diyl))bis(2-(but-
3-en-1-yl)-5-phenyl-1H-pyrrole-3-carboxylate)	(15h)	
1H	NMR	(250	MHz,	CDCl3)
	
13C	NMR	(63	MHz,	CDCl3)
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	 	 	 	 	 247		
Diethyl-(Z)-1,12-bis(4-iodophenyl)-4,5,8,9,14,15-hexahydrodipyrrolo[1,2-d:2',1'-
l][1,4]diazacyclododecine-3,10-dicarboxylate	(16b)	
1H	NMR	(250	MHz,	CDCl3)	
	
13C	NMR	(63	MHz,	CDCl3)	
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248	 	 	 	 	 		
Diethyl	8,8,10,10-tetramethyl-3,15-diphenyl-5,6,7,8,10,11,12,13,18,19,22,23-
dodecahydrodipyrrolo[1,2-f:2',1'-n][1]oxa[6,15]diaza[2,19]disilacyclononadecine-
1,17-dicarboxylate	(16h)	
This	compound	is	a	mix	of	isomer	A	and	isomer	B	(as	6.5:3.5)	
1H	NMR	(250	MHz,	CDCl3)
	
13C	NMR	(63	MHz,	CDCl3)
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	 	 	 	 	 249		
Methyl	(Z)-2-(7-methyl-1,4-diazepan-5-ylidene)acetate	(17a)	
1H	NMR	(250	MHz,	CDCl3)		
	
13C	NMR	(63	MHz,	CDCl3)	
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250	 	 	 	 	 		
Methyl	3,5-bis(allylamino)hex-2-enoate	(18)	
1H	NMR	(250	MHz,	CDCl3)	
	
	
13C	NMR	(63	MHz,	CDCl3)	
	
	 	
N
H
N
H
Me
O
OMe
	
	
	 	 	 	 	 251		
Methyl	1-allyl-2-(2-(allylamino)propyl)-5-phenyl-1H-pyrrole-3-carboxylate	(19a)	
1H	NMR	(250	MHz,	CDCl3)	
	
13C	NMR	(63	MHz,	CDCl3)	
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252	 	 	 	 	 		
Methyl	(Z)-3-acetyl-2-methyl-9-phenyl-2,3,4,7-tetrahydro-1H-pyrrolo[1,2-
a][1,5]diazonine-11-carboxylate	(20)	
1H	NMR	(250	MHz,	CDCl3)	
	
13C	NMR	(63	MHz,	CDCl3)	
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	 	 	 	 	 253		
Dimethyl-3,10-dimethyl-5,6,7,8-tetrahydro-13,17-(metheno)dipyrrolo[1,2-f:2',1'-
m][1,6]diazacyclotridecine-2,11-dicarboxylate	(21a)	
1H	NMR	(250	MHz,	CDCl3)	
	
13C	NMR	(63	MHz,	CDCl3)	
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254	 	 	 	 	 		
1,1'-(15,45,8,8,10,10-hexamethyl-11H,41H-9-oxa-8,10-disila-1,4(2,1)-dipyrrola-
2(1,3),3(1,4)-dibenzenacyclotridecaphane-14,44-diyl)bis(ethan-1-one)	(21f)	
1H	NMR	(250	MHz,	CDCl3)
	
13C	NMR	(63	MHz,	CDCl3)
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	 	 	 	 	 255		
1,2,3,4-tetrahydronaphthalene-2-carbaldehyde	(22a)	
1H	NMR	(250	MHz,	CDCl3)		
	
13C	NMR	(63	MHz,	CDCl3)	
	
	 	
	
	
256	 	 	 	 	 		
tbutyl	4-formylpiperidine-1-carboxylate		(22f)	
1H	NMR	(250	MHz,	CDCl3)		
	
13C	NMR	(63	MHz,	CDCl3)	
	
	 	
	
	
	 	 	 	 	 257		
(1,2,3,4-tetrahydronaphthalen-2-yl)metanol	(23a)	
1H	NMR	(250	MHz,	CDCl3)		
	
13C	NMR	(63	MHz,	CDCl3)	
	
	 	
	
	
258	 	 	 	 	 		
2-methylhex-5-en-1-ol	(23n)	
1H	NMR	(250	MHz,	CDCl3)		
	
13C	NMR	(63	MHz,	CDCl3)	
	
	 	
	
	
	 	 	 	 	 259		
2-(1,2,3,4-tetrahydronaphthalen-2-yl)-1H-benzimidazole	(24a)	
1H	NMR	(250	MHz,	CDCl3)		
	
13C	NMR	(63	MHz,	CDCl3)	
	
	 	
	
	
260	 	 	 	 	 		
2-(adamantan-2-yl)-1H-benzimidazole	(24h)	
1H	NMR	(250	MHz,	CDCl3)		
	
13C	NMR	(63	MHz,	CDCl3)	
	
	
	
